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Abstract 
 
This thesis aimed to contribute to current understanding of ‘intervention-generated inequalities’, 
that is, the concern that processes in the planning or delivery of an intervention may create or 
exacerbate the health differences between population groups. This was done by examining the 
impact of secondary and tertiary preventive interventions for type 2 diabetes by socio-
economic status (SES). Previous research has shown that the condition places a 
disproportionate burden on individuals from disadvantaged backgrounds. It addition, managing 
the condition involves a range of health care; all potentially exacerbating existing health 
inequalities.   
A systematic review was conducted and secondary data analyses of patient data collected by a 
hospital diabetes register. The Index of Multiple Deprivation 2004 was used as an indicator of 
patients’ SES. Multilevel models were fitted using repeated measurements, with patients nested 
within general practices. Interaction effects were used to determine inequalities over time and if 
interventions were associated with differential health outcomes by SES.  
The multilevel analyses showed that high SES patients were more likely to have lower blood 
glucose over time, but higher levels of cholesterol compared to low SES patients. In contrast, 
there were few differences in long-term health complications by SES over time. High SES 
patients were more likely to receive higher quality of care and shared care than low SES 
patients over time. Furthermore, there significant inequalities in health by SES were found in 
patients receiving the same care. There were also significant inequalities in prescriptions for 
treatments, conditional on other relevant covariates. 
The results in thesis indicate that there were intervention generated inequalities which are 
particularly important for practitioners. As these were either a result of interventions not being 
appropriately accessed and/or administered based on need or the efficacy of these 
interventions differed by SES. Further analyses are needed to unpick the direction of these 
associations. 
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MI   Multiple imputation 
ML   Maximum likelihood 
NDA    National Diabetes Audit 
NEPHO   North East Public Health Observatory 
NHS    National Health Service 
NICE    National Institute for Health and Clinical Excellence 
NSF    National Service Framework 
NS-SEC   National Statistics Socio-Economic Classification 
OECD   Organisation for Economic Co-operation and Development 
OHA   Oral anti hyperglycaemic agents 
ONS   Office for National Statistics 
PCT    Primary Care Trust 
PHO    Public Health Observatories 
PVD   Peripheral vascular disease 
QOF    Quality and Outcomes Framework 
sBP   Systolic blood pressure 
SEP    Socioeconomic position 
SES    Socio-economic status 
STROBE   STrengthening the Reporting of OBservational studies in Epidemiology 
TIA   Transient ischemic attack  
UK    United Kingdom 
YHPHO   Yorkshire and Humber Public Health Observatory 
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Chapter 1: Introduction 
 
The aim of this thesis was to contribute to the understanding of intervention generated 
inequalities (IGIs), that is, any process in the planning or delivery of an intervention aimed at 
improving health overall that has different outcomes in different social groupings in the target 
population [1]. This was achieved through a systematic review and secondary data analyses of 
inequalities associated with type 2 diabetes.  
The background to this study is rooted in both national and international political agendas 
related to unequal relationship between socio- demographic and economic conditions and 
health. This chapter discusses the definition and interpretation of this relationship and provides 
a broad look at the political history of addressing the issue, with a particular focus on England. 
The chapter then goes on to discuss the rationale for examining IGIs with the focus on type 2 
diabetes. Finally, the chapter discusses why the population of the South Tees, an area in the 
North East of England, was chosen and what was already known about diabetes and health 
inequalities in this locality by drawing upon routine data and existing analyses. 
 
Background to the study 
 
The unequal relationship between socio- demographic and economic conditions and health is 
often referred to as ‘health inequalities’. While this term is widely used its precise definition also 
has a broad interpretation, depending upon which axes of social differentiation are examined 
and how health is described and measured.  In broad terms, it is understood to refer to the 
differences in health between populations groups [2] according to socio-demographic and 
economic characteristics defined by, for example, location, race, ethnicity or culture, occupation, 
gender, religion, age, education or income [1].  
It should be acknowledged that ‘health inequalities’ and ‘health inequities’ are often used 
interchangeably when discussing this phenomenon. ‘Health inequalities’ is used throughout this 
thesis to ensure consistency, however, ‘health inequities’ could have easily been chosen instead. 
‘Health inequities’ is more often used to emphasise that differences in health between 
population groups are unfair and avoidable and tackling the issue requires societal change to 
redress the systemic failings [3].  
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In the United Kingdom (UK), there is a long history of seeking explanations and solutions to the 
issue of health inequalities. Since the nineteenth century Britain has led the rest of the world in 
systematic data collection and analysis with the Office of National Statistics, and its 
predecessors, investments in birth cohort and longitudinal studies [4-6]. A report in Liverpool 
in 1840 by Edwin Chadwick showed that the average age at death was 35 years for gentry and 
professional classes and 15 years for labourers [7]. These findings led to the introduction of the 
1848 Public Health Act which legislated for street cleaning, refuse collection, and establishing 
and improving water supplies and sewage systems [8]. 
In the UK, the National Health Service (NHS) was established in 1948 to provide free care for all. 
While it was not explicitly cited, there was an assumption made by many that inequalities in 
health would be rectified as a result. Subsequent research, however, has shown that this has not 
been the case. The Black Report in 1980 [8] was a milestone publication and re-established 
health inequalities on the political agenda in Britain. The authors of the report attributed the 
inequalities in health to the inequalities in other social circumstances, such as education and 
working conditions, and recommended improvements in preventative and primary health care. 
However, due to the political circumstances at the time, it was not until the Labour party 
returned to power in 1997 and the publication of the Acheson Report in 1998 that the issues 
and recommendations raised in these reports were addressed at a national policy level [8]. 
Following this report, tackling health inequalities formed a major part of the Labour party 
political agenda. In 1999, ‘Reducing health inequalities: an action Report’ was published which 
introduced initiatives such as ‘Sure Start’, ‘Health Action Zones’, national minimum wage, 
improved benefits and pension rates [9]. Spending was also increased on education, housing, 
urban regeneration and healthcare. This was followed by a cross-cutting review of tackling 
health inequalities [10] and a revised strategy ‘Tackling health inequalities: a Programme for 
Action’[11]. The strategy included details of how the national public service agreement target 
set in 2001 to reduce inequalities in health outcomes by 10 per cent as measured by infant 
mortality and life expectancy at birth was to be achieved [6, 11].  
Since then a series of status reports have been published which reveal that despite the scale of 
work and overall improvements in life expectancy and infant mortality rates, inequalities 
remain and in some instances have increased [4, 6]. In particular, the 2007 Status Report found 
that the relative gap in life expectancy between England as a whole and the fifth most deprived 
areas had increased by 2% for men and by 11% for females between 2003-05 and 2004-06[12]. 
As such the need for effective action on tackling health inequalities remains pertinent. The 
Marmot Review ‘Fair Society, Healthy Lives’ in 2010 reiterated previous assertions that the 
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need to tackle health inequalities is a matter of social justice. In addition, the 2010 review 
asserts that there is an economic benefit stating that if health inequalities were eradicated then 
the same disadvantaged groups would experience a further 2.8 million years of disability and 
long-term illness free life. This would also save the NHS in England an estimated £5.5 billion 
plus and other billions more in productivity, taxes and welfare payments losses [4].  
In 2010 the new Conservative-Liberal Democrat coalition government published the white 
paper ‘Equity and Excellence: Liberating the NHS’ [13]. In this white paper, the coalition 
outlined its plans to uphold the values and principles of the NHS; increase spending in real 
terms and making the NHS a world-class health service. Two major changes the coalition sought 
to introduce were, firstly, handing the majority of the budget to general practitioners and, 
secondly, the establishment of public health service primarily situated within local authorities 
(LAs) so that those responsible for commissioning and running services are closer to the 
population they serve [13]. The coalition also published a public health white paper ‘Healthy 
lives, healthy people: our strategy for public health in England’ later in 2010 [14]. 
Commentators on the white papers welcomed the continued commitment to public health and 
reducing health inequalities exemplified through the proposal of a ‘health premium’, which 
gives LAs additional funds for health improvement services. These funds are to be allocated 
depending upon improvements in health of the local population [13, 15, 16]. However, critics 
suggest that allocation based upon performance may actually widen health inequalities by 
perpetuating the inverse care law. That is, areas that have greater need, but do not achieve 
significant improvements in the health of the population, would not receive the extra funding. 
Lack of improvement may be due to initial poor funding therefore again increasing the 
challenge for these areas [15]. 
The changes in the health service arrangements introduced by the Conservative-Liberal 
Democrat coalition government and the responses to them show that tackling health 
inequalities is still a major political issue.  Yet, whilst there is on-going work to improve health 
and reduce inequalities there are growing concerns that some health strategies could actually 
lead to the widening of the health differences between population groups. 
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Rationale for thesis 
 
As mentioned above the aim of this thesis is to contribute the understanding of ‘intervention 
generated inequalities’, that is, how and why interventions aimed at improving population 
health overall could lead to the widening of the health differences between population groups. 
This section introduces the rationale for examining the phenomenon of IGIs and the focus of 
type 2 diabetes using data collected in the South Tees area.  
 
Intervention generated inequalities  
 
The phrase ‘intervention generated inequalities’ was coined by White et al in 2009 to bring 
together existing papers and theories which have noted the differences in the access, uptake 
and impact of intervention by population groups. The authors wanted to emphasise how IGIs 
can occur at any stage of the intervention process [1].  
One of the more famous pieces of work is Tudor-Hart’s ‘Inverse Care Law’ (ICL). Tudor-Hart’s 
paper was published in 1971 and related to primary care. The ICL states that patients’ access to 
good health care is inversely related to need. This has been interpreted to suggest that the most 
disadvantaged groups have the poorest access to health care as the need for such services is 
strongly related to socioeconomic position (SEP) [1]. This interpretation has become somewhat 
accepted and detached from its original inception. In particular, who has the greatest need for 
health services is not always associated with SEP. Increasing age has been shown to be more 
closely related to increased morbidity and mortality than deprivation for most conditions. 
Similarly, what is regarded as ‘good medical care’ is also debatable. For instance, good medical 
care that meets the needs of patients with diagnosed health problems or care which reduces 
risk and prevents illness [17, 18].  
Despite the argument that is not a ‘law’, as it is not based on a systematic review of evidence 
when it was first purported [19], and some subsequent skewed interpretations the ICL 
continues to be a widely cited explanation and has been supported by evidence from a wide 
range of settings. For example, in a recent review of attendance to health check-ups in 
developed countries, it was found that people from low SEP were less likely to attend but were 
also the people who were likely to have a greater clinical need or risk factors [20]. In addition, 
there are a few studies which have found evidence to contradict this law. One study in the North 
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East of England found that more deprived patients were geographically closer to general 
practices than the least deprived, however, this study did not measure medical need of the 
patients, the quality of the care and whether it was appropriately accessed [21]. Work has also 
been conducted to explain why this law persists. One study did this by conducting a 
questionnaire study of NHS patients in the West of Scotland. The authors also found that it was 
patients from more deprived areas who had the greatest clinical need. This increased burden in 
deprived areas lead to greater demands on primary care which is associated with reduced 
access to scheduled care, shorter consultations, higher GP stress and lower levels of patients 
being able to cope with and understand their psychosocial problems [22].  
A particular limitation of the ICL which White et al [1] highlighted is that it is primarily 
concerned with the provision of health services. This is only one type of intervention and one 
way that inequalities could be introduced or exacerbated and therefore has limited capacity to 
explain the overall phenomenon of IGIs [1].   
A more recent theory which White et al [1] brought under the IGI term is the ‘inverse equity 
hypothesis’. It has been described as a corollary to the ICL and could arguably be an evidence-
based version of the ‘inverse prevention law’ briefly referred to in the Acheson Report in 1999. 
The ‘inverse prevention law’ refers to the concept that individuals least likely to receive 
preventative measures are those most likely to benefit from them. Similarly to the ICL, no 
evidence was presented to support this theory when it was first purported [1] and in contrast it 
has been less widely cited. However, this maybe because that the ICL has been expanded to a 
range of interventions associated with health beyond the formal medical care for which the 
theory was initially devised [23]. In contrast, Victora et al [24] used analyses of time trends in 
child heath statuses in three Brazilian epidemiology datasets to demonstrate how new public 
health interventions initially show greater utilisation and health improvements in the most 
advantaged proportion of the population thereby increasing inequalities. These later reduce as 
utilisation broadens and the health improvements reach a new plateau.  This hypothesis has 
been used to explain the regional inequalities in liver cirrhosis mortality rates in Taiwan with 
differences in uptake in hepatitis B vaccination programmes [25]. 
While the ‘inverse equity hypothesis’ provides a testable framework, it has been shown that 
such trends may support an artefact theory of IGIs [26]. That is, while the existence of 
inequalities is not disputed the longitudinal trend in terms of whether the inequalities are 
increasing or decreasing is dependent upon the prevalence of the outcome being measured. For 
example, if two groups differ in their susceptibility to an outcome, the rarer the outcome the 
greater the relative inequalities will be and the more common the outcome the smaller the 
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relative inequalities will be. As such the prevalence of an outcome affects the change in the size 
of the perceived relative inequalities and is statistically expected to follow the pattern Victora et 
al described. As such it is not known whether increased usage of an initially rare intervention 
reflects a meaningful reduction in relative inequalities or if the data is just reflecting the 
expected statistical pattern. Careful reference therefore needs to be made to the prevalence of 
the outcome measurement when making conclusions about trends in inequalities using binary 
measures [26]. This is arguably evident in some of the findings in the DH 2007 ‘Status Report on 
the Programme for Action’ [12]. For instance, even though the overall prevalence of smoking 
during pregnancy has decreased slightly, between 2000 to 2005 there was a slight increase for 
‘routine and manual’ workers contributing to possible widening in inequalities.  
The ‘equity-effectiveness loop’ [27] was also discussed by White et al [1]. This framework and 
calculation approach was devised by Tugwell et al [27]. They emphasised that inequalities as a 
result of an intervention and its overall effectiveness can be affected by any stage of an 
intervention. Yet, no direct evidence was depicted to show a multiplicative effect, nor were the 
aspects of interventions which have an effect on inequalities been identified [1]. Studies 
elsewhere, however, have identified characteristics of interventions which are likely to increase 
inequalities. For instance, Capewell and Graham [28] reviewed various approaches to 
cardiovascular disease (CVD) prevention and found consistent evidence support for the 
Geoffrey Rose [29] approach to disease prevention through taking a dual strategy of whole-
population interventions as well targeting high-risk individuals. The authors found that while 
whole-population approaches may not reduce inequalities they do not increase either as 
interventions, such as smoke-free legislation and water fluoridation, work effectively across the 
social gradient. Whereas “agentic” interventions, that is those which are based on individual 
behaviour, such as breast screening programmes and primary prevention medications, require 
material and psychological resources and favour those with more to draw upon. This is usually 
people from less deprived backgrounds compared to those from the most deprived, thereby 
increasing inequalities [28]. This is supported by a recent review of reviews by Lorenc et al [30] 
which found ‘downstream’, non healthcare interventions which focused on individual factors 
are more likely to increase inequalities compared to ‘upstream’ interventions which operate on 
a social or policy level. Nettle [31] theorises that this social gradient in preventive health 
behaviour takes a behavioural ecological approach and argues that there is an ‘exacerbatory 
dynamic of poverty’ explaining that people from lower SEP have greater exposure to 
unavoidable harms which disincentives them from investing in positive health behaviours. As 
such agentic interventions relying on individual behaviour change are likely to introduce 
further inequalities [31]. These hypotheses are not always supported: Toft et al [32] found 
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evidence that a longitudinal, multifactorial lifestyle intervention to change dietary behaviour 
found a greater improved effect on lower educated and unemployed participations. However, 
the study’s low participation rates and high degree of attrition may have impacted upon the 
reliability of these results [32]. 
The way in which health systems operate also has the potential to increase health inequalities. 
Ali [33] argues that the personalisation of the NHS, exemplified in ‘The NHS Plan’ and ‘The 
Expert Patient’, could actually exacerbate inequalities as it is the already disadvantaged who 
will be less likely to be able to make an informed choice over which services to access. In turn, 
public reporting of quality of services could lead to further inequalities as health professionals 
and organisations avoid serving high-risk patients that hold the potential to reduce quality 
outcome measures. This is also a criticism of the increased use of private health service 
providers, which form part of the current coalition government plans, who potentially may 
‘cherry pick’ patients to ensure lower costs [34]. 
Much of the work investigating IGIs highlights that interventions that are based around 
individual behaviour are key sources of the emergence of inequalities. For example, choosing 
services based on quality requires the individual to seek out that information [33]. Preventative 
health care, such as changing lifestyle, attending screening services, adhering to medications are 
all dependent upon individual action. The implication from the work of Capewell et al [28], 
Graham et al [2] and Nettle [31] that interventions are not designed to overcome the lack of 
material and psychological resources and the ‘exacerbatory of dynamic of poverty’, is that 
individuals from more deprived socio-economic backgrounds are likely to experience poorer 
health outcomes from the same interventions compared to the least deprived.  
Despite this extensive work which has already been undertaken, Macintyre and Petticrew [35] 
have previously argued that there are widely held misconceptions that interventions aimed at 
improving health, and other social circumstances, only have the capacity to do good. In addition, 
there was an assumption that it is enough to know the intervention does good overall and not 
whether it has an equal, positive impact on all population groups, how it works and at what cost. 
Macintyre and Petticrew suggest these misconceptions, amongst others, explain why there has 
been reluctance amongst practitioners and social scientists to use evidence based medicine 
(EBM) principles in real-life, complex social settings [35]. This reluctance to use EBM principles, 
in addition to poor planning and limited subsequent evaluation [6, 36], could be regarded as 
possible reasons for the failure of the Labour government to meet their own targets to reduce 
inequalities. It could also be argued that this has continued both at national policy level and in 
interventions aimed at individuals and smaller populations. 
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In summary, there has been increasing attention to the adverse effects of health interventions 
yet more research is required to provide a broader picture of the type and nature of 
interventions which increase or decrease inequalities. A more robust set of evidence will enable 
the production of practical advice for policy makers, commissioners and practitioners to reduce 
health inequalities [1, 30]. 
 
Focus of thesis 
 
Type 2 diabetes  
 
Diabetes mellitus, or diabetes, is a condition characterised by hyperglycaemia resulting from 
defects in insulin secretion, insulin action, or both. Type 2 is one classification of the condition. 
Patients are considered to have type 2 diabetes when either the body does not produce enough 
insulin or it does not react effectively to it in order to maintain blood glucose levels at an 
appropriate level [37, 38]. This section outlines why type 2 diabetes is an increasingly 
important health issue, both in the UK and worldwide, and why it is also an ideal condition to be 
the focus of analysis examining IGIs. Chapter two provides a greater description of the health 
problems associated with type 2 diabetes and how it is managed.  
Firstly, diabetes is expected to affect an increasing proportion of the world population, 
frequently described at being of epidemic proportions. An estimated 246 million people 
worldwide suffer from diabetes [39]. In 2010, the estimated prevalence of both diagnosed and 
undiagnosed diabetes in England was 7.4%; 3,099,853 people aged 16 years or older. By 2030 it 
is estimated about one in ten of the population could have diabetes [40]. Type 2 diabetes 
accounts for approximately 90 to 95% of the prevalence of diabetes in adults worldwide [41].  
Secondly, whilst anyone can develop type 2 diabetes it is overrepresented in certain population 
groups, particularly those from lower SEP and particular ethic groups. The burden of diabetes 
also does not affect everyone equally; the most deprived groups in the UK are two and half 
times more likely to have diabetes and three and half times more likely to have severe 
complications [42]. In the North East of England there was a greater prevalence among men and 
women in the most deprived areas compared to the national average, 28% and 45% higher 
respectively [43]. Inequalities in type 2 diabetes by SEP have also been shown on an 
international scale. A systematic review of studies conducted between 1999 and 2009 found 
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that type 2 diabetes patients in a poorer SEP had a greater incidence, prevalence and mortality 
rates [44].  
Type 2 diabetes is a complex condition and patients can expect to be engage with a wide range 
of health services as part of their routine care. The diabetes care pathway is outlined in Figure 1. 
As such, there should be a wide range of health data collected on a routine basis for all type 2 
diabetes patients who are engaged with health care services [45]. Tugwell et al [27] purport 
that the equity effectiveness of health interventions in real settings and systems at community 
level is dependent upon the extent of awareness, access, or coverage; screening, diagnosis, or 
targeting; compliance of providers; and adherence of consumers. There is, therefore, a diverse 
range of processes involved in the management of type 2 diabetes which have the potential to 
introduce or exacerbate inequalities in outcome by different social groups.  
Finally, diagnosed patients are an easily identified population as it is recommended by the 
National Institute for Health and Clinical Excellence (NICE) that patients have at least one health 
service visit to receive an annual review of their condition [46]. In addition to primary care and 
hospital data this is facilitated by several current schemes and policies which encourage the 
routine registration and collection of laboratory and administrative data on all known diabetic 
patients. In England, this includes the Quality and Outcomes Framework (QOF) [47], the 
National Screening Programme for Diabetic Retinopathy [48] which requires an accurate 
diabetes register in order for it to achieve the target of 100% screening rate set out in the 
National Service Framework (NSF) for Diabetes [49] and the National Diabetes Audit (NDA) 
[50]. The audit, designed and delivered by the National Clinical Audit Support Programme, 
provides quality information and analysis for NHS organisations to implement the Diabetes NSF 
and ensure that resources are being utilised effectively and where they are most needed [51].  
At a local level, the South Tees area there is a diabetes register, hosted by the Diabetes Clinic at 
James Cook University Hospital. Established in 1987, the register aims to collect demographic 
and clinical information on all known diabetes patients in the Middlesbrough and Redcar & 
Cleveland. This dataset is described in more detail in later chapters as it forms the core dataset 
used for the secondary data analyses for this thesis. 
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Figure 1: Diabetes care pathway [52] 
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South Tees  
 
Figure 2: Primary care practices in the South Tees area [53] 
 
 
This section describes the rationale for having type 2 diabetes patients in the South Tees area as 
the target population of the analyses described in this thesis. It then goes on to introduce some 
of the existing analysis illustrating the extent and implications of diabetes on individuals and 
resources in the area. It also introduces some of the known inequalities between social groups.  
South Tees, compromising Middlesbrough Local Authority (LA) and Redcar & Cleveland LA, is a 
distinct geographical region in the North East of England. The area encompasses the industrial 
town of Middlesbrough and naturally bordered by the river Tees, the North Sea and the North 
York Moors [54, 55]. Mid-2010 population estimates recorded Middlesbrough LA as having a 
population of 142,000 and Redcar & Cleveland as 137,000. In the Public Health Observatories 
(PHO) for England 2012 Health Profiles, both LAs had higher deprivation and performed worse 
than England for a range of health indicators, including life expectancy, adult ‘healthy eating’ 
and obesity[56].  
There are 49 general practices in the South Tees area [57] and one NHS Foundation Trust. South 
Tees Hospitals NHS Foundation Trust provides hospital and community services for patients in 
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Middlesbrough, Redcar & Cleveland, Hambleton and Richmondshire and other areas. The 
majority of patients with diabetes are expected to be managed within primary care [58], 
however, the trust provides additional services for patients with specific care needs. This 
includes general diabetes clinics and specialist clinics for pregnant women and those planning a 
pregnancy, young people, patients treated with continuous subcutaneous insulin infusions using 
semi-automated infusion and for patients with or at risk of particular diabetes related 
complications. The Trust also provides a community diabetes service which features a 
multidisciplinary team which works with the hospital and patients general practitioners. This 
service operates clinics in primary care hospitals and other locations and provides additional 
services such as training and support for patients and their primary care team, structured 
diabetes education programmes and up to date information on diabetes complications, new 
treatments and other health services [59].  
As mentioned at the end of the previous section, the South Tees Hospitals NHS Foundation Trust 
also maintains a diabetes register hosted by the Diabetes Clinic at James Cook University 
Hospital. The aim of the register is to collect demographic and clinical information on all known 
diabetes patients in Middlesbrough and Redcar & Cleveland. Whilst the register has existed in 
some form since 1987, in 1999 the database was redesigned and data was no longer archived 
each year. Also due to time constraints in collecting the additional data from primary care, the 
dataset, in 2010, was only complete up until 2007. There was, therefore, an opportunity to 
conduct an analysis using repeated measurements at the patient level over a nine year period to 
compare changes in the rate of intermediate health outcomes and long-term complications [60]. 
In addition, it is possible to link it with other datasets enabling more features of the diabetes 
care pathway to be taken into account and measure patients’ socio-economic status (SES) 
allowing for more complex analyses.  
 
Type 2 diabetes in South Tees 
 
This section describes what is currently known about the impact diabetes has on individuals 
and the resources in the South Tees area, comparing the findings to other local, regional and 
national trends when appropriate. Due to the nature of the data available in this section 
diabetes refers to all types unless otherwise stated. 
In South Tees in 2010, both the primary care trusts (PCTs) in Middlesbrough and Redcar & 
Cleveland had an estimated prevalence of 7.9%; higher than the national rate  of 7.4% [40]. In 
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the 2009/10 NDA less than 80% of the predicted registrations were captured [50] therefore a 
notable proportion of the population appears to be going undiagnosed and consequently 
untreated. 
The Yorkshire and Humber Public Health Observatory (YHPHO), the diabetes lead for PHO for 
England, used information on diabetes prevalence, population estimates and all-cause mortality 
to identify diabetes attributable deaths estimates. In England in 2005, there were 26,300 excess 
deaths among people with diabetes aged between 20 and 79 years. Diabetes accounted for 
11.6% of all deaths in this age group. The proportion of excess deaths as a result of diabetes was 
similar in Redcar & Cleveland PCT to the national rate, in contrast Middlesbrough PCT had a 
rate of 12.3% [40].  
There is a mixed picture of how care has improved since the audits were introduced. Over the 
six audit periods, 2003/04 to 2008/09, there has been a reduction in the prevalence of 
ketoacidosis, myocardial infarction and retinopathy treatments for type 2 diabetes in England. 
However, there has been an increase in the prevalence of angina, cardiac failure, stroke and 
renal failure. During the same period, there has been an increase in the number of type 2 
diabetes patients receiving all nine recommended NICE care processes. The proportion has 
increased from 10.6% to 50.8%. This was still a low rate and significant variation between 
population groups exists [61].  
Figure 3 and Figure 4 are spine charts that show Middlesbrough PCT and Redcar & Cleveland 
PCT National Diabetes Audit 2007/08 indicators, respectively, compared with North East and 
England rates. This year was chosen as it reflects the last year of the data used for the 
subsequent analysis in the thesis. Earlier periods of data were not readily accessible from the 
Information Centre [50].  
The results in Figure 3 shows that Middlesbrough PCT had statistically significantly lower 
prevalence of myocardial infarction, stroke, renal failure and major amputations compared to 
England as a whole. Figure 4 shows that Redcar & Cleveland have statistically significantly 
lower prevalence of ketoacidosis and myocardial infarction compared to England as a whole. 
However, in both spine charts where there were statistically significant differences from the 
national rates for the percentage of care processes and target treatments achieved for patients 
the South Tees PCTs performed worse. Significantly fewer patients in Middlesbrough PCT had 
their BMI, albumin, creatinine and smoking status recorded and achieved treatment targets in 
terms of glycated haemoglobin (HbA1c) and blood pressure (BP) outcomes compared to 
patients nationally. Whilst there are fewer significant differences between patients in Redcar & 
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Cleveland compared to patients nationally there were lower proportions of patients having 
their BP, albumin and smoking status checked and recorded.  
 
Key1 
 
 
Figure 3: Middlesbrough PCT performance compared with North East and England rates in 
the 2007/08 National Diabetes Audit [50] 
 
 
                                                          
1
 The PCT result for each indicator is shown as a circle. The mean rate for England is shown as a grey bar. A red 
circle depicts an area significantly worse than England for that indicator, blue depicts no significance 
differences and green depicts a significantly better result than the national mean. However, the results here 
should be interpreted with caution as a green circle may still indicate a need for improvement in diabetes care. 
For example Redcar & Cleveland perform well for the proportion of patients receiving all nine recommended 
care processes, however, even the best performing PCT only manages to achieve 70%. 
Key:
Indicator
Local 
Number
Local 
Value
Eng 
Avg
Eng 
Worst
England Range
Eng 
Best
Ketoacidosis 35 0.7 0.5 1.3 0.2
Angina 212 4.1 2.9 6.1 0.9
Myocardial Infarction 29 0.6 0.6 1.0 0.2
Cardiac Failure 92 1.8 1.4 3.4 0.7
Stroke 29 0.6 0.6 2.9 0.1
Diabetic Retinopathy Treatments 67 1.3 0.4 2.5 0.0
Renal Failure 13 0.3 0.3 0.9 0.0
Amputation Minor 8 0.2 0.1 0.3 0.0
Amputation Major 3 0.1 0.1 0.2 0.0
BMI 4571 87.4 88.5 37.6 94.2
HBA1C 4799 91.8 90.8 64.4 96.3
Blood Pressure 4893 93.6 93.4 38.2 97.2
Albumin 3183 60.9 61.7 0.5 85.7
Creatinine 4587 87.7 90.8 64.4 95.9
Cholesterol 4697 89.8 89.6 61.8 94.8
Eye Exam 4713 90.1 68.3 28.3 90.1
Foot Exam 4168 79.7 76.2 30.3 88.2
Smoking 4237 81.0 85.9 33.2 94.0
All Care Processes 2565 49.1 39.0 0.3 62.7
NICE HbA1c <6.5 1304 24.9 25.4 10.5 38.7
NICE HbA1c <=7.5 3239 61.9 62.7 39.8 72.2
NICE Cholesterol <5.0 mmol/l 4097 78.3 78.0 70.4 83.1
NICE Diastolic <=75 and Systolic <=135 mm Hg 1525 29.2 30.2 22.6 43.6
Complication 
prevalence 
(%)
Care 
processes 
achieved (%)
Target 
treatments 
achieved (%)
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Figure 4: Redcar & Cleveland PCT performance compared with North East and England rates in the 
2007/08 National Diabetes Audit [50] 
 
 
The descriptive analyses discussed here highlight that there were statistically significant 
differences in diabetes outcomes and care in the South Tees area. Using individual level data 
accessed from other sources, this thesis explores whether there are significant differences in 
patient outcomes and care by SES in the South Tees area. In turn, it also examines whether 
interventions in the diabetes care pathway are associated with inequalities in patients’ health 
outcomes by SES.  
The next chapter provides a more detailed description of type 2 diabetes and the current policy 
and guidelines. This is then followed by a systematic review of type 2 diabetes and health 
inequalities which identifies what is currently known and gaps in the evidence. The thesis then 
moves on to discuss the methodological considerations for undertaking such analyses, which is 
then followed by the methods and a series of results chapter which address each research 
question in turn. 
 
Indicator
Local 
Number
Local 
Value
Eng 
Avg
Eng 
Worst
England Range
Eng 
Best
Ketoacidosis 25 0.5 0.5 1.3 0.2
Angina 194 4.0 2.9 6.1 0.9
Myocardial Infarction 27 0.6 0.6 1.0 0.2
Cardiac Failure 75 1.6 1.4 3.4 0.7
Stroke 37 0.8 0.6 2.9 0.1
Diabetic Retinopathy Treatments 55 1.1 0.4 2.5 0.0
Renal Failure 25 0.5 0.3 0.9 0.0
Amputation Minor 7 0.2 0.1 0.3 0.0
Amputation Major 4 0.1 0.1 0.2 0.0
BMI 4332 89.0 88.5 37.6 94.2
HBA1C 4441 91.2 90.8 64.4 96.3
Blood Pressure 4516 92.8 93.4 38.2 97.2
Albumin 2889 59.3 61.7 0.5 85.7
Creatinine 4435 91.1 90.8 64.4 95.9
Cholesterol 4422 90.8 89.6 61.8 94.8
Eye Exam 4292 88.1 68.3 28.3 90.1
Foot Exam 4045 83.1 76.2 30.3 88.2
Smoking 3863 79.3 85.9 33.2 94.0
All Care Processes 2267 46.6 39.0 0.3 62.7
NICE HbA1c <6.5 1384 28.4 25.4 10.5 38.7
NICE HbA1c <=7.5 3246 66.7 62.7 39.8 72.2
NICE Cholesterol <5.0 mmol/l 3844 79.0 78.0 70.4 83.1
NICE Diastolic <=75 and Systolic <=135 mm Hg 1480 30.4 30.2 22.6 43.6
Complication 
prevalence 
(%)
Care 
processes 
achieved (%)
Target 
treatments 
achieved (%)
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Chapter 2: Type 2 diabetes 
 
Following the introduction about the rationale for this thesis and its focus on type 2 diabetes 
this chapter provides a detailed description of the condition and how it is managed in general 
terms. The current policy and guidelines which influence its management in England are also 
outlined.  
 
Description 
 
Diabetes is a syndrome of metabolic disorders characterised by inappropriate hyperglycaemia 
resulting from defects in insulin secretion, insulin action, or both [37, 38]. There are different 
types of diabetes mellitus with different etiologic classifications: 
Type 1 occurs as a result of pancreatic islet ß-cell destruction. In the majority of cases this is 
caused by an autoimmune process, the rest are idiopathic. In adults, type 1 diabetes accounts 
for 5% to 10% of all diagnosed cases of diabetes [37, 38, 41, 62, 63]. 
Type 2 refers to a range of defects characterised mostly by insulin resistance or in some cases 
solely ß-cell function, along with an impairment in compensatory insulin secretion. In other 
words, the body either does not produce enough insulin or the body does not effectively react to 
the insulin to keep blood glucose levels at a normal level. It is associated with older age, obesity, 
family history of type 2 diabetes, history of gestational diabetes, impaired glucose metabolism, 
physical inactivity, and ethnicity, specifically South Asian, Afro-Caribbean and Middle Eastern 
decent. In adults, type 2 diabetes accounts for about 90% to 95% of all diagnosed cases of 
diabetes worldwide [37, 38, 41, 62, 63].  
Gestational diabetes is a form of glucose intolerance diagnosed during pregnancy occurring 
more frequently in certain ethnic groups, obese women and those with a family history of 
diabetes. Immediately after pregnancy 5% to 10% continue to have diabetes, usually type 2. 
Those who do not have type 2 diabetes immediately, have a 40% to 60% chance of developing 
type 2 diabetes within the next 5–10 years [37, 38, 41, 62, 63]. 
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Other types of diabetes can also result from specific genetic conditions, surgery, medications, 
infections, pancreatic disease, and other illnesses. Such types of diabetes account for 1% to 5% 
of all diagnosed cases [37, 38, 41, 62, 63].  
The symptoms of type 2 diabetes include tiredness, frequent urination, increased thirst, weight 
loss, blurred vision and frequent infections [49]. The symptoms of insulin deficiency which lead 
to raised blood glucose levels appear more gradually than Type 1 diabetes and usually worsen 
over time and with increasing age, resulting in the need for therapeutic intervention [46].  
 
Characteristics of disease progression 
 
Type 2 diabetes is a progressive disorder. The development from pre-diabetes or impaired 
glucose tolerance stems from ß-cell dysfunction which progresses over time. ß-cell 
deterioration can occur up to 12 years prior to diagnosis and can be well advanced by the time a 
person reaches the diabetes range. It continues to worsen as the disease develops, therefore the 
next stage in patients’ progression of the type 2 diabetes in the need for medication [64]. 
ß-cell deterioration leads to worsening glycaemic control. Continued hyperglycaemia can lead 
to the development of complications, which are discussed in the next section. Medication can 
lower patients’ blood glucose but they do not completely stop the deterioration of ß-cell 
dysfunction as such a patients’ condition will continue to worsen over time [64].  
 
Complications 
 
The greatest risk for diabetes patients is developing CVD which is five times greater than in non-
diabetic patients [63]; this increases to ten times greater than the background population if the 
patient has experienced a previous cardiovascular (CV) event. Cardiovascular diseases include 
coronary artery disease (myocardial infarction and angina), peripheral artery disease (leg 
claudication, gangrene) and cerebrovascular disease (accidents/stroke, dementia) [46, 63].  
Prolonged hyperglycaemia can also lead to microvascular complications: retinopathy, damage 
to eyes that can lead to visual impairment; nephropathy, damage to kidneys that can lead to 
progressive renal failure; neuropathy, damage to nerves that can lead to loss of sensation and 
function. Nerve damage can lead to foot ulcers, amputation, fainting on standing up, abnormal 
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sweating, gastrointestinal problems, difficulties in urination and erectile dysfunction. Other 
problems can include: cataracts, infections, soft issue conditions, skin conditions and mental 
health problems. [46, 49, 63]. 
 
Care 
 
Patients’ glycated haemoglobin (HbA1c) is measured, as part of the NICE recommended care 
guidelines, to indicate their blood glucose control over the preceding three-month period. 
HbA1c is formed when normal haemoglobin A (HbA) reacts with glucose in the blood. The 
reaction is slow and is dependent upon the amount of HbA and glucose. HbA remains in 
circulation for about 3 months, therefore HbA1c (%) is the amount of glycated haemoglobin 
proportional to total HbA over that period. Prolonged, higher levels of blood glucose can lead to 
atherosclerosis: fatty material building up on the walls of arteries. This can narrow or block the 
arteries preventing the efficient circulation of blood around the body which is needed to 
transfer oxygen and fuel to tissues and carry away waste products. This can lead to a number of 
complications [63]. Therefore, ideally, most patients should aim to have a HbA1c level of 
approximately 6.5% or less [46].  
Patients’ risk of developing many of the above complications can be reduced by maintaining 
optimal blood pressure (BP); as such it is also monitored as part of the NICE recommended care 
guidelines. Two values make up the overall BP measurement: systolic (sBP) and diastolic (dBP). 
sBP measures the pressure as the heart contracts to push blood through the body, dBP 
measures the pressure when the heart relaxes to refill with blood. In the general population 
elevated dBP is more common in those under 50 whereas sBP becomes a greater problem with 
increasing age [65]. The higher the blood pressure the more strain the arteries and heart is 
under increasing risk of complications such heart attacks, stroke or kidney disease. For diabetes 
patients, therefore, it is recommended that this should be 130/80 mmHg or lower [46, 63].  
Management of a patient’s lipid profile, the fatty substances in the blood system, is also a 
recommended part of diabetes care as it also plays a vital role in reducing risk of complications. 
There are four aspects a lipid profile: total cholesterol, high-density lipoprotein cholesterol 
(HDL-c), low-density lipoprotein cholesterol (LDL-c) and triglycerides. HDL-c is often referred 
to as the ‘good’ cholesterol as it carries cholesterol away from the cells to the liver where is 
broken down or passed out of the body as waste. Higher levels increase this process. LDL-c, the 
‘bad’ cholesterol, carries cholesterol from the liver to the cells. Too much LDL-c leads to more 
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cholesterol than the cells can use leading to a build-up and the narrowing of the artery walls. 
This in turn increases risk of the vascular complications; likewise with higher levels of 
triglycerides [46]. 
Monitoring patient’s kidney function is another recommended part of the annual, routine 
management of type 2 diabetes. This is to establish as early as possible if poorly controlled 
blood glucose levels has led to nephropathy. One method is measuring the level of creatinine in 
the blood. This is a chemical waste product and is usually relatively constant in a person’s blood. 
High levels, therefore, indicate possible kidney damage. Practitioners are advised to estimate 
the glomerular filtration rate (GFR), that is, how much creatinine is cleared from the blood. This 
is a more precise measure of kidney function. Normal GFR is 100mls/min/1.73m2. A lower rate 
indicates a greater severity of kidney damage [46, 66].  
Practitioners are also advised to measure patients albumin:creatinine ratio annually. This is 
done by measuring the level of protein in patients’ urine. Patients are considered to have 
microalbuminuria if the ratio is greater than 2.5 mg/mmol for men and greater than 3.5 
mg/mmol for women [46].  
Routine monitoring of these health indicators on at least an annual basis forms a major part of 
patients diabetes care. NICE recommend that patients should have the following nine care 
processes recorded on an annual basis: urinary albumin, BMI, cholesterol, blood creatinine, 
HbA1c and BP measured, eyes and feet examined and a smoking review [46, 61]. In addition 
patients should expect to receive individual care planning, the opportunity to attend a diabetes 
education course, access to specialist healthcare professionals including ophthalmologists, 
podiatrists and dieticians.  
 
Treatment 
 
Following a diagnosis of type 2 diabetes, if appropriate, patients are usually encouraged to treat 
their diabetes through changes in their diet and lifestyle. This includes advice on achieving a 
healthy balanced diet, increasing physical activity, losing weight and modifying alcohol intake. 
However, if patients are unable to achieve and/or maintain optimum levels of health outcomes 
introduction of personalised targets and medication are recommended [46].  
Therapies are initiated for patients whose blood glucose is inadequately controlled by lifestyle 
interventions alone. In the first instance metformin is usually prescribed. Sulphonylureas can be 
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considered as a first line therapy if patients are not overweight or obese or if their blood glucose 
levels are particularly high. If blood glucose levels continue to be inadequate or worsens 
another therapy, usually a sulphonylurea, is added. Rapid-acting insulin secretagogues are 
considered for those with an erratic lifestyle and acarbose for those who cannot use other oral 
glucose-lowering medications. Glitazones can be introduced in combination with metformin 
and/or a sulphonylurea when insulin is either unacceptable or inappropriate for various 
reasons. Insulin is usually the last blood glucose therapy to be introduced. Education for both 
patients and their carers should be offered and local arrangements made for the safe disposal of 
sharps.  
Lifestyle modification is also aimed at improving patients BP levels. However, medications are 
initiated if it is not maintained below 140/80 mmHg. In the first instance a once daily, generic 
angiotensin-converting enzyme inhibitor (ACEI) should normally be prescribed. For Afro-
Caribbean patients this is usually introduced with a diuretic or a generic calcium channel 
blocker. In patients with a continued intolerance of ACEIs, a substitution for an angiotensin II-
receptor antagonist is recommended. Other therapies are introduced if BP levels do not reduce 
or deteriorate. These include alpha-blockers, beta-blockers, or potassium-sparing diuretic. 
These therapies are prescribed for patients who have kidney damage. 
Unless patients have a low CV risk all patients aged 40 years old and over should be prescribed 
a statin. Prescription of a fibrate is recommended for patients whose triglyceride levels are 
continually above 4.5 mmol/l, or between 2.3-4.5 mmol/l despite statin therapy being initiated. 
Aspirin is offered to patients as an antiplatelet therapy [46]. 
These medications should be all continually reviewed in reference to how patients’ health 
develops, both in terms of intermediate and long term complications. Patients’ personal 
circumstances are also taken into consideration when treatments are being initiated [46]. 
In summary this chapter so far shows how the management of type 2 diabetes is very complex 
[46]. The next section outlines the current English national policies and guidelines, detailing 
some of the specific healthcare recommendations.  
 
National policies and guidelines 
 
This section describes the recent developments which have led to the current policies and 
guidelines for diabetes, with a particular focus on type 2 diabetes and the English context.  
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In 1997 ‘The New NHS: Modern, Dependable’ white paper introduced two initiatives that have 
influenced diabetes care in the UK in recent years. Firstly, the National Institute for Health and 
Clinical Excellence (NICE), who now lead on clinical and cost-effectiveness and provide 
guidelines for health and social care services, and the National Service Frameworks (NSF), 
which provides evidence-based strategies for consistent access and care quality nationally [67].  
The National Institute for Health and Clinical Excellence was established in 1999 known as the 
National Institute for Clinical Excellence with the remit of reducing variation associated with 
NHS treatments and care. The organisation then merged with the Health Development Agency 
in 2005 to become National Institute for Health and Clinical Excellence as the prevention of ill 
health and the promotion of good health were incorporated into its remit. Following the Health 
and Social Care Act 2012, it became a Non Departmental Public Body becoming accountable to 
the Department of Health and taking on responsibility of developed social care guidance and 
quality standards under its current title [68].  
The ‘National Service Framework (NSF) for Diabetes: Standards’ was published in 2001. Twelve 
standards and key interventions were outlined in the document designed to improve care by 
being patient focused. It was developed in partnership with a multidisciplinary team drawing 
upon skills and knowledge across services. Furthermore, the NSF for Diabetes aims to ensure 
that services are equitable according to individuals’ needs and outcomes, that is narrowing the 
gap between patients with the worst outcomes and the rest [52]. The ‘NSF for Diabetes Delivery 
Strategy’, 2003, was designed to support the achievement of the ‘Standards’ by 2013 the key 
elements of which were expected to be undertaken by PCTs. This included setting up a local 
network to champion the needs of local people, reviewing local baseline data and implementing 
local arrangements, participation in local and national audits, and developing education and 
training programmes for staff involved in diabetes care [49].  
The delivery strategy is underpinned by the clinical framework for diabetes developed  by NICE 
and it is recommended that they should be used together with the most up to date information 
[49].  
In March 2010, NICE updated their guidelines ‘The management of type 2 diabetes’. This 
replaced those published in 2008. The 2008 guidelines were an updated version of individual 
guidelines on diabetes care on retinopathy, renal disease, blood glucose and management of BP 
and blood lipids all published in 2002 and other NICE technology appraisals [69]. The key NICE 
recommendations, which include aspects of care and treatment targets, form the basis of the 
National Diabetes Audit (NDA). There are nine care processes which every diabetes patient 
should have measured and recorded annually. These are as follows: HbA1c, BMI, BP, albumin, 
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creatinine, cholesterol, eye exam, foot exam and smoking status. Each are chosen on the basis 
that they are risk factors or indicators of vascular damage and direct the types of interventions a 
patient requires [46, 63]. In addition, treatment targets are set to ensure that patients’ health 
outcomes are at safe levels. The treatment targets are as follows: HbA1c of either <6.5% or ≤ 
7.5% depending upon the health and treatments of the patients, cholesterol of <4.0 mmol/l and 
a target for BP of ≤ 140/80 for those without recorded eye, kidney or vascular disease or ≤ 
130/80 for those with recorded eye, kidney, or vascular disease. The NDA also records the 
prevalence of the following complications: angina, myocardial infarction, cardiac failure, stroke, 
diabetic retinopathy treatments, renal failure and amputations [61].  
In March 2011, NICE published quality standards for clinical best practice for adults with 
diabetes. The aim of which was to outline high-quality and cost-effective care to be delivered 
collectively to improve effectiveness, safety and experience for patients [46]. The introduction 
of these standards has been praised by patient advocates for emphasis on involving patients in 
their own care but that they should be wider to incorporate more aspects of patients care and 
evaluated to see whether high quality is achieved [63]. Other relevant NICE guidelines include 
TA248: Diabetes (type 2) – exenatide (prolonged release), CG119: Diabetic foot problems – 
inpatient management, CG87: Type 2 Diabetes – newer agents (partial update of CG66), CG66: 
Type 2 diabetes (partially updated by CG87) [46] and CG10: Type 2 diabetes – foot care [70].  
In the UK, another important initiative associated with diabetes care is the ‘Quality and 
Outcomes Framework’ (QOF) which is part of the General Medical Services contract [71]. QOF 
was one of the consequences of the Labour government’s aim to expand chronic disease 
management into primary care [58]. The framework is a voluntary annual reward and incentive 
programme established in general practices across the UK during 2004 with the aim to reward 
the provision of good quality care and improve standards [47, 72]. Whilst QOF has all the same 
care processes that NICE recommends for the management of type 2 diabetes featured in some 
form, the care targets vary. In particular, there are lower thresholds of intermediate outcomes 
in order for patients’ results to count towards the payments. Another drawback of QOF as an 
incentive to improve standards and quality of care is the ability of practices to use ‘exception 
reporting’ so that they are not penalised financially for various criteria including patients who 
do not attend for review, or refuse treatments and/or investigations [47]. The criticism of this 
approach is that patients could potentially be inappropriately excluded in order for practices to 
boost their payments. Also it has been shown that exception reporting is associated with the 
deprivation of patients. As a result the added incentive to improve the quality of care for 
“exempted“ patients, by implication the most deprived patients, circumvented leading to no 
improvements in standards in comparison to the included patients [73]. 
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This chapter has provided a broad overview of type 2 diabetes and the prominent guidelines 
and policy recommendations regarding the management of the condition in England. The 
subsequent secondary analysis examines whether interventions related to the type 2 diabetes 
care pathway are delivered equitably and whether these intervention differ in their association 
with health outcomes by patients SES, that is, the identification of potential IGIs. The next 
chapter features the systematic review which searched for and assessed the current evidence 
surrounding health inequalities associated with type 2 diabetes. 
 
Non-diabetes specific interventions 
 
Interventions aimed at improving population health, particular increasing healthy behaviours, will 
also impact on the prevention of type 2 diabetes and the management the condition in diagnosed 
patients [references].   
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Chapter 3: Are there inequalities associated with interventions to 
manage and treat Type 2 diabetes? 
 
Following the introduction to the rationale and contextual information, this chapter presents a 
systematic review of the current evidence surrounding health inequalities associated with type 
2 diabetes. The review had two main aims. The principal aim was to answer the chapter title  
question: Are there inequalities associated with interventions to manage and treat Type 2 
diabetes? The secondary aim of the review was to identify areas where evidence was lacking 
and if the methodology of previous research could potentially be improved upon in order to 
develop the research questions outlined at the end of the chapter. 
 
Methodological considerations 
 
A previous systematic review published in 2010 examined inequalities associated with diabetes 
and concluded that there was evidence of inequalities in treatment, control and service 
utilisation by ethnicity, socioeconomic inequalities in diagnosis and control, but no evidence of 
gender inequalities [74]. The present review revises and updates the 2010 review. Here the 
review focuses on type 2 diabetes only but with a more inclusive search strategy. In addition, a 
different approach was taken to the critical analysis of the final sample which enabled the 
quality of the methodology and design to be examined separately and graphically synthesised.  
This systematic review focuses on inequalities in the management and treatment of type 2 
diabetes from the point of diagnosis. Interventions associated with prevention were not 
included as they are often provided by organisations and services not specifically orientated to 
the management and treatment of diabetes [75]. The eligible studies were also limited to 
patients aged 16 and over with type 2 diabetes as adult services are often delivered differently 
to those provided for children and adolescents [76]. Studies examining inequalities in mortality 
were also excluded as this was the subject of recent review [44]. Due to the numerous related 
health complications that could be investigated as a consequence of type 2 diabetes studies 
were further limited to those examining outcomes which are routinely monitored, as 
recommended by NICE Type 2 diabetes guidelines [46]. 
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Like the 2010 review, the search strategy was limited to studies which were undertaken in 
countries belonging to the Organisation for Economic Co-operation and Development (OECD) 
with universal healthcare. This approach was chosen as the health systems and high economic 
development of these countries means that they are in a better position to prevent health 
inequalities than other countries [74]. The search was limited from 1st January 1998 to the date 
of abstraction, 6th August 2012. The start date was chosen as it was the year of the Acheson 
Report [77], an influential publication which shaped the subsequent health inequalities agenda 
both in the UK and worldwide. The 2010 review searched between 1967 and 2007. However, 
only one study prior to 1998 was included in the final sample and this focused on type 1 
diabetes only.  
The search strategy adopted here was chosen for its arguably more inclusive approach. The 
previous review used Medical Subject Headings (MeSH) and their equivalent terms [78]. It has 
been argued that using these terms leads to a more efficient search strategy than free text 
searches as they limit the results to specific subjects and their related terms [79]. However, this 
approach is reliant on these terms being assigned to studies and for this to be undertaken 
correctly and in a timely manner. There can often be a time delay in adding subject headings of 
up to three months therefore searches using subject headings may miss the most up to date 
research. A further problem, particularly with this review, is that the subject matter is quite 
broad and specific subject headings may not appropriately capture the topic under review [79]. 
A free text approach, therefore, was used instead. However, to ensure that the hits were 
relevant, the search was limited to studies which featured “diabetes” or “diabetic” in the title 
and/or abstract in common with the 2010 review. This is necessary as the drawback to free text 
searches is its low sensitivity. That is, they tend to generate a lot of hits, due to capturing articles 
containing the free text words, even if they are unrelated to the subject matter [80].   
The data from the studies were extracted and entered into Access 2007 [81] following an 
adapted version of a data extraction form used in another review examining inequalities 
associated with health interventions [82]. Study quality was assessed using the ‘Data Collection 
Instrument and Procedure for Systematic Reviews in the Guide to Community Preventive 
Services’ (CPS). This instrument was chosen as it was designed to be flexible enough to evaluate 
the reliability and validity of a diverse range of study designs and intervention types [83]. Other 
common quality assessment tools would have had to be considerably adapted specifically for 
this review. The 2010 review used the STrengthening the Reporting of OBservational studies in 
Epidemiology (STROBE) Statement.  However, this tool assesses the reporting quality rather 
than methodological quality of observational studies [84]. 
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The most distinct change from the previous review is in the use of ‘harvest plots’ to graphically 
synthesise the data. The key strength of harvest plots is that it can accommodate heterogeneous 
studies, both in terms of outcomes and quality of study design, therefore making use of all the 
available evidence. The graphical plots can display multiple of aspects of each of the studies 
allowing it to retain the immediacy of interpretation of the original ‘forest plot’ [85].  
 
Methods 
 
Search strategy 
 
The search strategies are outlined in Appendix A. The databases searched were PubMed, 
Excerpta Medica database (EMBASE), Cumulative Index to Nursing and Allied Health Literature 
(CINALH) and Applied Social Sciences Index and Abstracts (ASSIA). All the ‘hits’ were stored in 
Endnote X6 [86].  
 
Study selection and inclusion criteria 
 
Studies were included if they met the following criteria: 
i. It was a primary study. 
ii. The study analysed the association between one or more population sub-groups 
based on gender, ethnicity including immigrant versus native populations, or 
socioeconomic position, including individual and area-based measures, and any one 
aspect of type 2 diabetes interventions that are part of the patients’ usual care 
available.  
These were subsequently grouped into 5 categories: diagnosis, treatment, control, 
monitoring, services which are normally available for type 2 diabetics. This was 
done to provide a more coherent discussion of the findings and more concise 
harvest plots. Prevention, screening and education programmes were excluded as 
this review focused from the point of diagnosis onwards on services typically 
delivered within primary and secondary care settings. 
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iii. The primary health outcomes, if included in study, were those routinely monitored 
by health care professionals, as recommended by NICE Type 2 diabetes guidelines 
[46]. 
iv. These are broadly described as follows: blood glucose, plasma glucose, blood 
pressure, blood lipids, eye damage, nerve damage, kidney function and 
cardiovascular disease [46]. 
v. Had quantitative outcomes in terms of access to, uptake of, or outcome of the 
interventions 
vi. Patients of the primary studies had to be 16 years old or older with type 2 diabetes 
vii. The study had to be undertaken in community settings, that is, participants were not 
in residential institutions such as care homes or prisons.  
viii. Carried out in an OCED countries with universal healthcare: Australia, Austria, 
Belgium, Canada, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, 
Japan, Luxembourg, The Netherlands, New Zealand, Norway, Portugal, Spain, South 
Korea, Sweden,  or United Kingdom (England, Northern Ireland, Scotland or Wales) 
[87]. 
ix. Published in English  
x. Published from 1st January 1998 to 6th August 2012, the date that the databases 
were searched.  
 
All study designs with original results were included. Articles not related to type 2 diabetes, not 
original (e.g. narrative reviews, letters, editorials, opinion articles etc.) and qualitative only 
studies were excluded. Titles and abstracts were initially assessed for inclusion. The full texts of 
those which met the inclusion criteria were then read; those which did not meet the criteria 
were then excluded leaving the final sample. 
 
Data extraction and quality assessment 
 
The data from the studies were extracted and entered into Access 2007 [81] following an 
adapted version of the data extraction form [88]. Study quality was assessed using the ‘Data 
Collection Instrument and Procedure for Systematic Reviews in the Guide to Community 
Preventive Services’ (CPS) [83].  
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The CPS tool has five components relating to the descriptions, sampling, measurement, data 
analysis and the interpretation of results. In order to produce graphical syntheses of the data for 
this review, a scoring system was created in which a point was awarded if the study covered the 
relevant aspects of each component, with a maximum score of five. The suitability of the study 
design was assessed using a further adaption of the scale  developed by Thomas et al [88]: 1 = 
cross-sectional studies; 2 = more than one measurement at different time periods and no 
comparative group; 3 = more than one measurement at different time periods with a 
comparative group. 
 
Data synthesis 
 
The interventions were grouped into the following categories: diagnosis, monitoring, control, 
treatment or services. Due to the diverse range of interventions that can affect the management 
and outcomes of type 2 diabetes, the majority of studies fall into more than one category and 
therefore many studies were included more than once in the data synthesis. The hypothesis-
testing approach to data synthesis devised by Thomas et al [88] was used to examine the 
differential effects of each group of interventions separately. Each study was categorised 
depending upon which of the following hypotheses its findings most supported for each 
intervention: 
The null hypothesis was that for any given demographic or socio-economic characteristic there 
are no inequalities in the effectiveness of the intervention. 
The hypothesis of negative impact on social inequalities, defined as evidence that groups with a 
higher SEP gain the greatest benefit from the intervention. 
The hypothesis of positive impact on social inequalities, defined as evidence that groups with a 
lower SEP gain the greatest benefit from the intervention. 
Though not ideal, non-white ethnicities and immigrants, women and patients described to be in 
rural areas were considered the group with the more disadvantaged social group in respect to 
their counterparts. 
The results were graphically synthesised using the harvest plot method developed by Ogilvie et 
al [85] and used in two previous systematic reviews [82, 89]. In a harvest plot the rows consist 
of different axes of inequalities and three columns reflect the three competing hypotheses. Each 
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bar refers to one comparison from one study with the height of the bar indicating the suitability 
of study design and the number annotated above it indicating the methodological quality [85]. 
In this review a series of harvest plots were produced for each group of interventions using the 
data visualisation software Tableau Public 6.0 [90]. In the harvest plot each bar refers to one 
comparison from a study; studies that examined more than one intervention and more than one 
inequality are represented through multiple bars. The height of the bar represents the 
suitability of study design; here there are three possible heights with the tallest being the most 
suitable. Each bar is annotated with a number representing the methodological criteria which 
could be from zero to five, with five indicating the greatest quality. In this review, the colour of 
the bar indicates the consistency of the results: dark blue indicates that all or the vast majority 
of the results in that study support that hypothesis, the light blue indicates that there are 
findings which conflict with the overall result. If all of the outcomes in the study are in conflict it 
is marked down as representing the null hypothesis. A judgement was made on a case by case 
basis as to whether these conflicting findings support the null, negative or positive hypotheses. 
A narrative review accompanies each graphical display.  
 
Results 
 
2,758 references were identified: 938 in PubMed, 1737 in EMBASE, 213 in CINAHL and 99 in 
ASSIA with 1088 duplicates. Of these 33 met the inclusion criteria and were critically assessed. 
Many of the included analyses examined more than one intervention and/or inequality, and 
therefore appear in the graphical displays and narrative reviews below multiple times. 
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Figure 5: Flow diagram of study selection and exclusion 
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Diagnosis 
 
Figure 6 is the first of the five harvest plots and is the least populated. Only three studies met 
the inclusion criteria which examined if there were inequalities in the diagnosis of type 2 
diabetes. The focus of these studies was inequalities in the severity of diabetes related 
symptoms at diagnosis [91] and being clinically diagnosed or not [92, 93]. Two studies collected 
data via surveys [92] [93]. One survey randomly recruited participants from general 
practitioners’ lists in the UK [92]. The other survey recruited participants from the resident 
population of Augsburg, Germany [93]. A health service database held by Southampton 
University NHS Trust, UK was used for the other study [91]. 
 
Figure 6: Evidence of inequalities in the diagnosis of type 2 diabetes patients 
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In the UK, analyses of the results of newly diagnosed patients’ first retinal screening visit found 
no differences in the levels of deprivation of patients who had retinopathy compared to those 
who did not. Interestingly, an additional analysis of those who had a longer delay between 
diagnosis and first screening (24-72 months) found that those who had retinopathy were more 
affluent than those who did not; however, statistical significance levels were not reported [91]. 
This study only used univariate analyses and therefore did not control for multiple variables 
simultaneously.  
A nationwide UK women-only study found no inequalities by childhood or adult SEP in having 
undiagnosed diabetes, even after controlling for lifestyle and anthropometric indicators. There 
was a longitudinal aspect of this study. However, it was examining hazard ratios for all-cause 
mortality and therefore did not meet the inclusion criteria. In addition, it only compared non-
diabetic women with diabetic women and did not keep those undiagnosed at baseline as a 
separate group. As such it was not possible to assess the long-term implications of the potential 
delay in diagnosis [92]. After controlling for lifestyle, anthropometric and clinical characteristics 
a German study found no inequalities in being diagnosed or not by income or education for men 
and women. No inequalities were found by occupation status in being diagnosed for men, but 
there was a statistically significant association showing women with low occupational status 
were more likely to have undiagnosed diabetes than women with high occupational status [93]. 
The two surveys found conflicting evidence for inequalities by SEP in being diagnosed or not for 
women; however, the SEP measures used in these two studies were different.  
The results presented here favoured the null hypothesis indicating that there were no 
inequalities associated with timely diagnosis of type 2 diabetes. However, there were only a 
small number of studies using cross-sectional study designs focusing on different population 
groups. As such, additional evidence is required to reinforce the current evidence.  
 
Monitoring by health professionals 
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Figure 7: Evidence of inequalities in the monitoring of type 2 diabetes patients  
 
Six studies investigated inequalities associated with the monitoring of type 2 diabetes between 
2006 and 2012, recruited from a variety of sources (Figure 3)[94-99]. Studies were undertaken 
in Britain [99], Sweden [95], Canada [96, 97] and New Zealand [94, 98].  
Five studies examined inequalities in the monitoring of clinical characteristics by healthcare 
professionals by ethnicity [94, 96-99] and two by gender [95, 98]. Of these six, two had samples 
exceeding 10,000 participants. However, they had different results regarding ethnicity: the 
study based in Tayside, Scotland found a statistical significant association showing South Asians 
were more likely to have a structured review than non-South Asians patients. There were no 
statistically significant relationships between ethnicity and other checks except for BMI which 
was more likely to be recorded among South Asian women than non-South Asian women [99]. 
In contrast, the New Zealand study’s statistically significant results showed that more New 
Anna Christie Page 53 
Zealand Europeans than Maori and Pacific Islanders had both foot checks and retinal 
examinations. These analyses compared differences in proportions using chi-square tests 
without adjustment [94]. Another New Zealand study using Waikato Regional Diabetes Service 
data from three general practices found no statistically significant differences between both 
gender and ethnic groups for the odds of having had retinal screening over a two year period. 
Utilising marginal logistic regression, these analyses included ethnicity, gender and duration of 
diagnosis in the final model and also adjusted for the correlation between patients from the 
same practice. This adjustment suggests that patients’ practice affects the odds of having retinal 
screening recorded. It would have been interesting to know if there were any statistically 
significant inequalities prior to this adjustment to explore this suggestion [98]. Only the two 
New Zealand based studies were comparable in terms of outcomes measures and ethnic groups 
[94, 98]. Ralph-Campbell et al examined differences in screening activities between aboriginal 
and non-aboriginals in Northern Alberta at baseline and 6 months later. Of the five activities 
Aboriginal patients were less likely to have their kidneys checked at baseline and eyes checked 
at six month follow up than non-Aboriginals [97]. Shah et al compared differences in process 
measures between Chinese, South Asian and the general population and found that Chinese 
patients were less likely to have their feet examined  compared to the general population but no 
other significant differences [96]. Both these studies were of high methodological quality.   
Two studies examined inequalities in monitoring by gender but had different results. Using 
adjusted odds ratios, the New Zealand based study found no significant differences in receiving 
retinal screening by gender [98]. In univariate analyses in Sweden, women had poorer 
recording levels of HbA1c and blood lipids compared to men [95]. 
Overall, the results suggest that there were no inequalities associated with the monitoring of 
patients health by ethnicity. In contrast, the most robust study suggests that there were 
inequalities associated with monitoring by gender. Most studies achieved a methodological 
quality score of four or five but only one study used repeated measurements. The harvest plot in 
Figure 7 highlights that the majority of these studies examined inequalities in monitoring by 
ethnicity with none analysing differences by measures of SEP or area type therefore research is 
required to fill these gaps in the evidence. 
 
Treatment  
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Figure 8: Evidence of inequalities in the treatment of type 2 diabetes patients 
 
Between 2002 and 2012, fourteen studies examined inequalities associated with treatment for 
blood glucose control and/or associated diabetic health problems [92, 94, 100-111]. Seven of 
these studies had inequalities in treatments as the main focus of their study [92, 100-102, 106, 
110, 111]. All participants were recruited through health services in seven different countries, 
with three studies based in the UK [92, 107, 109]. The majority of the evidence found no 
inequalities in the treatment of type 2 diabetes and its associated complications. 
Of the seven studies which had treatments as the main focus of their study, three utilised repeat 
measurements [92, 100, 110]: An examination of medication involved in the CV risk 
management over time found no statistically significant inequalities between rural and urban 
participants in Australia [110]. Whilst this study adjusted for age and sex and used multilevel 
analyses to account for any potential clustering within practices and divisions, the authors did 
not take into account the clinical characteristics that determine the receipt of particular 
treatments. A UK prospective study looking at insulin use found a non-significant trend that 
southern European participants were more likely to be taking insulin after four years of follow-
up. Yet found no differences by ethnic groups in time to requirement for insulin; nor the 
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progression to insulin following adjustment for demographic and health status in the Cox 
proportional hazards model [100]. Another UK prospective cohort study found no evidence of 
inequalities in being managed by diet alone by childhood or adult SEP [92].  
The cross-sectional studies which had inequalities in treatment as part of the main focus of their 
study all examined differences by gender [101, 102, 106, 111] and with one by ethnicity and SES 
as well [101]. The New Zealand based study controlled for CV risk when investigating 
inequalities in treatment. Investigators found no evidence of inequalities by ethnicity and 
gender but patients from low status groups were less likely to receive treatment, with statistical 
significance as measured by 95% confidence intervals. However, this study had a relatively low 
methodological quality score [101]. A German study also controlled for CVD risk factors when 
examining inequalities in antihypertensive agents, lipid-lowering drugs and oral anti 
hyperglycaemic agents (OHAs) or insulin by gender and found in the main no significant 
differences. This study did find that women received significantly less lipid-lowering drugs 
amongst those with CVD, but not amongst those without CVD [102]. In Italy, analyses of 10 
hospital-based outpatient clinics found that women were more intensively treated than men, 
after controlling for obesity and age [111]. In contrast, Kramer et al found that it was men who 
were more intensively treated when controlling for a more extensive set of covariates [106].  
The other studies examined differences in treatment uses, either as part of an overall 
examination of diabetes care or in describing the socio-demographic and clinical characteristics 
of the studies’ patients [94, 103-105, 107-109]. The overall standard was relatively low with the 
majority of these studies having a methodological quality of three or less and only one adjusted 
the analysis to consider the health status of the participants [109]. Sedgwick et al examined the 
differences in insulin use between ethnic groups in south London and found no statistically 
significant differences before or after adjustment for demographic, socio-economic and health 
status indicators [109]. Of the rest of the studies only one analysis found inequalities in 
treatment. However, it was not possible to establish whether the findings reflect differences in 
access to treatment or differences in clinical profiles [105].  
The majority of the studies supported the null hypothesis i.e. that there are no inequalities 
associated with treatments for type 2 diabetes and its related complications by ethnicity [94, 
101, 107, 109], gender [101-104], rural/urban areas [110] or other composite measures of SEP 
[92, 108]. However, three studies found evidence for inequalities in treatment by individual 
measures of SEP [101] and gender [106, 111]. In addition, the strongest study design, which 
examined inequalities by ethnicity, supported the negative hypothesis [100]. Overall, the 
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harvest plot shows that whilst there has been varied investigation into inequalities in treatment 
interventions, there are still areas of inequalities that have not been sufficiently explored. 
 
Services 
 
Figure 9: Evidence of inequalities in uptake of and access to services for type 2 diabetes patients 
 
 
Eight studies examined inequalities in the access to and uptake of diabetes related services 
available to diabetes patients between 2003 and 2012 [97, 103, 106, 109, 110, 112-114] (Figure 
9).  
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One of the two studies using repeated measurements examined inequalities in referrals to 
ophthalmologist and optometrists and attendance at other allied professionals (diabetes 
educators and dieticians) between rural and urban patients in Australia general practices. 
However, following adjustment for age, sex and levels of care the only significant result was 
found in 2000, and not 2002, where urban patients were more likely to visit ophthalmologist 
and optometrists compared to rural patients [110].  
Univariate analyses between Irish and immigrant patients attending the same diabetes clinic 
found a statistically significant result that the latter were more likely to have never attended a 
dietician [114]. A London based cross-sectional survey found patients from black African and 
black Caribbean ethnicities were significantly more likely to visit a dietician than white patients 
after adjustment for demographic, socio-economic and health status variables. This study also 
found statistically significant results showing that black Caribbean patients were more likely to 
have visited a diabetes nurse and black African patients more likely to have visited an 
ophthalmologist than white patients. These findings remained significant following the same 
adjustments [109]. 
Findings from two diabetes education centres in Canada of newly referred patients found that 
there were no gender inequalities in access to patient services and continual access to services, 
but a statistically significant result showed women were more likely to have a professional 
health care team support for diabetes than men [103]. Another Canadian, longitudinal study 
examined inequalities between Aboriginal and non-Aboriginal patients and found no 
inequalities at baseline and six month follow up in terms of physician visits, both in general and 
specifically for diabetes. However, the authors did find that Aboriginal patients had a higher 
average number of physician visits overall at baseline after adjusting for covariates [97]. 
Inequalities in physician visits was also examined in a German study and found no differences 
by gender [106]. In contrast, multivariate analyses of patients in the Basque country, Spain 
found statistically significant relationships for patients of lower SES to have had more primary 
care consultations than affluent patients and for women having more than men of the same 
socio-economic group. Duration of diabetes was adjusted for in the analyses. Whilst this 
adjustment was arguably an appropriate decision because diabetic patients are likely to develop 
more complications over time it does not account for those with more uncontrolled diabetes 
and for health problems which are not a result of their diabetes and require more contact with 
health services [113]. In the UK, a British sample of Pakistani Moslems in Manchester found that 
there were no gender differences in terms of place of care [112]. However, these studies lacked 
in depth analyses as they only used univariate techniques.  
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In terms of inequalities associated with services there was a fairly even spread of evidence for 
negative, positive and null hypotheses by a range of population groups. However, the studies 
overall were quite heterogeneous in terms of which services were under investigation.  
Therefore, more investigations into this area are needed to reinforce these findings.  
 
Control 
 
Studies which examined patients intermediate and long-term complications were grouped into 
this category as patients’ health was regarded as proxy measurements of the effectiveness of the 
management of type 2 diabetes.  
Thirty-one out of the thirty three studies which met the inclusion criteria contained analyses of 
inequalities in patients’ control over their condition as measured by intermediate clinical 
characteristics [92, 94-108, 110-122] and diabetes morbidities [99, 100, 103-109, 112, 113, 
116, 121-123] dated from 1998 to 2012 (Figure 10).  
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Figure 10: Evidence of inequalities in control for type 2 diabetes patients 
 
 
The majority of studies in this area examined inequalities by ethnic groups [94-101, 105, 107, 
109, 114-116, 119, 122, 123]with the findings tending to support the negative hypothesis [94, 
98, 100, 101, 107, 115, 119, 123]. The groupings of ethnicities made direct comparisons 
difficult; however, three New Zealand studies examined inequalities in control by similar ethnic 
groups: European, Maori, Pacific, Asian, Indian and Other. Kenealy et al, using Cox proportional 
hazards model, found that Maori patients had a greater chance and east Asian patients had a 
lesser chance of having a CV event compared to European and Other patients combined over a 
five year period controlling for other risk factors [116]. Compared to other studies, this had a 
relatively strong design and methodology with consistent results. Agban et al looked at various 
intermediate outcomes using two-tailed paired t-tests and McNemar Chi-Square and found no 
consistent results. Of the groups that had a statistically significant two year change in their 
mean HbA1c levels, European and Maori patients’ health had declined whereas Pacific and 
Indian patients had improved. Pacific patients made greater improvement in sBP than European 
patients. Pacific patients also had greater improvements in total cholesterol compared to 
European and Asian patients. Both these findings reached statistical significance. No statistically 
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significant differences were found between the ethnic groups in the two year change of dBP or 
HDL-c [115]. A study examining inequalities in CV risk by ethnicity outlined the demographic 
and clinical characteristics of participants. However, no statistical tests were conducted to 
establish whether these characteristics were significantly different, therefore the results cannot 
be interpreted [101]. This was reflected in the study achieving a low score for its methodology. 
Three other studies conducted in New Zealand had statistical significant evidence supporting 
the negative hypothesis using diverse statistical techniques. Univariate analyses found that 
Maori and Pacific patients had worse intermediate outcomes [94]; Cox proportional hazards 
model showed that Maori patients had higher chances of having dialysis or kidney 
transplantation [123]; and adjusted odds ratios Maori, Asian and ‘Other’ ethnic groups had 
increased odds of having HbA1c greater than 8% all in comparison to New Zealand European 
patients [98].  
Three British studies examined intermediate outcomes and complications of South Asian 
patients in comparison to other ethnic groups had contrasting results: in multiple logistic 
regression analyses there was a statistically significant relationship between ethnicity and eye 
complications with South Asians more likely to have any retinopathy and maculopathy 
compared to white patients. There was no significant relationship between ethnicity and non-
sight-threatening retinopathy [124]. The other study examined a range of outcomes and the 
statistically significant findings showed that South Asian patients were more likely to have 
retinopathy and less likely to have hypertension compared to non-South Asian patients. When 
examining genders separately South Asian patients had a higher HbA1c and lower sBP in both 
men and women. South Asian men had lower BMI than non-South Asian men [99]. This was 
categorised as supporting the null hypotheses, that is, there are no inequalities in diabetes 
control by ethnicity, with conflicting results to reflect the inconsistent findings. A national UK 
longitudinal study aimed to examine inequalities in incidence of myocardial infarction rates 
between white, South Asian and Afro-Caribbean type 2 diabetes patients and found that after 
adjusting for relevant covariates that Afro-Caribbean patients had a lower risk of MI than white 
patients whereas there was no significant difference between South Asian and white patients 
[122]. Overall, the statistical confidence of these results was likely to have been reduced due to 
the small sample of South Asian patients which also limited the possibility for further stratified 
analyses. Results reaching statistical significance from a London based analysis found that black 
Caribbean patients were more likely to have hypertension and less likely to have had a heart 
attack and other heart problems compared to white participants. Mostly, however, there were 
no inequalities between black African and white patients and, as such, this comparison 
supported the null hypothesis with conflicting findings [109].  
Anna Christie Page 61 
The remaining seven studies examining inequalities between ethnic groups were mixed in 
terms of which ethnic groups were under investigation and what the results were [95-97, 100, 
105, 114, 119]. However, two of these studies had consistent findings using longitudinal data, 
therefore had relatively stronger study designs than other studies, but examined different 
ethnic groupings. A study based in Germany found that immigrants had poorer HbA1c both at 
baseline and at 12 months follow up compared to natives [119]. The results from a Canadian 
study supported the null hypothesis and found no significant differences in intermediate 
outcomes both at baseline and 6 months between aboriginal and non-aboriginal patients 
following adjustments of other covariates [97]. 
Several of the studies also examined gender inequalities [95, 98, 102-104, 106, 111-113, 120, 
121, 123]. The results were inconsistent but the majority supported the negative hypothesis 
[98, 104, 106, 112, 113, 120]. However, the overall quality of these studies was quite mixed and 
the majority had a cross-sectional study design. Statistical significant results from univariate 
analyses revealed that women were less likely to have retinopathy and heart disease [112] and 
lower predicted risk of non-fatal and fatal coronary heart disease, fatal coronary heart disease 
and non-fatal and fatal stroke [125]. However, one of these analyses found that women had 
higher absolute risk of coronary heart disease over time but there was variation in the statistical 
significance of other risk factors [120]; and the study found no gender inequalities in diabetes 
symptoms or related health conditions [126]. An univariate analyses of a cross-sectional survey 
in Italy found that women tended to have poorer CV risk factors than men [111]. In contrast 
univariate analyses of patients in Germany found that rates of CHD, intermittent claudication, 
stroke and nephropathy were statistically significantly higher in men than women [106]. The 
studies which utilised multivariate analyses to take into account potentially confounding 
variables, also found conflicting results. The findings which achieved statistical significance 
showed that women were less likely to have HbA1c greater than 8% [98], less likely to have 
macroangiopathy and nephropathy but not neuropathy and retinopathy [127], had worse 
glycaemic control, sBP and LDL-c cholesterol levels in patients with CV disease [102]. Another 
analysis found that non-South Asian women had higher sBP and BMI though most results from 
this study found no gender inequalities [99]. Another study found that overall women were 
significant less likely to achieve a range of treatment targets compared to men [95]. Three other 
studies found no gender inequalities in diabetes symptoms and related health conditions [126], 
renal events [123]and micro and macro vascular complications [121].  
The included studies which examined inequalities in control by education, income and 
occupational status all used a cross-sectional design [95, 108, 114, 117, 118, 121] with only two 
of the five studies having a methodological score of four or five [95, 108]. Univariate analyses 
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found that no inequalities in control by income in an Irish study [114] and by educational level 
as a result of a diabetes education programme in Germany [128]. The other four studies used 
multivariate analysis techniques: another German study looked at a range of health outcomes by 
education level, occupation status and socioeconomic status. It found no evidence of inequalities 
apart from a few exceptions which reached statistical significance: lower education, SES and 
occupational status participants were more likely to fail to reach HbA1c target of < 6.5% than 
their respective comparison groups and only the prevalence of diabetic retinopathy showed a 
statistically significant inverse association to SES in one of the two data sources the authors 
used. No other statistically significant associations were found with other measures [129]. A 
study in Northern Ireland of patients at a hospital diabetes clinic examined health indicators by 
three different socio-economic groups. The authors found no evidence for differences in 
glycaemic control, BP or cholesterol by income, deprivation or education levels, except for 
higher levels of cholesterol tended to be associated with those living in more deprived areas 
[118].  In Sweden, there were no statistically significant differences in micro and macro vascular 
complications by education, as measured by 95% confidence intervals [121]. Interestingly a 
second Swedish study found evidence that patients with 10-12 years of education were more 
likely to achieve intermediate treatment targets compared to those with more than 12 years yet 
patients with lower incomes were less likely to achieve these targets compared to those in the 
highest income bracket [95]. 
In addition to those already mentioned above three further studies in the UK [92], Spain [113] 
and New Zealand [116] used composite measures of SEP. Statistically significant results from 
the Spanish analysis found that patients in more deprived areas had poorer glycaemic control 
and higher levels of cholesterol, and were more likely to suffer from macroangiopathy than 
patients from less deprived areas. No statistically significant differences were found in the odds 
of having neuropathy, retinopathy or nephropathy [113]. The findings from the New Zealand 
study showed only a weak association between participants’ deprivation level and increased CV 
risk, while having a strong study design and large sample [116]. The UK study, following 
adjustment for smoking and exercise, found that both childhood and adult SEP were adversely 
related to fasting insulin, triglycerides, HDL-c-c and BMI, however, this data was not shown in 
the paper [92]. Only two longitudinal analyses looked at inequalities between rural and urban 
type 2 diabetic patients, both by the same investigating teams in Australia, and found that 
despite a number of initiatives rural patients health was inferior to their urban counterparts 
[110, 120].   
The results from this area of investigation shows that there is more support for the negative 
hypothesis, with minority ethnic groups, men and those from rural areas tending to have poorer 
Anna Christie Page 63 
control over their condition. These results also support the null hypothesis with no evidence of 
inequalities by other measures of SEP; however, these results are inconsistent. 
 
Discussion  
 
Principal findings 
 
From 2,974 initial ‘hits’, 33 studies met the inclusion criteria and were included in the review.  
Five sets of harvest plots were produced for: diagnosis, monitoring, treatment, control and 
access and uptake of services. Many studies were included in more than one harvest plot as 
multiple interventions and/or markers of social and economic position were examined. The 
most common intervention was control of diabetes measured by clinical characteristics and 
complications.   
The results displayed in the harvest plots showed that there was some evidence of inequalities 
associated with interventions to manage and treat Type 2 diabetes. Ethnic minorities, men, and 
those living in rural areas tended to have poorer control. The rest of the results examining 
inequalities in diabetes control by education, employment/occupation, income and by 
composite measures of SEP tended to support the null hypotheses. Studies that examined 
severity of symptoms at diagnosis found inequalities by SEP. Two studies looked at being 
diagnosed or not and found no differences by deprivation, education or income level but there 
were conflicting results regarding inequalities by occupation. There was evidence for 
inequalities associated with monitoring by ethnicity and only support for the null hypothesis by 
gender. No studies examined inequalities in monitoring by other population groups. The 
majority of the studies which examined inequalities associated with treatments supported the 
null hypothesis by ethnicity, gender, rural/urban and composite measures of SEP. Finally there 
was evidence for inequalities associated with diabetes services by education, ethnicity, gender 
and deprivation but not for between rural and urban patients.  
The results here indicate that in most circumstances there was no evidence of inequalities 
associated with type 2 diabetes interventions. However, there were some notable exceptions, 
particularly associated with control, suggesting that despite the high economic development 
and the universal health care systems of the included countries these macro level circumstances 
Anna Christie Page 64 
and the way diabetes care is planned and delivered are not enough prevent these inequalities 
occurring.  
These results differ somewhat to the 2010 systematic review which found evidence of 
inequalities in treatment, control and service utilisation by ethnicity, socioeconomic inequalities 
in diagnosis and control, and no evidence of gender inequalities [74]. The discrepancies in the 
results examining socioeconomic inequalities in diagnosis and gender inequalities could be 
explained by the inclusion of more recent studies and the focus being on type 2 diabetes 
patients only. 
 
Secondary findings 
 
The review also identified where evidence was lacking and if there were areas where the 
methodology of the available evidence base could potentially be improved. Firstly, few studies 
used repeat measurements. Overall only 9 out of 32 used repeat measurements data which is 
surprising as data regarding patients’ health and care are routinely collected by healthcare 
providers worldwide [130]. Due to the nature of diabetes care and the progression of the 
disease it is difficult to attribute the cause of inequalities to particular interventions. However, 
more complex analyses of repeat measurements would be able to begin unpick what 
contribution, if any, inequalities in diagnosis, monitoring, treatment, services and control of 
intermediate outcomes have on the development of patients’ diabetes and long-term 
complications by population groups.  
There were a comparatively fewer studies that examined inequalities by population groups 
stratified by SEP in contrast to those looking at inequalities by ethnicity and gender. This is 
probably due to these studies relying on anonymised data collected by health care providers 
which in many cases do not routinely collect such information. However, many countries collect 
area based statistics which are often used as proxy measurements of individuals’ SEP and could 
be used to fill this gap in the evidence base.  
When focussing on the types of interventions examined from the harvest plots it was clear that 
there were gaps in the current body of literature. Over this twelve year period only three 
studies investigated whether there were any inequalities in the diagnosis of type 2 diabetes, 
with only one of these analyses focusing on the timeliness of that diagnosis. Being diagnosed 
early is critical for preventing and delaying the debilitating complications of the disease. None of 
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the studies which met the inclusion criteria investigated inequalities by demographic and socio-
economic indicators other than ethnicity and gender in the monitoring of clinical indicators, 
again another key aspect of the effective management of the type 2 diabetes. There were more 
analyses of inequalities associated with the receipt of and access to various treatments and 
services as well as of a wide of range of indicators of control. There was no area which had a 
concentration of consistent findings. Consequently, this lack of consistent evidence makes it 
difficult to understand where and what action is needed, if any, to improve the equality of 
diabetes care.  
Finally only a few of the studies in the final sample examined or controlled for healthcare 
provider in their analyses [110, 120, 128, 131] and only two of these used multilevel modelling 
techniques in order to control for any clustering effect. This is an important issue to consider as 
patients nested within the same providers are likely to have similar outcomes compared to 
those from other providers and as such could be a key cause of the inequalities noted here 
[132]. For instance, poorer quality of care has been shown to be associated with general 
practices in more deprived areas [133, 134].   
 
Strengths and weaknesses of the review 
 
As discussed in the introduction to this literature review, this current work shared many 
characteristics with an existing systematic review. The major strength of the review was the 
methods utilised, particularly the use of harvest plots to synthesise the data. These graphical 
displays of the results replicate the immediacy of the ‘Forest Plot’, traditionally used in meta-
analyses, whilst incorporating all the available evidence. The construction of the plots ensures 
that it is still clear where the strongest evidence lies but it also highlights where gaps or 
inconsistent evidence occurs. In addition to being more up to date and incorporating a graphical 
synthesis of the evidence, the quality assessment tool for this review was also arguably more 
appropriate as it is assessed the methodological rather than the reporting quality of each study 
[135]. 
Using all available evidence was also a drawback of this review as type 2 diabetes care 
incorporates many different interventions and can affect patients’ health in many different 
ways. As such, comparison between studies is difficult and synthesis does not necessarily 
produce a more reliable set of evidence. However, this review does produce a greater insight 
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into the diabetes care pathway overall and may stimulate a series of more focused systematic 
reviews which could in turn provide greater insight into this complex area.  
Whilst this review followed many of the methods of a Cochrane Systematic Review it differed in 
key ways in addition to the change of approach to data synthesis. The review did have a clearly 
defined aims and a sensitive search strategy. However, the existing data extraction and critical 
analyses forms were used but they were adapted in order to suit the types of studies which 
were included in the final sample and enabled the graphical synthesis of the results. Not all 
databases were searched because only primary studies examining the usual care of type 2 
diabetes patients were included which made searches of some databases inappropriate. Finally, 
only one reviewer undertook the review which could potentially introduce bias in the selection 
of the studies and the synthesis and interpretation of the results [136]. 
 
Current implications 
 
Whilst the majority the findings indicated no evidence of inequalities across the five groups of 
interventions a notable proportion of the studies relied upon univariate analyses of cross-
sectional data. There was also little investigation into inequalities associated with the timeliness 
of diagnosis and monitoring of type 2 diabetes by SEP, and the effect this may have on patients’ 
health outcomes over time. To enable unpicking of the causes and to control confounding 
factors in the health outcomes associated with inequalities of patients continuing care more 
complex analyses using repeat measurements are required. The majority of the studies 
examining inequalities in diabetes and other treatments were unable to control for patients 
health status and as such were unable to determine whether prescriptions were appropriately 
administered or not. There were also few studies that investigated the organisational structure 
of the delivery of interventions designed to manage and treat type 2 diabetes. That is, the 
relationship between management of patients in primary care and/or secondary care services 
and patients’ health outcomes in addition to the care they receive as an individual. 
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As a consequence of these findings, the following research questions were identified:  
 
1. Are there socio-economic inequalities in intermediate outcomes and long-term 
complications associated with type 2 diabetes over time?  
2. Are there socio-economic inequalities in interventions associated with type 2 
diabetes over time? 
3. Are there intervention-generated inequalities in type 2 diabetes care? 
4. What impact do general practices have on inequalities by socio-economic status in 
diabetes care and health outcomes? 
 
Having identified where new, substantive evidence could be added to the existing literature the 
next chapter discusses the methodological considerations and the outlines the methods chosen 
to conduct the secondary data analyses. 
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Chapter 4: Methods 
 
Following the systematic review, this thesis seeks to examine socio-economic inequalities in 
intermediate health outcomes and long-term health complications over time associated with the 
timeliness of diagnosis, the receipt of recommended care processes and treatment of blood 
glucose, BP and lipids. The structural arrangements of patients care and the quality of these 
organisations were also examined. These interventions were investigated utilising secondary 
datasets held by, and accessible to, the North East Public Health Observatory (NEPHO) as per 
part of the original proposal for this project [137].  
This chapter discusses the key methodological issues and the chosen methods of the secondary 
data analyses. In particular, the chapter covers existing diabetes related datasets and other 
sources of relevant data discussing the strengths and limitations of each. The chapter moves 
onto discuss measurement issues relating to individuals’ health outcomes, diabetes 
interventions and SES. This leads onto the next section which outlines some of the common 
methodological problems with secondary data analysis. At the end of each section the chosen 
methods are explained. 
 
Data sources 
 
In epidemiology and public health research data is determined as primary or secondary 
depending on the relationship between why it was collected and why it was analysed. If the data 
was collected specifically for the research team then the data are considered primary. If the data 
was collected for a specific purpose then subsequently used for analysis for another purpose 
and/or research team then the data are considered secondary [138]. 
The main strengths of using secondary data for research are the availability and cost. The data 
have already been collected reducing the time and cost in sourcing such information. This has 
become increasingly important as research budgets are being squeezed; using secondary data 
can provide more cost-efficient use of resources. When using primary data, costs generally 
increase in relation to sample size. Using secondary data with large sample size and/or number 
of records can avoid this increasing cost, as it is usually incurred during the initial data 
collection process, as well as increasing the power of any subsequent analyses [138-140].  
Anna Christie Page 69 
There are also a number of limitations. The main one being that because the data are already 
collected the research team cannot influence what data are collected and how. This can lead to 
gaps in the information required and to concerns regarding how variables are measured. 
Measurement issues, which are discussed further later in this chapter, as well as the political 
context in which they are produced, can reduce the reliability and variability of the final 
datasets [140].  
In their overview of IGIs, White et al [1] highlighted how socioeconomic outcome inequalities 
can occur at multiple stages of the planning and delivery of interventions. An ideal dataset to 
investigate how and why these trends occur would therefore need to include variables which 
measure the provision, uptake and efficacy of an intervention as well as patient’s long-term 
compliance and health outcomes [1]. In addition other variables which impact on patients’ 
health, but are not directly addressed by the interventions being investigated, would be 
included to delineate the relative contribution each element makes on patients health. Figure 11 
synthesises the broad categories which are often described as the social determinants of health 
[141]. Each of these categories refer to wide and varied number of issues. For example, in the 
Marmot Review [4] energy efficiency, tenure status, neighbourhoods, neighbours, quality, 
affordability, overcrowding, access to green space and insulation were all referred to in relation 
to housing being a social determinant of health. As such, capturing all social determinants of 
health in one dataset would be an extensive and potentially impossible task. 
These analyses, therefore, take a pragmatic approach by initially sourcing data which can 
identify patients’ who have type 2 diabetes, and routinely records their health and their 
diabetes care over multiple occasions. These are discussed in the next section ‘Diabetes health 
datasets’. The next step was to find data which could supplement and/or validate this initial 
data to provide a more reliable and comprehensive dataset for the investigation of IGIs. This 
included ‘Other heath datasets’ and ‘Socio-economic status data’ which are discussed separately.  
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Figure 11: Social determinants of health [141] 
Anna Christie Page 71 
Diabetes health datasets 
 
Diabetic patients, due to the nature of their condition, are normally engaged with a range of 
different services and treatments from primary and secondary healthcare that usually vary 
according to need, as well as for other reasons.  As a result, data associated with diabetes care 
are collected and stored by several different organisations. This section discusses the major 
national diabetes related datasets in England and what data are available locally in the South 
Tees area.  
 
National Diabetes Audit (NDA) 
 
First undertaken in 2003/04 and one of the world’s largest clinical audits, the NDA is probably 
the most wide-ranging, longitudinal diabetes datasets currently collected. The data collected 
relates to the NSF for Diabetes and includes health outcomes, treatment targets and care 
processes from NHS organisations across England and Wales [51].  
The dataset, which aims to collect information about all diagnosed diabetes patients in England 
and Wales, however, still has notable variation in participation rates. The first audit in England 
collected data during 2003/04 and had a participation rate of 20% from primary and secondary 
care organisations involving records of more than 253,000 patients [142]. In England in 
2009/10, all 151 PCTs were represented with data on 1,929,985 patient records included. 
However, the participation rates within PCTs varied, for example in 24 PCTs less than 50% of 
the practices participated [51].   
This is a valuable source of data as it creates a national picture of diabetes care using data from 
a range of sources. This information is normally stored by individual providers using a range of 
different data systems. Collating into one dataset annually enables analysis, benchmarking and 
feedback of clinical effectiveness across the NHS [51]. The range of organisations involved 
causes two main problems in terms of research. Firstly, the recording of data can vary between 
NHS organisations and as such extensive data cleaning would be required. Secondly, the terms 
of use and information governance issues are still being negotiated to allow for particular levels 
of analysis. This makes accessing the data and secondary data analyses currently very 
restrictive [143]. 
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NHS Diabetic Eye Screening Programme 
 
The NHS Diabetic Eye Screening Programme is a nationally led programme delivered locally 
resulting in multiple standardised datasets across England [48]. It was set up to support health 
authorities to reach the NSF for Diabetes: Delivery Strategy [49] target that by 2006 a minimum 
of 80% of diabetic patients should be offered screening for diabetic retinopathy, rising to 100% 
in 2007. The achievement of this target is also supported by QOF indicator incentivising general 
practitioners to include their patients in a screening programme [47]. The programme aims to 
capture all diabetes patients aged 12 years and over as recommended by current guidelines [48, 
144], in Middlesbrough PCT and Redcar & Cleveland PCT rates of over 80% have been achieved 
between 2006/07 and 2009/10 [51]. 
In terms of data quality, each screening programme is annually audited to ensure that each 
meets the national standards [48]. This ensures greater confidence in the dataset having 
consistent methods for recording the data. It is the most reliable source of retinal screening 
outcomes as it is the primary source of this information and therefore should be more complete 
than that held by organisations, such as general practices, who record the results subsequently. 
The South Tees Hospitals NHS Trust ophthalmic department hosts the local screening 
programme and runs clinics in Middlesbrough, Redcar & Cleveland and Hambleton & Richmond 
locations in order to serve patients closer to home [145]. The Ophthalmic department has been 
using digital photography and grading images for approximately seven years. There have been a 
number of changes to the grading protocols since the NHS Diabetic Eye Screening Programme 
guidelines were introduced. The current database houses data from 2006 relating to the patient 
and their screening activity. Patient data includes demographic data such as NHS number, name, 
address, sex, date of birth, general practice and PCT codes, and non-demographic data including 
diabetes type, date of diagnosis and information relating to screening care [48].  
The advantage of this dataset is the graded categories of patients’ retinal screening outcomes. 
There are seven categories providing the potential for greater differentiation in patients’ health. 
The major disadvantage of this dataset, in terms of utilising it for research, is that the data 
system which records the retinal screening results does not allow for multiple records to be 
extracted regarding specific criteria. For example, a dataset of solely type 2 diabetic patients 
graded outcome data cannot be generated. Also, very limited additional data are recorded 
limiting the possibilities for analysis when solely using this dataset [48].  
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South Tees Hospitals NHS Trust Diabetes register 
 
Disease registers are generally regarded as databases with all known cases of a particular 
condition within a defined denominator population. The data from registers can be used to 
evaluate clinical care, services and technology and, along with the denominator population, be 
used in epidemiological research and needs assessment. The progressive nature of diabetes and 
severity of associated complications means that registers can provide effective support for 
health professionals to pro-actively and continuously manage disease. For example, registers 
can provide a list of patients due for their annual review [146].  
Ideally registers should be active and continuous, in contrast to clinical audits which are 
collated at specific times. The UK has one of the most comprehensive cancer registration 
systems worldwide with every incidence of cancer being collated by one of 11 regional 
registries across the country [147]. Diabetes registries on the other hand have not been 
established in the same systematic way with the registries being hosted by many different types 
of organisations covering varying geographies. Since 2003 the QOF requires all general 
practices to be able to produce a register of all diabetes patients aged 17 and over and whether 
they have type 1 and type 2. However, it does not require them to produce a dataset relating to 
multiple aspects of patients diabetes care nor be standardised with other practices. These data 
are still collected as part of their usual care but without a register it is not necessarily easily 
accessed, analysed or recorded in a systematic way. 
There are many hospital based diabetes registers in the UK including James Cook University 
Hospital, a hospital local to where this research was undertaken. James Cook University 
Hospital which is governed by South Tees Hospitals NHS Trust hosts a comprehensive diabetes 
register which covers the South Tees area spanning Middlesbrough LA and Redcar & Cleveland 
LA. Also, a specialist nurse annually collects data on patients who are managed in the South 
Tees area but do not attend the diabetes clinic in the hospital.  As part of this process the setting 
of each patient visit is recorded, e.g. the Diabetes Care Centre or their general practice. This, 
therefore, provides an opportunity to explore the impact that receiving additional non primary 
care has on socioeconomic inequalities diabetes outcomes [60]. 
This diabetes register collects over 100 indicators relating to diabetes and has been in existence 
since 1987 [60]. As such it is a valuable and comprehensive longitudinal dataset ideally placed 
for investigating diabetes care and its long term impact. However, there are two main 
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drawbacks. Firstly, the register data are largely collected through paper proforma from the 
diabetes clinic, other hospital departments and general practices in the South Tees area. 
Therefore, the data quality can vary quite widely between original sources. Secondly, other 
health demands of patients can impact upon the quality of patients’ care and outcomes which 
are not routinely recorded via the proforma, such as non-diabetes related co-morbid conditions, 
therefore limiting the scope of analysis if relying solely upon this dataset. 
 
Other health datasets 
 
Whilst the datasets detailed in the previous section are specifically related to diabetes patients 
there are other health data which could be used. This section discusses some of the other data 
available in the UK that could be potentially used to measure diabetes interventions, 
particularly those that operate on the level of the individual patient but affect the context in 
which diabetes care is delivered. In addition, this section discusses datasets which could be 
drawn upon to capture other health conditions. Knowing about these co-morbidities is 
important as they can have an immense impact of a patients’ quality of care and subsequent 
health outcomes [148].   
 
Primary care data 
 
All NHS diabetes patients should be registered with a general practice and like certain other 
long term conditions, national policies aims to have the majority of these patients managed 
within primary care (for example: [47, 49]). Ideally, all information about all general practice 
registered patients’ care and outcomes should be recorded within these organisations. Such 
data could be accessed through individual practices or from databases generated from general 
practice records [149].  
There are a number of primary care databases covering a range of issues such as practice 
quality, disease incidence and prevalence, morbidity, consultation rates, health promotion and 
prescribing. Whilst these datasets provide opportunities to investigate specific health issues 
there are a number of drawbacks. Firstly, they are often reliant upon voluntary participation 
and as such they may not be representative of all primary care. Another source of bias is in the 
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quality and completeness of these databases which can vary quite widely. Also, information 
regarding patients’ social circumstances and certain demographic data are often not recorded 
[149]. 
Data could be potentially extracted from practices individually, however, there are a number of 
problems with this. Firstly, it is a labour intensive process both in terms of gaining access (see 
section below for further discussion) and collating the data into a consistent format. Secondly, 
not all practices use the same data systems and the coding of data can vary widely between 
practices [150, 151]. Whilst there has been work at the level of PCTs to increase the consistency 
of recording using Read Codes to act as a central site for data extraction, the current climate of 
NHS reforms has had a major impact on the ability of staff to accommodate such a request [152].  
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Quality and Outcomes Framework 
 
Quality and Outcomes Framework (QOF)was introduced by the new General Medical Services 
contract and was one of the consequences of the government’s aim to expand chronic disease 
management into primary care [1]. QOF is a voluntary annual reward and incentive programme 
established in general practices across the UK during 2004 with the aim to reward the provision 
of good quality care and improve standards [2, 3].   
QOF was not designed to be a comprehensive data source about the quality of care in general 
practices, however, it does provide the opportunity to use the data in this way. It has the 
advantage over the datasets already discussed in that it is freely available online via The Health 
and Social Care Information Centre. The dataset has national coverage across England and 
Wales and uses a range of indicators of quality of care related to diabetes. The main drawback 
though is that it only contains practice-level data, therefore, it does not provide the opportunity 
to control for the individual patient clinical or socio-demographic characteristics. However, the 
dataset does provide good general information about general practices in terms of practice list 
size, patient experience and additional services. However, some of these fields published refer 
to the number of points achieved for a particular quality indicator in which there is often not a 
great deal of difference in achievement. Therefore, some of the fields may vary enough to 
warrant further analysis [47].  
 
Hospital episodes statistics 
 
Established in 1987, Hospital Episode Statistics (HES) is a database which contains information 
about each episode of care provided by NHS hospitals and for NHS hospital patients treated by 
non-NHS providers. Data collected each financial year since 1989-90 are available but the 
procedures and structures of data collection have changed over time [153].  
Whilst the quality of the data collated in emergency and outpatient departments is poor, HES 
could be a source of patients’ diabetes complications and other health needs which result in 
inpatient hospital care. Obviously not all co-morbidities which impact on patients’ health and 
diabetes related care result in being admitted to hospital yet using HES for this purpose has the 
advantage that it is a centrally accessed dataset with national and longitudinal coverage.  
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Public Health Observatories of England General Practice Profiles 
 
In 2011, the network of Public Health Observatories published The National General Practices 
Profiles accessed freely online via the network’s website. They are designed to assist general 
practitioners and commissioning groups in providing healthcare services to meet the needs of 
their local population. The profiles bring together 2009/10 results from population data from 
the Attribution Dataset (ADS), GP Patient Survey data, QOF data and admission rates from NHS 
Comparators. The results are then displayed in various charts to enable comparison of GP level 
outcomes with PCT and national rates. The metadata which are used to generate each indicator 
is also available to download [154]. 
This is a valuable resource that can enable comprehensive and systematic comparisons of 
general practice quality and activity. Unfortunately profiles are only available for years 2010 
and 2011 due to the type of data available which makes up the profiles, therefore, longitudinal 
analyses using this data is limited. 
  
Survey data 
 
Survey data could provide greater insight into routine health data and supplement it as 
demonstrated by many of the studies in the literature review. However, they are usually 
designed around particular issues, cross-sectional in terms of the data collection, not readily 
available or widely publicised. The value of survey data could be increased by linking survey 
data with routine health data but this would pose particular ethical and information governance 
issues, which could potentially hinder time efficient research in this area. 
 
Socio-economic status data 
 
When utilising secondary data for analysis the researcher is generally restricted in the choice of 
indicators of socio-economic status by what was initially recorded. Choice is restricted further if 
relying solely on routine health data. Demographic data, such as gender, age and ethnicity, are 
routinely collected by a range of services, however, measurements of SES, such as income, 
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education and occupation, are less common. None of the data sources described so far routinely 
record this type of information. A widely used solution to this is to link health data to census 
and administrative data measured at a particular geographical level via the patient addresses. 
This data can then be used as proxy indicators of individuals’ social position [155, 156]. In this 
section the two primary sources in the UK are described. The specific indicators are discussed 
later.  
 
Office for National Statistics Neighbourhood statistics 
 
In the UK the Office for National Statistics (ONS) collect, analyse and disseminate a vast amount 
of data at differing levels of geography including data about the social and physical 
environment, education, services and crime. The timeliness and range of indicators for each 
topic is dependent upon the source of the data which include a range of government 
departments. For example, information from the Department for Work and Pensions is made 
public on an annual basis. However, information which is gathered through the census can be 
only produced on a ten yearly basis. The major advantage of utilising data from this source is 
that is freely available online and, depending upon which indicators are used, measured at small 
geographic levels [157, 158].  
 
Marketing data 
 
Geo-classification systems produced by marketing companies, such as ACORN and 
SuperProfiles, are an alternative for measuring individual SES at the area level. These systems 
are created to help their clients with advertising, marketing and targeting products to particular 
consumer groups. These systems are predominantly new methods of categorised Census data, 
however, SuperProfiles does include market research data and credit information too. Due to 
the purpose of these systems they generally incur a fee [157].  
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Summary 
 
There was an ideal opportunity in South Tees to construct a robust diabetes related dataset by 
linking the data from the South Tees Hospitals NHS Trust Diabetes register and NHS Diabetic 
Eye Screening Programme to compare changes in the rate of intermediate health outcomes and 
complications by patients’ socio-economic status. The diabetes register was chosen as the core 
dataset as it contains a vast range of repeat measurements for a large population sample. Data 
dated from 1999 to 2007 inclusively could be relatively easily accessed following the 
appropriate permissions and contains consistent variables and identifiers to enable linkage 
with other datasets. It has also the added advantage of having staff with an in depth knowledge 
of diabetes, dataset and the local area which enables a greater insight into the data and 
understanding the analyses. This data were limited to the years 1999 to 2007 inclusively as it 
was the most up to date information at the time of extraction. Through this core dataset, 
information about patients’ health, lifestyle and anthropometric status as well as about their 
care in terms of their general practice, monitoring and receipt of secondary services could be 
extracted. In addition, publically available data from ONS, QOF and Practice profiles could be 
linked to the core dataset to provide proxy measurement of their SES and further information 
about their general practices. This latter data was chosen due to its public availability and 
coverage.  
 
Study population 
 
Following the identification of the most appropriate data, the study population was identified 
and defined. This was done through the core dataset, the South Tees Hospitals NHS Trust 
Diabetes Register. These inclusion criteria were designed to capture type 2 diabetes patients 
using established epidemiological methods and avoid recording error of type of diabetes in the 
register dataset. This identified study population sample should receive the same access and 
quality of care from the community services situated in the two PCTs. The Diabetes Care Centre 
and the local branch of the NHS Diabetic Eye Screening Programme both serve the South Tees 
area as a whole. Children and adolescents with diabetes were excluded as they are managed 
differently and therefore constitute a different care pathway which is not the focus of this 
research [52].  
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Patients’ data were included in the final analyses if they met all the following criteria: 
 Type 2 diabetes patients. Patients from the diabetes register were identified as having 
type 2 diabetes through the following established epidemiological definition [55, 159, 
160]: if they were diagnosed with diabetes over the age of 35 or recorded as not using 
insulin.  
 Living and registered with a general practice in the South Tees area. The South Tees 
area is defined as Middlesbrough LA and Redcar & Cleveland LA. Patients were 
considered living in South Tees if the LSOA of residence falls into this area as 
determined by ONS data [158] and GeoConvert [161]. Middlesbrough PCT and Redcar & 
Cleveland PCT are coterminous with the LA areas and practices which fall under their 
responsibility according to where patients live were defined as being in the South Tees 
area. 
 Aged 16 years old or older 
 
Data extraction and construction of final dataset 
 
As discussed previously, the South Tees Hospital NHS Trust Diabetes Register provides the core 
dataset for this project and to increase data coverage additional datasets were linked to this 
dataset. For this to be done effectively, both or more datasets had to share common identifiers 
to which the data refers. 
In the UK, every NHS patients has a unique 10 digit number which is recorded during every visit 
with a NHS provider. They were introduced with the aim to improve safety and efficiency of 
healthcare [162] and have the benefit of enabling the straight forward linkage of patient level 
NHS data. Data linkage between patient level, non-NHS datasets would require multiple 
indicators of identifiable data and carries a higher risk that the linkage is inaccurate [163]. Using 
identifiable data for the purpose of data linkage, however, requires either patient consent or if 
this is not possible and/or a practical option then a section 251 approval has to be sought from 
the National Information Governance Board [164].   
To avoid the timely process of acquiring patient consent and/or adhering to conditions 
associated with a section 251 approval the data linkage process was done by staff with prior 
access to the datasets. The following data were used and then removed from the final data 
extract by the data manager, Elaine Hall, before being pseudonymised for final external use: 
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NHS numbers, postcodes and dates of births. Details about how these fields were used are 
discussed throughout this chapter. A separate table containing the study patients’ NHS number 
and a new unique study number was generated and retained by the data manager to allow 
direct linkage between the register and retinal screening programme datasets.  
The final data extraction of the register data was sent by the data manager to NEPHO care of 
Professor John Wilkinson via their NHS secure email accounts. The data was sent in ten tables, 
one for each year of recorded data and one containing the demographic data of the patients 
which do not change: age at the end of 2007, year of diagnosis, sex and ethnic origin. All tables 
featured the study numbers unique to each patient to enable the linkage between the tables. 
These were then formatted in a long table format with each row containing one year of data for 
one patient. Prior to any data cleaning the initial extract contained 69,894 records for 13,687 
patients. 
Graded retinal screening outcome data for all patients from 2006 and 2007 was requested to 
increase the completeness and accuracy of the recording of this field. Where there were any 
discrepancies in the values between the two sources, the screening programme data was 
favoured. This data were sent from the South of Tees NHS Diabetic Eye Screening Programme to 
the diabetes register data manager, both situated within the South Tees Hospital NHS Trust. The 
data manager at the register then used the table containing the two sets of identifiers to assign 
the new unique study numbers to screening data. The NHS numbers and all the records of 
patients who were not identified through the diabetes register were then removed. This data 
was sent to NEPHO via the same method described above. 
Information about patients’ general practices was sourced from QOF and Public Health 
Observatories (PHO) of England General Practice Profiles. Quality and Outcomes Framework 
data were used to provide indicators of quality of care in general practices. These were 
generally from the diabetes domain of the framework and were extracted for all general 
practices in Middlesbrough PCT and Redcar & Cleveland PCT from the period 2004/05, the time 
period QOF was introduced, until 2007/08 from the Information Centre website [47]. The 
deprivation scores from the Practice Profiles were used to provide a proxy measure of the 
deprivation profile of South Tees general practice populations [154]. These data were linked to 
the register data via the general practice code for each patient for that year.  
The national rank position data for each lower super output area (LSOA) using the 2004 Index 
of Multiple Deprivation (IMD) scores in England were downloaded from the Office for National 
Statistics (ONS) Neighbourhood Statistics website [158]. These were used as proxy measures 
for individual’s SES. Whilst IMD data have been constructed during other time periods the 
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methodologies have changed over time [158], therefore, only one set of IMD data was used to 
keep a reliable indicator of SES over the study period. All LSOA located in Middlesbrough LA and 
Redcar & Cleveland LA were identified using the same downloaded data from the ONS and a 
table of these areas and the postcodes which fall into these areas was generated using 
GeoConvert [161]. Where postcodes covered more than one area the LSOA, the LSOA which the 
greatest proportion of the postcode area covered was used. This was identified through the 
percentage matched which is generated alongside the corresponding area by GeoConvert. This 
table was then emailed to the data manager at the diabetes register who linked data via 
patients’ postcode for each year. The postcodes were then removed. This data linkage was done 
by the diabetes register data manager to protect the sensitive postcode data before releasing 
the data. 
 
Data access 
 
Data access here refers to the ethical and information governance issues that needed to be 
addressed when undertaking university based research and more importantly when seeking to 
use patient level health data. Durham University postgraduate students are required to conform 
to their academic school’s policies, in this case, the School of Medicine and Health, and the 
University’s policies on ethics in research [165]. In addition, if using NHS data, undertaking 
research with NHS staff and/or researching within NHS environments ethnical and information 
governance approval from the National Research Ethics Service [166] and the appropriate 
Research and Development are required. In turn, if patient identifiable data without prior 
consent is needed, an application to the National Information Governance Board for section 251 
approvals is also required [164]. Gaining the appropriate approvals can potentially be a lengthy 
process, therefore, the efficiency of extracting the subsequent data is also an important 
consideration especially when there is a restricted time frame to undertaken the research. 
 
Once the datasets were chosen, approval to access the data and undertake the research was 
sought and granted by the following organisations (Appendix B): 
 School of Medicine and Health Ethics Committee, Durham University 
Ref: ESC2/2010/12 
 County Durham & Tees Valley Research Ethics Committee, National Research Ethics 
Service 
Ref: 10/H0908/63 
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 Research & Development / Academic Division, South Tees Hospitals NHS Foundation 
Trust 
 
Dataset and variable construction 
 
This section discusses the key methodological issues related to each variable. This is followed 
by descriptions of where the variable was sourced from, how it was measured and/or derived. 
This included what data cleaning procedures were administered to ensure the most reliable and 
valid data. A summary table of the source and formatting of each variable are provided in 
Appendix C. In addition, the level of missing data per variable over the study period are detailed 
in Appendix D. 
 
Type 2 diabetes interventions 
 
Diagnosis 
 
There is evidence that early diagnosis of type 2 diabetes and the initiation of secondary 
prevention interventions can reduce and/or delay the presentation of diabetes related 
complications [167]. The studies from the literature review looked at two related issues 
regarding diagnosis: firstly timeliness of diagnosis, that is patients’ health statuses at the point 
of diagnosis [168], and being diagnosed or not [92, 93]. The two studies which examined 
timeliness of diagnosis measured this as the level of retinopathy at diagnosis [168]. The former 
of these two studies utilised routine health data assessing patients’ outcomes at their first 
retinal screening visit. However, this may occur months or years after patients’ initial diagnosis 
but other health datasets have potential for examining other clinical indicators nearer to the 
time of intervention.  
The main issue with using routine health data only means that the circumstances which led up 
to being diagnosed are unlikely to be routinely and systematically recorded. Survey data could 
potentially be a source of this data. However, no survey available through the UK Data Archive 
[169] and Data.Gov.UK [170] had looked at this issue. In addition, there are potential 
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information governance issues to address if patient identifiable information is required to link 
the data with other longitudinal health data in order to investigate the long-term consequence 
of a delayed diagnosis.  
This thesis is concerned with patients from the point of diagnosis onwards. As such, the study 
population covers those who have previously been diagnosed. What could be investigated was 
the severity of patients’ symptoms near the time of diagnosis, or what could be regarded as the 
timeliness of diagnosis. Here, indicators measured during the year the patient was diagnosed 
and analysed using only for patients diagnosed during the study period recorded in all their 
records. 
Ideally, an indicator not prone to changes in an individual’s temporal circumstances would have 
been chosen. Using the available data for this thesis, this would have been retinopathy. However 
the coverage of this indicator was poor and more so in the cohort who was diagnosed during the 
study. Consequently, due to its coverage and its importance as an indicator of diabetic control, 
the severity of patients’ HbA1c at the time of diagnosis was used as a proxy indicator. This was 
based on the assumption that a lower HbA1c at diagnosis indicates that the diabetes was 
diagnosed earlier. 
 
Monitoring 
 
Receiving recommended care processes could be regarded as an aspect of care quality. Few 
studies that met the inclusion criteria of the literature review examined inequalities in 
monitoring. This was surprising as it is an important part of diabetes care, forming part of many 
prominent guidelines for the management of type 2 diabetes [52, 69, 171]. In the UK, 
monitoring rates should be routinely captured in health datasets due to  guidelines such as 
those by the NICE [46] and QOF [47]. In terms of monitoring, the NICE guidelines for type 2 
diabetes state that patients should have nine anthropometric and clinical outcomes measured 
annually as part of their on-going care. These are recommended in order to achieve the best 
standard of care for the patient [69]. The NDA regularly reports the percentage of patients in a 
given area who have received all care processes [61].  
The reason for the lack of investigation in this area may be due to one of they key weaknesses of 
using monitoring rates as a proxy measure of quality of care. That is, because using routine 
health data alone does not effectively capturing sufficient information to analyses the impact on 
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a patient’s health. That is because in routine health data, the same information tends to capture 
the recording of the outcomes and the actual outcome. For example, if a patient has not had 
their eyes screened it is not known what level of retinopathy they have and therefore what 
impact non receipt of this care process has had. There are two solutions to this, firstly 
examining the overall number of care processes a patient receives during their routine visit and 
what impact this has on the health outcomes which are recorded. Whilst this is not ideal, by 
using a total ‘score’ this could act a proxy measurement for this particular aspect of patient care 
as it captures the level of compliance with national guidelines. A second solution is using the 
recorded data to impute, estimate or simulate the missing data. Imputation and simulation 
methods, which are discussed later in this chapter, have several advantages: firstly it avoids the 
bias which could be introduced if analysis is conducted upon complete case analysis alone 
[172]. For instance, missing data may be more prevalent in more deprived patients. Secondly, it 
allows the examination the lack of recording of care processes on the outcome that process 
monitors.  
Another weakness is that the reliance upon routine health data and these approaches cannot 
account for those patients who do not engage with services at all as they are not represented in 
any of the recorded data. Also, it cannot distinguish between missing data as a result of not 
receiving that care process and data missing for other reasons. Data which may be missing may 
simply be due to the practitioner not recording the data even though the process was 
performed. It could also be the result of ineffective data sharing, especially when care is 
dispersed across many different services. Without effective data sharing, patients could be 
regarded as receiving sub-standard care when it is not actually the case.  
In addition, there are other aspects of quality of care, such as those in the 2011 NICE quality 
standards programme for diabetes in adults [173] which are not routinely measured. Therefore, 
using monitoring rates as a proxy indicator of quality of care has the advantage of being 
routinely measured. In the statistical analyses in this thesis, quality of care refers to the number 
of NICE recommended care processes patients have received. Each year, patients should have 
the following data measured and recorded: BMI, HbA1c, BP, albumin, creatinine, cholesterol, 
smoking status and examination of their eyes and feet. For this study data on only eight 
processes of processes were extracted. The diabetes register team highlighted that the data 
relating to foot examinations are poorly recorded and recommended not to use this data [174]. 
Prior to the cleaning of these variables eight new variables were constructed to indicate 
whether the patients had received each care process described above; ‘1’ indicated ‘Yes’, ‘0’ for 
‘No’. The following variables were used to construct these new indicators: BMI, HbA1c, BP 
(either systolic or diastolic had to be recorded, not necessarily both), microalbuminuria, 
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creatinine, cholesterol (total, HDL-c, LDL-c or triglycerides), retinopathy and smoking status. A 
total score was then constructed which ranged from 0 to 8. As the majority of patients either 
received 4 to 8 of the care processes this variable was recoded into a categorical variable: 1 = 
less than 7, 2 = 7 and 3 = 8 care processes received. These are described in the results section as 
poor, medium or high quality of care. 
 
Treatments 
 
Only a limited proportion of type 2 diabetes patients manage to control their glucose levels 
through lifestyle changes for more than a few months, therefore, the use of oral glucose-
lowering drugs and/or insulin are likely to be prescribed. Type 2 diabetes patients also have a 
high risk of developing CVD, eye damage, kidney disease and microvascular damage which can 
be reduced through improved BP, cholesterol and blood lipid profile. Patients, therefore, with 
poor intermediate outcomes are likely to be prescribed therapies to improve their control [46]. 
Investigating inequalities associated with treatments is complex as the type, dosage, the starting 
of treatments and its duration are dependent upon multiple factors such as health status and 
patients willingness to engage with certain treatments. Secondary data analyses of these issues 
are unlikely to be able to capture all factors involved in the treatment of diabetes and its 
associated complications but it can begin to unpick whether there are systematic differences in 
treatments between different population groups.  
The health status of patients is something which is likely to be routinely recorded in various 
health datasets. Of the seven studies from the literature review which primarily focused on 
inequalities in treatment [92, 100-102, 106, 110, 111],  only four of these studies took this into 
account [100-102, 106]. Without this information it is not clear whether there are inequalities 
in treatment use or if these inequalities are acting a proxy indicator for inequalities in control as 
a result of other factors.  
The diabetes register proforma had a section relating to which drug treatments patients were 
prescribed. A recording of ‘1’ indicated if a patient was receiving that particular type of diabetes 
treatment and ‘0’ if not. A major weakness of using these data is that they do not capture all the 
pertinent factors mentioned above relating to a patients treatment. However, a key strength is 
that they have the benefit of being extracted along with patients health status data. As such, it 
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can be established whether there are systematic differences in the treatments patients were 
being prescribed.  
The following diabetes treatments were extracted: ‘Diet Alone’, Insulin, Sulphonylureas, 
Metformin, Acarbose, Glitazone. If a patient was recorded as having a diabetes treatment other 
than diet alone and diet alone was recorded as 1 this was recoded as 0. This was based on the 
assumption that the recording of a ‘1’ for a particular diabetes treatment is more accurate. This 
data were recoded into one categorical variable due to the presence of collinearity between 
some of the binary variables and low use of acarbose and glitazone treatments. The categories 
were broadly based upon glucose lowering therapy algorithm in the NICE Type 2 diabetes 
guideline. The new variable was categorised as follows: 1 = Diet alone, 2 = Metformin or 
sulphonylureas only, 3 = Diabetes treatment combination excluding insulin, 4 = Insulin only and 
5 = Diabetes treatment combination including insulin.  
Blood pressure treatments – diuretics, beta blockers, alpha blockers, ACE inhibitors and calcium 
antagonists, lipid therapies and aspirin were also extracted. BP treatments were recoded into 
one categorical variable due to the low prescription rates of some of the treatments. The new 
variable was categorised broadly based upon BP treatments algorithm in the NICE Type 2 
diabetes guideline [46]. The categories were as follows: 1 = No BP treatment, 2 = ACEIs only, 3 = 
ACEIs plus any combination of other BP treatments and 4 = other treatment(s). These 
categories is a simplification of the scheme for the management of BP for people with Type 2 
diabetes found in the NICE type 2 diabetes guidelines. Most patients should move from category 
1 through to 3 if their BP deteriorates with category 4 possible depending upon other factors 
such as ethnicity, pregnancy and having microalbuminuria [46]. Details of lipid therapy were 
recorded on the proforma as follows: 0 = None, 1 = Statin, 2 = Other, 3 = Multiple. However, the 
prevalence of the prescriptions of these therapies is relatively low for ‘Other’ and ‘Multiple 
therapies’, therefore, this was recoded into a binary variable with ‘1’ indicating the patient was 
receiving any lipid therapy(s) and ‘0’ for none.  
 
Services 
 
Many of the studies in the literature review examined inequalities associated with what was 
broadly described as services. The use of ‘services’ here refers to types of services, as opposed 
to the process of care being undertaken, including places of care and services delivered 
dependent upon the qualification of staff involved. Due to the range of interventions that these 
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services encompass, and the various characteristics of each these services, there are potentially 
multiple ways inequalities could occur.  
There are several issues when investigating inequalities associated with diabetes services. 
Firstly, there are services that all diabetes patients should be offered as recommended by 
national guidelines therefore ensuring that patients are offered and use these services. Receipt 
of these services could be regarded as an indicator of quality of providers who act as the 
gatekeeper to these services. Likewise quality, as measured by the rate providers adhere to 
recommended monitoring rates over the entire service population, which can vary between 
similar providers, therefore inequalities could occur due to being registered at one rather than 
another. Whilst these may not be considered indicators of quality there are other features of 
services like general practices which may influence equality of care such as the size of the 
practice, the level of staff and their skills, and the internal procedures. These issues were not 
considered in the final sample of the studies in literature review. Also, there are many sets of 
guidelines outlining what care diabetes patients should receive but there is little stating which 
professionals should deliver this care. The new ‘Diabetes in adults quality standards’ refer to an 
appropriately trained healthcare professional rather than a GP or dietician, for example [173]. It 
was not clear from the current literature if this has an impact on health inequalities or not. 
A weakness of investigating the receipt of particular services using routine health data is that it 
is dependent upon information being systematically collected. Providers adhering to monitoring 
rates will be collected as these are part of their care, however, who delivered the care and the 
details about those services are less likely to be recorded. In addition, the problem of non-
engagement with services cannot be evaluated using this data. Information about providers 
themselves is available from sources, such NHS websites and various NHS surveys (for example: 
[175, 176]), however, the historical nature of this data varies making analysis over time difficult. 
As such none of the available datasets enabled the investigation of these issues. 
The strength of using the diabetes register as the core dataset for the statistical analyses it was 
possible to investigate several aspects of patients’ services. Firstly, where the patient visit 
occurred was recorded each time the proforma was completed. This data was extracted and was 
recoded into a binary variable to indicate whether patients were being managed in primary care 
only or received additional specialist care within a particular year. Patients were coded as ‘1’ for 
‘shared care’ if the ‘Source of Form’, a field included in the original data extraction’ was recorded 
as ‘Diabetes Care Centre’ or ‘Community Intermediate Clinic’, and ‘0’ if this was recorded as 
‘General Practice’ only.  Secondly, a variable was constructed to indicate whether patients were 
being managed by Middlesbrough PCT or Redcar & Cleveland PCT within a given year. Patients 
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were coded as ‘1’ for ‘Middlesbrough PCT’ if the practice they were registered with that year 
was in Middlesbrough. Patients were coded as ‘0’ for ‘Redcar & Cleveland PCT’ if the practice 
they were registered with that year was in Redcar & Cleveland.  
In addition, increased practice size, diabetes prevalence and more socio-economically deprived 
patients have been shown to be associated with poorer quality of care [177] therefore the 
following variables were collected to be included in the analyses. General practice deprivation 
scores were constructed using the Index of Multiple Deprivation (IMD) 2007 applied 
proportionally to the Attribution Dataset practice populations, 2010 for the production of the 
National Practice profiles by the network of Public Health Observatories [154]. Scores for all 
English practices were downloaded and divided into quartiles.  The number of patients on 
practice and diabetes register and the practice diabetes prevalence were extracted from the 
QOF datasets on the Information Centre website. The diabetes register size is the number of 
patients with any diagnosed diabetes aged 17 and over registered at that practice. The 
prevalence is the percentage of the diabetes register over the practice list size for patients aged 
17 and over.  
Diabetes is one of the twenty clinical domains featured in QOF. This domain has featured 25 
different indicators, some of which have varied between years [47]. The indicators which were 
consistently measured between 2004 and 2007 inclusively were included in the analyses 
providing a broad picture of diabetes care at a practice level. For each practice the percentage of 
patients for which each performance indicator was achieved was calculated using the size of 
practices’ diabetes registers as the denominators. This is the method which is used in the 
Network of Public Health Observatories practice profiles as it retains all patients in the 
denominator, including those which have been excluded by the practice for calculation for 
payment on performance [154]. 
The following indicators are used and recalculated using the above method: 
 Percentage of patients with diabetes whose notes record BMI in the previous 15 months 
 Percentage of patients with diabetes in whom the last HbA1c is 10 or less (or equivalent 
test/reference range depending on local laboratory) in the previous 15 months 
 Percentage of patients with diabetes with a record of the presence or absence of peripheral 
pulses in the previous 15 months 
 Percentage of patients with diabetes with a record of neuropathy testing in the previous 15 
months 
 Percentage of patients with diabetes who have a record of the BP in the previous 15 months 
 Percentage of patients with diabetes in whom the last BP is 145/85 or less 
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 Percentage of patients with diabetes who have a record of micro-albuminuria testing in the 
previous 15 months (exception reporting for patients with proteinuria) 
 Percentage of patients with diabetes with a diagnosis of proteinuria or micro-albuminuria 
who are treated with ACEIs (or A2 antagonists) 
 Percentage of patients with diabetes who have a record of total cholesterol in the previous 
15 months 
 Percentage of patients with diabetes whose last measured total cholesterol within the 
previous 15 months is 5mmol/l or less 
 Percentage of patients with diabetes who have had influenza immunisation in the preceding 
1 September to 31 March 
With the exception of the practice list size which counts all registered patients, these indicators 
refer to patients with both type 1 and type 2 diabetes. QOF indicators are measured over a 15 
month period. Due to the discrepancy in time periods between QOF and the diabetes register 
data the QOF data recorded for 2004/05 were regarded as a measure of 2004 performance, 
2005/06 for 2005 and so on. These data were linked to patient-year records via the National 
Practice Code of the practice the patient was registered at for that year. 
Following initial analyses Practice Deprivation and Practice list size were recoded into 
categorical variables in order to establish if there were any non-linear trends. All of the practice 
deprivation scores from the Practice Profiles were divided into quartiles. All the practices in the 
final dataset were then assigned to a quartile. No practice in South Tees fell into the least the 
least deprived quartile, as such, the three remaining categories are referred to as ‘1’ high, ‘2’ mid 
and ‘3’ low practice deprivation. Practice list size was recoded ‘1’ if there were less than 7,000, 
‘2’ if there between 7,000 and 9,999 inclusively, and ‘3’ if there were 10,000 or more patients 
registered with the practice. 
 
Socio-economic status 
 
Inequalities in health can occur across a range of population groups categorised by their socio-
demographic and socio-economic status. For example, location, race, ethnicity, culture, 
occupation, gender, religion, age, education or income[1]. To investigate the extent of socio-
economic inequalities associated with type 2 diabetes interventions stratified measurements of 
patients SES are required. However, SES can be conceptualised and measured in multiple 
different ways. The existence and extent of health inequalities are influenced by the choice of 
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indicators. For example, an analysis of the British Household Survey found that among initially 
healthy economically active respondents the strongest predictor of self-rated health was the 
National Statistics Socio-Economic Classification (NS-SEC), but for the initially healthy 
economically inactive was the respondents’ Household Cambridge Scale Score. The NS-SEC is 
based upon respondents’ most recent occupation. The Household Cambridge Scale Score is also 
based upon occupation but takes it account of lifestyles and resources too. Other measures 
analysed were personal income and household income [178]. 
As reflected in the multiple ways SES can be measured, it is widely recognised it is a multi-
dimensional concept and there have been a number of indices which aim to capture this in a 
single measure or indices of deprivation. Many countries have constructed indices of 
deprivation utilising routinely collected area based statistics. In the UK the most well-known 
include the Townsend Index, Jarman, Carstairs and Morris Scottish Deprivation Score and 
Indexes of Multiple Deprivation [157].  
The Townsend Index is measured using four variables taken from the Censuses incorporating 
both material and social deprivation. These are as follows: lack of access to good housing, lack of 
material possessions, lack of access to private transport and unemployment. Carstairs and 
Morris Scottish Deprivation Score, also known as Scotdep, is similar to the Townsend Index but 
replaces the housing variable with low social class. This was to reflect that within Scotland there 
is a higher proportion of social housing which reduced the sensitivity of the Townsend Index. 
The Indexes of Multiple Deprivation (IMD) also incorporates both measures of social and 
material deprivation but uses a greater range of indicators grouped into seven domains: income, 
employment, health and disability, education, skills and training, barriers to housing and 
services, living environment and crime. In addition to the greater range of variables used to 
produce the index, it is also assigned to smaller geographical areas than the previous two 
indexes [157]. These smaller geographical areas are lower super output areas (LSOA) which 
represent a minimum of 1,000 residents and 400 households [74].  
The main problem with using any of these measures as a proxy for an individual’s socio-
economic status is that they inevitably under- or overestimate the personal circumstances of 
individuals in a given area as the deprivation score is an average of that areas population 
circumstances [179]. In addition, whilst IMD incorporates a greater range of indicators than the 
other indices mentioned and its methodology has been criticised for not being explicitly clear 
which could lead to a misinterpretation of the deprivation patterns [179]. Having said that it has 
been widely used and therefore it is invaluable in being able to compare results from other 
studies and could make meta-analyses more effective.   
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Despite its limitations, the 2004 IMD was chosen as it is the most comprehensive indicator of 
patients’ socio-economic circumstances and measured at a small geographic area. The 2004 
Index was chosen, rather than another year, as this made available during the study period and 
therefore most likely to reflect patients’ circumstances that period. Using more one than one 
index was not appropriate as the way the indices were measured changed between time periods 
therefore would not be consistent [180].  
A number steps had to be undertaken to assign each patient into a SES group. Firstly, all the 
English LSOA were divided into five equal groups, quintiles, using the ranked position based on 
the IMD deprivation score. Quintile 1 indicated the most deprived fifth of all English LSOA. The 
rank position and corresponding quintile were linked to the diabetes extract using patients’ 
LSOA per year. Groups were used in the analysis instead of using the rank or score so that 
trends could be more easily identified [181]. However, it was clear from initial analyses that 
fewer groups were required to gain more robust results. Therefore, quintiles one and two 
remained the same, that is patients who live in the two most deprived fifths of areas in England. 
The remaining three quintiles were recoded into one category to represent the least deprived 
patients. This method was favoured over assigning patients into nationally created tertiles. This 
was explored, but, the majority of patients in the South Tees area live in the most deprived third 
of English LSOA therefore the above method was chosen as it produced three fairly evenly 
distributed groups whilst being related to a national scale. 
 
Health status, socio-demographic, anthropometric and lifestyle data 
 
The following data discussed in this section measure a wide range of aspects of patients’ health 
which were used as either outcome variables and/or controlled for in the statistical analyses. 
This was to establish what impact the difference in diabetes care patients receive has on their 
health and/or whether patients with the same health status receive different care. Indicators of 
patients’ socio-demographic, anthropometric and lifestyle which can have an impact on 
patients’ health outcomes were also extracted. These were chosen based on what was available 
from the chosen datasets and their relevance to the statistical analyses. As such, all data were 
extracted from the diabetes register as this dataset contained a large sample of patients who 
had multiple measurements taken over time.  
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Socio-demographic, anthropometric and lifestyle data 
 
Patients’ sex and ethnicity as inequalities in health outcomes by these population groups have 
been well documented (for example: [182-186]) and specifically for type 2 diabetes as shown in 
the literature review for this study in chapter three. In the proforma, patients’ ethnicity was 
coded as either: ‘White’, ‘South Asian’, ‘Afro-Caribbean’ or ‘Other ethnicity’. To aid interpretation 
in the statistical analyses the ethnicity variable was recoded into three categories. White and 
South Asian categories remained the same and Afro-Caribbean ethnicity was recoded to be 
included in the ‘Other ethnicity’ due to the small numbers of both these categories. The 93 
records, from 56 patients, with no ethnicity recorded were also removed. Seven records, from 
one patient, did not have a recording of sex. Therefore these were also removed. 
Patients’ ages were extracted as insulin deficiency increases over time. It is recognised that 
diabetes care should be delivered taking into account the age of the patients [46]. Therefore, 
this could be an important explanatory variable in the analyses. The age in whole years of all 
patients at the end of 2007 were extracted by the database manager using patients’ dates of 
birth. The dates of birth were then removed before releasing the data in order to protect this 
patient identifiable data. This variable was 100% complete. Patients’ age per year was 
calculated using this data plus the year of visit. Again, to enable identification of non-linear 
relationships this variable was recoded into a categorical variable where 1 = patients aged 
under 60 years old, 2 = 60 and over and less than 75 years old, and 3 = aged 75 and over.  
Due to the progressive nature of the condition the duration since diagnosis is an important 
determinant of health outcomes. The years of patients’ diagnosis, which are routinely recorded 
on the diabetes register performa, was extracted. The duration of patients diabetes in whole 
years was calculated using this and the year of visit. Following cross tabulation, those who had 
the year of diagnosis following the year of visit had these values removed: 112 values from 85 
patients. This variable was recoded into a categorical variables where 1 = 0-3, 2 = 4-9 years and 
3 = 10 or more years since diagnosis.  
Body mass index (BMI) and smoking status were also extracted as these both measure aspects 
of patients’ lifestyle which can impact on many of the health outcome variables used for this 
analysis [46]. Body mass index (kg/m2) is calculated by the data input team from weight and 
height which are measured by the practitioner. Both patients’ weight and BMI were extracted; 
from these values patients’ heights were calculated. As recommended by the diabetes register 
team recordings of weight outside 0-220 kg and height below or equal to 0.8 and greater than or 
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equal to 2.1 metres were considered inaccurate and were removed from the dataset. When 
inspecting the BMI data by patient over time, both with the original BMI values and ‘cleaned’ 
weight and calculated height values, there were many instances of large variation. For instance, 
of those patients with more than one recording of BMI, approximately 20% of these values for 
BMI differed by over 5 kg/m2. An increase of over 5 kg/m2 could mean a patient is categorised 
as underweight then overweight. However, due to the nature of diabetes, it is possible that 
patients experience sudden weight gain and/or loss over a short period of time. It is, therefore, 
not possible to judge with confidence whether these large variations in patients’ BMI was an 
accurate reflection of their body mass due to changes in health and/or result of treatments or 
result of recording and/or measurement error. To minimise the risk of measurement error, the 
median height for patients with three or more values which were able to be calculated were 
used for a recalculation of patients’ BMI at all time points. Median values were chosen as the 
mean is skewed more by extreme values. These median height values were also used to 
calculate the BMI for patients who did not have their height recorded for that year but had their 
weight recorded. BMI values greater than 100 were subsequently removed following this 
recalculation. Where less than three calculations of height per patient occurred the original BMI 
calculation was used. 
Following initial modelling, the BMI variable was further formatted to establish whether there 
were non-linear trends and was recoded into a categorical variable where 1 = ‘Under or normal 
weight’ where BMI is less than 25 kg/m2, 2 = ‘Overweight’ where  BMI is equal to or greater than 
25 kg/m2 and less than 30 kg/m2,  and 3 = ‘Obese’ where BMI is equal to or greater than 30 
kg/m2. 
On the diabetes register proforma patients’ smoking status is recorded as either yes, no or ex-
smoker, noted as 0, 1, or 2 respectively. This information is based on self-report. From a visual 
inspection of the data it is clear that some patients have been categorised as non-smokers whilst 
having been recorded as a smoker in previous years, therefore, any recording of ‘0’ following a 
recording of ‘1’ in an earlier year was changed to a recording of ‘2’ to reflect the previous and 
current smoking status per patient. This is based on the assumption that an ex-smoker is more 
likely to be inaccurately recorded as a non-smoker than an inaccurate recording of being a 
smoker previously. 
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Health status data 
 
Intermediate outcomes 
 
As outlined in more detail in chapter two, type 2 diabetes patients have an increased risk of 
cardiovascular and micro vascular complications. Good control of blood glucose levels, BP and 
lipid profiles can reduce patients’ risk of these complications. These risk factors are therefore 
recommended by NICE to be routinely monitored to enable effective decision making regarding 
appropriate treatments [46].  
HbA1c is a measurement of a patients’ blood glucose control over the previous three months. 
High levels of HbA1c increases patients’ risk of complications and HbA1c should ideally be 
maintained at 6.5% or lower [46]. As recommended by the register staff, values were limited to 
those greater than or equal to 2.5 and less than or equal to 23. 198 values outside this range 
were removed, leaving 80 patients without a recording for HbA1c during the study period 
[187].  
High BP also carries increased risk of complications and therefore it is recommended in care 
guidelines that patients should be maintained at 130/80 millimetre of mercury (mmHg) or 
lower [46]. Whilst there were no specific limits for expected values of systolic BP (sBP, the 
numerator value) or diastolic BP (dBP, the denominator value) were provided by the register 
team, if the corresponding sBP was equal to or less than its dBP value both were removed. 
However, following a visual inspection of the range of values for both measures, any value of 
sBP less than 60 and greater than 260 were removed. Likewise, values of dBP less than or equal 
to 0 were removed. These were done of the basis of the marked differences in values compared 
to the rest of the study population.  
To enable more complex analyses only sBP was analysed as an outcome variable. This figure 
was chosen, rather than dBP or a binary hypertensive variable, because sBP deteriorates with 
age.  In addition, dBP is more commonly evaluated in people aged less than 50 years old [65].  
Cholesterol (mmHg) is one indicator which makes up an individuals’ lipid profile and it is 
recommended by NICE to be monitored and targeted to ensure that patients’ risk of 
cardiovascular disease (CVD) is reduced. As recommended by the register staff, values were 
limited to those greater than or equal to 1.5 mmHg  and less than or equal to 40 mmHg [187]. 
Values outside this range were removed. LDL-c, HDL-c and triglycerides form the rest of the 
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lipid profile and were also extracted from the register dataset. Yet despite them being identified 
as key risk factors for CVD, the low level of the recording for these indicators over the study 
period (see appendix D) meant they were not as suitable for inclusion in the analysis of 
cholesterol.  
National Institute for Health and Care Excellence recommends measuring creatinine and the 
estimated glomerular filtration rate (eGFR) using the abbreviated modification of diet in renal 
disease (MDRD) four-variable equation annually. Estimated glomerular filtration rate is 
discussed in the next section. Both are indicators of patients’ kidney function, with higher rates 
indicating poorer function. However, both measures are problematic due to variation depending 
upon other factors, such as body muscle mass. Creatinine levels can vary quite dramatically. 
Following advice from the diabetes register staff, these values were limited to those greater 
than or equal to 20 and less than or equal to 1400. Values outside this range were removed. In 
addition, a new binary variable indicating whether patients had a creatinine level greater than 
300 μmol/l was created in order to control for this when analysing blood glucose outcomes. 
Having a high creatinine levels can affect the way blood glucose is treated. 
 
Diabetes related complications 
 
Chapter two outlined in more detail the consequences of type 2 diabetes. The complications 
described here are those which were recorded in the final dataset. 
Patients’ vascular history is recorded as ‘1’ for ‘Yes (ever)’ and ‘0’ for ‘No’ for the following 
groups of conditions: ‘Ischaemic Cardiac Disease’ (ICD), this refers to angina, myocardial 
infarction and/or heart attack [188]; a stroke or transient ischemic attack (TIA); and/or 
peripheral vascular disease (PVD). However, the date of the first vascular event is not recorded. 
To retain consistency in the recording of these indicators any recording of ‘0’ for ‘No’ following a 
recording of ‘1’ for yes was recode to ‘1’. This was based on the assumption that the initial 
recording was more likely to be accurate. 
Retinopathy, at the time these data were extracted, was recorded in the diabetes register as 
follows: 0 = None, 1 = Background, 2 = Pre-Proliferative, 3 = Proliferative. However, during the 
study period these categories have changed several times, as such, the database manager 
recoded the data prior to releasing the data. The new variables were categorised as follows: 0 = 
None, 1 = Background, 2 = Advanced; where advanced retinopathy is anything more serious 
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than background retinopathy. The data from the diabetic retinal screening programme for 2006 
and 2007 were recorded as follows: R0M0 = No diabetic retinopathy, no maculopathy; R1M0 = 
Background diabetic retinopathy, no maculopathy; R1M1 = Background diabetic retinopathy, 
maculopathy; R2M0 = Pre-proliferative diabetic retinopathy, no maculopathy; R2M1 = Pre-
proliferative diabetic retinopathy, maculopathy; R3M0 = Proliferative diabetic retinopathy, 
maculopathy; R3M1 = Proliferative diabetic retinopathy, maculopathy. Due to the prevalence of 
some of the grades being very low, particular at the severe end of the scale, all the retinopathy 
data were recoded into a binary variable with any retinopathy recorded 1 and 0 if not. In 180 
cases the values between the sources conflicted. In these cases the values from the retinal 
screening programme were favoured as this is the primary source. 
Estimated glomerular filtration rates were calculated per patient per year for those who had a 
recording of their age, ethnicity and creatinine level. The calculation was made using 
abbreviated Modification of Diet in Renal Disease equation as recommended by NICE, SIGN, and 
the Renal Association [66]:  
eGFRml/min/1.73m2 = 186 x (Creatinine / 88.4)-1.154 x (Age)-0.203 x (0.742 if female) x 
(1.210 if black) 
This calculation estimates the severity of kidney damage. Normal kidney function is considered 
greater than 90mls/min/1.73m2. The lower the eGFR the greater the damage to kidney function 
[66]. It should be emphasised that this calculation is only an estimate and several factors are 
likely to affect the accuracy of the result including: extreme body types, for example amputees; 
some ethnic groups and if creatinine levels are unstable or near normal. For near normal levels 
of creatinine the calculation tends to underestimate eGFR [66]. 
Ideally eGFR would have been modelled as an outcome variable, however, the results were not 
robust enough. As a consequence, the binary variable indicating whether microalbuminuria was 
present or not was used. This variable was chosen as monitoring for microalbuminuria is one of 
the NICE recommended care processes.  
 
Missing data 
 
Secondary datasets can have varying degrees of quality in terms of accuracy and consistency of 
recording. Data can be missing from a dataset for various reasons and can cause various 
problems for analysis with varying degrees of severity. 
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One of the biggest problems associated with missing data is unit non-response; cases where no 
data was collected. This is contrasted with item non response where partial data is available but 
for individual indicators data is missing. This missing data results in these patients not being 
represented within analysis. This becomes a particular problem when it is particular population 
groups who do not engage with services as bias can be introduced to the analysis. Unfortunately 
this problem cannot be overcome with particular statistical techniques and can only be 
overcome by improvements in the initial data collection [172, 189]. 
Item non-response is a greater or lesser problem depending upon the pattern of ‘missingness’. 
The first reason and least problematic is missing completely at random (MCAR). That is, the 
measurement missing is not related to its value or any other measurements in the dataset. For 
example, this would be violated if not having BMI recorded was related to patients being 
heavier and/or more deprived than those who had their BMI recorded. Missing completely at 
random is the most unlikely pattern of missing data. A more plausible assumption is that data 
are missing at random (MAR). In this scenario missing body mass index data, for example, could 
be related to another indicator such as deprivation but not with the value of BMI itself. It is not 
possible to be completely certain whether data is MAR as the value of the missing data is not 
available [172, 189]. There are various statistical analysis techniques which can be used for 
tackling the problem of MCAR or MAR data, however, missing data which does not satisfy these 
assumptions are more problematic. Whilst there are techniques for handling other missing data 
these are a lot more complicated and the estimated data is very sensitive to the models used. In 
addition, a very good knowledge of the reasons for missingness is required [172].  
There are several methods for how to deal with partially missing data, however, many are 
relatively naïve and can introduce bias and reduce the precision of the subsequent analyses. An 
extremely common solution to dealing with missing data would be to only use complete cases; 
also known as listwise deletion. It is a technique that can be used for any type of statistical 
analysis. If the data is MCAR then the remaining cases represent a subsample of the larger 
sample but if it is MAR then bias can be introduced, especially if patterns of association vary 
between different population groups. In multivariate analyses the regression coefficient will be 
biased if the chance of being a complete case is related to the outcome variable after controlling 
for the other variables in the model. Pairwise deletion or available case analysis are similar to 
complete-case analysis but retains the complete cases for the variables for particular analyses. 
These also suffers the same potential in reduce precision and introduction of bias [172, 189]. 
There are several methods that could be described as single imputation where missing values 
are replaced with an estimated value. These methods include using the mean, median or values 
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generated from regression analysis of the observed data which could be from complete data of 
the same dataset or using similar, external data. In longitudinal data, carrying the last 
observation forward can be used to replace the missing data. All these techniques tend to 
underestimate the variance and again can introduce potential bias in the parameter estimates 
[172, 189].  
The general principle of multiple imputation (MI) is to use the existing correlations between the 
observed data to predict a range of other plausible values. The variability in the range of values 
allows this uncertainty to be included in the final analysis whilst maintaining statistical power, 
unlike the more naïve approaches described above. This is also in contrast to maximum 
likelihood (ML), which accounts for the missing data but does not predict what it may have been 
[190].  
Modelling data using MI is computationally intensive and becomes more complex when data has 
underlying multilevel structure.  A less demanding approach to overcoming uncertainty in point 
estimates in statistical analyses due to missing data is Markov Chain Monte Carlo (MCMC) 
estimation.  The advantage of this technique is that it can be applied to a wide number of 
statistical models and can take into account data with multilevel structures, MCMC estimations 
take a large number of random samples from the known data to estimate the unknown 
parameters with the aim to produce more robust interval estimates. It is an iterative process 
using the previous results to produce the next set of estimations with the aim to produce values 
based upon the unknown parameters and produce more accurate interval estimates [191]. 
Prior to any statistical analyses, the prevalence and patterns of cases overall and per patient, the 
completeness of each variable and potential mechanism of missing data were explored. The 
purpose of examining these issues was to establish the appropriateness of study design, analysis 
methods and which variables to use. This was done in three steps. 
Firstly, a table of patients’ attendance at any participating healthcare provider per year was 
created using the final linked dataset. Then the missing patterns command in STATA [192] was 
used to examine the pattern of patient attendance over the study period. Figure 12 depicts the 
25 most frequent patterns of patients’ attendance, at any participating healthcare provider, 
representing just over 90% of the 13,597 subjects whose data is included in the final dataset. 
The most common pattern of attendance at any participating healthcare provider is every year 
between 1999 and 2007. However, this equates to only 21% of the study population. Markedly, 
the second most frequent pattern is subjects’ having data recorded in 2006 and 2007, 8% of the 
study population. The overall pattern in Figure 12 shows that in general data capture improves 
over the study period. This is likely to reflect the increased prevalence of this period but may 
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also be a result of improved care and recall procedures; something which is explored further in 
these analyses. 
In addition, Figure 12 shows that the final dataset contains unbalanced repeated measurements 
for over 10,000 patients. Unbalanced refers to the varying number of cases for each patient. 
Multilevel regression models are the most appropriate set of methods for this dataset as these 
methods can account for this clustering of measurements within patients and there is no 
assumption of equal numbers of cases for each patient [193].  
 
Figure 12: Top 25 most frequent patterns of subjects’ attendance at any participating healthcare 
provider 
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The second step with examining missing data was to the rate to which each variable was 
complete as a total of the number of cases for that year. The purpose of this was to establish 
which variables were appropriate for the inclusion in the final analyses. As mentioned 
previously, Appendix D contains tables showing the percentage that each variable considered 
for the analyses as a total of the numbers of cases per year. The tables were conditionally 
formatted with colour to ease interpretation: Bright yellow indicates 100% completed with red 
at the other end of the spectrum indicating no data for that variable that year. 
The level of missing data per variable per year was discussed in more detail in the Appendix D. 
Two particular findings were of note: the level of missing data regarding HbA1c at the time of 
diagnosis and QOF data being recorded from 2004 onwards. These data were therefore 
analysed separately. 
The final issue to explore regarding missing data was whether data was MCAR, MAR or not at 
random. As there is no way no knowing what the missing values were it is assumed that the 
data are either MCAR or MAR. To explore this issue the outcome variables were recoded as ‘1’ 
for recorded and ‘0’ for missing. Then using logistic regression analyses, the odds ratio of these 
new outcomes variables were calculated controlling for the following demographic variables: 
deprivation level, ethnicity, age and sex. The results in Appendix E show that the mechanism for 
missing data is not random and there are statistically significant relationships between the 
demographic of patients and missing data. However, these relationships were not uniform 
across all variables and patient characteristics.  
From these analyses of missing data, multilevel regression techniques were chosen using 
available case analyses. Using available cases instead of complete case retains more data in the 
model as patients with data for some years but not others can be retained. Multiple imputation 
of the dataset was considered to overcome the potential bias the missing data could introduce. 
However, due to the size of the dataset, the number of variables and the cross-classified, 
multilevel structure of the data producing robust imputations would be extremely 
computationally demanding. To overcome the uncertainty of the point estimates produced in 
analyses, the data were modelled with MLwiN in Stata using Markov Chain Monte Carlo (MCMC) 
estimation option [191]2. These methods take a large number of random samples from the 
known data to estimate the unknown parameters with the aim to produce more robust interval 
estimates [191]. 
                                                          
2
 The initial plan was to fit the models using the maximum likelihood (ML) method, IGLS (iterative generalized 
least squares), followed by the final models being fitted with MCMC. The rerun of the final models was going 
to act as a sensitivity analyses on IGLS fitted models which are computationally less demanding. However, 
many of the models using IGLS failed to convergence rendering the results unreliable therefore MCMC was 
used throughout. 
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The MCMC method has the added advantage that it can handle cross-classified data [191], which 
is data which is not strictly hierarchical. That is whilst repeated measurements are nested 
within patients who in turn are nested within general practices; about 7% of the patients in the 
study population changed practices at least once during the study period. Not accounting for 
these changes in the nesting of the data may bias the results. The diagram below illustrates the 
structure of the data. 
 
Figure 13: Diagram of the cross-classified data structure 
 
 
 
Statistical analyses 
 
The literature review highlighted the lack of complex analyses over time. This was mainly due to 
most of the data used in the final sample either being cross-sectional or only having two or 
three different measurements over time. This limited the type of analysis that could be 
conducted.  
Two papers in the final sample made use of multilevel analyses [110, 120]; statistical methods 
which are becoming increasingly popular in health research. However, whilst the authors had 
repeat measurements these were not treated as such, with measurement occasions (years) 
being nested within subjects and analysed using multilevel regression models. Instead the 
authors only accounted for the clustering within place of care.  One of the advantages of 
multilevel analyses is that it does not assume equal number of measurement occasions and 
allows for all observations to be retained in the model. This is in contrast to analyses such as 
MANOVA where, if there is a missing observation of an outcome variable, the entire case is 
Anna Christie Page 103 
removed from the analyses [193]. Here that would mean entire cases would be removed 
potentially leading to bias in the results.  In contrast, multilevel analyses retains each occasion 
where the outcome variable is recorded rather than deleting the entire case. However, this only 
applies to outcome variables. That is, if any explanatory variable was missing that case data was 
deleted. 
Multilevel analysis, and Generalized Estimating Equations (GEE), are both able to take into 
account the potential hierarchical nature of health datasets. For example, patients are clustered 
within general practices which can influence their health outcomes. Using these techniques 
allows for the exploration of these factors, as well as controlling for them [193]. However, 
multilevel analysis is generally favoured as it is more flexible in terms of comparing 
relationships between groups, i.e. random coefficients, as well more complex data structure 
such as cross-classified and multiple memberships. That is, not all data are strictly hierarchical, 
as patients may change practices during a study period (cross-classified) or belong to two 
services at the same time (multi-membership).  
Multilevel modelling techniques, such as time-lag models and autoregressive, are also able to 
take into account the relationships between repeated measurements using random coefficient 
regression. These techniques have the advantage that they are able to measure change over 
time and can measure the relationship between explanatory and outcome variables being 
modelled. However, assumptions, particularly with observational data, have to be taken about 
the directional of the relationships between the variables and what constitutes change in the 
outcome variables. Measuring change in particularly problematic when there are floor and 
ceiling effects in continuous variables, for example HbA1c [194]. 
Ideally random coefficient modelling would have been used for the statistical analyses. 
However, it was not possible using this data as the models failed to convergence. As a 
consequence, interaction effects between visit year and SES were used an alternative to 
exploring longitudinal change by SES. This is a common, practical alternative to measuring 
differences in outcome variables over time by different groups (for example: [32, 195, 196]).  
The remainder of this section describes each stage of analysis beginning with the general 
aspects moving through to specific analyses used to answer each question. This was an iterative 
process with earlier stages informing the remaining analyses.  
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Stage one: Descriptive univariate analyses 
 
The purpose of this stage was to describe the final dataset. These summary statistics are useful 
for establishing if there were any initial patterns of inequalities but they do not take into 
account any explanatory variables.  
Univariate analyses were conducted calculating the mean, median or proportion of each 
variable by SES, as measured by IMD grouped into quintiles reflecting the national distribution. 
Ninety-five percent confidence intervals were used here and in subsequent analyses, where 
appropriate, to identify if any inequalities reached statistical significance. Variable were 
considered to make a statistically significant contribution to a model if the 95% confidence 
intervals did not cross 0. When examining comparative results, findings are considered 
statistically significant from each other if the confidence intervals did not overlap [197].  
The median rate for each general practice and QOF variable was calculated, along with the 
interquartile range, by PCT. These outcomes were particularly skewed; therefore the mean was 
an inappropriate statistic. This data were compared by PCT as calculating the distribution by 
patient would have been inappropriate due to practices with a high proportion of type 2 
diabetes patients would have been overrepresented in the analyses. These descriptive analyses 
provide an overview of the variation in these variables whilst comparing the quality of general 
practices by PCT. 
Finally, intermediate outcomes, complications and interventions variables, which were used as 
dependent variables in the multilevel models, were graphical analysed by SES over time to 
examine whether they varied. Mean or percentage rates were used with 95% confidence 
intervals calculated to identify if any inequalities reached statistical significance. Due to the way 
patients’ history of vascular disease were recorded the results from year 2000 onwards reflect 
only new incidences of these complications for that year. As such, once a patient had been 
recorded as having ICD, stroke or TIA or PVD their records were not included in subsequent 
years. This was done to avoid double counting. The same approach was used in the multilevel 
modelling, where data from 1999 was also excluded to ensure the results were not biased by 
patients with existing complications prior to 1999. 
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Stage two: Random intercept multilevel modelling 
 
Prior to fitting any multilevel models, a series of analyses were estimated to establish whether 
multilevel models were statistically necessary. These models were also estimated to see if 
having random intercept and/or random coefficients of SES were appropriate and at which 
level. These initially showed that due to the lack of variance of SES at the patient level that 
random coefficient models with SES at this level was not appropriate. A random intercept was, 
therefore, used at each level of the linear and practice and patient levels only for logistic 
multilevel regression analyses. Except where stated otherwise, all models were fitted with 
repeated measurements nested within patients who were cross-classified with general 
practices. 
To ensure that the models had converged effectively each modelled was fitted using MCMC 
estimation for 100,000 iterations after a 10,000 burn-in, the number of iterations conducted 
before the iterations for the final MCMC estimation. This was chosen as a compromise between 
accuracy and timeliness as while a longer burn in length may have produced more reliable 
results an increase would have required more time and be more computationally demanding.  
The Deviance Information Criterion (DIC) is often used as a measure of how a model fits the 
data, using information about both the fit and complexity of a particular model [191]. Here the 
Bayesian DIC statistics were compared to see if the more complex models fitted the data better 
than previous, simpler models. A smaller result indicates that there is less unexplained variance 
in the model and therefore it has a better fit. The intraclass correlation coefficients (ICC) of the 
null were calculated to establish how much variation was explained at the level of general 
practice level.  
 
Ƿ = 
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Stage three: Analyses of research question one and two 
 
1. Are there socio-economic inequalities in intermediate outcomes and 
complications associated with type 2 diabetes over time?  
2. Are there socio-economic inequalities in interventions associated with type 2 
diabetes over time? 
 
A series of models with each intermediate outcome, long-term complication and intervention as 
the dependent variable were estimated to see if there were inequalities by patients’ SES. These 
models were fitted with an interaction effect between SES and visit year to examine if 
inequalities occurred throughout the study period.  
A stepwise approach to the analyses was used to compare how much the variation was 
explained by the introduction of sets of variables. In the first step, a null model was fitted to 
establish how much variance of the dependent variable occurred at each level. Secondly, the 
interaction effect between SES and visit year was added to see if there were statistically 
significant associations with the outcome variable occurred prior to other data being added to 
the model. Next, relevant socio-demographic, anthropometric, lifestyle and health covariates 
were added to see if any significant inequalities were explained by controlling for this data. In 
all models these data were as follows: socio-demographic – age, duration of diabetes, ethnicity, 
gender; lifestyle – smoking status and BMI. The included health data varied depending upon the 
outcome variable as not all were directly relevant. Having a creatinine level greater than 300 
was only included when analysing patients’ HbA1c. Being hypertensive was included in all 
models except when blood pressure treatments were under investigation where the separate 
continuous variables sBP and dBP were used instead. Cholesterol was included in all models 
except when analysing HbA1c and cholesterol. eGFR was included was analysing long-term 
complications and intervention outcomes. History of ICD, stroke or TIA and PVD were included 
in the analyses of intermediate health outcomes and intervention variables. Retinopathy and 
microalbuminuria were not included as their low recording rates would have reduced the 
number of available cases and therefore the robustness of the results. In the final step 
intervention data were added. In general, all other intervention data were considered important 
factors in the outcomes and, therefore, included in the models with a few exceptions. Firstly, it 
was not included when it was the dependent variable. General practice data were only included 
in sub-analyses for question four, due to only being recorded in the latter half of the study 
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period. Diabetes treatments were not included in cholesterol model, lipid therapies and aspirin 
were not included in HbA1c model, and no other treatment data were included when 
inequalities by SES in prescription of treatments were being modelled. This was because these 
relationships would have been difficult to interpret.  
The health outcomes HbA1c and cholesterol, and the variables indicating the quality of care a 
patient receives and the timeliness of diagnosis were modelled as continuous outcome variables 
using linear mixed effect models: 
  
All long-term complications and variables indicating patients’ receipt of diabetes treatments, BP 
treatments, aspirin, lipid therapies and shared care were modelled as binary variables using 
logistic random-intercept models.  
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Stage four: Analyses of research question three 
 
3. Are there intervention-generated inequalities in type 2 diabetes care? 
 
This question was answered by modelling health outcomes with interaction effects between SES 
and interventions. Significant results in the interaction effects were interpreted as the 
intervention differed in its association with the health outcome according to the patients SES 
and therefore could indicate the presence of intervention generated inequalities. That is, that 
interventions were differentially effective according to SES.  
A stepwise approach to the analyses was used to compare how much the variation was 
explained by the introduction of sets of variables. Firstly, the null model to establish how much 
variance of the dependent variable occurred at each level. Secondly, an SES only to see if there 
were statistically significant associations with the outcome variable occurred prior to other data 
being added to the model. Next relevant socio-demographic, anthropometric, lifestyle and 
health covariates, the same which were used for the models estimates for question one and visit 
year, were added to see if any significant inequalities were explained by controlling for this 
data. Next relevant intervention data were added, the same as question one, and finally the 
interaction effect between the intervention of interest and SES.  
 
Stage five: Analyses of research question four 
 
4.  What impact do general practices have on inequalities by socio-economic status 
in diabetes care and health outcomes? 
 
This question was addressed in two ways. Firstly, two series of models with HbA1c and 
cholesterol as dependent variables were fitted using the same forward stepwise approach as 
question three, excluding the interaction term. Here general practice data, including QOF 
indicators, were added as a final step of these analyses. This was to establish whether any of 
these indicators had an impact on the relationship between SES and intermediate outcomes.  
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Secondly, the ICC of all the multilevel analyses was reviewed to establish what impact 
accounting for clustering at general practice had on the overall analyses. A larger coefficient at 
this level indicates a greater variation in health outcomes and uptake of interventions by 
general practices suggesting care was not consistent across all practices.  
 
Presentation of results 
 
In the following five chapters, the results are displayed in a series of tables and described, with a 
chapter for the initial descriptive analyses and one for each of the four research questions. The 
results of the fully saturated models are displayed, with the preceding stepwise models 
displayed in Appendices F-I. Due to the relationship between each set of analyses these chapters 
should be viewed together as cross references between them are made throughout.  
The results for the research questions in the subsequent chapters were followed by a summary 
of the principle findings. The main discussion in chapter eleven explores the strength and 
limitations of the data and methods, the possible mechanisms and implications for clinicians 
and policymakers and finally the unanswered questions and future research. 
Due to the volume of tables and variables included in each model the variables which reached 
statistical significance were coloured coded to ease the interpretation of the results. In the 
descriptive results, the SES group with the highest results were coloured red and the lowest was 
coded green, if the results were significantly different were each other. In the multilevel 
analyses, the variables were coloured red or green if they were positively or negatively 
associated with the outcome variable, respectively.  
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Chapter 5: Descriptive Results 
 
This chapter provides an overview of the final dataset using univariate analyses to illustrate the 
distribution of the available variables for the analysis across three socio-economic status 
groups. In addition, the outcome variables used in the multilevel models were also graphically 
analysed to examine whether there were socio-economic inequalities over time. The results 
were summarised and referred to in the subsequent results chapters.  
 
Socio-demographic, anthropometric and lifestyle data 
 
Table 1 contains patients’ socio-demographic, anthropometric and lifestyle data by socio-
economic status. The results show that there were a higher proportion of men than women 
across each SES group in the study population. Over 90% of the patients were White and there 
was a statistically significant higher proportion of non-White patients in low SES patients 
compared to the high SES patients. Low SES patients were significantly younger at the end of 
2007 and at the time of diagnosis than the rest of the study population. Using all patient records, 
the mean BMI and weight by SES indicated negative social gradients, with low SES patients 
having a significantly greater BMI and weight than the rest of the study population. 
Interestingly, high SES patients were both significantly more likely to be ‘under or normal 
weight’ or overweight but significantly less likely to be obese than low SES patients. There were 
significant social gradients in rates of current and non-smokers in patient records overall. With 
greater proportions of smokers in low SES patients. There are no differences in the duration of 
diabetes in whole years.  
 
Health status data 
 
Using all available patients’ records, Table 2 contains the intermediate health outcomes 
statistics for study population by SES. The results show that there were statistically significant 
differences by SES in mean sBP, with low SES patients having lower sBP than the rest of the 
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study population. In contrast, there were no significant differences in mean dBP or when these 
variables were measured as a binary variable indicating hypertension. Low SES patients had a 
significantly higher mean HbA1c compared to the rest of the study population. There were no 
differences in mean levels of cholesterol. Interestingly, mean creatinine levels were significantly 
lower in low SES patients compared to the high SES patients. 
Table 3 displays the results for long-term complications statistics for the study population by 
SES. Long-term complications were compared by patients, and not patient records, with the 
‘worst’ outcomes compared. There were clear negative social gradients in rates of PVD and 
retinopathy, with higher rates seen in low SES patients compared to high SES patients. Higher 
rates of ICD and stroke or TIA tended to be associated with low SES patients compared to high 
SES patients, but were not statistically significant. Rates of eGFR by SES reflect the findings for 
creatinine levels, with low SES patients having higher rates than high SES patients. However, 
there were no significant differences in microalbuminuria by SES.
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Table 1: Socio-demographic, anthropometric and lifestyle data by socio-economic status  
 Statistic Low SES Mid SES High SES Total No. of Obs 
Number Number 
(%) 
6,319 
(46.5) 
3,262 
(24.0) 
4,016 
(29.5) 
  
Male % 
(95% CI) 
52.6  
(51.3, 53.8) 
53 .2 
(51.5, 54.3) 
55.8  
(54.3, 57.3) 
53.7 
(52.8, 54.5) 
13,597 
Ethnicity White % 
(95% CI) 
91.6  
(90.9, 92.3) 
96.8  
(96.2, 97.4) 
96.0 
(95.4, 96.6) 
94.2 
(93.8, 94.6) 
South Asian % 
(95% CI) 
7.1  
(6.4, 7.7) 
2.7  
(2.2, 3.3) 
3.4  
(2.8, 4.0) 
4.9 
(4.6, 5.3) 
Other % 
(95% CI) 
1.3 
(1.0, 1.6) 
0.5 
(0.2, 0.7) 
0.5 
(0.3, 0.8) 
0.9 
(0.7,1.0) 
Age at the of end of 2007 (years) Mean 
(95% CI) 
66.6  
(66.3, 67.0) 
69.3  
(68.9, 69.8) 
69.7  
(69.2, 70.4) 
68.2  
(67.9, 68.4) 
Age at diagnosis (years) Mean 
(95% CI) 
58.0  
(57.6, 58.3) 
60.6  
(60.1, 61.1) 
61.0  
(60.6, 61.4) 
59.5  
(59.3. 59.7) 
Duration of diabetes (years) Median 
(IQR) 
7 
(7, 7) 
7 
(7, 7) 
7 
(7, 7) 
7 
(7, 7) 
69,226 
BMI (kg/m2) Mean 
(95% CI) 
31.4  
(31.4, 31.5) 
30.8  
(30.7, 30.9) 
30.1  
(30.0, 30.2) 
30.9  
(30.8, 30.9) 
53,342 
BMI categories Under or 
normal weight 
% 
(95% CI) 
14.2 
(13.8, 14.6) 
14.6 
(14.0, 15.2) 
16.3 
(15.7, 16.8) 
14.9 
(14.6, 15.2) 
 Overweight % 
(95% CI) 
30.8 
(30.2, 31.4) 
35.5 
(34.6, 36.3) 
39.1 
(38.4, 39.9) 
34.4 
(34.0, 34.8) 
 Obese % 
(95% CI) 
55.0 
(54.4, 55.6) 
49.9 
(49.0, 50.8) 
44.6 
(43.8, 45.4) 
50.7 
(50.3, 51.2) 
Weight (kg) Mean 
(95% CI) 
86.5  
(86.3, 86.8) 
85.9  
(85.5, 86.2) 
84.9  
(84.6, 85.2) 
85.9  
(85.7, 86.1) 
56,275 
Smoking Status No % 
(95% CI) 
34.5 
(34.0, 35.1) 
39.6 
(38.8, 40.4) 
42.3 
(41.6, 42.9) 
38.0 
(37.6, 38.4) 
58,974 
Yes % 
(95% CI) 
22.6 
(22.1, 23.1) 
15.5 
(14.9, 16.1) 
10.5 
(10.0, 11.0) 
17.5 
(17.1, 17.8) 
Ex % 
(95% CI) 
42.8 
(42.3, 43.4) 
44.9 
(44.1, 45.7) 
46.4 
(45.4, 47.5) 
44.6 
(44.2, 45.0) 
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Table 2: Intermediate health outcomes statistics for study population by socio-economic status 
 Statistic Low SES Mid SES High SES Total No. of Obs 
sBP (mmHg) Mean 
(95% CI) 
139.4  
(139.2, 139.6) 
140.8 
(140.5, 141.1) 
140.6 
(140.3, 140.9) 
140.1  
(139.9, 140.2) 
62,195 
dBP (mmHg) Mean 
(95% CI) 
77.9  
(77.7, 78.0) 
77.6  
(77.4, 77.7) 
77.6  
(77.4, 77.7) 
77.7  
(77.6, 77.8) 
60,573 
Hypertensive 
(mmHg) 
% 
(95% CI) 
36.8 
(36.2, 37.3) 
36.7 
(35.9, 37.5) 
35.9 
(35.2, 36.6) 
36.5 
(36.1, 36.9) 
60,545 
HbA1c (%) Mean 
(95% CI) 
7.8  
(7.8, 7.8) 
7.6  
(7.6, 7.6) 
7.6  
(7.5, 7.6) 
7.7  
(7.7, 7.7) 
61,368 
Cholesterol 
(mmol/l) 
Mean 
(95% CI) 
4.8  
(4.7, 4.8) 
4.8  
(4.8, 4.8) 
4.7  
(4.7, 4.7) 
4.8  
(4.7, 4.8) 
60,437 
Creatinine (μmol/l) Mean 
(95% CI) 
101.0 
(100.6, 101.5) 
101.9 
(101.2, 102.5) 
102.6 
(102.0, 103.2) 
101.7 
(101.4, 102.0) 
60,886 
 
Table 3: Long-term health outcomes statistics recorded during the study period by socio-economic status 
 Statistic Low SES Mid SES 5 = High SES Total No. of Obs 
eGFR Mean 
(95% CI) 
65.6  
(65.4, 65.9) 
64.1  
(63.8, 64.4) 
63.9  
(63.6, 64.1) 
64.7  
(64.6, 64.9) 
57,880 
ICD 
 
% 
(95% CI) 
34.0 
(32.9, 35.2) 
34.5 
(32.8, 36.2) 
31.7 
(30.2, 33.1) 
33.6 
(32.8, 34.4) 
13,178| 
Stroke or TIA 
 
% 
(95% CI) 
14.0 
(13.1, 14.9) 
15.3 
(14.0, 16.6) 
13.6 
(12.5, 14.7) 
14.2 
(13.6, 14.8) 
13,168 
PVD % 
(95% CI) 
11.0 
(10.2, 11.8) 
10.5 
(9.5, 11.6) 
8.8 
(7.9, 9.7) 
10.2 
(9.7, 10.8) 
13,139 
Any retinopathy % 
(95% CI) 
28.1 
(26.9, 29.4) 
27.7 
(25.9, 29.4) 
21.4 
(17.0, 25.7) 
27.5 
(26.7, 28.4) 
10,713 
Microalbuminuria % 
(95% CI) 
54.6 
(53.3, 56.0) 
48.9 
(47.0, 50.8) 
53.7 
(48.2, 59.3) 
52.1 
(51.1, 53.0) 
10,701 
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Table 4: Mean HbA1c (%) at diagnosis for patients diagnosed during the study period by socio-economic status 
 Statistic Low SES Mid SES High SES Total No. of Obs. 
HbA1c at diagnosis Mean 
(95% CI) 
7.9 
(7.9, 8.0) 
7.8 
(7.7, 7.9) 
7.6 
(7.5, 7.7) 
7.8 
(7.7, 7.8) 
5,687 
 
Table 5: Prevalence of prescriptions for treatments for study population by socio-economic status 
 Statistic Low SES Mid SES High SES Total No. of Obs. 
Diabetes 
treatments 
Diet alone % 
(95% CI) 
21.5 
(21.0, 21.9) 
26.0 
(25.3, 26.7) 
27.3 
(26.7, 28.0) 
24.2 
(23.9, 24.5) 
67,063 
 Metformin or 
sulphonylureas 
only 
% 
(95% CI) 
39.1 
(38.6, 39.7) 
36.6 
(35.9, 37.4) 
36.0  
(35.3, 36.7) 
37.6 
(37.3, 38.0) 
 Combination 
excluding insulin 
% 
(95% CI) 
19.6 
(19.1, 20.0) 
19.0 
(18.4, 19.6) 
17.7 
(17.1, 18.2) 
18.9 
(18.6, 19.2) 
 Insulin only % 
(95% CI) 
12.3  
(12.0, 12.7) 
11.3 
(10.8, 11.8) 
13.2 
(12.7, 13.7) 
12.3 
(12.1, 12.6) 
 Combination 
including insulin 
% 
(95% CI) 
7.5 
(7.2, 7.8) 
7.1 
(6.7, 7.5) 
5.8 
(5.5, 6.2) 
6.9 
(6.7, 7.1) 
BP 
treatments 
No BP treatments % 
(95% CI) 
28.4 
(27.9, 28.9) 
24.8 
(24.1, 25.5) 
26.9 
(26.2, 27.5) 
27.1 
(26.8, 27.5) 
61,329 
 ACEIs only % 
(95% CI) 
11.0 
(10.7, 11.9) 
11.4 
(10.9 11.9) 
12.5 
(12.0, 13.0) 
11.5 
(11.3, 11.8) 
 ACEIs plus other BP 
treatment 
% 
(95% CI) 
30.7 
(30.2, 31.2) 
32.7 
(31.9, 33.4) 
30.5 
(29.8, 31.2) 
31.1 
(30.7, 31.5) 
 Other BP treatment 
combination 
% 
(95% CI) 
29.9 
(29.3, 29.3) 
31.1 
(29.3, 30.4) 
30.1 
(29.4, 35.8) 
30.2 
(29.9, 30.6) 
Aspirin % 
(95% CI) 
42.8 
(42.3, 43.4) 
43.1 
(42.3, 43.9) 
41.6 
(40.8, 42.4) 
42.5 
(42.1, 42.9) 
64,016 
Lipid therapies % 
(95% CI) 
57.3 
(56.7, 57.9) 
56.3 
(55.4, 57.1) 
57.1 
(56.4, 57.8) 
57.0 
(56.6, 57.4) 
60,952 
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Table 6: Proportion of care processes recorded for study population by socio-economic status 
 Statistic Low SES Mid SES High SES Total No. of Obs 
Number of care 
processes recorded 
Mean 
(95% CI) 
6.0 
(6.0, 6.0) 
6.2 
(6.1, 6.2) 
6.2 
(6.1, 6.2) 
6.1 
(6.1, 6.1) 
67,967 
 
Table 7: Proportion of patients by place of care for study population by socio-economic status 
 Statistic Low SES Mid SES High SES Total No. of Obs 
Shared care % 
(95% CI) 
29.0 
(28.5, 29.5) 
23.0 
(22.3, 23.6) 
25.6 
(25.0, 26.2) 
26.6 
(26.3, 26.9) 
67,947 
Middlesbrough PCT % 
(95% CI) 
62.9 
(62.4, 63.4) 
25.7 
(25.1, 26.4) 
47.4 
(46.8, 48.2) 
49.7 
(49.4, 50.1) 
67,947 
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Intervention data 
 
Table 4 shows the mean HbA1c (%) at diagnosis for patients diagnosed during the study period 
by SES.; the proxy measurement used as timeliness of diagnosis. The results show that there 
was an inverse trend between timeliness of diagnosis and SES, with the low SES patients having 
significantly higher HbA1c at diagnosis compared to high SES patients. Table 5 shows the 
percentage of patients with a prescription for treatments by SES. 
The results show that there was a social gradient in the proportion of patients being treated by 
diet alone. Low SES patients were less likely to be treated this way compared to the rest of the 
population. This trend was reversed for all the other diabetes treatments regimens except for 
being prescribed insulin only. Mid SES patients were significantly less likely to be prescribed 
insulin only compared to high SES patients.  
Low SES patients were significantly more likely to be prescribed no BP treatments and less 
likely to be prescribed ACEI only compared to high SES patients. Mid SES patients were 
significantly more likely to be prescribed ACEI in combination with other BP treatments 
compared to both high and low SES patients. There were no statistically significant differences 
in prescriptions for other combinations of BP treatments, aspirin and lipid therapies.  
Table 6 shows the mean number of care processes for the study population by SES. The results 
shows that low SES patients significantly having a lower number of care processes recorded 
compared to high SES patients. Finally, Table 7 shows that the percentage of patients managed 
in shared care and Middlesbrough PCT. Low SES patients were significantly more likely to 
receive shared care and Middlesbrough as their PCT of responsibility than high SES patients.  
 
Practice level data 
 
Table 7 below summarizes the practice level data both overall and by PCT. The results show 
that practices in Middlesbrough PCT serve more deprived populations. Across each process and 
outcome indicators, practices in Middlesbrough PCT perform worse than those in Redcar & 
Cleveland PCT. The varying number of observations reflects the introduction and suspension of 
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particular QOF indicators over the study period. As a result, only those which appear 
consistently since the introduction of QOF were used in the subsequent analysis for this thesis
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Table 8: Median rates of practice level variables by PCT 
 Stat. Middlesbrough 
PCT 
Redcar & 
Cleveland PCT 
Total No. of 
Obs.  
Practice deprivation score Median 
(IQR) 
42.0 
(33.0, 46.0) 
29.0 
(23.0, 34.0) 
34.0 
(29.0, 46.0) 
197 
Practice list size (N) Median 
(IQR) 
7474 
(5372, 9598) 
6305 
(5191, 9006) 
7080 
(5278, 8683) 
155 
Diabetes register size (N) Median 
(IQR) 
256  
(177, 332) 
260 
(197, 315) 
259 
(178, 321) 
155 
QOF DM prevalence (%) Median 
(IQR) 
3.4 
(2.8, 3.7) 
3.8 
(3.5, 4.2) 
3.6 
(3.2, 4.0) 
155 
BMI recording level (%) Median 
(IQR) 
92.0 
(89.8, 94.7) 
93.7 
(92.1, 95.9) 
92.8 
(90.7, 95.6) 
155 
Smoking recording level (%) Median 
(IQR) 
97.8 
(96.1. 99.0) 
97.9 
(97.0, 99.0) 
97.9 
(96.9, 99.0) 
69 
HbA1c recording level (%) Median 
(IQR) 
96.4 
(94.1, 97.9) 
97.0 
(95.6, 97.9) 
96.7  
(94.9, 97.9) 
155 
Patients achieving HbA1c ≤ 7.4% 
(%) 
Median 
(IQR) 
46.3 
(42.9, 49.9) 
52.9 
(46.1, 57.6) 
48.4 
(44.2, 55.9) 
69 
Patients achieving HbA1c ≤ 10% (%) Median 
(IQR) 
87.7 
(84.3, 89.6) 
90.6 
(88.1, 92.8) 
86.4 
(89.1, 91.5) 
155 
Retinal screening level (1) (%) Median 
(IQR) 
84.8 
(78.6, 88.5) 
87.8 
(82.0, 91.1) 
86.5 
(80.9, 89.7) 
69 
Peripheral pulses recording level 
(%) 
Median 
(IQR) 
86.6 
(79.7, 89.2) 
89.6 
(86.2, 92.9) 
88.1 
(83.3, 91.5) 
155 
Neuropathy test recording level (%) Median 
(IQR) 
85.9 
(80.0, 89.2) 
90.0 
(86.0, 92.1) 
88.0 
(83.3, 91.5) 
155 
BP recording level (%) Median 
(IQR) 
97.4 
(96.0, 98.4) 
98.4 
(97.3, 99.0) 
97.8 
(96.7, 98.8) 
155 
Patients achieving BP ≤ 145/85 
(mmHg) level (%) 
Median 
(IQR) 
71.2 
(67.3, 76.4) 
74.2 
(66.7, 80.3) 
72.6 
(67.1, 79.0) 
155 
Microalbuminuria recording level 
(%) 
Median 
(IQR) 
81.4 
(73.5, 87.3) 
83.8 
(77.1, 87.2) 
82.6 
(75.6, 87.2) 
155 
Serum creatinine recording level (%) Median 
(IQR) 
97.4 
(96.1, 98.2) 
97.9 
(96.2, 98.8) 
97.6 
(96.2, 98.5) 
69 
Proteinuria/microalbuminuria 
treated w. ACE inhibitors level (%) 
Median 
(IQR) 
3.0 
(1.3, 7.8) 
10.6 
(5.6, 17.6) 
6.8 
(1.5, 13.1) 
155 
Total cholesterol recording level (%) Median 
(IQR) 
96.5 
(94.2, 98.0) 
97.8 
(96.4, 98.7) 
95.7 
(97.4, 98.3) 
155 
Patients achieving total cholesterol ≤ 
5mmol/l (%) 
Median 
(IQR) 
74.2 
(68.1, 77.3) 
75.9 
(71.6, 79.1) 
75.0 
(69.8, 78.1) 
155 
Influenza immunisation level (%) Median 
(IQR) 
77.2 
(73.4, 81.8) 
81.0 
(78.2, 83.1) 
79.4 
(74.6, 82.7) 
155 
Patients achieving HbA1c ≤ 7.5% 
(%) 
Median 
(IQR) 
60.3 
(54.2, 63.5) 
66.2 
(62.8, 71.3) 
62.9 
(57.8, 67.3) 
86 
Retinal screening level (2) (%) Median 
(IQR) 
82.9 
(79.4, 85.4) 
86.3 
(84.0, 90.6) 
84.9 
(80.2, 87.5) 
86 
eGFR or serum creatinine recording 
level (%) 
Median 
(IQR) 
96.1 
(94.6, 97.8) 
97.2 
(97.9, 99.1) 
97.5 
(95.4, 98.4) 
86 
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Graphical analyses 
 
This section examines the mean levels or proportion of the outcome variables used in the 
multilevel models in the subsequent chapters. The results were displayed in a series of bar 
charts with their 95% confidence intervals to establish the statistical significance of the results. 
 
Health outcomes 
 
The first two figures indicate that there has been dramatic improvements in these two 
intermediate outcomes over the study period. These results are likely to reflect the changes in 
particular interventions in the diabetes care pathway over time, which were shown in the 
analyses in the next section. However, these time trends may also reflect the introduction of 
macro level policy initiatives which cannot be adequately accounted for, such as the NSF for 
Diabetes which outlined a number of standards and targets to be achieved [52]. The remaining 
figures in this section examine the levels of long-term complications by SES over the study 
period. 
 
Figure 14: HbA1c (%) by SES from 1999 to 2007 (N = 61,368) 
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Figure 15: Mean cholesterol level (mmol/l) by SES from 1999 to 2007 (N = 60,437) 
 
 
Figure 14 shows that there were statistically significant differences in HbA1c and that these 
differences have occurred over time. From 2000 patients with lowest SES consistently have 
significantly higher blood glucose control compared to with the highest SES patients; with a 
clear social gradient occurring in most years. In contrast, Figure 15 shows that statistically 
significant differences in cholesterol levels by SES only occurred in 1999 patients with the 
highest SES having the lower mean level of cholesterol compared to those with mid SES.  
Figure 16, Figure 17 and Figure 18 display the levels of ICD, stroke or TIA and PVD by SES per 
visit year. The higher levels in 1999 reflect the proportion of patients who have a recording of 
these complications at the beginning of the study period. Subsequent results indicate a new 
recording for patients who with a 0 or no data recorded previously. 
Figure 16 shows that there were statistically significant differences in the proportions of 
patients with existing ICD in 1999 by SES, with the lowest SES patients having significant higher 
levels than highest SES patients. There were no significant differences in the levels of ICD by SES 
in the other years but there was been a significant reduction in levels overall in years 2006 and 
2007 compared to levels between 2000 and 2004.  
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Figure 17 and Figure 18 show that there were lower levels of stroke or TIA and PVD over the 
study period compared to levels of ICD yet the pattern of the results were similar. There were 
no significant differences in any year for levels of stroke or TIA and PVD but there were 
statistically significant improvements in the levels in 2006 and 2007 compared to earlier years. 
 
Figure 16: Percentage levels of ischaemic cardiac disease by SES from 1999 to 2007(N = 46,531) 
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Figure 17: Percentage of levels of stroke or TIA by SES from 1999 to 2007 (N = 55,400) 
 
Figure 18: Percentage of levels of PVD by SES from 1999 to 2007(N = 56,214) 
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Figure 19 shows that in 2007, there were a statistically significant greater proportion of low SES 
patients who had any level retinopathy compared to high SES patients. No other year showed 
any statistically significant differences in retinopathy by SES. Unlike the figures depicting the 
percentage of patients with other vascular disease, there were no indications of any reductions 
in levels over time. In addition, there was a marked difference in the results for 2006 than the 
rest of the study period.  
Figure 20 shows the percentage of patients with microalbuminuria during the study period. 
Between 2004 and 2006 there was a significant increase in the proportion of patients recorded 
as having microalbuminuria with low SES patients having statistically significant higher levels 
than the other patients. The levels of the outcome falls again in 2007, however, the wider 
confidence intervals were likely to reflect the poorer recording levels of this variable during this 
time (see Appendix D). 
 
Figure 19: Percentage of patients with any retinopathy by SES from 1999 to 2007(N = 30,980) 
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Figure 20: Percentage of patients with microalbuminuria by SES from 1999 to 2007 (N = 31,391) 
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SES patients more likely to have a higher mean HbA1c to other status groups in 2002 and from 
2004 to 2007. 
 
Figure 21: Mean HbA1c at diagnosis by socio-economic status over study period (N= 5,687) 
  
Quality of care 
 
Figure 22 shows a steady improvement in the mean number of care processes that patients 
received by SES up to and including 2006. Low SES patients had significantly lower mean 
number of care processes compared to other status groups in most years. 
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Figure 22: The mean number of care processes by patients socio-economic status over the study 
period (N= 67,967) 
 
 
Glucose control treatments 
 
Table 22 displays marked statistically significant differences with patients from the lowest 
status group who were consistently less likely to receive no diabetes treatments. Between 1999 
and 2001 high status patients were more likely to be treated this way compared to low status 
patients and from 2002 onwards both high and mid status groups. Interestingly, the levels of 
patients receiving no diabetes treatments appear to have fallen for low SES patients over time, 
but not for other SES groups.  
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Figure 24 shows an increasing prevalence of patients’ diabetes being treated by metformin or 
sulphonylureas only over the study period. From 1999 through to 2004 there appears to be a 
negative social gradient in being treated with this regimen, with statistically significant 
differences in the first five years between high and low SES groups. In contrast, the 
prescriptions of more than one diabetes treatments with no insulin (Figure 25) and insulin only 
(Figure 26) have decreased over the study period with no significant differences by SES. The 
percentage of patients being prescribed insulin in combination with one or more diabetes 
treatment including insulin significantly increased between 1999 and 2005.  From 2002 
patients from low status groups were significantly more likely to be prescribed this treatment 
combination compared high status patients (Figure 27).  
 
Figure 23: Percentage of patients prescribed no diabetes treatments by SES over the study period (N = 
67,822) 
 
 
  
15
20
25
30
35
1999 2000 2001 2002 2003 2004 2005 2006 2007
P
e
rc
e
n
ta
ge
 (
%
) 
Visit year 
Low Medium High
Anna Christie Page 128 
Figure 24: Percentage of patients prescribed metformin or sulphonylureas only by socio-economic status 
over the study period (N = 67,822) 
 
Figure 25: Percentage of patients prescribed combination of diabetes treatments with no insulin by socio-
economic status over the study period (N = 67,822) 
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Figure 26: Percentage of patients prescribed insulin only by socio-economic status over the study period 
(N = 67,822) 
  
Figure 27: Percentage of patients prescribed other diabetes treatments and/or combinations by socio-
economic status over the study period (N = 67,822) 
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Blood pressure treatments 
 
The results displayed in Figure 28 show an increase in blood pressure treatments being 
prescribed over the period with significant differences by SES occurring in a number of years. In 
particular, there were statistically significant higher proportions of low SES patients receiving 
no BP treatments compared to mid SES patients in 2006 and 2007.  
Figure 29 and Figure 30 indicate that there were steady increases in the percentage prescribed 
ACEI, both alone and in combination with other treatments, in the earlier stages of study period 
which does not occur in the later years. Whilst there appears to have been a fairly consistent 
negative social gradient in the receipt of ACEI only, there were no statistically significant 
differences. There were no differences in use of ACEI in combination with other treatments 
(Figure 30).  
Figure 31 shows that there was a steady decline in the use of other BP treatments in the first 
half of the study period and that there were no differences by SES. 
 
Figure 28: Percentage of patients prescribed no blood pressure treatments by socio-economic status over 
the study period (N = 61,329) 
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Figure 29: Percentage of patients prescribed ACE inhibitors only by socio-economic status over the study 
period (N = 61,329) 
  
Figure 30: Percentage of patients prescribed ACE inhibitors plus other blood pressure treatment(s) by 
socio-economic status over the study period (N= 61,329) 
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Figure 31: Percentage of patients prescribed other blood pressure treatment(s), excluding ACE inhibitors, 
by socio-economic status over the study period (N= 61,329) 
  
 
Antithrombotic and lipid therapies 
 
Figure 32 and Figure 33 display the proportion of patients prescribed aspirin and lipid 
therapies by SES over time, respectively.  The use of both types of therapies has increased over 
the study period. There were statistically significant differences between mid SES patients and 
high SES in the use of aspirin during 2002. Also, in 1999, there were also statistically significant 
differences between low SES patients and mid SES patients in the prescription of lipid therapies. 
Otherwise, there were no significant differences in the prescriptions of these treatments by SES 
over time. 
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Figure 32: Percentage of patients prescribed aspirin by socio-economic status over the study period (N= 
64,016) 
 
Figure 33: Percentage of patients prescribed lipid therapy(s) by socio-economic status over the study 
period (N = 60,952) 
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Shared care 
 
Figure 34: Percentage of patients receiving shared care by socio-economic status over the study period 
(N= 69,647) 
 
 
Figure 34 shows statistically significant differences in the receipt of shared care from 2000 to 
2007. The chart shows a higher percentage of patients from low SES backgrounds compared to 
other status groups. Interestingly, it seems it was patients at the extreme ends of SES groups 
that were most likely to receive shared care, with this pattern reaching statistical significance in 
2002 and 2003. 
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Principle findings 
 
This chapter describes the extensive dataset used for the secondary data analyses and 
highlights where the results indicate inequalities by SES in terms of both health outcomes and 
interventions. Low SES patients were found to be more likely to be younger overall and at 
diagnosis. There were negative social gradients in BMI and current smoking levels which 
reflected trends found elsewhere (for example:[198, 199]. In terms of health outcomes low SES 
patients were more likely to be hypertensive, have poorer HbA1c, and long-term complications 
but have lower levels of kidney problems. There were statistically significant differences in 
timeliness of diagnosis as measured patients’ HbA1c, prescriptions for treatments and 
indicators of quality and place of care. 
The graphical analyses indicated improvements over the study period for HbA1c, cholesterol, 
ICD, stroke or TIA and PVD. Levels of retinopathy were similar across the study period with a 
marked reduction in incidences in 2006. Levels of microalbuminuria increased over the study 
period. The charts also showed that there were improvements in timeliness of diagnosis and the 
level of care patients received. There were marked changes in prescriptions of treatments over 
time and a steady reduction in the proportions of patients receiving shared care. Generally, low 
SES patients had higher HbA1c overall and at time of diagnosis over time. There were significant 
differences in microalbuminuria in the later study years. There were marked significant 
differences in being treated by diet alone, receiving combination of diabetes treatments, and 
receiving shared care.  
The next four chapters address each of the research questions, drawing and building upon these 
initial analyses.  
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Chapter 6: Are there socio-economic inequalities in intermediate 
outcomes and complications associated with type 2 diabetes over 
time? 
 
This chapter describes the multilevel models, which were fitted to examine whether there were 
socio-economic inequalities in intermediate outcomes and complications associated with type 2 
diabetes over time, once other explanatory variables and structure of the data had been taken 
into account.   
 
Intermediate health outcomes 
 
Table 9 shows the results for the saturated linear regression multilevel model for the 
comparison of HbA1c and cholesterol by SES. There were 38,413 available cases for the model 
comparing HbA1c by SES. The findings show that there were no significant differences in HbA1c 
by SES (Table 9); this finding was the same for each step of the modelling process. However, 
there were some statistically significant interactions effects between SES and time with high SES 
patients more likely to have greater HbA1c in 2000 and 2003 than low SES patients in 1999. 
Overall, visit year was statistically significant in all models supporting the graphical analyses 
that there have been reductions in HbA1c levels for type 2 diabetes patients in the South Tees 
area over time.  
When examining the stepwise models (Table 56, Appendix F), the interaction effect between 
SES and time was partially explained by the introduction of socio-demographic, anthropometric, 
lifestyle and health data into the model. Increasing age, being male and having a creatinine level 
less than 300 were significantly associated with lower HbA1c. In contrast, increasing duration, 
being from a minority ethnic background, being a current or ex-smoker, overweight or obese, 
hypertensive and a having history of ICD and PVD were associated with higher levels of HbA1c.  
The significant interactions effects were explained further when intervention data were added 
to the model. Increasing quality of care and time were significantly associated with lower 
HbA1c. All diabetes treatment regimens were significantly associated with higher HbA1c 
compared to those being treated by diet alone; similarly, shared care was significantly 
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associated with higher HbA1c. There were no differences in HbA1c across PCTs. Following the 
introduction of intervention data into the final model, being overweight and history of ICD were 
no longer significant and interestingly having a history of stroke or TIA and PVD became 
significantly positively related to HbA1c.  
 
Table 9: Saturated linear regression multilevel models examining HbA1c and cholesterol by SES 
from 1999 to 2007 with interaction effect between SES and visit year, conditional on relevant 
explanatory variables 
 HbA1c Cholesterol 
Social-economic status & visit year 
Social-economic status, reference group: Low SES 
Mid SES -0.09 (-0.26, 0.06) 0.06 (-0.13, 0.26) 
High SES 0.04 (-0.10,  0.19) -0.22 (-0.40, -0.05) 
Visit year, reference group: 1999 
2000 -0.24 (-0.37, -0.12) -0.25 (-0.38, -0.12) 
2001 -0.47 (-0.59, -0.35) -0.28 (-0.41, -0.16) 
2002 -0.49 (-0.60, -0.38) -0.29 (-0.41, -0.16) 
2003 -0.53 (-0.64, -0.43) -0.43 (-0.55, -0.31) 
2004 -0.61 (-0.71, -0.50) -0.64 (-0.76, -0.52) 
2005 -0.68 (-0.79, -0.58) -0.79 (-0.91, -0.67) 
2006 -1.16 (-1.27, -1.06) -0.92 (-1.04, -0.80) 
2007 -1.11 (-1.22, -1.00) -0.99 (-1.11, -0.87) 
SES*Visit year, reference group: Low SES*1999 
Mid SES*2000 0.01 (-0.20, 0.23) -0.01 (-0.24, 0.22) 
Mid SES*2001 0.14 (-0.07, 0.35) -0.02 (-0.24, 0.20) 
Mid SES*2002 -0.04 (-0.23, 0.15) -0.02 (-0.23, 0.20) 
Mid SES*2003 0.01 (-0.18, 0.20) -0.04 (-0.25, 0.17) 
Mid SES*2004 0.03 (-0.15, 0.22) -0.06 (-0.27, 0.15) 
Mid SES*2005 0.05 (-0.13, 0.24) -0.08 (-0.29, 0.13) 
Mid SES*2006 0.08 (-0.11, 0.26) 0.02 (-0.18, 0.23) 
Mid SES*2007 0.11 (-0.07, 0.30) -0.03 (-0.24, 0.18) 
High SES*2000 -0.26 (-0.46, -0.06) 0.16 (-0.05, 0.37) 
High SES*2001 -0.09 (-0.28, 0.10) 0.26 (0.06, 0.46) 
High SES*2002 -0.16 (-0.34, 0.02) 0.22 (0.02, 0.41) 
High SES*2003 -0.20 (-0.37, -0.02) 0.20 (0.01, 0.39) 
High SES*2004 -0.11 (-0.28, 0.06) 0.22 (0.04, 0.41) 
High SES*2005 -0.14 (-0.31, 0.03) 0.22 (0.04, 0.41) 
High SES*2006 -0.11 (-0.28, 0.05) 0.27 (0.08, 0.45) 
High SES*2007 -0.13 (-0.30, 0.04) 0.21 (0.02, 0.39) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age, reference group: <60 years 
Age: 60-74 years -0.33 (-0.36, -0.29) -0.20 (-0.23, -0.17) 
Age: 75+ years -0.41 (-0.46, -0.37) -0.26 (-0.30, -0.23) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years 0.06 (0.02, 0.09) -0.09 (-0.11, -0.06) 
Duration 10+ years 0.05 (0.01, 0.10) -0.13 (-0.16, -0.10) 
Ethnicity, reference group: White 
South Asian 0.46 (0.39, 0.54) -0.08 (-0.14, -0.02) 
Other Ethnicity 0.47 (0.31, 0.63) 0.08 (-0.05, 0.20) 
Male -0.06 (-0.09, -0.03) -0.34 (-0.36, -0.32) 
Smoking status, reference group: Non smoker 
Smoker 0.23 (0.19, 0.27) 0.08 (0.05, 0.11) 
Ex-smoker 0.05 (0.02, 0.08) 0.00 (-0.03, 0.02) 
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There were 37,085 available cases for the model that compared cholesterol by SES. The results 
in Table 9 shows that there were statistically significant differences in cholesterol by SES, with 
high SES patients having more favourable cholesterol levels compared to the lowest status 
patients. In contrast, there were statistically significant interactions between SES and visit year 
with highest status patients having higher cholesterol levels compared to low SES patients in 
1999. Visit year was consistently significant in all steps, which again supported the graphical 
analyses that there have been reductions in cholesterol levels for South Tees type 2 diabetes 
patients over time. 
The introduction of explanatory variables did not explain the significant differences in 
cholesterol levels by SES and actually increased the number of years where the interaction 
effect between SES and visit year was statistically significant. This suggests that there were 
possible further interaction effects not controlled for in the model. 
Following the introduction of socio-demographic, anthropometric and lifestyle covariates into 
the model, increasing age, duration, being South Asian, male and having a history of ICD and 
stroke or TIA were significantly associated with lower cholesterol. Being a smoker and 
hypertensive were significantly associated with higher cholesterol. All remained significant, 
BMI status, reference group: Low & normal weight 
Overweight 0.02 (-0.02, 0.07) 0.03 (0.00, 0.07) 
Obese 0.08 (0.04, 0.13) 0.03 (0.00, 0.07) 
Creatinine > 300 -0.81 (-1.06, -0.56)  
Hypertensive 0.10 (0.07, 0.13) 0.14 (0.12, 0.16) 
Ischaemic Cardiac 0.00 (-0.04, 0.03) -0.13 (-0.15, -0.10) 
Stroke or TIA -0.06 (-0.10, -0.01) -0.02 (-0.06, 0.01) 
PVD -0.06 (-0.12, -0.01) 0.01 (-0.03, 0.05) 
Interventions 
Quality of Care level, reference group: Low quality 
Mid quality -0.13 (-0.16, -0.09) -0.10 (-0.13, -0.07) 
High quality -0.15 (-0.19, -0.11) -0.15 (-0.18, -0.11) 
Diabetes treatment, reference group diet alone 
Metformin or sulphonylureas only 0.81 (0.77, 0.85)  
Combo. no insulin 1.25 (1.20, 1.29)  
Insulin only 1.67 (1.61, 1.73)  
Combo. with insulin 1.75 (1.69, 1.82)  
Aspirin  -0.09 (-0.11, -0.06) 
Lipid therapy(s)  -0.28 (-0.31, -0.26) 
Shared care 0.17 (0.13, 0.21) -0.07 (-0.10, -0.04) 
Middlesbrough PCT 0.10 (0.00, 0.20) -0.03 (-0.09, 0.03) 
Cons 7.56 (7.42, 7.70) 5.98 (5.85, 6.12) 
Variance estimate at: 
Practice level 0.02 (0.01, 0.04)  0.01 (0.01, 0.01)  
Patient level 0.00 (0.00, 0.02)  0.00 (0.00, 0.01)  
Visit year 1.91 (1.88, 1.94)  1.14 (1.13, 1.16)  
Bayesian DIC 133988.98 110350.13 
Available cases (N) 38,413 37,085 
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except having a history of stroke or TIA, following the introduction of intervention data into the 
model. Increasing quality of care, being treated with aspirin and lipid therapies and receiving 
shared care were all significantly associated with healthier cholesterol levels.  
The Bayesian DIC statistics indicates that in both sets of stepwise models in Table 56 and Table 
57 in Appendix F that more variance were explained as each set of variables were added to the 
model, improving the model fit. In the null model of both sets, the ICC for practice and patient 
level were less than 2%, suggesting that there was very little clustering of the data at these 
levels for intermediate health outcomes.  
 
Long-term complications 
 
Table 10 and Table 11 show the results for the saturated logistic regression multilevel models 
examining long-term complications by SES.  
There were 24,004 available cases for the comparison between incidences of ICD by SES. The 
results in Table 10 show that mid SES patients had statistically significant lower incidences of 
ICD over the study period compared to low SES patients. In addition, there was one statistically 
significant interaction result indicating the incidences were significantly higher for mid SES 
patients in 2003 than low SES patients in 2000. This finding was significant in all steps of 
analyses (Table 58, Appendix F) and was not explained by the introduction of other covariates. 
In contrast, there were no significant differences in the incidences of stroke or TIA (29,800 
available cases), PVD (30,053 available cases), microalbuminuria (23,304 available cases) or 
retinopathy (18,665 available cases); nor any significant interactions between SES and visit 
year. These findings were consistent over each step of analyses for both outcomes.  
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Table 10: Saturated logistic regression multilevel models examining incidences of vascular 
disease by SES 2000 to 2007 with interaction effect between SES and visit year, conditional on 
relevant explanatory variables 
 ICD Stroke or TIA PVD 
Social-economic status & Visit year 
Social-economic status, reference group: Low 
Mid -0.73 (-1.31, -0.15) 0.20 (-0.50, 0.93) 0.06 (-0.85, 0.98) 
High -0.30 (-0.83, 0.23) 0.05 (-0.69, 0.80) -0.99 (-2.04, 0.01) 
Visit year, reference group: 1999 or 2000 
2000    
2001 -0.55 (-0.97, -0.10) 0.32 (-0.25, 0.92) -0.38 (-1.00, 0.23) 
2002 -0.36 (-0.73, 0.03) 0.21 (-0.32, 0.78) -0.17 (-0.71, 0.37) 
2003 -0.68 (-1.04, -0.30) 0.31 (-0.19, 0.85) 0.11 (-0.39, 0.63) 
2004 -0.84 (-1.20, -0.45) 0.09 (-0.41, 0.64) 0.16 (-0.34, 0.67) 
2005 -1.34 (-1.72, -0.94) -0.20 (-0.71, 0.39) -0.40 (-0.94, 0.14) 
2006 -1.89 (-2.27, -1.46) -0.87 (-1.45, -0.24) -0.62 (-1.18, -0.06) 
2007 -1.95 (-2.35, -1.52) -0.53 (-1.11, 0.09) -1.09 (-1.76, -0.45) 
SES*Visit year, reference group: Low SES*1999 or Low SES*2000 
Mid SES*2000    
Mid SES*2001 0.54 (-0.26, 1.31) -0.25 (-1.20, 0.67) 0.47 (-0.52, 1.49) 
Mid SES*2002 0.41 (-0.28, 1.09) -0.24 (-1.12, 0.62) 0.39 (-0.49, 1.32) 
Mid SES*2003 0.91 (0.25, 1.58) -0.05 (-0.89, 0.77) -0.12 (-1.04, 0.80) 
Mid SES*2004 0.60 (-0.09, 1.24) -0.41 (-1.25, 0.41) -0.18 (-1.04, 0.73) 
Mid SES*2005 0.41 (-0.28, 1.08) -0.20 (-1.07, 0.65) -0.05 (-0.99, 0.93) 
Mid SES*2006 0.69 (-0.02, 1.37) 0.16 (-0.75, 1.04) -0.23 (-1.21, 0.75) 
Mid SES*2007 0.37 (-0.37, 1.08) -0.70 (-1.67, 0.26) -0.02 (-1.10, 1.10) 
High SES*2000    
High SES*2001 0.49 (-0.23, 1.21) -0.13 (-1.09, 0.82) 0.13 (-0.87, 1.13) 
High SES*2002 -0.11 (-0.76, 0.53) -0.40 (-1.32, 0.50) -0.81 (-1.81, 0.19) 
High SES*2003 0.30 (-0.32, 0.92) -0.56 (-1.44, 0.29) -0.17 (-0.98, 0.68) 
High SES*2004 0.13 (-0.48, 0.73) 0.16 (-0.67, 0.98) -0.42 (-1.25, 0.44) 
High SES*2005 0.02 (-0.60, 0.63) 0.17 (-0.71, 1.02) 0.35 (-0.48, 1.22) 
High SES*2006 0.20 (-0.45, 0.84) 0.06 (-0.88, 0.99) -0.46 (-1.40, 0.49) 
High SES*2007 0.18 (-0.47, 0.83) -0.07 (-1.00, 0.83) -0.14 (-1.21, 0.91) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age, reference group: <60 years 
Age: 60-74 years 0.33 (0.18, 0.48) 0.74 (0.50, 0.99) 0.63 (0.38, 0.89) 
Age: 75+ years 0.60 (0.41, 0.78) 1.10 (0.82, 1.38) 0.83 (0.52, 1.14) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9  -0.59 (-0.74, -0.45) -0.31 (-0.49, -0.12) 0.13 (-0.10, 0.35) 
Duration 10+  -0.63 (-0.80, -0.47) -0.18 (-0.39, 0.03) 0.38 (0.14, 0.62) 
Ethnicity, reference group: White 
South Asian  0.08 (-0.25, 0.40) 0.11 (-0.34, 0.53) -0.79 (-1.52, -0.16) 
Other Ethnicity -0.68 (-1.55, 0.09) -1.17 (-3.07, 0.17) -0.04 (-1.10, 0.84) 
Male 0.33 (0.21, 0.45) -0.11 (-0.28, 0.06) 0.39 (0.20, 0.58) 
Smoking status, reference group: non smoker 
Smoker 0.15 (-0.02, 0.32) 0.28 (0.05, 0.51) 0.94 (0.68, 1.19) 
Ex-smoker 0.31 (0.18, 0.44) 0.14 (-0.04, 0.31) 0.38 (0.17, 0.59) 
BMI status, reference group: under & normal weight 
Overweight -0.02 (-0.20, 0.15) -0.08 (-0.29, 0.13) -0.20 (-0.46, 0.05) 
Obese 0.12 (-0.06, 0.29) -0.19 (-0.41, 0.03) -0.25 (-0.50, 0.00) 
HbA1c 0.07 (0.03, 0.11) 0.02 (-0.03, 0.07) 0.01 (-0.05, 0.07) 
Hypertensive -0.28 (-0.40, -0.16) 0.14 (-0.01, 0.30) 0.13 (-0.05, 0.31) 
Cholesterol -0.23 (-0.29, -0.17) -0.09 (-0.17, -0.02) -0.05 (-0.13, 0.03) 
eGFR -0.01 (-0.01, 0.00) -0.01 (-0.01, 0.00) -0.01 (-0.01, 0.00) 
Interventions 
Quality of care level, reference group: Low quality OR Mid quality  
Mid quality -0.31 (-0.44, -0.17) -0.17 (-0.36, 0.03) -0.18 (-0.42, 0.06) 
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High quality -0.40 (-0.57, -0.24) -0.03 (-0.24, 0.19) 0.19 (-0.06, 0.43) 
Diabetes treatment, reference group diet alone 
Sulphonylureas/metformin only -0.28 (-0.42, -0.13) -0.18 (-0.38, 0.02) -0.05 (-0.31, 0.21) 
Combination, no insulin -0.40 (-0.60, -0.20) -0.30 (-0.56, -0.04) -0.12 (-0.43, 0.20) 
Insulin only 0.12 (-0.12, 0.37) -0.08 (-0.39, 0.23) 0.33 (0.00, 0.67) 
Combination, with insulin -0.29 (-0.58, -0.01) -0.29 (-0.68, 0.08) 0.33 (-0.05, 0.71) 
Blood pressure treatment, reference group: No treatments 
ACE inhibitors only 0.26 (0.00, 0.52) 0.31 (0.03, 0.61) 0.50 (0.17, 0.83) 
ACE & other(s) 1.50 (1.31, 1.70) 0.16 (-0.08, 0.40) 0.43 (0.15, 0.72) 
Other combination 1.25 (1.05, 1.44) 0.18 (-0.05, 0.43) 0.38 (0.10, 0.67) 
Aspirin 1.38 (1.26, 1.50) 1.06 (0.89, 1.23) 0.57 (0.40, 0.76) 
Lipid therapy 0.61 (0.48, 0.74) 0.08 (-0.09, 0.26) 0.10 (-0.09, 0.30) 
Middlesbrough PCT -0.20 (-0.39, -0.01) -0.12 (-0.39, 0.14) -0.17 (-0.54, 0.21) 
Shared care 0.27 (0.11, 0.43) 0.45 (0.24, 0.65) 0.85 (0.63, 1.07) 
Cons -3.50 (-4.69, -2.18) -5.14 (-6.50, -4.01) -6.09 (-7.60, -4.69) 
Variance estimate at: 
Practice level 0.05 (0.02, 0.11) 0.11 (0.04, 0.22) 0.28 (0.14, 0.48) 
Patient level 2.15 (0.53, 7.50) 1.36 (0.33, 4.57) 1.43 (0.34, 4.92) 
Bayesian DIC 9208.63 6143.66 5033.64 
Available cases (N) 24,004 29,800 30,053 
 
Table 11: Saturated logistic regression multilevel models examining incidences of vascular 
disease by SES 2000 to 2007 with interaction effect between SES and visit year, conditional on 
relevant explanatory variables 
 Microalbuminuria Retinopathy 
Social-economic status & Visit year 
Social-economic status, reference group: Low 
Mid 0.52 (-0.20, 1.29) -0.38 (-1.07, 0.26) 
High 0.36 (-0.27, 1.07) -0.45 (-1.00, 0.12) 
Visit year, reference group: 1999 or 2000 
2000 -0.11 (-0.60, 0.41) -0.17 (-0.60, 0.26) 
2001 -0.35 (-0.83, 0.16) -0.25 (-0.67, 0.17) 
2002 -0.35 (-0.83, 0.16) -0.10 (-0.51, 0.30) 
2003 -0.44 (-0.89, 0.05) -0.17 (-0.56, 0.23) 
2004 0.30 (-0.14, 0.78) -0.06 (-0.46, 0.34) 
2005 0.51 (0.07, 1.00) 0.11 (-0.31, 0.53) 
2006 0.90 (0.46, 1.38) -0.94 (-1.36, -0.50) 
2007 0.56 (-0.15, 1.27) 0.23 (-0.18, 0.64) 
SES*Visit year, reference group: Low SES*1999 or Low SES*2000 
Mid SES*2000 -0.49 (-1.38, 0.36) 0.46 (-0.29, 1.25) 
Mid SES*2001 -0.45 (-1.28, 0.38) 0.48 (-0.26, 1.25) 
Mid SES*2002 -0.20 (-1.01, 0.57) 0.10 (-0.62, 0.85) 
Mid SES*2003 -0.53 (-1.32, 0.23) -0.05 (-0.77, 0.71) 
Mid SES*2004 -0.66 (-1.43, 0.08) 0.24 (-0.47, 0.98) 
Mid SES*2005 -0.69 (-1.47, 0.04) 0.31 (-0.41, 1.05) 
Mid SES*2006 -0.69 (-1.46, 0.03) 0.54 (-0.16, 1.29) 
Mid SES*2007 -0.63 (-1.60, 0.35) 0.37 (-0.31, 1.10) 
High SES*2000 -0.67 (-1.50, 0.11) 0.36 (-0.32, 1.11) 
High SES*2001 -0.52 (-1.29, 0.21) 0.48 (-0.18, 1.20) 
High SES*2002 -0.18 (-0.93, 0.50) 0.39 (-0.23, 1.10) 
High SES*2003 -0.57 (-1.31, 0.10) 0.35 (-0.26, 1.04) 
High SES*2004 -0.39 (-1.10, 0.25) 0.35 (-0.27, 1.05) 
High SES*2005 -0.46 (-1.18, 0.18) 0.62 (-0.01, 1.32) 
High SES*2006 -0.51 (-1.23, 0.13) 0.45 (-0.18, 1.15) 
High SES*2007 -0.45 (-1.78, 0.82) 0.22 (-0.38, 0.89) 
Socio-demographic, anthropometric, lifestyle and health covariates 
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Age, reference group: <60 years 
Age: 60-74 years 0.01 (-0.06, 0.09) 0.00 (-0.11, 0.11) 
Age: 75+ years 0.38 (0.28, 0.47) -0.11 (-0.25, 0.03) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9  -0.01 (-0.09, 0.06) 0.47 (0.34, 0.60) 
Duration 10+  0.18 (0.09, 0.27) 1.60 (1.47, 1.73) 
Ethnicity, reference group: White 
South Asian  0.22 (0.05, 0.38) -0.16 (-0.39, 0.08) 
Other Ethnicity 0.30 (-0.07, 0.67) 0.53 (0.08, 0.95) 
Male 0.24 (0.18, 0.31) 0.25 (0.16, 0.34) 
Smoking status, reference group: non smoker 
Smoker 0.26 (0.17, 0.36) -0.13 (-0.27, 0.00) 
Ex-smoker 0.07 (0.00, 0.14) -0.12 (-0.22, -0.03) 
BMI status, reference group: under & normal weight 
Overweight -0.01 (-0.11, 0.08) -0.09 (-0.22, 0.04) 
Obese 0.06 (-0.04, 0.16) -0.10 (-0.23, 0.03) 
HbA1c 0.18 (0.11, 0.24) 0.05 (0.02, 0.08) 
Hypertensive 0.03 (0.00, 0.06) 0.33 (0.25, 0.42) 
Cholesterol 0.09 (0.06, 0.11) -0.02 (-0.06, 0.03) 
eGFR  -0.01 (-0.01, -0.01) 
Interventions 
Quality of care level, reference group: Low quality OR Mid quality  
Mid quality -0.13 (-0.54, 0.25)  
High quality -0.25 (-0.66, 0.14) -0.07 (-0.17, 0.04) 
Diabetes treatment, reference group diet alone 
Sulphonylureas/metformin only 0.14 (0.04, 0.24) 0.40 (0.24, 0.56) 
Combination, no insulin 0.02 (-0.10, 0.13) 0.70 (0.52, 0.87) 
Insulin only 0.18 (0.04, 0.32) 1.05 (0.86, 1.23) 
Combination., with insulin 0.20 (0.10, 0.30) 1.16 (0.96, 1.36) 
Blood pressure treatment, reference group: No treatments 
ACE inhibitors only 0.36 (0.25, 0.47) 0.32 (0.17, 0.46) 
ACE & other(s) 0.52 (0.43, 0.61) 0.22 (0.10, 0.35) 
Other combination 0.32 (0.22, 0.41) 0.13 (0.00, 0.26) 
Aspirin 0.08 (0.01, 0.14) 0.05 (-0.04, 0.15) 
Lipid therapy -0.05 (-0.12, 0.02) -0.06 (-0.16, 0.04) 
Middlesbrough PCT 0.58 (0.29, 0.86) -0.05 (-0.22, 0.13) 
Shared care -0.92 (-1.01, -0.83) 0.52 (0.42, 0.63) 
Cons -2.73 (-3.43, -2.11) -2.83 (-3.48, -2.19) 
Variance estimate at: 
Practice level 0.21 (0.13, 0.34) 0.05 (0.03, 0.10) 
Patient level 0.01 (0.00, 0.03) 0.00 (0.00, 0.02) 
Bayesian DIC 25480.02 14536.53 
Available cases (N) 23,304 18,665 
 
 
Comparing the five models in Table 10 and Table 11 there were some statistically significant 
results indicating improvements in the incidences of stroke or TIA, PVD and, in particular, ICD 
over the study period. In contrast, in 2005 and 2006, rates of microalbuminuria were 
significantly worse than 1999. These results support the graphical analyses displayed in chapter 
five. Increasing age, in contrast to the intermediate outcomes, was a statistically significant 
predictor of higher rates of all long-term complications with the exception of retinopathy. 
Interestingly, increased duration of diabetes was associated with lower incidences of ICD and 
stroke or TIA but higher incidences of PVD. South Asian patients had significantly lower 
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incidences of PVD but higher of microalbuminuria compared to white patients. Interestingly, the 
relationship between ethnicity and microalbuminuria was only significant following the 
introduction of intervention data suggesting a potential interaction effect not included in the 
model. Patients of an ‘other’ ethnicity had significantly higher rates of retinopathy compared to 
white patients. There were no other significant relationships between ethnicity and rates of 
vascular disease modelled here. The results show that non-smokers had lower rates of 
complications in comparison to smokers and/or ex-smokers, but these findings were not 
consistent.  
When looking at the health status data, increased HbA1c was significantly associated with 
higher rates of ICD, microalbuminuria and retinopathy. Being hypertensive was significantly 
associated with lower incidences of ICD but higher rates of retinopathy. Increased cholesterol 
was significantly associated with lower incidences of ICD and stroke or TIA but higher rates of 
retinopathy. There was a small but significant association with increased eGFR with lower rates 
of retinopathy. Interestingly, BMI status was not significantly associated with any of outcomes. 
However, patients classified as obese were significantly more likely to have had ICD and 
microalbuminuria prior to the intervention data being included in the final models, suggesting 
that diabetes care mediates this relationship.  
The results of the diabetes interventions indicators showed that increased quality of care was a 
significant predictor of lower incidences of ICD but was not associated with any other long-term 
complication. Where diabetes treatments were significant, the results showed they were 
associated with lower incidences of ICD and stroke or TIA incidences but were higher rates of 
microalbuminuria and retinopathy, compared to being prescribed no treatments. Where 
prescriptions for BP treatments, aspirin and lipid therapies were significant, they were 
associated with higher rates of long-term complications. Receiving shared care was significantly 
associated with all long-term complications, with the exception of microalbuminuria where it 
was associated with lower rates. Interestingly, being managed in Middlesbrough PCT was a 
significant predictor of lower incidences of ICD and higher rates of microalbuminuria, compared 
to being managed in Redcar & Cleveland PCT. 
The Bayesian DIC statistics from the stepwise models indicated that model fit increasingly 
improved with the inclusion of each set of variables. The ICC of practice level in the null model 
indicated that 5.74% and 6.44% of the variance of rates of PVD and microalbuminuria 
respectively were explained by patients’ general practice. Approximately 2% or less of the 
variance were explained by general practice with the other outcomes.  
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Principle findings 
 
The results in this chapter showed some evidence of SES inequalities in intermediate outcomes 
and long-term complications over time. However, the results showed that this did not always 
favour the same SES group. In particular, high SES patients were significantly more likely to 
have lower HbA1c but in contrast, they were significantly more likely to have higher cholesterol 
over the study period. In contrast, there were no statistically significant interactions between 
SES and visit year with any long-term complication. There was one exception, however, which 
indicated mid SES patients were more likely to have higher incidences of ICD than low SES 
patients.  
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Chapter 7: Are there socio-economic inequalities in interventions 
associated with type 2 diabetes over time?  
 
This chapter describes the multilevel models that were fitted to examine whether there were 
socio-economic inequalities in the rate of type 2 diabetes interventions reported by SES over the 
study period once other explanatory variables and clustering of data within individuals and 
general practices have been taken into account.  
 
Timeliness of diagnosis 
 
Table 12 shows the results for the saturated linear regression multilevel model that examined 
timeliness of diagnosis by SES. There were 3,071 available cases were modelled.  
 
Table 12: Saturated linear regression multilevel model examining timeliness of diagnosis with 
interaction effect between SES and visit from 1999 to 2007, conditional on relevant explanatory 
variables  
 Timeliness of diagnosis 
Social-economic status 
Social-economic status, reference group: Low 
Mid 0.69 (-0.20, 1.55) 
High 0.27 (-0.49, 1.03) 
Visit year, reference group: 1999 
2000 -0.24 (-0.90, 0.39) 
2001 -0.76 (-1.37, -0.18) 
2002 -0.12 (-0.68, 0.42) 
2003 -0.42 (-0.95, 0.12) 
2004 -0.42 (-0.97, 0.11) 
2005 -0.59 (-1.14, -0.05) 
2006 -0.99 (-1.54, -0.44) 
2007 -1.14 (-1.73, -0.57) 
SES*Visit year, reference group: Low SES*1999 
Mid SES*2000 -0.40 (-1.50, 0.71) 
Mid SES*2001 0.25 (-0.80, 1.31) 
Mid SES*2002 -1.11 (-2.08, -0.12) 
Mid SES*2003 -0.64 (-1.60, 0.32) 
Mid SES*2004 -0.91 (-1.84, 0.04) 
Mid SES*2005 -0.41 (-1.35, 0.54) 
Mid SES*2006 -0.37 (-1.33, 0.60) 
Mid SES*2007 -0.45 (-1.41, 0.55) 
High SES*2000 -0.76 (-1.75, 0.23) 
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High SES*2001 -0.03 (-0.96, 0.90) 
High SES*2002 -0.70 (-1.53, 0.16) 
High SES*2003 -0.50 (-1.33, 0.34) 
High SES*2004 -0.33 (-1.14, 0.49) 
High SES*2005 -0.44 (-1.28, 0.39) 
High SES*2006 -0.43 (-1.26, 0.42) 
High SES*2007 -0.24 (-1.08, 0.61) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age at diagnosis, reference group: <60 
60-74 -0.08 (-0.22, 0.07) 
75+ -0.12 (-0.33, 0.08) 
Ethnicity, reference group: white 
South Asian 0.47 (0.17, 0.77) 
Other Ethnicity 0.32 (-0.32, 0.98) 
Male 0.05 (-0.08, 0.17) 
Smoking status, reference group: non-smoker 
Smoker 0.21 (0.05, 0.36) 
Ex-smoker 0.03 (-0.11, 0.16) 
Obesity status, reference group: Under and normal weight 
Overweight 0.16 (-0.03, 0.35) 
Obese 0.05 (-0.14, 0.24) 
Hypertensive 0.04 (-0.08, 0.17) 
Cholesterol 0.16 (0.12, 0.20) 
Creatinine > 300 0.53 (-1.78, 2.75) 
eGFR 0.00 (0.00, 0.01) 
Ischaemic Cardiac 0.09 (-0.09, 0.26) 
Stroke or TIA -0.10 (-0.37, 0.18) 
PVD -0.01 (-0.41, 0.39) 
Interventions 
Care level, reference group: <7 
Care level: 7 -0.20 (-0.34, -0.05) 
Care level: 8 -0.11 (-0.29, 0.08) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas 
only 
1.01 (0.87, 1.15) 
Combination, no insulin 1.03 (0.82, 1.25) 
Insulin only 2.00 (1.65, 2.35) 
Combination with insulin 1.64 (1.44, 1.84) 
BP treatment, reference group no treatments 
ACE inhibitors only -0.32 (-0.54, -0.10) 
ACE & other(s) -0.25 (-0.42, -0.07) 
Other BP  -0.13 (-0.29, 0.03) 
Aspirin 0.04 (-0.11, 0.19) 
Lipid therapy -0.11 (-0.24, 0.03) 
Shared care 0.20 (0.01, 0.38) 
Middlesbrough PCT 0.14 (-0.09, 0.38) 
Cons 6.79 (6.06, 7.50) 
Practice level 0.10 (0.05, 0.18) 
Patient level 2.57 (2.45, 2.71) 
Bayesian DIC 11700.65 
N = 3,071 
 
The results in Table 12 show that there were no statistically significant differences by SES in the 
timeliness of diagnosis as measured by HbA1c at time of diagnosis. This was consistent over 
each step of analysis (Table 63, Appendix G). However, there was some evidence of statistically 
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significant differences in timeliness of diagnosis over time, with mid SES patients more likely to 
have a lower HbA1c at diagnosis in 2002 compared to low SES in 1999. There was more 
evidence in earlier steps, however, these become non-significant following the introduction of 
other covariates, particularly intervention data. This suggests that there were differences in 
timeliness of diagnosis, however, diabetes care initiated during the first year mediates the effect 
of these differences.  
Prior to intervention data being added to the model, age had a significant negative association 
with HbA1c at diagnosis, with the older patients the more likely to have a more favourable 
HbA1c at diagnosis. However, being South Asian, a smoker and increasing cholesterol were 
significantly associated with a greater HbA1c at diagnosis. Once intervention data were added, 
age was no longer significant. Mid quality of care compared to low quality, and being treated 
with ACEIs either alone or in combination with other BP treatments had a significant negative 
association with HbA1c at diagnosis, suggesting a relationship with earlier diagnosis. In 
contrast, being treated with any diabetes treatment and receiving shared care were significantly 
associated with a higher HbA1c at diagnosis, suggesting a later diagnosis results in the initiation 
of treatments and specialist care within a year.  
The Bayesian DIC statistics indicated that more variance was explained as each set of variables 
were added to the model, improving model fit. In the null model, 3.57% of variation in 
timeliness of diagnosis was accounted for by the practice the patient was registered with, as 
measured by ICC (Table 63, Appendix G). 
 
Quality of care 
 
Table 13 shows the results for the saturated linear regression multilevel model that examined 
quality of care by SES. There were 33,115 available cases for this model. The results show that 
there was a statistically significant difference in the quality of care, with high SES associated 
with lower quality. However, the interaction effect resulted in a statistically significant 
association between high SES and time, suggesting that high SES patients have received greater 
quality of care compared to low SES patients from 2002 to 2007 compared to 1999. These 
patterns remained consistent across each step of the analyses suggesting that the relationship 
occurs regardless of a patients’ other characteristics and health care needs. The significant 
positive association between visit year and quality of care suggests that quality of care has 
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increased over time, with the exception of 2007. This reflects the results from the graphical 
analyses.  
Prior to the interventions being added to the model, being aged 75 years and over, South Asian, 
a smoker and increasing cholesterol had a significant negative association with quality of care. 
Duration categories of more than 3 years had a significant positive association with quality of 
care. Once intervention data were added having diabetes 10 years or more was no longer 
significant. Interestingly, being aged 60-74 become significant and indicated that this age group 
were likely to receive greater quality of care compared to those aged under 60 years old.  
Other intervention data were added to the model to determine whether these were related to 
the level of quality of care. The results show that being treated with insulin and other diabetes 
treatments, ACEI solely and shared care were also significant predictors of increased quality of 
care. The latter relationship suggests that place of care was an important determinant of quality 
care. However, the ICC at practice level variance in the null model was 6%, indicating that 
patients’ general practice makes only a small contribution to the level of care they receive. The 
Bayesian DIC indicates that more variance was explained as each set of variables were added to 
the model, improving model fit.  
 
Table 13: Saturated linear regression multilevel model examining quality of care with 
interaction effect between SES and visit from 1999 to 2007, conditional on relevant explanatory 
variables  
 Quality of care 
Socio-economic status 
Social-economic status, reference group: Low 
Mid -0.04 (-0.16, 0.09) 
High -0.16 (-0.28, -0.05) 
Visit year, reference group: 1999 
2000 0.05 (-0.03, 0.14) 
2001 0.11 (0.02, 0.19) 
2002 0.06 (-0.02, 0.14) 
2003 0.06 (-0.01, 0.14) 
2004 0.15 (0.07, 0.23) 
2005 0.02 (-0.06, 0.10) 
2006 0.27 (0.19, 0.34) 
2007 -0.40 (-0.47, -0.32) 
SES*Visit year, reference group: Low SES*1999 
Mid SES*2000 -0.03 (-0.18, 0.12) 
Mid SES*2001 -0.01 (-0.16, 0.13) 
Mid SES*2002 0.11 (-0.03, 0.24) 
Mid SES*2003 0.07 (-0.07, 0.21) 
Mid SES*2004 -0.01 (-0.14, 0.13) 
Mid SES*2005 0.03 (-0.10, 0.17) 
Mid SES*2006 0.06 (-0.07, 0.20) 
Mid SES*2007 0.08 (-0.05, 0.22) 
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High SES*2000 0.09 (-0.05, 0.22) 
High SES*2001 0.11 (-0.02, 0.24) 
High SES*2002 0.21 (0.09, 0.33) 
High SES*2003 0.17 (0.05, 0.29) 
High SES*2004 0.18 (0.06, 0.30) 
High SES*2005 0.19 (0.07, 0.31) 
High SES*2006 0.21 (0.09, 0.32) 
High SES*2007 0.16 (0.03, 0.28) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age, reference group: <60 
60-74 0.04 (0.02, 0.06) 
75+ -0.01 (-0.03, 0.02) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years 0.06 (0.04, 0.07) 
Duration 10+ years 0.01 (-0.01, 0.03) 
Ethnicity, reference group: white 
South Asian -0.08 (-0.12, -0.04) 
Other Ethnicity -0.08 (-0.16, 0.00) 
Male -0.01 (-0.03, 0.00) 
Smoking status, reference group: non-smoker 
Smoker -0.06 (-0.09, -0.04) 
Ex-smoker 0.02 (0.00, 0.04) 
Obesity status, reference group: Under and normal weight 
Overweight 0.03 (0.01, 0.05) 
Obese 0.00 (-0.02, 0.02) 
Hypertensive -0.03 (-0.04, -0.01) 
HbA1c -0.01 (-0.02, -0.01) 
Cholesterol -0.02 (-0.03, -0.02) 
Creatinine > 300 -0.07 (-0.19, 0.06) 
eGFR 0.00 (0.00, 0.00) 
Ischaemic Cardiac -0.03 (-0.05, -0.01) 
Stroke or TIA -0.01 (-0.03, 0.02) 
PVD 0.02 (-0.01, 0.04) 
Interventions 
Diabetes treatment, reference group diet alone 
Sulphonylureas / metformin only 0.05 (0.03, 0.08) 
Diab. comb. no insulin 0.02 (-0.01, 0.04) 
Insulin only 0.02 (-0.01, 0.05) 
Insulin & other diab. treatments 0.04 (0.02, 0.07) 
BP treatment, reference group no treatments 
ACE inhibitors only 0.04 (0.01, 0.06) 
ACE & other(s) 0.02 (0.00, 0.05) 
Other BP  0.02 (0.00, 0.04) 
Aspirin 0.00 (-0.02, 0.01) 
Lipid therapy 0.02 (0.00, 0.03) 
Shared care 0.27 (0.25, 0.29) 
Middlesbrough PCT -0.07 (-0.18, 0.03) 
Cons 7.06 (6.93, 7.19) 
Practice level 0.03 (0.02, 0.05) 
Patient level 0.00 (0.00, 0.01) 
Visit year level 0.42 (0.41, 0.43) 
Bayesian DIC 65285.29 
Available cases (N) 33,115 
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Diabetes treatments 
 
Table 14 shows the results for the saturated logistic regression multilevel model that examined 
diabetes treatments by SES. There were 36,161 available cases available for each set of analyses.  
 
Table 14: Saturated logistic regression multilevel model examining diabetes treatments with 
interaction effect between SES and visit from 1999 to 2007, conditional on relevant explanatory 
variables  
 Diet alone Metformin or 
sulphonylureas 
Combination, 
no insulin 
Insulin only Insulin & 
others 
Social-economic status 
Social-economic status, reference group: Low 
Mid -0.31  
(-0.65, 0.03) 
0.27  
(-0.04, 0.59) 
0.24  
(-0.06, 0.53) 
-0.26  
(-0.61, 0.09) 
-0.10  
(-0.42, 0.20) 
High -0.05  
(-0.34, 0.25) 
-0.49  
(-0.87, -0.14) 
0.00  
(-0.28, 0.27) 
-0.11  
(-0.45, 0.24) 
0.22  
(-0.06, 0.50) 
Visit year, reference group: 1999 
2000 -0.45  
(-0.71, -0.17) 
0.11  
(-0.14, 0.37) 
-0.25  
(-0.51, 0.00) 
0.06  
(-0.22, 0.33) 
0.29  
(0.06, 0.52) 
2001 -0.69  
(-0.96, -0.43) 
0.10  
(-0.15, 0.34) 
-0.39  
(-0.64, -0.14) 
0.11  
(-0.17, 0.39) 
0.47  
(0.24, 0.70) 
2002 -0.62  
(-0.87, -0.37) 
0.17  
(-0.05, 0.39) 
-0.45  
(-0.68, -0.23) 
-0.23  
(-0.49, 0.03) 
0.64  
(0.44, 0.84) 
2003 -0.74  
(-0.97, -0.51) 
0.17  
(-0.04, 0.39) 
-0.72  
(-0.94, -0.49) 
-0.21  
(-0.46, 0.04) 
0.80  
(0.61, 1.00) 
2004 -0.81  
(-1.04, -0.58) 
0.30  
(0.09, 0.51) 
-1.10  
(-1.32, -0.88) 
-0.14  
(-0.39, 0.11) 
0.96  
(0.76, 1.15) 
2005 -0.95  
(-1.18, -0.72) 
0.31  
(0.10, 0.52) 
-1.17  
(-1.40, -0.94) 
-0.12  
(-0.38, 0.13) 
1.04  
(0.84, 1.24) 
2006 -1.15  
(-1.37, -0.92) 
0.34  
(0.14, 0.55) 
-1.25  
(-1.48, -1.02) 
-0.05  
(-0.31, 0.21) 
1.03  
(0.84, 1.23) 
2007 -1.21  
(-1.45, -0.98) 
0.53  
(0.32, 0.75) 
-1.48  
(-1.73, -1.24) 
-0.03  
(-0.29, 0.24) 
1.08  
(0.88, 1.27) 
SES*Visit year, reference group: Low SES*1999 
Mid SES*2000 0.10  
(-0.38, 0.57) 
-0.28  
(-0.73, 0.16) 
0.03  
(-0.37, 0.44) 
-0.01  
(-0.50, 0.46) 
0.16  
(-0.24, 0.56) 
Mid SES*2001 0.27  
(-0.17, 0.72) 
-0.52  
(-0.95, -0.08) 
-0.11  
(-0.51, 0.29) 
-0.11  
(-0.59, 0.37) 
0.36  
(-0.02, 0.76) 
Mid SES*2002 0.17  
(-0.26, 0.57) 
-0.34  
(-0.73, 0.05) 
-0.27  
(-0.64, 0.12) 
0.46  
(0.00, 0.90) 
0.12  
(-0.23, 0.50) 
Mid SES*2003 0.37  
(-0.04, 0.77) 
-0.31  
(-0.68, 0.06) 
-0.19  
(-0.55, 0.19) 
0.40  
(-0.04, 0.84) 
0.04  
(-0.29, 0.39) 
Mid SES*2004 0.29  
(-0.11, 0.67) 
-0.25  
(-0.60, 0.10) 
-0.06  
(-0.42, 0.31) 
0.19  
(-0.25, 0.62) 
0.00  
(-0.33, 0.35) 
Mid SES*2005 0.54  
(0.15, 0.94) 
-0.34  
(-0.70, 0.01) 
-0.33  
(-0.71, 0.05) 
0.36  
(-0.06, 0.80) 
0.01  
(-0.33, 0.36) 
Mid SES*2006 0.39  
(0.00, 0.76) 
-0.40  
(-0.76, -0.05) 
-0.25  
(-0.62, 0.12) 
0.37  
(-0.06, 0.80) 
0.14  
(-0.20, 0.48) 
Mid SES*2007 0.47  
(0.08, 0.87) 
-0.44  
(-0.80, -0.09) 
-0.28  
(-0.68, 0.13) 
0.40  
(-0.04, 0.84) 
0.13  
(-0.20, 0.48) 
High SES*2000 0.10  
(-0.33, 0.53) 
-0.09  
(-0.59, 0.40) 
0.08  
(-0.30, 0.47) 
0.34  
(-0.12, 0.80) 
-0.24  
(-0.61, 0.13) 
High SES*2001 0.09  
(-0.32, 0.49) 
0.22  
(-0.23, 0.68) 
0.19  
(-0.18, 0.57) 
0.07  
(-0.38, 0.52) 
-0.25  
(-0.61, 0.11) 
High SES*2002 0.01  
(-0.37, 0.38) 
0.23  
(-0.19, 0.66) 
0.17  
(-0.17, 0.53) 
0.38  
(-0.04, 0.80) 
-0.30  
(-0.64, 0.03) 
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High SES*2003 0.05  
(-0.31, 0.40) 
0.33  
(-0.06, 0.76) 
0.22  
(-0.12, 0.56) 
0.38  
(-0.03, 0.79) 
-0.38  
(-0.71, -0.06) 
High SES*2004 0.05  
(-0.30, 0.39) 
0.31  
(-0.08, 0.72) 
0.16  
(-0.18, 0.50) 
0.31  
(-0.10, 0.72) 
-0.30  
(-0.60, 0.02) 
High SES*2005 0.15  
(-0.20, 0.48) 
0.45  
(0.07, 0.87) 
0.05  
(-0.29, 0.40) 
0.23  
(-0.19, 0.65) 
-0.33  
(-0.64, -0.01) 
High SES*2006 0.14  
(-0.20, 0.47) 
0.43  
(0.05, 0.84) 
0.02  
(-0.31, 0.37) 
0.46  
(0.05, 0.86) 
-0.35  
(-0.66, -0.04) 
High SES*2007 0.25  
(-0.10, 0.59) 
0.41  
(0.03, 0.82) 
0.04  
(-0.32, 0.42) 
0.32  
(-0.11, 0.73) 
-0.36  
(-0.67, -0.04) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age, reference group: <60 years 
Age: 60-74 years 0.19  
(0.11, 0.27) 
-0.03 (-0.09, 
0.04) 
0.21  
(0.12, 0.30) 
-0.46  
(-0.55, -0.36) 
0.00  
(-0.06, 0.06) 
Age: 75+ years 0.44  
(0.34, 0.54) 
-0.01 (-0.10, 
0.08) 
0.52  
(0.41, 0.63) 
-0.63  
(-0.76, -0.50) 
-0.31  
(-0.39, -0.22) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 yrs -1.07  
(-1.14, -1.00) 
-0.42  
(-0.48, -0.36) 
0.14  
(0.07, 0.22) 
0.57  
(0.46, 0.68) 
1.14  
(1.08, 1.20) 
Duration 10+ yrs -1.64  
(-1.74, -1.55) 
-1.20 
(-1.28, -1.11) 
-0.27  
(-0.36, -0.18) 
1.42  
(1.31, 1.53) 
1.43  
(1.36, 1.50) 
Ethnicity, reference group: white 
South Asian 0.13  
(-0.06, 0.32) 
0.07  
(-0.08, 0.21) 
0.12  
(-0.06, 0.29) 
-0.58  
(-0.77, -0.39) 
0.08  
(-0.05, 0.21) 
Other Ethnicity 0.10  
(-0.33, 0.51) 
-0.37  
(-0.73, -0.04) 
-0.11  
(-0.56, 0.31) 
0.55  
(0.19, 0.89) 
-0.18  
(-0.45, 0.09) 
Male 0.28  
(0.22, 0.35) 
-0.18  
(-0.24, -0.12) 
0.34  
(0.26, 0.41) 
-0.07  
(-0.15, 0.01) 
-0.17  
(-0.23, -0.12) 
Smoking status, reference group: non-smoker 
Smoker -0.07  
(-0.16, 0.03) 
0.06  
(-0.02, 0.14) 
0.07  
(-0.03, 0.17) 
0.16  
(0.05, 0.27) 
-0.05  
(-0.13, 0.02) 
Ex-smoker -0.09  
(-0.16, -0.02) 
0.03  
(-0.03, 0.09) 
0.02  
(-0.06, 0.09) 
0.00  
(-0.08, 0.08) 
0.05  
(-0.01, 0.10) 
BMI status, reference group: under and normal weight 
Overweight -0.23  
(-0.32, -0.14) 
0.46  
(0.36, 0.56) 
-0.25  
(-0.34, -0.17) 
-0.40  
(-0.51, -0.30) 
0.32  
(0.24, 0.40) 
Obese -0.43  
(-0.52, -0.34) 
0.63  
(0.54, 0.73) 
-0.70  
(-0.79, -0.61) 
-0.87  
(-0.97, -0.76) 
0.72  
(0.65, 0.81) 
HbA1c -0.82  
(-0.85, -0.79) 
-0.07  
(-0.09, -0.06) 
0.01  
(-0.01, 0.04) 
0.24  
(0.22, 0.26) 
0.27  
(0.25, 0.28) 
Hypertensive 0.03  
(-0.04, 0.09) 
-0.02  
(-0.08, 0.04) 
0.02  
(-0.05, 0.09) 
-0.13  
(-0.21, -0.05) 
0.04  
(-0.01, 0.09) 
Cholesterol 0.24  
(0.21, 0.27) 
-0.01  
(-0.04, 0.02) 
0.00  
(-0.03, 0.03) 
0.02  
(-0.01, 0.05) 
-0.18  
(-0.20, -0.15) 
Creatinine > 300 -0.18  
(-0.75, 0.34) 
-3.11 
(-6.17, -1.20) 
0.25  
(-0.21, 0.69) 
0.46  
(-0.01, 0.93) 
-1.15  
(-1.79, -0.56) 
eGFR 0.00  
(-0.01, 0.00) 
0.01  
(0.01, 0.01) 
-0.01  
(-0.02, -0.01) 
-0.02  
(-0.03, -0.02) 
0.01  
(0.01, 0.01) 
Ischaemic 
Cardiac 
0.06  
(-0.01, 0.13) 
-0.04  
(-0.11, 0.02) 
-0.01  
(-0.08, 0.06) 
0.18  
(0.10, 0.27) 
-0.11  
(-0.17, -0.06) 
Stroke or TIA -0.08  
(-0.19, 0.03) 
-0.07  
(-0.17, 0.03) 
0.06  
(-0.04, 0.17) 
0.15  
(0.04, 0.26) 
-0.04  
(-0.12, 0.04) 
PVD -0.33  
(-0.46, -0.19) 
-0.06  
(-0.18, 0.05) 
-0.09  
(-0.22, 0.03) 
0.38  
(0.27, 0.50) 
-0.09  
(-0.18, 0.00) 
Interventions 
Care level, reference group: <7  
Care level: 7 -0.15  
(-0.22, -0.07) 
0.08  
(0.00, 0.15) 
0.06  
(-0.03, 0.14) 
-0.07  
(-0.17, 0.03) 
0.10  
(0.03, 0.16) 
Care level: 8 -0.14  
(-0.23, -0.05) 
0.15  
(0.06, 0.23) 
-0.05  
(-0.15, 0.05) 
-0.04  
(-0.15, 0.07) 
0.12  
(0.05, 0.20) 
Shared care -1.33  
(-1.43, -1.23) 
-0.54 
(-0.61, -0.46) 
-0.62  
(-0.71, -0.53) 
2.12  
(2.04, 2.21) 
0.09  
(0.03, 0.15) 
M’brough PCT 0.01  
(-0.34, 0.36) 
0.14  
(-0.05, 0.32) 
-0.01  
(-0.19, 0.18) 
-0.13  
(-0.35, 0.08) 
-0.08  
(-0.28, 0.10) 
Cons 5.43  -1.73  -0.22  -3.42  -4.76  
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(5.02, 5.88) (-2.08, -1.40) (-0.65, 0.19) (-3.88, -2.97) (-5.12, -4.41) 
Variance estimate at: 
Practice level 0.32  
(0.20, 0.51) 
0.09  
(0.05, 0.14) 
0.07  
(0.04, 0.13) 
0.11  
(0.06, 0.18) 
0.09  
(0.05, 0.14) 
Patient level 0.01  
(0.00, 0.03) 
0.00  
(0.00, 0.02) 
0.00  
(0.00, 0.01) 
0.00  
(0.00, 0.01) 
0.01  
(0.00, 0.02) 
Bayesian DIC 27148.92 32952.79 25654.38 19561.96 40361.07 
N = 36,161 
 
With the exception of being treated by a combination of diabetes treatments with no insulin, 
Table 14 shows that were statistically significant differences in diabetes treatment regimens by 
SES over time. Mid SES patients were more likely to be treated by diet alone and less likely to be 
prescribed a mono-therapy of metformin or sulphonylureas compared to low SES patients in 
particular years. In addition, high SES patients were significantly more likely to be prescribed 
with a mono-therapy of metformin or sulphonylureas or insulin only and less likely to be 
treated with a combination of insulin with other diabetes treatment(s) compared low SES 
patients in particular years. These relationships were not explained by demographic, 
anthropometric, lifestyle and health care needs.  
The final saturated model which examined differences in patients having their blood glucose 
levels managed by diet alone shows that were no significant differences by SES overall. 
However, prior to adding intervention data into the model, there were statistically significant 
results indicating that mid SES were more likely to be treated by diet alone, both overall and 
over time (Table 65, Appendix G).  The stepwise models in Table 66 in Appendix G shows that 
high SES patients were significantly more likely to be prescribed a mono-therapy of metformin 
or sulphonylureas overall and that this relationship was not explained by other covariates. In 
contrast, there no were statistically significant differences by SES in being prescribed any of the 
remaining treatment regimens in any step of the analyses (Table 67, Table 68 and Table 69, 
Appendix G). 
Increasing age was significantly associated with being more likely to be with treated diet alone 
and combination of diabetes treatments with no insulin and being less likely to prescribed 
insulin only and in combination with other diabetes treatments. The direction of the 
relationship between treatment regimens and duration of diabetes follows expectations: with 
increased duration associated with being less likely to be treated with diet alone and mono-
therapies of metformin or sulphonylureas and more likely to be treated with insulin either 
solely or in combination. There were significant differences between ethnicity and sex and 
treatment regimens which were not easily explained.  
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Being a smoker and ex-smoker were significantly associated with being less likely to be treated 
by diet alone. Being a smoker was also significantly associated with being more likely to be 
treated with insulin only. Increased BMI was also a significant predictor of diabetes treatment 
regimens but not in a consistent manner as was demonstrated with duration of diabetes. As 
expected, increased HbA1c had a significant negative association with being treated by diet 
alone and a mono-therapy of metformin or sulphonylureas and positive association with being 
treated with insulin either alone or in combination with other diabetes treatment(s). Other 
indicators of patients’ health status showed some significant relationships with diabetes 
treatment outcomes but not in a consistent way. 
The ICC of the null models indicate that the general practice at which patients were registered 
with explained more of the variation in being treated by diet alone than other treatment 
regimens with 10.51% of the variation explained at this level. 4.26% of the variation in being 
prescribed insulin only and approximately 2% of the variation in prescription for combinations 
of diabetes treatments without insulin and for diabetes treatments with insulin were explained 
at this level. In all sets of analyses the Bayesian statistics indicate improved model fit with the 
introduction of set of variables.  
 
Blood pressure treatments 
 
Table 15: Saturated logistic regression multilevel model examining BP treatments with 
interaction effect between SES and visit from 1999 to 2007, conditional on relevant explanatory 
variables 
 No BP ACEI only ACEI comb. Other comb. 
Social-economic status 
Social-economic status, reference group: Low 
Mid 0.11 (-0.18, 0.42) 0.30 (-0.14, 0.74) 0.00 (-0.37, 0.35) -0.23 (-0.52, 0.08) 
High 0.35 (0.06, 0.63) 0.33 (-0.07, 0.73) -0.36 (-0.72, 0.00) -0.31 (-0.62, -0.01) 
Visit year, reference group: 1999 
2000 -0.21 (-0.45, 0.03) 0.40 (0.05, 0.75) 0.30 (0.03, 0.58) -0.23 (-0.46, 0.00) 
2001 -0.27 (-0.50, -0.04) 0.46 (0.12, 0.80) 0.57 (0.30, 0.83) -0.44 (-0.66, -0.21) 
2002 -0.45 (-0.66, -0.24) 0.48 (0.16, 0.79) 0.78 (0.52, 1.03) -0.51 (-0.72, -0.30) 
2003 -0.73 (-0.94, -0.52) 0.44 (0.14, 0.75) 0.89 (0.65, 1.13) -0.40 (-0.60, -0.19) 
2004 -0.81 (-1.01, -0.60) 0.37 (0.07, 0.67) 0.96 (0.71, 1.20) -0.38 (-0.58, -0.18) 
2005 -0.99 (-1.20, -0.79) 0.50 (0.21, 0.81) 0.99 (0.75, 1.22) -0.36 (-0.56, -0.15) 
2006 -0.92 (-1.12, -0.71) 0.56 (0.27, 0.87) 0.98 (0.73, 1.22) -0.43 (-0.63, -0.23) 
2007 -1.11 (-1.33, -0.89) 0.60 (0.31, 0.91) 1.06 (0.82, 1.30) -0.42 (-0.63, -0.21) 
SES*Visit year, reference group: Low SES*1999 
Mid SES*2000 -0.17 (-0.59, 0.24) 0.04 (-0.53, 0.62) 0.02 (-0.44, 0.50) 0.11 (-0.29, 0.50) 
Mid SES*2001 -0.18 (-0.58, 0.21) -0.02 (-0.56, 0.51) 0.00 (-0.42, 0.44) 0.16 (-0.23, 0.55) 
Mid SES*2002 -0.18 (-0.55, 0.18) -0.17 (-0.68, 0.33) -0.03 (-0.42, 0.38) 0.25 (-0.10, 0.60) 
Mid SES*2003 -0.06 (-0.42, 0.30) -0.31 (-0.81, 0.19) 0.09 (-0.29, 0.49) 0.11 (-0.24, 0.46) 
Mid SES*2004 0.02 (-0.33, 0.37) -0.28 (-0.77, 0.21) -0.06 (-0.45, 0.34) 0.18 (-0.16, 0.51) 
Mid SES*2005 -0.09 (-0.44, 0.26) -0.25 (-0.74, 0.24) -0.01 (-0.40, 0.38) 0.20 (-0.14, 0.54) 
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Mid SES*2006 -0.14 (-0.48, 0.21) -0.23 (-0.71, 0.25) -0.01 (-0.40, 0.38) 0.22 (-0.12, 0.54) 
Mid SES*2007 -0.18 (-0.56, 0.18) -0.13 (-0.61, 0.35) 0.01 (-0.38, 0.41) 0.14 (-0.20, 0.47) 
High SES*2000 0.00 (-0.38, 0.38) -0.26 (-0.79, 0.28) 0.22 (-0.23, 0.68) 0.02 (-0.37, 0.42) 
High SES*2001 -0.20 (-0.56, 0.17) -0.36 (-0.87, 0.15) 0.07 (-0.35, 0.50) 0.43 (0.05, 0.81) 
High SES*2002 -0.42 (-0.76, -0.07) -0.2 (-0.66, 0.28) 0.18 (-0.21, 0.58) 0.47 (0.12, 0.82) 
High SES*2003 -0.39 (-0.72, -0.06) -0.21 (-0.67, 0.26) 0.34 (-0.05, 0.72) 0.32 (-0.02, 0.67) 
High SES*2004 -0.29 (-0.61, 0.05) -0.27 (-0.72, 0.19) 0.37 (-0.01, 0.76) 0.23 (-0.11, 0.57) 
High SES*2005 -0.27 (-0.59, 0.06) -0.34 (-0.79, 0.12) 0.26 (-0.12, 0.65) 0.37 (0.03, 0.71) 
High SES*2006 -0.30 (-0.61, 0.03) -0.32 (-0.76, 0.13) 0.21 (-0.17, 0.59) 0.43 (0.11, 0.76) 
High SES*2007 -0.26 (-0.59, 0.08) -0.23 (-0.67, 0.23) 0.22 (-0.16, 0.60) 0.35 (0.01, 0.68) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age, reference group: <60 years 
Age: 60-74 years -0.43 (-0.50, -0.36) -0.13 (-0.21, -0.05) 0.19 (0.13, 0.26) 0.39 (0.32, 0.45) 
Age: 75+ years -0.41 (-0.51, -0.31) -0.37 (-0.49, -0.25) 0.01 (-0.07, 0.09) 0.59 (0.50, 0.67) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 yrs -0.24 (-0.31, -0.18) 0.32 (0.24, 0.40) 0.23 (0.17, 0.29) -0.18 (-0.24, -0.13) 
Duration 10+ yrs -0.21 (-0.29, -0.13) 0.42 (0.33, 0.52) 0.39 (0.33, 0.46) -0.44 (-0.51, -0.37) 
Ethnicity, reference: White 
South Asian 0.44 (0.31, 0.58) -0.05 (-0.22, 0.12) -0.53 (-0.68, -0.39) -0.03 (-0.17, 0.10) 
Other Ethnicity 0.20 (-0.09, 0.49) -1.01 (-1.55, -0.53) -0.10 (-0.41, 0.19) 0.24 (-0.06, 0.53) 
Male 0.01 (-0.05, 0.07) 0.25 (0.18, 0.33) 0.27 (0.22, 0.32) -0.40 (-0.46, -0.35) 
Smoking status, reference: non-smoker 
Smoker 0.25 (0.17, 0.33) 0.01 (-0.10, 0.11) -0.11 (-0.19, -0.04) -0.10 (-0.18, -0.03) 
Ex-smoker -0.07 (-0.14, 0.00) 0.04 (-0.03, 0.12) 0.02 (-0.03, 0.08) 0.01 (-0.04, 0.07) 
BMI status, reference: under and normal weight 
Overweight -0.37 (-0.45, -0.29) 0.01 (-0.09, 0.11) 0.29 (0.21, 0.37) 0.03 (-0.05, 0.11) 
Obese -0.87 (-0.95, -0.78) -0.10 (-0.20, 0.00) 0.58 (0.50, 0.66) 0.17 (0.10, 0.25) 
sBP -0.02 (-0.02, -0.02) 0.00 (0.00, 0.00) 0.01 (0.01, 0.01) 0.00 (0.00, 0.01) 
dBP 0.01 (0.00, 0.01) 0.01 (0.01, 0.02) -0.01 (-0.01, -0.01) 0.00 (0.00, 0.00) 
HbA1c 0.07 (0.05, 0.08) 0.01 (-0.01, 0.04) -0.03 (-0.05, -0.01) -0.04 (-0.06, -0.02) 
Cholesterol 0.14 (0.12, 0.17) -0.02 (-0.05, 0.01) -0.11 (-0.14, -0.09) 0.00 (-0.03, 0.02) 
eGFR 0.02 (0.02, 0.02) 0.01 (0.00, 0.01) -0.01 (-0.02, -0.01) 0.00 (-0.01, 0.00) 
Ischaemic Cardiac -1.66 (-1.75, -1.58) -0.93 (-1.03, -0.84) 0.81 (0.76, 0.86) 0.48 (0.43, 0.54) 
Stroke or TIA -0.49 (-0.61, -0.37) 0.2 (0.09, 0.32) 0.16 (0.08, 0.23) -0.04 (-0.12, 0.04) 
PVD -0.32 (-0.46, -0.19) 0.29 (0.16, 0.41) 0.02 (-0.07, 0.11) -0.06 (-0.15, 0.03) 
Interventions 
Care level, reference group: <7 
Care level: 7 -0.03 (-0.10, 0.05) 0.04 (-0.05, 0.13) 0.01 (-0.05, 0.08) 0.00 (-0.06, 0.07) 
Care level: 8 -0.14 (-0.22, -0.05) 0.10 (0.00, 0.20) 0.04 (-0.03, 0.12) 0.02 (-0.05, 0.10) 
M’brough PCT 0.08 (-0.12, 0.28) 0.01 (-0.21, 0.25) -0.08 (-0.22, 0.07) 0.00 (-0.14, 0.15) 
Shared care 0.05 (-0.03, 0.12) 0.01 (-0.07, 0.09) 0.03 (-0.03, 0.10) -0.16 (-0.23, -0.10) 
Cons 1.05 (0.55, 1.49) -3.81 (-4.33, -3.28) -1.96 (-2.39, -1.60) -0.68 (-1.11, -0.28) 
Variance estimate at: 
Practice level 0.10 (0.06, 0.16) 0.12 (0.07, 0.20) 0.04 (0.02, 0.08) 0.05 (0.03, 0.09) 
Patient level 0.00 (0.00, 0.02) 0.01 (0.00, 0.03) 0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 
Bayesian DIC 31019.58 24581.11 39653.78 39748.14 
N = 34,231 
 
 
Table 15 shows the results for the saturated logistic regression multilevel model that examined 
BP treatments by SES. There were 34,231 available cases for each set of analyses. The results in 
Table 15 show that there were some statistically significant differences by SES, both overall 
and over time, in being prescribed no BP treatments and combination of BP treatments without 
ACEI. High SES patients were more likely to receive no BP treatments overall but in 2002 and 
2003 were less likely to be prescribed no BP treatments compared to low SES patients. In 
contrast, high SES patients were less likely to be prescribed another combination of BP 
treatments and yet, in a number of years, these patients were more likely to be prescribed this 
treatment regimen compared to low SES patients. There was evidence of inequalities in the 
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prescriptions of ACEI, alone and in combination with other BP treatments, by SES (Table 71 & 
Table 72, Appendix G) however, these relationships were no longer significant following the 
introduction of other covariates.  
As expected the time trends which were noted in the four figures displayed in chapter five were 
supported by the statistically significant association between visit year and BP treatment 
regimens in the final models in Table 15. Age also followed expectations, with increasing age 
significantly associated with being less likely to be prescribed no BP treatments and ACEI only, 
and more likely to be prescribed a combination of BP treatments. The relationship between age 
and the two BP combination treatment regimens were expected as BP usually deteriorates with 
increased age [65]. The relationship between BMI categories and treatment outcomes did follow 
an expected pattern with obese patients less likely to be prescribed no BP treatments and more 
likely to receive combinations of BP treatments. Interestingly, duration of diabetes was 
significant associated with all BP treatments regimens but did not follow a linear pattern. 
Increased duration was negatively associated with no BP treatments and other combinations of 
BP treatments and positively associated with ACEI alone and in combination. Like with diabetes 
treatments, there were significant differences by ethnicity and sex.  
The variables measuring patients’ health produced some unexpected results. Increased HbA1c, 
cholesterol and eGFR significantly associated with being more likely to be prescribed no BP 
treatments and less likely to be prescribed ACEI in combination with other BP treatments. 
However, the relationships between the outcome variables and history of vascular disease were 
more predictable. History of ICD, stroke or TIA and PVD were negatively associated with being 
prescribed no BP treatments, with the former also negatively associated with being prescribed 
ACEI only. There were significant positive associations between history of ICD and both BP 
treatment combinations, history of stroke or TIA and ACEI only and in combination with other 
BP treatments, and finally history of PVD with ACEI only.  
Quality of care and receiving shared care were not associated with BP treatments which should 
be expected, however, there were exceptions. High quality of care was negatively associated 
with receiving no BP treatments compared to low quality of care. The Bayesian statistics 
indicated that there was improved model fit in each set of analyses with the introduction of 
other variables, but with the exception of when intervention data were added to the modelling 
of ACEI alone and in combination with BP treatments. This reflects the lack of statistical 
significance of these variables. Around 3% or less variation was explained at the level of general 
practice as measured by the ICC of the null models. This suggests that the general practice at 
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which patients are registered with played a very small role in determining their BP 
management.  
 
Antithrombotic and lipid profile treatments 
 
Table 16 shows the results for the saturated logistic regression multilevel model that examined 
prescriptions for lipid therapies and aspirin by SES. There were 33,603 available cases for each 
set of analyses. The results show that there were no significant differences in the prescription of 
aspirin and lipid therapies by SES either overall or over time. These findings were consistent 
over each step of analyses (Table 74 and Table 75, Appendix G). 
Both models indicated a statistically significant increase in prescriptions for these treatments 
over the study period, again supporting the graphical analyses in chapter five. The direction of 
the relationship between the treatment outcomes and the status of patients BMI, smoking and 
health were very similar in both final models. Smokers, ex-smokers, increased BMI, decreased 
cholesterol and history of ICD, stroke or TIA and PVD all had a significant positive association 
with both treatment outcomes. HbA1c also had a significant positive associated with 
prescription of lipid therapies but not with aspirin. Increased cholesterol was significantly 
associated with being less likely to be prescribed these treatments. This may be a reflection of 
patients cholesterol being reduced by the treatment as patients with high cholesterol are 
considered at high risk of CV complications [46].  
Interestingly, increased quality of care had a significant positive association with patients being 
prescribed lipid therapies but not aspirin. In addition, shared care was significantly associated 
with both treatment outcomes but with different directions. These findings were not expected, 
especially the level of significant variables in the lipid therapies as there was a relatively high 
prescription rates with over 70% of patients receiving this treatment from 2005 onwards. 
Bayesian DIC statistics indicated improvement in model fit when each set of variables were 
added to both models. Only between 2% and 3% of variation was explained at practice level.  
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Table 16: Saturated logistic regression multilevel model examining lipid therapies and aspirin 
with interaction effect between SES and visit from 1999 to 2007, conditional on relevant 
explanatory variables  
 Lipid therapies Aspirin 
Social-economic status 
Social-economic status, reference group: Low 
Mid -0.05 (-0.52, 0.41) -0.02 (-0.56, 0.45) 
High 0.11 (-0.34, 0.52) -0.19 (-0.67, 0.23) 
Visit year, reference group: 1999 
2000 0.16 (-0.17, 0.47) 0.06 (-0.29, 0.38) 
2001 0.39 (0.07, 0.69) 0.16 (-0.17, 0.48) 
2002 0.89 (0.59, 1.17) 0.14 (-0.18, 0.44) 
2003 1.56 (1.27, 1.84) 0.42 (0.11, 0.72) 
2004 2.11 (1.81, 2.38) 0.55 (0.23, 0.84) 
2005 2.38 (2.08, 2.66) 0.64 (0.32, 0.94) 
2006 2.56 (2.27, 2.84) 0.72 (0.40, 1.02) 
2007 2.70 (2.39, 2.98) 0.86 (0.53, 1.16) 
SES*Visit year, reference group: Low SES*1999 
Mid SES*2000 0.15 (-0.40, 0.70) 0.10 (-0.45, 0.70) 
Mid SES*2001 0.15 (-0.38, 0.67) -0.08 (-0.62, 0.50) 
Mid SES*2002 0.13 (-0.37, 0.63) 0.14 (-0.38, 0.69) 
Mid SES*2003 0.03 (-0.46, 0.52) -0.01 (-0.51, 0.54) 
Mid SES*2004 0.12 (-0.38, 0.61) 0.04 (-0.45, 0.59) 
Mid SES*2005 0.12 (-0.38, 0.61) 0.08 (-0.41, 0.63) 
Mid SES*2006 -0.01 (-0.50, 0.49) 0.06 (-0.44, 0.61) 
Mid SES*2007 0.11 (-0.40, 0.62) 0.11 (-0.39, 0.66) 
High SES*2000 -0.08 (-0.58, 0.43) -0.06 (-0.56, 0.48) 
High SES*2001 -0.16 (-0.62, 0.32) -0.28 (-0.75, 0.26) 
High SES*2002 -0.12 (-0.56, 0.35) 0.04 (-0.42, 0.55) 
High SES*2003 -0.28 (-0.71, 0.20) 0.02 (-0.43, 0.53) 
High SES*2004 -0.08 (-0.51, 0.39) 0.16 (-0.27, 0.66) 
High SES*2005 -0.13 (-0.57, 0.33) 0.12 (-0.31, 0.62) 
High SES*2006 -0.08 (-0.51, 0.39) 0.21 (-0.23, 0.71) 
High SES*2007 -0.19 (-0.63, 0.29) 0.08 (-0.36, 0.58) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age, reference group: <60 years 
Age: 60-74 years 0.01 (-0.06, 0.08) 0.47 (0.40, 0.53) 
Age: 75+ years -0.67 (-0.75, -0.58) 0.46 (0.37, 0.54) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years 0.04 (-0.02, 0.10) 0.07 (0.01, 0.13) 
Duration 10+ years -0.10 (-0.17, -0.03) 0.20 (0.14, 0.27) 
Ethnicity, reference: White 
South Asian -0.35 (-0.49, -0.22) 0.03 (-0.11, 0.16) 
Other Ethnicity -0.71 (-0.98, -0.42) -0.01 (-0.31, 0.29) 
Male -0.33 (-0.39, -0.28) 0.27 (0.21, 0.32) 
Smoking status, reference: non-smoker 
Smoker 0.09 (0.01, 0.17) 0.22 (0.14, 0.30) 
Ex-smoker 0.10 (0.04, 0.15) 0.10 (0.04, 0.15) 
BMI status, reference: under and normal weight 
Overweight 0.43 (0.35, 0.51) 0.22 (0.14, 0.30) 
Obese 0.45 (0.37, 0.53) 0.32 (0.24, 0.40) 
Hypertensive -0.01 (-0.07, 0.04) 0.06 (0.01, 0.11) 
HbA1c 0.06 (0.04, 0.08) 0.00 (-0.02, 0.01) 
Cholesterol -0.28 (-0.30, -0.25) -0.11 (-0.13, -0.08) 
eGFR -0.01 (-0.01, 0.00) 0.00 (0.00, 0.00) 
Ischaemic Cardiac 0.95 (0.89, 1.01) 1.73 (1.67, 1.79) 
Stroke or TIA 0.23 (0.15, 0.32) 0.86 (0.78, 0.95) 
PVD 0.17 (0.07, 0.27) 0.33 (0.23, 0.43) 
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Interventions 
Care level, reference group: <7 
Care level: 7 0.14 (0.07, 0.21) 0.04 (-0.03, 0.10) 
Care level: 8 0.10 (0.03, 0.18) -0.01 (-0.09, 0.07) 
M. PCT 0.17 (-0.03, 0.37) 0.12 (-0.14, 0.38) 
Shared care -0.10 (-0.16, -0.03) 0.29 (0.22, 0.36) 
Cons -0.41 (-0.98, 1.64) -1.78 (-2.22, -1.24) 
Variance estimate at: 
Practice level 0.09 (0.05, 0.15) 0.16 (0.10, 0.26) 
Patient level 0.41 (0.00, 5.15) 0.00 (0.00, 0.01) 
Bayesian DIC 36560.43 37629.34 
N = 33,603 
 
 
Shared care 
 
Table 17: Saturated logistic regression multilevel model examining shared care with interaction 
effect between SES and visit from 1999 to 2007, conditional on relevant explanatory variables 
 Shared care 
Social-economic status 
Social-economic status, reference group: Low 
Mid 0.25 (-0.27, 0.80) 
High -0.61 (-1.08, -0.17) 
Visit year, reference group: 1999 
2000 -0.82 (-1.19, -0.46) 
2001 -1.51 (-1.88, -1.17) 
2002 -1.91 (-2.26, -1.59) 
2003 -2.35 (-2.70, -2.03) 
2004 -2.84 (-3.20, -2.52) 
2005 -3.16 (-3.51, -2.84) 
2006 -3.52 (-3.88, -3.19) 
2007 -3.08 (-3.44, -2.75) 
SES*Visit year, reference group: Low SES*1999 
Mid SES*2000 -0.30 (-0.93, 0.33) 
Mid SES*2001 -0.51 (-1.13, 0.09) 
Mid SES*2002 -0.42 (-1.01, 0.15) 
Mid SES*2003 -0.33 (-0.93, 0.24) 
Mid SES*2004 -0.04 (-0.63, 0.53) 
Mid SES*2005 0.14 (-0.45, 0.71) 
Mid SES*2006 0.15 (-0.43, 0.72) 
Mid SES*2007 0.13 (-0.46, 0.72) 
High SES*2000 0.47 (-0.06, 1.01) 
High SES*2001 0.44 (-0.06, 0.97) 
High SES*2002 0.72 (0.24, 1.23) 
High SES*2003 0.76 (0.29, 1.26) 
High SES*2004 0.76 (0.28, 1.25) 
High SES*2005 0.85 (0.37, 1.34) 
High SES*2006 0.72 (0.24, 1.22) 
High SES*2007 0.69 (0.20, 1.19) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age, reference group: <60 years 
60-74 -0.46 (-0.53, -0.38) 
75+ -0.85 (-0.96, -0.75) 
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Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years 0.01 (-0.07, 0.09) 
Duration 10+ years 0.54 (0.45, 0.63) 
Ethnicity, reference: White 
South Asian 0.13 (-0.02, 0.28) 
Other Ethnicity 0.72 (0.39, 1.05) 
Male 0.06 (0.00, 0.13) 
Smoking status, reference: non-smoker 
Smoker -0.32 (-0.42, -0.22) 
Ex-smoker -0.04 (-0.12, 0.03) 
BMI status, reference: under and normal weight 
Overweight 0.08 (-0.02, 0.18) 
Obese 0.39 (0.28, 0.49) 
HbA1c 0.11 (0.09, 0.13) 
Hypertensive  0.47 (0.41, 0.54) 
Cholesterol -0.08 (-0.11, -0.05) 
Creatinine > 300 0.06 (-0.47, 0.58) 
eGFR -0.01 (-0.01, 0.00) 
Ischaemic Cardiac 0.21 (0.13, 0.29) 
Stroke or TIA 0.17 (0.06, 0.27) 
PVD 0.7 (0.59, 0.81) 
Interventions 
Quality of care level, reference group: Low quality 
Care level: 7 0.60 (0.52, 0.69) 
Care level: 8 1.25 (1.15, 1.35) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas 
only 0.75 (0.62, 0.88) 
Comb. no insulin 0.78 (0.65, 0.92) 
Insulin only 3.28 (3.14, 3.43) 
Insulin & others 1.59 (1.47, 1.71) 
BP treatment, reference group no treatments 
ACE inhibitors only -0.04 (-0.15, 0.07) 
ACE & other(s) -0.01 (-0.10, 0.08) 
Other BP  -0.10 (-0.19, -0.01) 
Aspirin 0.22 (0.15, 0.30) 
Lipid therapy -0.20 (-0.28, -0.13) 
Middlesbrough PCT 0.65 (0.17, 1.21) 
Cons -1.19 (-1.77, -0.50) 
Variance estimate at: 
Practice level 1.00 (0.62, 1.62) 
Patient level 0.01 (0.00, 0.03) 
Bayesian DIC 25638.09 
N = 33,115 
 
Table 17 shows the results for the saturated logistic regression multilevel model that examined 
shared care by SES. There were 33,115 available cases available for each set of analyses. The 
results shows that were significant differences in the receipt of shared care by SES with high 
SES patients less likely to receive shared care, however, over time these were more likely to 
receive shared care compared to low SES patients in 1999. These findings suggest a possible 
increase in differences by SES compared to 1999. These results remained consistent following 
the introduction of other covariates into the model (Table 76, Appendix G). 
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Increased age, being a smoker and higher cholesterol all had a significant negative association 
with receiving shared care. Having diabetes for 10 years or more was significantly associated 
with receiving shared care compared to those who had the condition for less than 4 years. This 
was likely to reflect the progressive nature of diabetes and the longer patients have diabetes the 
more complications they were likely to have. The idea that having poorer control and more 
complex care needs was also supported by the significant positive associations of being obese, 
hypertensive, increased HbA1c, having a history of ICD, stroke or TIA and PVD  and being 
prescribed any diabetes treatment combination and aspirin with this outcome. However, this 
does not explained the significant negative association that cholesterol, being prescribed other 
BP treatments and lipid therapies have with receipt of shared care. 
Increased quality of care also had a significant positive association with shared care. This may 
support the theory here that patients with more complex needs receive greater levels of care. It 
may also reflect that greater quality of care occurs in shared care than primary care and/or the 
quality of recording from these different locations than the actual care patients receive. 
Interestingly patients under the responsibility of Middlesbrough PCT were more likely to 
receive shared care. There are many potential explanations for this. On a macro level 
Middlesbrough PCT may be more inclined to fund patients’ referral to specialist care. However, 
it may be more a reflection in terms of access as the Diabetes Care Centre is located within 
Middlesbrough PCT and the majority of Redcar & Cleveland PCT is rural requiring extensive 
journey time to attend this clinic. The results also show that there has been a significant 
reduction in the rate of patients receiving shared care over the study period. This reflects the 
national policy trend of moving chronic disease management into primary from secondary care.  
The ICC showed that 23.26% of variation in the receipt of shared care was explained at the 
practice level. This was notably higher than the variation of any of the other interventions 
modelled in this chapter. This should be explored further as it may indicate that patients in 
certain practices are being denied access to specialist services or in contrast, it may be because 
some practices may be more effective at managing patients within a primary care setting and 
therefore there is potential to identify best practice techniques.  
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Principle findings 
 
Overall, these analyses found socio-economic inequalities in quality of care, some diabetes and 
BP treatments regimens, and the receipt of shared care over time. There was also one 
statistically significant result that indicated inequalities in timeliness of diagnosis over time. 
These results were not explained by controlling for other relevant variables.  
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Chapter 8: Are there intervention-generated inequalities in type 2 
diabetes care? 
 
The previous two chapters have examined inequalities in intermediate outcomes, long-term 
complications and type 2 diabetes interventions by SES over time. This chapter moves on from 
these analyses and aims to establish whether the same interventions differ in their association 
with patients’ health outcomes by SES. This was achieved by modelling health outcomes with 
interaction effects between SES and interventions. Significant results in the interaction effects 
would indicate that the intervention differed in its association with the health outcome 
according to the patients SES and therefore could indicate the presence of intervention 
generated inequalities.  
Whilst health variables were used as the dependent variable in this section, the focus was on the 
possible differential effect of interventions as measured by differences in health by SES. As such, 
this section was organised by interventions with a variety of health outcomes examined. The 
description of the results focuses on the intervention of interest and the interaction with SES 
results whilst in the discussion evidence from the previous two chapters were drawn upon to 
highlight where there was evidence of intervention generated inequalities.  
 
Timeliness of diagnosis 
 
The graphical analyses in chapter five showed some evidence of differences in timeliness of 
diagnosis by SES; with low SES patients having a higher HbA1c to another status groups in 2002 
and from 2004 to 2007 (Figure 19). In the statured multilevel analyses in chapter 7, there was 
only one incidence of evidence of statistically significant differences in timeliness of diagnosis 
over time, with mid SES more likely to have a lower HbA1c at diagnosis in 2002 compared to 
low SES patients in 1999 (Table 12).  
Table 18 shows the results for the saturated logistic regression multilevel models comparing 
retinopathy and microalbuminuria with interactions of timeliness of diagnosis and SES. There 
were 6,957 available cases for the model with retinopathy as the dependent variable and 8,260 
available cases for the model with microalbuminuria as the dependent variable. The results in 
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Table 18 show that delay of diagnosis, as measured by the level of HbA1c at diagnosis, was a 
significant positive predictor of retinopathy but microalbuminuria. There was no significant 
interaction effect between timeliness of diagnosis and SES in either model suggesting that there 
was no difference by SES in the effect of timeliness of diagnosis on these outcomes.  
 
Table 18: Saturated logistic regression multilevel models examining retinopathy and 
microalbuminuria with interaction effect between SES and HbA1c at diagnosis by 1999 to 2007, 
conditional on relevant explanatory variables 
 Retinopathy Microalbuminuria 
Interactions 
HbA1c at diagnosis, reference group: Low SES*HbA1c at diagnosis 
Mid SES*HbA1c at diagnosis -0.02 (-0.13, 0.09) 0.05 (-0.01, 0.12) 
High SES*HbA1c at diagnosis 0.00 (-0.10, 0.11) 0.03 (-0.04, 0.09) 
Social-economic status, reference group: low 
Mid 0.08 (-0.88, 1.03) -0.54 (-1.13, 0.01) 
High 0.05 (-0.85, 0.91) -0.28 (-0.81, 0.25) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age, reference group: <60 years 
Age: 60-74 years 0.06 (-0.18, 0.31) -0.11 (-0.24, 0.02) 
Age: 75+ years 0.13 (-0.20, 0.45) 0.16 (-0.01, 0.34) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years 0.16 (-0.07, 0.38) -0.01 (-0.14, 0.11) 
Ethnicity, reference group: White 
South Asian  0.10 (-0.58, 0.70) 0.22 (-0.10, 0.54) 
Other Ethnicity 0.72 (-0.17, 1.55) 0.20 (-0.59, 0.95) 
Male 0.15 (-0.05, 0.36) 0.19 (0.07, 0.30) 
Smoking status, reference: non-smoker 
Smoker -0.13 (-0.43, 0.17) 0.37 (0.21, 0.53) 
Ex-smoker 0.00 (-0.21, 0.23) 0.21 (0.09, 0.33) 
BMI status, reference group: under and normal weight 
Overweight -0.24 (-0.54, 0.06) 0.13 (-0.04, 0.30) 
Obese -0.40 (-0.69, -0.10) 0.19 (0.03, 0.37) 
eGFR -0.01 (-0.02, 0.00) -0.01 (-0.01, 0.00) 
Hypertensive 0.48 (0.29, 0.68) 0.17 (0.06, 0.29) 
Cholesterol -0.06 (-0.15, 0.04) 0.03 (-0.02, 0.08) 
Interventions 
HbA1c at diagnosis 0.10 (0.04, 0.17) -0.54 (-1.13, 0.01) 
Quality of care, reference group: Low (Microalbuminuria) or Mid (Retinopathy) 
Mid  0.24 (-0.58, 1.05) 
High -0.05 (-0.30, 0.21) 0.01 (-0.81, 0.82) 
Diabetes treatment, reference group diet alone  
Metformin or sulphonylureas only 0.34 (0.09, 0.60) 0.19 (0.05, 0.33) 
Combination, with no insulin 0.56 (0.25, 0.87) 0.05 (-0.14, 0.24) 
Insulin only 0.33 (-0.15, 0.79) 0.09 (-0.25, 0.41) 
Combination with insulin 0.68 (0.20, 1.14) 0.32 (0.16, 0.48) 
BP treatment, reference group: no treatment  
ACE Inhibitors only 0.47 (0.15, 0.81) 0.25 (0.07, 0.44) 
Combination with ACI 0.45 (0.16, 0.75) 0.34 (0.19, 0.50) 
Combination no ACEI 0.21 (-0.07, 0.52) 0.14 (-0.01, 0.29) 
Aspirin 0.00 (-0.20, 0.20) -0.04 (-0.15, 0.07) 
Lipid therapy -0.11 (-0.33, 0.12) 0.13 (0.00, 0.25) 
Shared care 0.28 (0.01, 0.54) -1.26 (-1.46, -1.07) 
Middlesbrough PCT -0.17 (-0.49, 0.15) 0.77 (0.35, 1.18) 
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Visit year, reference group: 1999  
2000 -0.80 (-1.98, 0.37) -1.52 (-2.61, -0.32) 
2001 -0.38 (-1.38, 0.64) -1.53 (-2.42, -0.48) 
2002 -0.34 (-1.28, 0.63) -1.75 (-2.61, -0.74) 
2003 -0.36 (-1.28, 0.59) -1.56 (-2.39, -0.57) 
2004 -0.13 (-1.06, 0.82) -0.63 (-1.45, 0.36) 
2005 0.26 (-0.65, 1.22) -0.44 (-1.26, 0.55) 
2006 -1.16 (-2.09, -0.18) 0.00 (-0.81, 0.99) 
2007 0.47 (-0.44, 1.41) -0.49 (-1.42, 0.61) 
Cons -2.77 (-4.07, -1.41) -1.32 (-2.76, -0.16) 
Variance estimate at:  
Practice level 0.15 (0.05, 0.30) 0.38 (0.23, 0.62) 
Patient level 0.01 (0.00, 0.07) 0.01 (0.00, 0.04) 
Bayesian DIC 3516.17 8919.12 
Available case (N) 6957 8260 
 
 
Quality of care 
 
In chapter 5, increased quality of care was a statistically significant predictor of lower levels of 
HbA1c, retinopathy and incidences of PVD (Table 2 and Table 3). The graphical analyses (Figure 
20) in the same chapter found some, but inconsistent, evidence of statistically significant 
differences in the level of care patients receive over time. Patients with low SES were found to 
have a lower mean number of care processes in most years compared to another status group. 
The multilevel analyses found statistically significant differences in quality of care, with high 
SES associated with a lower quality of care. In contrast, the interaction effect between SES and 
visit year resulted in a statistically significant association between high SES and time, suggesting 
that high SES patients have received greater quality of care compared to low SES patients from 
2002 to 2007 compared to 1999. As such if low SES patients were likely to receive poorer care 
over time and high quality of care was associated with more favourable health outcomes this 
suggests the potential that quality of care may contribute to health inequalities by SES. 
Table 19, Table 20 and Table 21 show the results of the saturated linear and logistic regression 
multilevel models examining health outcomes with interaction effects between SES and quality 
of care. The results in Table 19 show that quality of care had a differential relationship with 
HbA1c by SES, but not with cholesterol. High SES patients receiving high quality care were 
significantly more likely to have poorer HbA1c compared to low SES patients. However, overall 
high SES patients were more likely to have more favourable HbA1c levels than low SES patients 
and low quality of care. There were no differences in cholesterol levels by SES. The results in 
Table 20 and Table 21 show that overall the relationship between quality of care and long-term 
complications did not differ by SES. However, there was one exception. Mid SES patients were 
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significantly more likely to have PVD compared to low SES patients. Overall, however, mid 
status patients were less likely to have PVD.  
Overall, the association between quality of care and health outcomes was consistent across SES. 
However, there was some, but not consistent evidence, that quality of care could have a 
differential impact on patients HbA1c, an important indicator of patients’ diabetes control, and 
incidences of PVD.  
 
Table 19: Saturated linear regression multilevel models examining HbA1c and cholesterol levels 
with interaction effect between SES and quality of care by 1999 to 2007, conditional on relevant 
explanatory variables  
 HbA1c Cholesterol 
Social-economic status, reference group: low 
Mid -0.07 (-0.15, 0.01) 0.06 (0.00, 0.12) 
High -0.14 (-0.21, -0.07) -0.02 (-0.07, 0.03) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age, reference group: <60 years  
Age: 60-74 years -0.33 (-0.36, -0.29) -0.20 (-0.23, -0.17) 
Age: 75+ years -0.41 (-0.46, -0.37) -0.26 (-0.30, -0.23) 
Duration of diabetes, reference group: 0-3 years  
Duration: 4-9 years 0.06 (0.02, 0.09) -0.09 (-0.11, -0.06) 
Duration 10+ years 0.05 (0.01, 0.10) -0.13 (-0.16, -0.10) 
Ethnicity, reference group: White 
South Asian  0.46 (0.39, 0.53) -0.08 (-0.14, -0.02) 
Other Ethnicity 0.48 (0.31, 0.64) 0.08 (-0.05, 0.20) 
Male -0.06 (-0.09, -0.03) -0.34 (-0.36, -0.32) 
Smoking status, reference: non-smoker 
Smoker 0.23 (0.19, 0.27) 0.08 (0.05, 0.11) 
E*-smoker 0.05 (0.02, 0.08) 0.00 (-0.03, 0.02) 
Obesity category, reference group: under and normal weight 
Overweight 0.02 (-0.02, 0.07) 0.03 (0.00, 0.07) 
Obese 0.08 (0.04, 0.13) 0.03 (0.00, 0.07) 
Creatinine > 300 -0.80 (-1.04, -0.56)  
Hypertensive 0.10 (0.07, 0.13) 0.14 (0.12, 0.16) 
ICD 0.00 (-0.04, 0.03) -0.13 (-0.15, -0.10) 
Stroke or TIA -0.06 (-0.10, -0.01) -0.02 (-0.06, 0.01) 
PVD -0.06 (-0.12, -0.01) 0.01 (-0.03, 0.06) 
Interventions 
Quality of care, reference group: Low  
Mid  -0.14 (-0.19, -0.09) -0.09 (-0.13, -0.05) 
High -0.19 (-0.25, -0.13) -0.16 (-0.20, -0.11) 
Diabetes treatment, reference group diet alone  
Metformin or sulphonylureas only 0.81 (0.77, 0.84)  
Combination, with no insulin 1.25 (1.20, 1.29)  
Insulin only 1.67 (1.61, 1.73)  
Combination with insulin 1.75 (1.69, 1.82)  
Aspirin  -0.09 (-0.11, -0.06) 
Lipid therapy  -0.28 (-0.31, -0.26) 
Middlesbrough PCT  0.10 (0.01, 0.20) -0.03 (-0.09, 0.03) 
Shared care 0.17 (0.13, 0.21) -0.07 (-0.10, -0.04) 
Visit year, reference group: 1999 
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2000 -0.32 (-0.40, -0.23) -0.20 (-0.29, -0.11) 
2001 -0.47 (-0.55, -0.39) -0.21 (-0.30, -0.12) 
2002 -0.55 (-0.63, -0.47) -0.22 (-0.31, -0.13) 
2003 -0.59 (-0.67, -0.52) -0.37 (-0.46, -0.29) 
2004 -0.63 (-0.71, -0.56) -0.58 (-0.66, -0.50) 
2005 -0.72 (-0.79, -0.64) -0.74 (-0.82, -0.65) 
2006 -1.18 (-1.26, -1.11) -0.84 (-0.92, -0.75) 
2007 -1.12 (-1.20, -1.05) -0.93 (-1.02, -0.85) 
Interactions 
Quality of care, reference group: Low SES & Low quality  
Mid SES*Mid quality 0.01 (-0.08, 0.10) -0.05 (-0.12, 0.03) 
Mid SES*High quality 0.07 (-0.03, 0.17) -0.02 (-0.10, 0.06) 
High SES*Mid quality 0.05 (-0.03, 0.14) 0.00 (-0.07, 0.06) 
High SES*High quality 0.10 (0.01, 0.19) 0.05 (-0.02, 0.12) 
Cons 7.62 (7.49, 7.74) 5.92 (5.81, 6.03) 
Variance estimate at: 
Practice level 0.02 (0.01, 0.04) 0.01 (0.01, 0.01) 
Patient level 0.00 (0.00, 0.02) 0.00 (0.00, 0.01) 
Visit year 1.91 (1.88, 1.94) 1.14 (1.13, 1.16) 
Bayesian DIC 133976.66 110338.38 
Available cases (N) 38,413 37,085 
 
 
Table 20: Saturated logistic regression multilevel models examining incidences of ICD, stroke or 
TIA and PVD with interaction effect between SES and quality of care by 2000 to 2007, 
conditional on relevant explanatory variables 
 ICD Stroke or TIA PVD 
Social-economic status, reference group: low 
Mid -0.26 (-0.55, 0.03) -0.30 (-0.73, 0.11) -0.62 (-1.19, -0.09) 
High -0.19 (-0.44, 0.07) -0.14 (-0.52, 0.23) -0.30 (-0.77, 0.17) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age, reference group: <60 years 
Age: 60-74 years 0.34 (0.19, 0.48) 0.74 (0.50, 0.99) 0.61 (0.37, 0.87) 
Age: 75+ years 0.60 (0.41, 0.79) 1.10 (0.83, 1.38) 0.81 (0.51, 1.11) 
Duration of diabetes, reference group: 0-3 years   
Duration: 4-9 years -0.59 (-0.73, -0.45) -0.31 (-0.50, -0.12) 0.13 (-0.09, 0.35) 
Duration 10+ years -0.63 (-0.80, -0.46) -0.18 (-0.39, 0.02) 0.38 (0.14, 0.62) 
Ethnicity, reference group: White  
South Asian  0.08 (-0.25, 0.41) 0.11 (-0.33, 0.52) -0.80 (-1.51, -0.17) 
Other Ethnicity -0.67 (-1.54, 0.10) -1.17 (-3.02, 0.15) -0.06 (-1.14, 0.83) 
Male 0.32 (0.20, 0.44) -0.11 (-0.27, 0.05) 0.39 (0.20, 0.59) 
Smoking status, reference: non-smoker  
Smoker 0.15 (-0.03, 0.32) 0.28 (0.05, 0.51) 0.94 (0.68, 1.19) 
E*-smoker 0.32 (0.19, 0.45) 0.14 (-0.03, 0.31) 0.37 (0.16, 0.59) 
Obesity category, reference group: under and normal weight  
Overweight -0.02 (-0.19, 0.16) -0.09 (-0.30, 0.13) -0.20 (-0.46, 0.05) 
Obese 0.12 (-0.05, 0.30) -0.19 (-0.41, 0.03) -0.25 (-0.50, 0.00) 
eGFR -0.01 (-0.01, 0.00) -0.01 (-0.01, 0.00) -0.01 (-0.01, 0.00) 
Hypertensive -0.27 (-0.39, -0.16) 0.14 (-0.01, 0.30) 0.13 (-0.05, 0.31) 
Cholesterol -0.23 (-0.29, -0.17) -0.09 (-0.16, -0.01) -0.05 (-0.13, 0.03) 
HbA1c 0.07 (0.03, 0.11) 0.02 (-0.04, 0.07) 0.01 (-0.05, 0.07) 
Interventions 
Quality of care, reference group: Low 
Mid  -0.30 (-0.49, -0.11) -0.32 (-0.59, -0.05) -0.35 (-0.68, -0.03) 
High -0.50 (-0.73, -0.27) -0.10 (-0.41, 0.20) 0.10 (-0.22, 0.43) 
Diabetes treatment, reference group diet alone 
Metformin or sulphonylureas only -0.28 (-0.43, -0.14) -0.18 (-0.38, 0.03) -0.05 (-0.31, 0.21) 
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Combination, with no insulin -0.40 (-0.60, -0.21) -0.29 (-0.56, -0.03) -0.11 (-0.42, 0.19) 
Insulin only 0.12 (-0.13, 0.36) -0.07 (-0.38, 0.24) 0.34 (0.00, 0.68) 
Combination with insulin -0.31 (-0.61, -0.03) -0.28 (-0.66, 0.08) 0.35 (-0.03, 0.73) 
BP treatment, reference group: no treatment 
ACE inhibitors only 0.27 (0.01, 0.53) 0.30 (0.01, 0.59) 0.48 (0.16, 0.81) 
Combination, with ACEI  1.51 (1.31, 1.70) 0.15 (-0.08, 0.40) 0.42 (0.14, 0.71) 
Combination, no ACEI 1.25 (1.05, 1.45) 0.18 (-0.06, 0.42) 0.37 (0.09, 0.66) 
Aspirin 1.37 (1.25, 1.49) 1.06 (0.89, 1.23) 0.58 (0.39, 0.76) 
Lipid therapy 0.61 (0.47, 0.75) 0.09 (-0.09, 0.27) 0.10 (-0.10, 0.29) 
Shared care 0.28 (0.12, 0.44) 0.44 (0.24, 0.64) 0.84 (0.62, 1.05) 
Middlesbrough PCT -0.20 (-0.39, -0.01) -0.12 (-0.39, 0.15) -0.19 (-0.56, 0.19) 
Visit year, reference group: 2000  
2001 -0.29 (-0.59, 0.01) 0.21 (-0.18, 0.61) -0.23 (-0.65, 0.18) 
2002 -0.30 (-0.57, -0.03) 0.03 (-0.34, 0.40) -0.25 (-0.62, 0.13) 
2003 -0.40 (-0.66, -0.14) 0.14 (-0.21, 0.50) 0.03 (-0.33, 0.39) 
2004 -0.67 (-0.93, -0.40) 0.03 (-0.33, 0.39) 0.00 (-0.36, 0.36) 
2005 -1.25 (-1.52, -0.97) -0.20 (-0.57, 0.18) -0.30 (-0.68, 0.08) 
2006 -1.67 (-1.97, -1.38) -0.81 (-1.21, -0.40) -0.79 (-1.21, -0.37) 
2007 -1.81 (-2.11, -1.51) -0.73 (-1.14, -0.32) -1.14 (-1.60, -0.68) 
Interactions 
Quality of care, reference group: Low SES & Low quality   
Mid SES*Mid quality 0.01 (-0.33, 0.37) 0.40 (-0.09, 0.90) 0.71 (0.09, 1.37) 
Mid SES*High quality 0.23 (-0.16, 0.61) 0.32 (-0.19, 0.85) 0.38 (-0.24, 1.03) 
High SES*Mid quality -0.02 (-0.34, 0.30) 0.26 (-0.19, 0.71) 0.14 (-0.44, 0.70) 
High SES*High quality 0.15 (-0.21, 0.51) 0.04 (-0.45, 0.54) 0.08 (-0.48, 0.64) 
Cons -3.89 (-4.89, -2.90) -4.88 (-6.37, -3.29) -5.82 (-7.13, -4.70) 
Variance estimate at:  
Practice level 0.05 (0.02, 0.11) 0.11 (0.04, 0.22) 0.27 (0.14, 0.48) 
Patient level 1.98 (0.53, 6.31) 1.41 (0.33, 5.19) 1.39 (0.34, 4.41) 
Bayesian DIC 9200.75 6137.51 5025.34 
 
 
Table 21: Saturated logistic regression multilevel models examining recorded microalbuminuria 
and retinopathy with interaction effect between SES and quality of care by 2000 to 2007, 
conditional on relevant explanatory variables 
 Microalbuminuria Retinopathy 
Social-economic status, reference group: low 
Mid 0.24 (-0.71, 1.10) 4.06 (-1.65, 9.97) 
High -0.60 (-1.41, 0.25) -5.83 (-11.03, 0.13) 
Covariates 
Age, reference group: <60 years  
Age: 60-74 years 0.01 (-0.06, 0.09) 0.00 (-0.11, 0.11) 
Age: 75+ years 0.38 (0.28, 0.47) -0.11 (-0.25, 0.04) 
Duration of diabetes, reference group: 0-3 years  
Duration: 4-9 years -0.01 (-0.09, 0.06) 0.47 (0.34, 0.60) 
Duration 10+ years 0.18 (0.09, 0.27) 1.60 (1.46, 1.73) 
Ethnicity, reference group: White 
South Asian  0.21 (0.05, 0.38) -0.15 (-0.39, 0.08) 
Other Ethnicity 0.30 (-0.08, 0.68) 0.52 (0.08, 0.96) 
Male 0.24 (0.18, 0.31) 0.25 (0.16, 0.34) 
Smoking status, reference: non-smoker 
Smoker 0.26 (0.17, 0.36) -0.13 (-0.26, 0.00) 
Ex-smoker 0.07 (0.00, 0.14) -0.12 (-0.22, -0.02) 
Obesity category, reference group: under and normal weight 
Overweight -0.01 (-0.11, 0.09) -0.09 (-0.22, 0.05) 
Obese 0.06 (-0.04, 0.16) -0.10 (-0.23, 0.04) 
eGFR  -0.01 (-0.01, -0.01) 
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Hypertensive 0.18 (0.11, 0.24) 0.34 (0.25, 0.42) 
Cholesterol 0.03 (0.00, 0.06) -0.02 (-0.06, 0.02) 
HbA1c 0.09 (0.06, 0.11) 0.05 (0.02, 0.08) 
Interventions 
Quality of care, reference group: Low  
Mid  -0.19 (-0.84, 0.44) -0.19 (-1.90, 1.67) 
High -0.30 (-0.94, 0.34) -0.28 (-2.00, 1.58) 
Diabetes treatment, reference group diet alone  
Metformin/sulphonylureas only 0.14 (0.04, 0.24) 0.40 (0.24, 0.57) 
Combination, with no insulin 0.02 (-0.10, 0.13) 0.70 (0.53, 0.87) 
Insulin only 0.18 (0.04, 0.32) 1.05 (0.85, 1.23) 
Combination with insulin 0.20 (0.10, 0.30) 1.16 (0.96, 1.37) 
BP treatments, reference group: No BP treatment 
ACE Inhibitors only 0.37 (0.26, 0.47) 0.31 (0.17, 0.46) 
Combination with ACI 0.53 (0.43, 0.62) 0.22 (0.09, 0.34) 
Combination no ACEI 0.32 (0.23, 0.41) 0.12 (-0.01, 0.25) 
Aspirin 0.08 (0.01, 0.14) 0.05 (-0.04, 0.14) 
Lipid therapy -0.05 (-0.12, 0.02) -0.06 (-0.16, 0.03) 
Shared care -0.93 (-1.02, -0.84) 0.53 (0.42, 0.63) 
Middlesbrough PCT 0.59 (0.31, 0.89) -0.05 (-0.22, 0.14) 
Visit year, reference group: 1999 
2000 -0.36 (-0.70, -0.03) 0.01 (-0.29, 0.31) 
2001 -0.58 (-0.90, -0.27) -0.02 (-0.32, 0.27) 
2002 -0.81 (-1.12, -0.50) 0.00 (-0.28, 0.28) 
2003 -0.69 (-1.00, -0.40) -0.12 (-0.40, 0.17) 
2004 0.07 (-0.23, 0.36) 0.06 (-0.22, 0.35) 
2005 0.26 (-0.04, 0.55) 0.33 (0.04, 0.64) 
2006 0.63 (0.32, 0.92) -0.70 (-1.00, -0.40) 
2007 0.34 (-0.10, 0.76) 0.36 (0.06, 0.65) 
Interactions 
Quality of care, reference group: Low SES & Low quality  
Mid SES*Mid quality -0.33 (-1.21, 0.63) -4.13 (-10.02, 1.61) 
Mid SES*High quality -0.33 (-1.21, 0.62) -4.14 (-10.04, 1.55) 
High SES*Mid quality 0.53 (-0.33, 1.34) 5.69 (-0.25, 10.90) 
High SES*High quality 0.49 (-0.37, 1.31) 5.81 (-0.13, 11.01) 
Cons -2.40 (-3.18, -1.69) -2.75 (-4.71, -0.95) 
Variance estimate at: 
Practice level 0.21 (0.13, 0.34) 0.05 (0.03, 0.10) 
Patient level 0.01 (0.00, 0.03) 0.00 (0.00, 0.02) 
Bayesian DIC 25472.88 14526.88 
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Diabetes treatments 
 
In chapter 6, all diabetes treatments regimens had a statistically significant association with 
poorer levels of HbA1c compared to patients who were treated through lifestyle modification. 
This result was somewhat expected as it is when patients HbA1c deteriorates that these 
treatments would be initiated. However, when examining the results where long-term 
complications were modelled the results show that most of the diabetes treatment regimens 
were significantly associated with lower rates of ICD but with higher rates of retinopathy. Being 
treated with combination of diabetes treatments without insulin was also significantly 
associated with lower incidences of stroke or TIA.  
The graphical analyses in chapter 5 showed some evidence of differences in diabetes treatments 
by SES over time (Figure 23, Figure 22, Figure 25, Figure 26 and Figure 27). This was 
particularly evident in being prescribed no diabetes treatments (Figure 23). The results from 
the multilevel modelling showed that there were statistically significant differences in the 
prescription of diabetes treatments over time whilst taking into account patients’ health status, 
and other variables (Table 14). These results may indicate that these treatments were not being 
prescribed methodically across patients groups and could potentially account for the divergent 
associations between diabetes treatments regimen and long-term complications. 
Table 22, Table 23 and Table 24 contain the results from modelling patient’s health outcomes 
with an interaction effect between SES and diabetes interventions. Whilst the majority of the 
results from these models indicated that there were no significant differences in the impact of 
diabetes treatments on health by SES, there was some evidence of potential intervention 
generated inequalities.  
The results from Table 22 show that, for high SES patients, there was a significant association 
between having lower HbA1c and prescriptions for insulin, either alone or in combination with 
other diabetes treatments compared to low SES patients. The results from long-term 
complications in Table 23 and Table 24 shows that for high SES patients, compared to low SES 
patients, there were significant associations between lower rates of ICD and retinopathy and 
prescriptions for insulin in combination with other diabetes treatment and insulin only 
respectively. In contrast, mid SES patients prescribed insulin only were significantly more likely 
to have higher microalbuminuria rates compared to low SES patients. There were no other 
statistically significant results indicating that in general diabetes interventions were not 
associated with differences in health by SES.  
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Table 22: Saturated linear regression multilevel models examining HbA1c levels with 
interaction effect between SES and diabetes treatment regimens by 1999 to 2007, conditional 
on relevant explanatory variables 
 HbA1c 
Social-economic status, reference group: low 
Mid 0.01 (-0.07, 0.08) 
High 0.00 (-0.07, 0.07) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age, reference group: <60 years 
Age: 60-74 years -0.33 (-0.36, -0.29) 
Age: 75+ years -0.41 (-0.46, -0.37) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years 0.06 (0.02, 0.09) 
Duration 10+ years 0.06 (0.02, 0.10) 
Ethnicity, reference group: White 
South Asian  0.46 (0.39, 0.53) 
Other Ethnicity 0.46 (0.30, 0.63) 
Male -0.06 (-0.09, -0.03) 
Smoking status, reference: non-smoker 
Smoker 0.23 (0.19, 0.27) 
Ex-smoker 0.05 (0.02, 0.08) 
Obesity category, reference group: under and normal weight 
Overweight 0.03 (-0.02, 0.07) 
Obese 0.08 (0.04, 0.13) 
Creatinine > 300 -0.80 (-1.05, -0.56) 
Hypertensive 0.10 (0.07, 0.13) 
Ischaemic Cardiac -0.01 (-0.04, 0.02) 
Stroke or TIA -0.06 (-0.10, -0.01) 
PVD -0.07 (-0.12, -0.01) 
Interventions 
Quality of care, reference group: Low 
Mid  -0.13 (-0.16, -0.09) 
High -0.15 (-0.19, -0.11) 
Diabetes treatment, reference group diet alone 
Metformin or sulphonylureas only 0.84 (0.78, 0.89) 
Combination, with no insulin 1.31 (1.24, 1.37) 
Insulin only 1.77 (1.69, 1.85) 
Combination with insulin 1.82 (1.73, 1.91) 
Middlesbrough PCT  0.10 (0.00, 0.20) 
Shared care 0.17 (0.13, 0.21) 
Visit year, reference group: 1999 
2000 -0.32 (-0.40, -0.23) 
2001 -0.47 (-0.55, -0.39) 
2002 -0.55 (-0.63, -0.47) 
2003 -0.59 (-0.67, -0.51) 
2004 -0.63 (-0.71, -0.56) 
2005 -0.71 (-0.79, -0.64) 
2006 -1.18 (-1.26, -1.10) 
2007 -1.12 (-1.20, -1.04) 
Interaction 
Diabetes treatment, reference group: Diet alone & Low SES 
Mid SES*Metformin/sulphonylureas only -0.04 (-0.13, 0.06) 
Mid SES*Combination with no insulin -0.11 (-0.22, 0.00) 
Mid SES*Insulin only -0.11 (-0.24, 0.02) 
Mid SES*Combination with insulin -0.02 (-0.16, 0.13) 
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High SES*Metformin/sulphonylureas only -0.05 (-0.14, 0.03) 
High SES*Combination, with no insulin -0.10 (-0.20, 0.00) 
High SES*Insulin only -0.24 (-0.36, -0.13) 
High SES*Combination with insulin -0.23 (-0.37, -0.10) 
Cons 7.55 (7.42, 7.68) 
Variance estimate at: 
Practice level 0.02 (0.01, 0.04) 
Patient level 0.00 (0.00, 0.02) 
Visit year 1.91 (1.88, 1.94) 
Bayesian DIC 133960.84 
 
 
Table 23: Saturated logistic regression multilevel models examining incidences of ICD, stroke or 
TIA and PVD with interaction effect between SES and diabetes treatments by 2000 to 2007, 
conditional on relevant explanatory variables 
 ICD Stroke or TIA PVD 
Social-economic status, reference group: low 
Mid -0.29 (-0.55, -0.03) 0.06 (-0.30, 0.44) -0.15 (-0.60, 0.32) 
High -0.18 (-0.42, 0.05) 0.07 (-0.27, 0.42) -0.49 (-0.99, 0.00) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years 0.34 (0.19, 0.49) 0.74 (0.50, 0.98) 0.61 (0.36, 0.86) 
Age: 75+ years 0.60 (0.42, 0.79) 1.09 (0.82, 1.37) 0.81 (0.51, 1.11) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years -0.59 (-0.73, -0.45) -0.30 (-0.50, -0.11) 0.13 (-0.09, 0.35) 
Duration 10+ years -0.62 (-0.79, -0.46) -0.17 (-0.39, 0.04) 0.38 (0.14, 0.61) 
Ethnicity, reference group: White 
South Asian  0.09 (-0.25, 0.40) 0.10 (-0.35, 0.51) -0.82 (-1.52, -0.20) 
Other Ethnicity -0.66 (-1.52, 0.12) -1.18 (-3.02, 0.15) -0.07 (-1.13, 0.81) 
Male 0.32 (0.20, 0.44) -0.11 (-0.28, 0.05) 0.39 (0.20, 0.59) 
Smoking status, reference: non-smoker 
Smoker 0.16 (-0.02, 0.33) 0.27 (0.04, 0.50) 0.93 (0.67, 1.17) 
E*-smoker 0.32 (0.19, 0.44) 0.13 (-0.04, 0.30) 0.37 (0.16, 0.58) 
Obesity category, reference group: under and normal weight 
Overweight -0.01 (-0.19, 0.17) -0.09 (-0.30, 0.13) -0.20 (-0.45, 0.05) 
Obese 0.12 (-0.06, 0.29) -0.19 (-0.41, 0.03) -0.26 (-0.50, -0.01) 
eGFR -0.01 (-0.01, 0.00) -0.01 (-0.01, 0.00) -0.01 (-0.01, 0.00) 
Hypertensive -0.28 (-0.40, -0.16) 0.14 (-0.01, 0.30) 0.13 (-0.04, 0.31) 
Cholesterol -0.23 (-0.29, -0.17) -0.09 (-0.16, -0.01) -0.05 (-0.13, 0.03) 
HbA1c 0.07 (0.03, 0.11) 0.02 (-0.04, 0.07) 0.01 (-0.05, 0.07) 
Interventions 
Quality of care, reference group: Low 
Mid  -0.30 (-0.44, -0.16) -0.16 (-0.36, 0.04) -0.19 (-0.42, 0.05) 
High -0.40 (-0.56, -0.23) -0.03 (-0.25, 0.19) 0.17 (-0.08, 0.41) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas only -0.40 (-0.61, -0.20) -0.16 (-0.46, 0.15) -0.12 (-0.47, 0.26) 
Combination, with no insulin -0.35 (-0.61, -0.09) -0.29 (-0.67, 0.10) -0.38 (-0.83, 0.05) 
Insulin only 0.11 (-0.20, 0.42) 0.08 (-0.33, 0.49) 0.37 (-0.06, 0.81) 
Combination with insulin -0.22 (-0.59, 0.15) -0.08 (-0.59, 0.41) 0.20 (-0.28, 0.70) 
BP treatment, reference group: no treatment 
ACE inhibitors only 0.27 (0.01, 0.53) 0.30 (0.00, 0.59) 0.48 (0.16, 0.79) 
Combination, with ACEI  1.51 (1.32, 1.70) 0.15 (-0.09, 0.40) 0.41 (0.14, 0.69) 
Combination, no ACEI 1.25 (1.06, 1.45) 0.18 (-0.06, 0.43) 0.36 (0.08, 0.65) 
Aspirin 1.37 (1.26, 1.50) 1.06 (0.89, 1.22) 0.57 (0.39, 0.76) 
Lipid therapy 0.61 (0.47, 0.74) 0.08 (-0.09, 0.26) 0.10 (-0.10, 0.30) 
Shared care 0.28 (0.12, 0.43) 0.44 (0.24, 0.65) 0.85 (0.63, 1.06) 
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Middlesbrough PCT -0.20 (-0.39, -0.01) -0.11 (-0.37, 0.16) -0.19 (-0.56, 0.18) 
Visit year, reference group: 2000 
2001 -0.29 (-0.59, 0.01) 0.20 (-0.19, 0.59) -0.24 (-0.65, 0.17) 
2002 -0.30 (-0.57, -0.03) 0.04 (-0.32, 0.40) -0.25 (-0.63, 0.13) 
2003 -0.39 (-0.66, -0.13) 0.14 (-0.21, 0.50) 0.02 (-0.34, 0.38) 
2004 -0.66 (-0.93, -0.39) 0.03 (-0.33, 0.39) -0.02 (-0.38, 0.34) 
2005 -1.24 (-1.52, -0.95) -0.20 (-0.56, 0.18) -0.31 (-0.69, 0.08) 
2006 -1.67 (-1.96, -1.37) -0.8 (-1.21, -0.41) -0.80 (-1.21, -0.38) 
2007 -1.81 (-2.11, -1.50) -0.72 (-1.12, -0.31) -1.14 (-1.61, -0.68) 
Interactions 
Diabetes treatment, reference group: Diet alone & Low SES 
Mid SES*Metformin/sulphonylurea only 0.27 (-0.07, 0.61) 0.05 (-0.42, 0.52) -0.04 (-0.63, 0.54) 
Mid SES*Combination with no insulin -0.06 (-0.50, 0.36) -0.17 (-0.78, 0.41) 0.28 (-0.41, 0.94) 
Mid SES*Insulin only 0.02 (-0.49, 0.51) -0.10 (-0.72, 0.50) -0.38 (-1.08, 0.29) 
Mid SES*Combination with insulin 0.16 (-0.45, 0.74) -0.81 (-1.75, 0.04) 0.09 (-0.68, 0.85) 
High SES*Metformin/sulphonylurea only 0.21 (-0.11, 0.53) -0.09 (-0.55, 0.37) 0.26 (-0.35, 0.88) 
High SES*Combination, with no insulin -0.16 (-0.58, 0.24) 0.13 (-0.42, 0.67) 0.69 (0.00, 1.38) 
High SES*Insulin only -0.01 (-0.46, 0.44) -0.53 (-1.16, 0.07) 0.15 (-0.48, 0.80) 
High SES*Combination with insulin -0.73 (-1.45, -0.05) -0.16 (-0.91, 0.56) 0.41 (-0.35, 1.17) 
Cons -3.99 (-5.39, -2.83) 0.05 (-0.42, 0.52) -5.76 (-7.03, -4.62) 
Variance estimate at: 
Practice level 0.05 (0.02, 0.11) 0.11 (0.04, 0.22) 0.27 (0.14, 0.48) 
Patient level 2.19 (0.56, 7.35) 1.39 (0.34, 4.85) 1.35 (0.32, 4.48) 
Bayesian DIC 9198.43 6140.12 5031.91 
 
 
Table 24: Saturated logistic regression multilevel models examining microalbuminuria and 
retinopathy rates with interaction effect between SES and diabetes treatments by 2000 to 2007, 
conditional on relevant explanatory variables 
 Microalbuminuria Retinopathy 
Social-economic status, reference group: low 
Mid -0.14 (-0.31, 0.03) 0.00 (-0.35, 0.34) 
High -0.10 (-0.26, 0.06) 0.23 (-0.11, 0.56) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years 0.02 (-0.06, 0.09) 0.00 (-0.11, 0.11) 
Age: 75+ years 0.38 (0.29, 0.48) -0.11 (-0.24, 0.03) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years -0.02 (-0.09, 0.06) 0.47 (0.34, 0.60) 
Duration 10+ years 0.18 (0.09, 0.27) 1.61 (1.47, 1.74) 
Ethnicity, reference group: White 
South Asian  0.22 (0.06, 0.38) -0.16 (-0.40, 0.07) 
Other Ethnicity 0.30 (-0.08, 0.68) 0.49 (0.05, 0.92) 
Male 0.24 (0.18, 0.31) 0.25 (0.16, 0.34) 
Smoking status, reference: non-smoker 
Smoker 0.26 (0.17, 0.36) -0.14 (-0.27, 0.00) 
E*-smoker 0.07 (0.00, 0.14) -0.12 (-0.22, -0.02) 
Obesity category, reference group: under and normal weight 
Overweight -0.01 (-0.11, 0.08) -0.09 (-0.22, 0.04) 
Obese 0.06 (-0.04, 0.15) -0.10 (-0.24, 0.03) 
HbA1c 0.09 (0.06, 0.11) 0.05 (0.02, 0.08) 
Hypertensive 0.18 (0.11, 0.25) 0.34 (0.25, 0.43) 
Cholesterol 0.03 (0.00, 0.06) -0.01 (-0.06, 0.02) 
Interventions 
Quality of care, reference group: Low  
Mid  -0.10 (-0.49, 0.27) -0.66 (-2.24, 0.85) 
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High -0.21 (-0.60, 0.16) -0.73 (-2.29, 0.79) 
Diabetes treatment, reference group diet alone  
Metformin or sulphonylureas only 0.12 (-0.03, 0.26) 0.52 (0.27, 0.78) 
Combination, with no insulin 0.00 (-0.17, 0.17) 0.79 (0.53, 1.06) 
Insulin only 0.06 (-0.12, 0.25) 1.29 (1.02, 1.57) 
Combination with insulin 0.21 (0.07, 0.35) 1.24 (0.96, 1.54) 
BP treatments, reference group: No BP treatment 
ACE Inhibitors only 0.36 (0.25, 0.47) 0.32 (0.17, 0.47) 
Combination with ACI 0.53 (0.44, 0.62) 0.22 (0.09, 0.34) 
Combination no ACEI 0.32 (0.23, 0.41) 0.12 (-0.01, 0.26) 
Aspirin 0.08 (0.01, 0.14) 0.05 (-0.04, 0.14) 
Lipid therapy -0.05 (-0.12, 0.02) -0.06 (-0.16, 0.04) 
Shared care -0.93 (-1.02, -0.84) 0.53 (0.43, 0.64) 
Middlesbrough PCT 0.61 (0.31, 0.90) -0.04 (-0.22, 0.14) 
Visit year, reference group: 1999 
2000 -0.41 (-0.74, -0.08) 0.03 (-0.27, 0.33) 
2001 -0.61 (-0.93, -0.31) 0.00 (-0.30, 0.30) 
2002 -0.85 (-1.15, -0.55) 0.02 (-0.27, 0.31) 
2003 -0.74 (-1.04, -0.45) -0.09 (-0.39, 0.20) 
2004 0.02 (-0.27, 0.30) 0.08 (-0.21, 0.38) 
2005 0.21 (-0.09, 0.49) 0.35 (0.05, 0.66) 
2006 0.58 (0.29, 0.87) -0.68 (-0.98, -0.37) 
2007 0.27 (-0.15, 0.68) 0.38 (0.08, 0.67) 
Interactions 
Diabetes treatment, reference group: Diet alone & Low SES 
Mid SES*Metformin/sulphonylureas only 0.01 (-0.23, 0.24) -0.16 (-0.55, 0.23) 
Mid SES*Combination with no insulin -0.05 (-0.33, 0.23) -0.05 (-0.44, 0.35) 
Mid SES*Insulin only 0.51 (0.22, 0.80) -0.16 (-0.57, 0.26) 
Mid SES*Combination with insulin 0.01 (-0.20, 0.22) 0.08 (-0.35, 0.51) 
High SES*Metformin/sulphonylureas only 0.08 (-0.14, 0.30) -0.22 (-0.60, 0.16) 
High SES*Combination, with no insulin 0.09 (-0.18, 0.34) -0.22 (-0.60, 0.17) 
High SES*Insulin only -0.01 (-0.28, 0.26) -0.62 (-1.00, -0.22) 
High SES*Combination with insulin -0.04 (-0.24, 0.16) -0.31 (-0.74, 0.11) 
Cons -2.49 (-3.00, -1.94) -2.46 (-3.96, -0.89) 
Variance estimate at: 
Practice level 0.21 (0.13, 0.34) 0.05 (0.03, 0.10) 
Patient level 0.01 (0.00, 0.03) 0.00 (0.00, 0.02) 
Bayesian DIC 25462.24 14526.17 
 
 
Blood pressure treatments 
 
In general the results in chapter six, BP regimens were found to be significant predictors of 
higher incidences of long-term complications compared to no BP treatments (Table 10 and 
Table 11). The graphical analyses in chapter 5 showed, in general, there were no differences in 
the prescription of BP treatments by SES over time, however, there were some significant 
differences in particular years in not having a prescription for any BP treatment. The multilevel 
analyses enabled other variables to be taken into account and the results indicated the presence 
of significant differences over time in patients being prescribed no BP treatments and a 
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combination of BP treatments excluding ACEI. Interestingly, high SES were significantly less 
likely to receive no BP and more likely to receive a combination without ACI in comparison to 
low SES. However, these results were not consistent over time.  
The evidence from the previous two chapters therefore suggests that BP treatments were not 
necessarily prescribed in accordance with patients’ health outcomes, as measured in these 
models and that these differences were stratified by patients’ SES . In this chapter, the results 
from Table 25 and Table 26 indicate that there were no differences in the association between 
these treatments and long-term complications by SES, though there were two exceptions. High 
SES patients prescribed a combination of BP treatments excluding ACEI were significantly more 
likely to have microalbuminuria and significantly more likely have retinopathy when prescribed 
ACEI only compared to low SES patients.  
The results presented in this section indicate that there was limited evidence of differences in 
the association with BP treatments by SES in health outcomes suggesting that overall BP 
management was unlikely to be a cause of subsequent inequalities in type 2 diabetes patients’ 
health.  
 
Table 25: Saturated logistic regression multilevel models examining incidences of ICD, stroke or 
TIA and PVD with interaction effect between SES and BP treatments by 2000 to 2007, 
conditional on relevant explanatory variables 
 ICD Stroke or TIA PVD 
Social-economic status, reference group: low 
Mid -0.21 (-0.64, 0.22) 0.02 (-0.45, 0.49) -0.56 (-1.19, 0.02) 
High -0.02 (-0.41, 0.37) -0.29 (-0.77, 0.18) -0.31 (-0.86, 0.20) 
Socio-demographic, anthropometric, lifestyle and health 
Age, reference group: <60 years   
Age: 60-74 years 0.34 (0.19, 0.49) 0.75 (0.52, 0.99) 0.62 (0.37, 0.88) 
Age: 75+ years 0.60 (0.42, 0.79) 1.11 (0.84, 1.39) 0.82 (0.52, 1.12) 
Duration of diabetes, reference group: 0-3 years   
Duration: 4-9 years -0.59 (-0.73, -0.45) -0.31 (-0.50, -0.12) 0.13 (-0.09, 0.35) 
Duration 10+ years -0.63 (-0.80, -0.46) -0.19 (-0.40, 0.03) 0.38 (0.14, 0.62) 
Ethnicity, reference group: White  
South Asian  0.09 (-0.25, 0.41) 0.11 (-0.33, 0.52) -0.80 (-1.54, -0.16) 
Other Ethnicity -0.67 (-1.53, 0.10) -1.19 (-3.09, 0.14) -0.06 (-1.13, 0.83) 
Male 0.31 (0.19, 0.44) -0.11 (-0.27, 0.05) 0.39 (0.20, 0.58) 
Smoking status, reference: non-smoker  
Smoker 0.15 (-0.02, 0.33) 0.27 (0.04, 0.50) 0.93 (0.68, 1.18) 
Ex-smoker 0.31 (0.18, 0.44) 0.14 (-0.04, 0.31) 0.37 (0.16, 0.58) 
Obesity category, reference group: under and normal weight  
Overweight -0.01 (-0.19, 0.17) -0.10 (-0.31, 0.13) -0.20 (-0.45, 0.05) 
Obese 0.13 (-0.05, 0.31) -0.20 (-0.42, 0.02) -0.26 (-0.51, -0.01) 
eGFR -0.01 (-0.01, 0.00) -0.01 (-0.01, 0.00) -0.01 (-0.01, 0.00) 
Hypertensive -0.28 (-0.40, -0.16) 0.14 (-0.01, 0.30) 0.13 (-0.05, 0.31) 
Cholesterol -0.23 (-0.29, -0.17) -0.09 (-0.16, -0.01) -0.05 (-0.14, 0.03) 
HbA1c 0.07 (0.03, 0.11) 0.02 (-0.03, 0.07) 0.01 (-0.04, 0.07) 
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Interventions 
Quality of care, reference group: Low 
Mid  -0.31 (-0.45, -0.17) -0.16 (-0.35, 0.04) -0.18 (-0.41, 0.05) 
High -0.40 (-0.56, -0.24) -0.02 (-0.25, 0.19) 0.18 (-0.06, 0.42) 
Diabetes treatment, reference group diet alone 
Metformin or sulphonylureas only -0.28 (-0.42, -0.13) -0.17 (-0.38, 0.04) -0.06 (-0.32, 0.20) 
Combination, with no insulin -0.40 (-0.59, -0.21) -0.29 (-0.56, -0.03) -0.13 (-0.45, 0.18) 
Insulin only 0.12 (-0.13, 0.36) -0.07 (-0.38, 0.24) 0.33 (0.00, 0.67) 
Combination with insulin -0.31 (-0.6, -0.02) -0.28 (-0.66, 0.09) 0.34 (-0.04, 0.71) 
BP treatment, reference group: no treatment 
ACE inhibitors only 0.36 (0.00, 0.72) 0.2 (-0.24, 0.63) 0.44 (0.01, 0.87) 
Combination, with ACEI  1.54 (1.29, 1.82) 0.06 (-0.27, 0.41) 0.28 (-0.08, 0.64) 
Combination, no ACEI 1.28 (1.02, 1.57) 0.14 (-0.19, 0.48) 0.26 (-0.11, 0.63) 
Aspirin 1.37 (1.26, 1.49) 1.06 (0.89, 1.23) 0.58 (0.40, 0.76) 
Lipid therapy 0.61 (0.47, 0.74) 0.09 (-0.09, 0.26) 0.10 (-0.10, 0.30) 
Shared care 0.28 (0.12, 0.44) 0.44 (0.24, 0.64) 0.84 (0.62, 1.06) 
Middlesbrough PCT -0.20 (-0.39, -0.02) -0.12 (-0.38, 0.15) -0.20 (-0.60, 0.19) 
Visit year, reference group: 2000  
2001 -0.29 (-0.58, 0.02) 0.21 (-0.17, 0.60) -0.23 (-0.65, 0.18) 
2002 -0.30 (-0.56, -0.02) 0.04 (-0.33, 0.41) -0.25 (-0.62, 0.14) 
2003 -0.39 (-0.65, -0.12) 0.14 (-0.20, 0.51) 0.02 (-0.35, 0.40) 
2004 -0.66 (-0.93, -0.39) 0.03 (-0.32, 0.40) -0.02 (-0.38, 0.36) 
2005 -1.24 (-1.52, -0.96) -0.2 (-0.57, 0.18) -0.31 (-0.70, 0.09) 
2006 -1.67 (-1.96, -1.37) -0.81 (-1.20, -0.41) -0.80 (-1.21, -0.37) 
2007 -1.81 (-2.10, -1.51) -0.71 (-1.12, -0.30) -1.14 (-1.62, -0.68) 
Interactions  
BP treatments, reference group: No BP treatment & Low SES 
Mid SES*ACEI only 0.22 (-0.44, 0.87) 0.11 (-0.62, 0.84) 0.42 (-0.41, 1.24) 
Mid SES*Combo. w. ACI -0.01 (-0.49, 0.47) -0.02 (-0.59, 0.53) 0.48 (-0.19, 1.17) 
Mid SES*Combo. no ACEI 0.03 (-0.47, 0.51) -0.10 (-0.67, 0.46) 0.39 (-0.31, 1.11) 
High SES*ACEI only -0.54 (-1.16, 0.10) 0.27 (-0.44, 0.97) -0.21 (-0.97, 0.57) 
High SES*Combo w. ACI -0.11 (-0.55, 0.33) 0.39 (-0.16, 0.95) 0.19 (-0.40, 0.79) 
High SES* Combo. no ACEI -0.14 (-0.60, 0.31) 0.27 (-0.29, 0.83) 0.15 (-0.48, 0.79) 
Cons -3.88 (-5.00, -2.69) -4.99 (-6.39, -3.83) -5.80 (-7.32, -4.57) 
Variance estimate at: 
Practice level 0.05 (0.02, 0.11) 0.11 (0.04, 0.21) 0.28 (0.14, 0.49) 
Patient level 2.09 (0.53, 6.98) 1.36 (0.33, 4.57) 1.40 (0.34, 4.83) 
Bayesian DIC 9201.75 6142.00 5030.83 
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Table 26: Saturated logistic regression multilevel models examining microalbuminuria and 
retinopathy rates with interaction effect between SES and BP treatments by 1999 to 2007, 
conditional on relevant explanatory variables 
 Microalbuminuria Retinopathy 
Social-economic status, reference group: low 
Mid -0.20 (-0.37, -0.02) -0.12 (-0.37, 0.13) 
High -0.23 (-0.39, -0.07) -0.12 (-0.34, 0.11) 
Covariates 
Age, reference group: <60 years  
Age: 60-74 years 0.01 (-0.06, 0.09) 0.00 (-0.11, 0.11) 
Age: 75+ years 0.37 (0.28, 0.47) -0.11 (-0.25, 0.03) 
Duration of diabetes, reference group: 0-3 years  
Duration: 4-9 years -0.01 (-0.09, 0.06) 0.47 (0.34, 0.59) 
Duration 10+ years 0.18 (0.10, 0.27) 1.60 (1.47, 1.73) 
Ethnicity, reference group: White 
South Asian  0.21 (0.04, 0.37) -0.15 (-0.39, 0.08) 
Other Ethnicity 0.29 (-0.09, 0.66) 0.52 (0.08, 0.94) 
Male 0.24 (0.18, 0.31) 0.25 (0.16, 0.34) 
Smoking status, reference: non-smoker 
Smoker 0.26 (0.16, 0.35) -0.13 (-0.26, 0.01) 
Ex-smoker 0.07 (0.00, 0.14) -0.12 (-0.22, -0.02) 
Obesity category, reference group: under and normal weight 
Overweight -0.01 (-0.11, 0.09) -0.09 (-0.22, 0.04) 
Obese 0.06 (-0.04, 0.16) -0.10 (-0.23, 0.03) 
eGFR  -0.01 (-0.01, -0.01) 
Hypertensive 0.18 (0.12, 0.25) 0.34 (0.25, 0.43) 
Cholesterol 0.03 (0.00, 0.06) -0.01 (-0.06, 0.02) 
HbA1c 0.08 (0.06, 0.11) 0.05 (0.02, 0.08) 
Interventions 
Quality of care, reference group: Low  
Mid  -0.14 (-0.53, 0.29) -0.29 (-1.96, 1.27) 
High -0.26 (-0.64, 0.18) -0.35 (-2.02, 1.19) 
Diabetes treatment, reference group diet alone  
Metformin/ sulphonylureas only 0.14 (0.05, 0.24) 0.40 (0.23, 0.56) 
Combination, with no insulin 0.02 (-0.09, 0.14) 0.70 (0.53, 0.87) 
Insulin only 0.18 (0.04, 0.32) 1.04 (0.85, 1.23) 
Combination with insulin 0.20 (0.11, 0.30) 1.16 (0.96, 1.36) 
BP treatments, reference group: No BP treatment 
ACE Inhibitors only 0.34 (0.19, 0.50) 0.22 (0.00, 0.44) 
Combination with ACI 0.48 (0.35, 0.60) 0.18 (0.00, 0.36) 
Combination no ACEI 0.17 (0.05, 0.30) 0.15 (-0.03, 0.34) 
Aspirin 0.08 (0.01, 0.14) 0.05 (-0.04, 0.14) 
Lipid therapy -0.05 (-0.12, 0.02) -0.06 (-0.16, 0.04) 
Shared care -0.93 (-1.02, -0.84) 0.53 (0.42, 0.63) 
Middlesbrough PCT 0.59 (0.28, 0.89) -0.04 (-0.22, 0.13) 
Visit year, reference group: 1999 
2000 -0.34 (-0.66, 0.02) 0.03 (-0.27, 0.32) 
2001 -0.55 (-0.86, -0.21) 0.00 (-0.30, 0.29) 
2002 -0.78 (-1.08, -0.45) 0.02 (-0.27, 0.29) 
2003 -0.67 (-0.97, -0.34) -0.10 (-0.38, 0.18) 
2004 0.09 (-0.19, 0.42) 0.09 (-0.20, 0.37) 
2005 0.29 (0.00, 0.61) 0.36 (0.06, 0.65) 
2006 0.66 (0.37, 0.99) -0.68 (-0.98, -0.38) 
2007 0.36 (-0.06, 0.79) 0.38 (0.08, 0.67) 
Interactions 
BP treatments, reference group: No BP treatment & Low SES 
Mid SES*ACEI only 0.10 (-0.18, 0.38) -0.06 (-0.44, 0.31) 
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Mid SES*Comb. w. ACI 0.08 (-0.14, 0.28) 0.11 (-0.18, 0.40) 
Mid SES*Comb. no ACEI 0.22 (-0.01, 0.44) 0.02 (-0.29, 0.32) 
High SES*ACEI only 0.00 (-0.26, 0.26) 0.36 (0.03, 0.71) 
High SES*Comb. w. ACI 0.12 (-0.08, 0.31) 0.04 (-0.23, 0.31) 
High SES* Comb. no ACEI 0.33 (0.12, 0.53) -0.11 (-0.40, 0.18) 
Cons -2.35 (-2.90, -1.73) -2.70 (-4.24, -1.11) 
Variance estimate at: 
Practice level 0.21 (0.13, 0.34) 0.05 (0.03, 0.09) 
Patient level 0.01 (0.00, 0.03) 0.00 (0.00, 0.02) 
Bayesian DIC 25466.08 14525.92 
 
 
Antithrombotic and Lipid profile treatments 
 
In chapter 6, both prescriptions of aspirin and lipid therapies were statistically significant 
predictors of lower cholesterol levels; this was contrary to expectation of diabetes treatments, 
which was associated with poorer HbA1c (Table 9). In the models with long-term complications 
as the dependent variable, aspirin was a significant predictor of incidences of ICD, stroke or TIA, 
PVD and microalbuminuria and lipid therapies was a significant predictor of ICD. The graphical 
analyses in chapter 5 showed that, in general, there were some significant differences in these 
treatments over time with one year in each figure displaying statistically significant differences 
(Figure 32 and Figure 33). However, once other variables and the structured of the data were 
taken into account, no differences were found between either variable by SES overall or over 
time. In contrast, the results here show that there was some evidence of statistically significant 
differences between these treatments and health outcomes by SES.  
The results in Table 27 shows that mid SES patients prescribed aspirin were significantly more 
likely to have lower cholesterol levels compared to low SES patients, however, this treatment 
was not associated with differences with long-term complications by SES (Table 28 and Table 
29). In Table 30 the results show that mid and high SES patients prescribed lipid therapies were 
significantly more likely to have lower cholesterol levels compared to low SES. Like with aspirin, 
the results in Table 31 and Table 32 show that there were no significant interaction effects 
between SES and lipid therapies associated with long-term complications, with one exception. 
Mid SES patients prescribed lipid therapies were significantly more likely to have more 
favourable microalbuminuria rates compared to low SES patients. 
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Table 27: Saturated linear regression multilevel models examining cholesterol levels with 
interaction effect between SES and aspirin by 1999 to 2007, conditional on relevant explanatory 
variables 
 Cholesterol 
Social-economic status, reference group: low 
Mid 0.06 (0.03, 0.10) 
High 0.02 (-0.02, 0.05) 
Socio-demographic, anthropometric, lifestyle and health 
Age, reference group: <60 years 
Age: 60-74 years -0.20 (-0.23, -0.17) 
Age: 75+ years -0.26 (-0.30, -0.23) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years -0.09 (-0.11, -0.06) 
Duration 10+ years -0.13 (-0.16, -0.10) 
Ethnicity, reference group: White 
South Asian  -0.08 (-0.14, -0.02) 
Other Ethnicity 0.08 (-0.04, 0.21) 
Male -0.34 (-0.36, -0.32) 
Smoking status, reference: non-smoker 
Smoker 0.08 (0.04, 0.11) 
Ex-smoker 0.00 (-0.03, 0.02) 
Obesity category, reference group: under and normal weight 
Overweight 0.03 (0.00, 0.07) 
Obese 0.03 (0.00, 0.07) 
Hypertensive 0.14 (0.12, 0.16) 
Ischaemic Cardiac -0.13 (-0.15, -0.10) 
Stroke or TIA -0.02 (-0.06, 0.01) 
PVD 0.01 (-0.03, 0.05) 
Interventions 
Quality of care, reference group: Low 
Mid  -0.10 (-0.13, -0.08) 
High -0.15 (-0.18, -0.11) 
Aspirin -0.06 (-0.09, -0.02) 
Lipid therapy -0.28 (-0.31, -0.26) 
Middlesbrough PCT  -0.03 (-0.09, 0.04) 
Shared care -0.07 (-0.10, -0.04) 
Visit year, reference group: 1999 
2000 -0.20 (-0.29, -0.11) 
2001 -0.21 (-0.30, -0.12) 
2002 -0.22 (-0.30, -0.14) 
2003 -0.37 (-0.46, -0.29) 
2004 -0.58 (-0.66, -0.50) 
2005 -0.73 (-0.82, -0.65) 
2006 -0.83 (-0.92, -0.75) 
2007 -0.93 (-1.02, -0.85) 
Interactions 
Quality of care, reference group: Low SES & Aspirin 
Mid SES*Aspirin -0.07 (-0.13, -0.01) 
High SES*Aspirin -0.05 (-0.10, 0.00) 
Cons 5.90 (5.80, 6.01) 
Variance estimate at: 
Practice level 0.01 (0.00, 0.01) 
Patient level 0.00 (0.00, 0.01) 
Visit year 1.14 (1.13, 1.16) 
Bayesian DIC 110332.92 
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Table 28: Saturated logistic regression multilevel models examining incidences in ICD, stroke or 
TIA and PVD with interaction effect between SES and aspirin by 2000 to 2007, conditional on 
relevant explanatory variables 
 ICD Stroke or TIA PVD 
Social-economic status, reference group: low 
Mid -0.13 (-0.37, 0.10) 0.12 (-0.22, 0.44) -0.08 (-0.43, 0.26) 
High -0.13 (-0.35, 0.08) 0.02 (-0.29, 0.32) 0.02 (-0.31, 0.33) 
Socio-demographic, anthropometric, lifestyle and health 
Age, reference group: <60 years 
Age: 60-74 years 0.34 (0.19, 0.49) 0.73 (0.49, 0.97) 0.61 (0.37, 0.87) 
Age: 75+ years 0.60 (0.42, 0.79) 1.09 (0.81, 1.36) 0.81 (0.50, 1.11) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years -0.59 (-0.73, -0.45) -0.31 (-0.50, -0.11) 0.12 (-0.10, 0.34) 
Duration 10+ years -0.62 (-0.79, -0.46) -0.18 (-0.40, 0.03) 0.38 (0.14, 0.62) 
Ethnicity, reference group: White  
South Asian  0.09 (-0.25, 0.42) 0.11 (-0.32, 0.53) -0.80 (-1.53, -0.15) 
Other Ethnicity -0.67 (-1.54, 0.09) -1.16 (-3.04, 0.19) -0.03 (-1.08, 0.86) 
Male 0.32 (0.20, 0.44) -0.11 (-0.28, 0.05) 0.39 (0.20, 0.58) 
Smoking status, reference: non-smoker 
Smoker 0.15 (-0.02, 0.33) 0.28 (0.05, 0.51) 0.93 (0.68, 1.19) 
Ex-smoker 0.31 (0.19, 0.44) 0.14 (-0.04, 0.31) 0.37 (0.16, 0.59) 
Obesity category, reference group: under and normal weight 
Overweight -0.02 (-0.20, 0.16) -0.09 (-0.30, 0.12) -0.21 (-0.45, 0.04) 
Obese 0.12 (-0.06, 0.30) -0.19 (-0.41, 0.02) -0.26 (-0.50, -0.01) 
eGFR -0.01 (-0.01, 0.00) -0.01 (-0.01, 0.00) -0.01 (-0.02, 0.00) 
Hypertensive -0.27 (-0.39, -0.16) 0.14 (-0.01, 0.30) 0.13 (-0.05, 0.31) 
Cholesterol -0.23 (-0.28, -0.17) -0.09 (-0.17, -0.02) -0.06 (-0.14, 0.03) 
HbA1c 0.07 (0.03, 0.11) 0.02 (-0.04, 0.07) 0.01 (-0.05, 0.07) 
Interventions 
Quality of care, reference group: Low 
Mid  -0.30 (-0.44, -0.16) -0.16 (-0.35, 0.04) -0.18 (-0.41, 0.06) 
High -0.40 (-0.56, -0.23) -0.03 (-0.24, 0.19) 0.18 (-0.06, 0.43) 
Diabetes treatment, reference group diet alone 
Metformin/ sulphonylureas only -0.28 (-0.43, -0.14) -0.18 (-0.38, 0.03) -0.06 (-0.32, 0.20) 
Combination, with no insulin -0.41 (-0.60, -0.21) -0.30 (-0.56, -0.03) -0.12 (-0.43, 0.20) 
Insulin only 0.11 (-0.13, 0.35) -0.08 (-0.39, 0.23) 0.33 (-0.01, 0.65) 
Combination with insulin -0.32 (-0.61, -0.03) -0.28 (-0.66, 0.09) 0.34 (-0.04, 0.72) 
BP treatment, reference group: no treatment 
ACE inhibitors only 0.27 (0.01, 0.52) 0.30 (0.00, 0.59) 0.48 (0.15, 0.80) 
Combination, with ACEI  1.51 (1.32, 1.70) 0.16 (-0.08, 0.40) 0.42 (0.15, 0.70) 
Combination, no ACEI 1.25 (1.06, 1.44) 0.18 (-0.06, 0.42) 0.37 (0.09, 0.65) 
Aspirin 1.40 (1.24, 1.57) 1.12 (0.89, 1.36) 0.72 (0.47, 0.98) 
Lipid therapy 0.61 (0.47, 0.74) 0.09 (-0.09, 0.26) 0.09 (-0.11, 0.29) 
Shared care 0.28 (0.12, 0.44) 0.44 (0.23, 0.64) 0.84 (0.62, 1.06) 
Middlesbrough PCT -0.20 (-0.39, -0.01) -0.13 (-0.40, 0.14) -0.20 (-0.59, 0.18) 
Visit year, reference group: 2000  
2001 -0.28 (-0.58, 0.02) 0.20 (-0.18, 0.59) -0.23 (-0.65, 0.19) 
2002 -0.30 (-0.57, -0.02) 0.02 (-0.34, 0.40) -0.25 (-0.63, 0.14) 
2003 -0.39 (-0.65, -0.13) 0.13 (-0.22, 0.49) 0.02 (-0.33, 0.40) 
2004 -0.66 (-0.93, -0.39) 0.02 (-0.34, 0.38) -0.02 (-0.37, 0.37) 
2005 -1.24 (-1.53, -0.95) -0.21 (-0.57, 0.16) -0.31 (-0.69, 0.09) 
2006 -1.67 (-1.96, -1.37) -0.83 (-1.22, -0.42) -0.80 (-1.21, -0.38) 
2007 -1.80 (-2.11, -1.51) -0.73 (-1.12, -0.32) -1.14 (-1.61, -0.67) 
Interactions  
Aspirin, reference group: Low SES & Aspirin   
Mid SES*Aspirin -0.08 (-0.37, 0.20) -0.19 (-0.58, 0.20) -0.16 (-0.58, 0.27) 
High SES*Aspirin -0.04 (-0.31, 0.23) -0.05 (-0.41, 0.33) -0.39 (-0.80, 0.02) 
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Cons -4.18 (-5.76, -3.07) -4.96 (-6.37, -3.76) -5.87 (-7.23, -4.52) 
Variance estimate at: 
Practice level 0.05 (0.02, 0.11) 0.11 (0.04, 0.21) 0.28 (0.14, 0.49) 
Patient level 2.32 (0.56, 7.71) 1.40 (0.33, 4.81) 1.41 (0.34, 4.63) 
Bayesian DIC 9198.05 6135.98 5023.44 
 
 
Table 29: Saturated logistic regression multilevel models examining microalbuminuria and 
retinopathy rates with interaction effect between SES and aspirin by 1999 to 2007, conditional 
on relevant explanatory variables 
 Microalbuminuria Retinopathy 
Social-economic status, reference group: low 
Mid -0.12 (-0.22, -0.01) -0.03 (-0.19, 0.12) 
High -0.12 (-0.22, -0.02) -0.04 (-0.18, 0.10) 
Socio-demographic, anthropometric, lifestyle and health 
Age, reference group: <60 years  
Age: 60-74 years 0.01 (-0.07, 0.09) 0.01 (-0.11, 0.11) 
Age: 75+ years 0.37 (0.28, 0.47) -0.10 (-0.25, 0.04) 
Duration of diabetes, reference group: 0-3 years  
Duration: 4-9 years -0.01 (-0.09, 0.06) 0.47 (0.34, 0.59) 
Duration 10+ years 0.18 (0.09, 0.27) 1.60 (1.47, 1.73) 
Ethnicity, reference group: White 
South Asian  0.21 (0.05, 0.38) -0.15 (-0.39, 0.07) 
Other Ethnicity 0.29 (-0.08, 0.67) 0.52 (0.08, 0.94) 
Male 0.24 (0.18, 0.31) 0.25 (0.16, 0.34) 
Smoking status, reference: non-smoker 
Smoker 0.26 (0.17, 0.36) -0.13 (-0.27, 0.00) 
Ex-smoker 0.07 (0.00, 0.14) -0.12 (-0.22, -0.02) 
Obesity category, reference group: under and normal weight 
Overweight -0.01 (-0.11, 0.08) -0.09 (-0.22, 0.04) 
Obese 0.06 (-0.04, 0.15) -0.10 (-0.23, 0.03) 
eGFR  -0.01 (-0.01, -0.01) 
Hypertensive 0.18 (0.11, 0.25) 0.33 (0.24, 0.42) 
Cholesterol 0.03 (0.00, 0.06) -0.02 (-0.06, 0.03) 
HbA1c 0.08 (0.06, 0.11) 0.05 (0.02, 0.08) 
Interventions 
Quality of care, reference group: Low  
Mid  -0.15 (-0.54, 0.29) -0.05 (-1.25, 1.82) 
High -0.26 (-0.67, 0.18) -0.12 (-1.31, 1.78) 
Diabetes treatment, reference group diet alone  
Metformin/sulphonylureas only 0.14 (0.04, 0.24) 0.40 (0.24, 0.56) 
Combination, with no insulin 0.02 (-0.10, 0.13) 0.70 (0.53, 0.87) 
Insulin only 0.18 (0.04, 0.31) 1.04 (0.85, 1.23) 
Combination with insulin 0.20 (0.10, 0.30) 1.16 (0.96, 1.36) 
BP treatments, reference group: No BP treatment 
ACE Inhibitors only 0.37 (0.26, 0.48) 0.31 (0.16, 0.46) 
Combination with ACI 0.53 (0.44, 0.62) 0.22 (0.09, 0.34) 
Combination no ACEI 0.32 (0.23, 0.41) 0.12 (0.00, 0.26) 
Aspirin 0.05 (-0.05, 0.14) 0.09 (-0.03, 0.22) 
Lipid therapy -0.05 (-0.12, 0.02) -0.06 (-0.16, 0.04) 
Shared care -0.93 (-1.01, -0.84) 0.53 (0.42, 0.64) 
Middlesbrough PCT 0.58 (0.27, 0.86) -0.04 (-0.22, 0.14) 
Visit year, reference group: 1999 
2000 -0.44 (-0.79, -0.08) 0.04 (-0.27, 0.34) 
2001 -0.65 (-0.98, -0.30) 0.01 (-0.30, 0.31) 
2002 -0.88 (-1.21, -0.54) 0.03 (-0.26, 0.32) 
2003 -0.77 (-1.09, -0.43) -0.08 (-0.39, 0.21) 
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2004 -0.01 (-0.33, 0.32) 0.10 (-0.20, 0.40) 
2005 0.17 (-0.15, 0.51) 0.37 (0.06, 0.67) 
2006 0.55 (0.22, 0.88) -0.67 (-0.99, -0.36) 
2007 0.24 (-0.22, 0.69) 0.39 (0.09, 0.70) 
Interactions 
Aspirin, reference group: Low SES & Aspirin  
Mid SES*Aspirin 0.05 (-0.10, 0.21) -0.10 (-0.30, 0.11) 
High SES* Aspirin 0.06 (-0.08, 0.20) -0.06 (-0.26, 0.14) 
Cons -2.37 (-3.01, -1.71) -3.00 (-4.71, -1.70) 
Variance estimate at: 
Practice level 0.21 (0.13, 0.34) 0.05 (0.03, 0.10) 
Patient level 0.01 (0.00, 0.03) 0.00 (0.00, 0.02) 
Bayesian DIC 25471.46 14529.81 
 
 
Table 30: Saturated linear regression multilevel models examining cholesterol levels with 
interaction effect between SES and lipid therapies by 1999 to 2007, conditional on relevant 
explanatory variables 
 Cholesterol 
Social-economic status, reference group: low 
Mid 0.10 (0.06, 0.15) 
High 0.06 (0.02, 0.11) 
Socio-demographic, anthropometric, lifestyle and health 
Age, reference group: <60 years 
Age: 60-74 years -0.20 (-0.22, -0.17) 
Age: 75+ years -0.26 (-0.30, -0.23) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years -0.09 (-0.11, -0.06) 
Duration 10+ years -0.14 (-0.17, -0.10) 
Ethnicity, reference group: White 
South Asian  -0.08 (-0.14, -0.02) 
Other Ethnicity 0.08 (-0.04, 0.21) 
Male -0.34 (-0.36, -0.32) 
Smoking status, reference: non-smoker 
Smoker 0.08 (0.04, 0.11) 
Ex-smoker 0.00 (-0.03, 0.02) 
Obesity category, reference group: under and normal weight 
Overweight 0.03 (0.00, 0.07) 
Obese 0.03 (0.00, 0.06) 
Hypertensive 0.14 (0.12, 0.16) 
Ischaemic Cardiac -0.13 (-0.15, -0.10) 
Stroke or TIA -0.02 (-0.06, 0.01) 
PVD 0.01 (-0.03, 0.05) 
Interventions 
Quality of care, reference group: Low 
Mid  -0.10 (-0.13, -0.08) 
High -0.15 (-0.18, -0.11) 
Aspirin -0.09 (-0.11, -0.06) 
Lipid therapy -0.22 (-0.26, -0.19) 
Middlesbrough PCT  -0.03 (-0.09, 0.03) 
Shared care -0.07 (-0.10, -0.04) 
Visit year, reference group: 1999 
2000 -0.20 (-0.29, -0.11) 
2001 -0.21 (-0.29, -0.12) 
2002 -0.22 (-0.30, -0.13) 
2003 -0.37 (-0.46, -0.29) 
2004 -0.58 (-0.66, -0.50) 
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2005 -0.73 (-0.82, -0.65) 
2006 -0.83 (-0.92, -0.75) 
2007 -0.93 (-1.02, -0.85) 
Interactions 
Lipid therapy, reference group: Low SES & Lipid therapy 
Mid SES* Lipid therapy -0.11 (-0.17, -0.06) 
High SES* Lipid therapy -0.11 (-0.16, -0.06) 
Cons 5.88 (5.77, 5.99) 
Variance estimate at: 
Practice level 0.01 (0.00, 0.01) 
Patient level 0.00 (0.00, 0.01) 
Visit year 1.14 (1.13, 1.16) 
Bayesian DIC 110316.16 
 
 
Table 31: Saturated logistic regression multilevel models incidences of ICD, stroke or TIA and 
PVD with interaction effect between SES and lipid therapies by 2000 to 2007, conditional on 
relevant explanatory variables 
 ICD Stroke or TIA PVD 
Social-economic status, reference group: low 
Mid -0.20 (-0.46, 0.05) 0.02 (-0.29, 0.33) -0.06 (-0.40, 0.27) 
High -0.20 (-0.45, 0.04) -0.12 (-0.42, 0.19) -0.20 (-0.55, 0.13) 
Socio-demographic, anthropometric, lifestyle and health 
Age, reference group: <60 years   
Age: 60-74 years 0.34 (0.18, 0.49) 0.73 (0.50, 0.97) 0.61 (0.37, 0.86) 
Age: 75+ years 0.60 (0.41, 0.79) 1.08 (0.81, 1.36) 0.80 (0.51, 1.09) 
Duration of diabetes, reference group: 0-3 years   
Duration: 4-9 years -0.59 (-0.73, -0.45) -0.31 (-0.50, -0.12) 0.13 (-0.09, 0.35) 
Duration 10+ years -0.62 (-0.79, -0.46) -0.18 (-0.40, 0.03) 0.38 (0.14, 0.61) 
Ethnicity, reference group: White  
South Asian  0.09 (-0.25, 0.41) 0.11 (-0.33, 0.52) -0.8 (-1.53, -0.16) 
Other Ethnicity -0.67 (-1.58, 0.10) -1.16 (-3.02, 0.18) -0.04 (-1.10, 0.83) 
Male 0.32 (0.20, 0.45) -0.11 (-0.28, 0.05) 0.39 (0.20, 0.58) 
Smoking status, reference: non-smoker  
Smoker 0.16 (-0.02, 0.33) 0.28 (0.05, 0.50) 0.93 (0.69, 1.18) 
Ex-smoker 0.31 (0.19, 0.44) 0.14 (-0.04, 0.30) 0.37 (0.16, 0.58) 
Obesity category, reference group: under and normal weight  
Overweight -0.01 (-0.19, 0.16) -0.09 (-0.30, 0.13) -0.21 (-0.46, 0.04) 
Obese 0.12 (-0.05, 0.29) -0.19 (-0.41, 0.03) -0.26 (-0.52, -0.01) 
eGFR -0.01 (-0.01, 0.00) -0.01 (-0.01, 0.00) -0.01 (-0.01, 0.00) 
Hypertensive -0.27 (-0.39, -0.16) 0.14 (-0.01, 0.30) 0.13 (-0.05, 0.31) 
Cholesterol -0.23 (-0.28, -0.16) -0.09 (-0.17, -0.02) -0.06 (-0.14, 0.02) 
HbA1c 0.07 (0.03, 0.11) 0.02 (-0.04, 0.07) 0.01 (-0.05, 0.07) 
Interventions 
Quality of care, reference group: Low 
Mid  -0.30 (-0.44, -0.17) -0.16 (-0.36, 0.04) -0.18 (-0.41, 0.07) 
High -0.40 (-0.56, -0.24) -0.03 (-0.24, 0.20) 0.18 (-0.06, 0.42) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas only -0.28 (-0.43, -0.14) -0.18 (-0.38, 0.03) -0.06 (-0.32, 0.19) 
Combination, with no insulin -0.40 (-0.60, -0.21) -0.30 (-0.56, -0.03) -0.12 (-0.44, 0.20) 
Insulin only 0.11 (-0.13, 0.35) -0.08 (-0.40, 0.23) 0.33 (-0.01, 0.66) 
Combination with insulin -0.32 (-0.61, -0.03) -0.29 (-0.68, 0.09) 0.33 (-0.05, 0.71) 
BP treatment, reference group: no treatment 
ACE inhibitors only 0.27 (0.01, 0.53) 0.30 (0.01, 0.58) 0.48 (0.16, 0.80) 
Combination, with ACEI  1.50 (1.31, 1.70) 0.15 (-0.08, 0.39) 0.42 (0.15, 0.70) 
Combination, no ACEI 1.25 (1.05, 1.45) 0.18 (-0.06, 0.41) 0.37 (0.09, 0.65) 
Aspirin 1.37 (1.26, 1.49) 1.06 (0.89, 1.23) 0.57 (0.39, 0.76) 
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Lipid therapy 0.58 (0.40, 0.77) 0.06 (-0.17, 0.30) 0.15 (-0.12, 0.42) 
Shared care 0.28 (0.12, 0.43) 0.44 (0.24, 0.63) 0.84 (0.62, 1.05) 
Middlesbrough PCT -0.20 (-0.38, 0.00) -0.12 (-0.39, 0.14) -0.19 (-0.57, 0.20) 
Visit year, reference group: 2000  
2001 -0.28 (-0.57, 0.02) 0.20 (-0.19, 0.60) -0.24 (-0.65, 0.17) 
2002 -0.30 (-0.56, -0.02) 0.02 (-0.34, 0.40) -0.26 (-0.64, 0.12) 
2003 -0.39 (-0.65, -0.11) 0.13 (-0.22, 0.50) 0.01 (-0.33, 0.38) 
2004 -0.66 (-0.92, -0.38) 0.02 (-0.34, 0.38) -0.03 (-0.38, 0.34) 
2005 -1.23 (-1.51, -0.94) -0.21 (-0.58, 0.16) -0.32 (-0.69, 0.06) 
2006 -1.66 (-1.95, -1.36) -0.82 (-1.22, -0.42) -0.81 (-1.21, -0.41) 
2007 -1.80 (-2.10, -1.50) -0.73 (-1.13, -0.32) -1.15 (-1.61, -0.70) 
Interactions 
Lipid therapy, reference group: Low SES & Lipid therapy 
Mid SES*Lipid therapy 0.03 (-0.28, 0.33) -0.06 (-0.44, 0.33) -0.18 (-0.61, 0.24) 
High SES*Lipid therapy 0.06 (-0.21, 0.35) 0.15 (-0.21, 0.52) -0.02 (-0.42, 0.40) 
Cons -3.98 (-5.26, -2.61) -4.85 (-6.13, -3.63) -5.83 (-6.96, -4.51) 
Variance estimate at:  
Practice level 0.05 (0.02, 0.11) 0.11 (0.04, 0.22) 0.28 (0.14, 0.48) 
Patient level 2.18 (0.54, 7.22) 1.35 (0.32, 4.88) 1.41 (0.33, 4.95) 
Bayesian DIC 9199.07 6136.29 5025.41 
 
 
Table 32: Saturated logistic regression multilevel models microalbuminuria and retinopathy 
rates with interaction effect between SES and lipid therapies by 1999 to 2007, conditional on 
relevant explanatory variables 
 Microalbuminuria Retinopathy 
Social-economic status, reference group: low 
Mid 0.08 (-0.05, 0.21) -0.15 (-0.32, 0.03) 
High -0.02 (-0.15, 0.11) -0.12 (-0.28, 0.04) 
Socio-demographic, anthropometric, lifestyle and health 
Age, reference group: <60 years  
Age: 60-74 years 0.01 (-0.06, 0.09) 0.00 (-0.11, 0.11) 
Age: 75+ years 0.38 (0.28, 0.47) -0.11 (-0.25, 0.04) 
Duration of diabetes, reference group: 0-3 years  
Duration: 4-9 years -0.01 (-0.09, 0.06) 0.47 (0.34, 0.59) 
Duration 10+ years 0.18 (0.09, 0.27) 1.60 (1.47, 1.72) 
Ethnicity, reference group: White 
South Asian  0.22 (0.05, 0.38) -0.15 (-0.39, 0.08) 
Other Ethnicity 0.31 (-0.07, 0.67) 0.52 (0.08, 0.96) 
Male 0.24 (0.18, 0.31) 0.25 (0.16, 0.34) 
Smoking status, reference: non-smoker 
Smoker 0.26 (0.17, 0.36) -0.13 (-0.27, 0.00) 
Ex-smoker 0.07 (0.00, 0.14) -0.12 (-0.22, -0.03) 
Obesity category, reference group: under and normal weight 
Overweight -0.01 (-0.10, 0.09) -0.09 (-0.22, 0.04) 
Obese 0.06 (-0.03, 0.16) -0.10 (-0.23, 0.03) 
eGFR  -0.01 (-0.01, -0.01) 
Hypertensive 0.18 (0.11, 0.24) 0.33 (0.25, 0.42) 
Cholesterol 0.03 (0.00, 0.06) -0.01 (-0.05, 0.03) 
HbA1c 0.09 (0.06, 0.11) 0.05 (0.02, 0.08) 
Interventions 
Quality of care, reference group: Low  
Mid  -0.09 (-0.48, 0.34) -0.43 (-1.75, 0.85) 
High -0.20 (-0.60, 0.22) -0.49 (-1.81, 0.77) 
Diabetes treatment, reference group diet alone  
Metformin/sulphonylureas only 0.14 (0.04, 0.24) 0.40 (0.24, 0.56) 
Combination, with no insulin 0.02 (-0.09, 0.14) 0.70 (0.52, 0.87) 
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Insulin only 0.18 (0.04, 0.31) 1.04 (0.86, 1.23) 
Combination with insulin 0.20 (0.10, 0.30) 1.16 (0.96, 1.36) 
BP treatments, reference group: No BP treatment 
ACE Inhibitors only 0.36 (0.25, 0.47) 0.32 (0.17, 0.47) 
Combination with ACI 0.53 (0.44, 0.62) 0.22 (0.09, 0.34) 
Combination no ACEI 0.32 (0.23, 0.41) 0.13 (0.00, 0.26) 
Lipid therapy 0.04 (-0.06, 0.14) -0.11 (-0.25, 0.03) 
Aspirin 0.07 (0.01, 0.14) 0.05 (-0.04, 0.15) 
Shared care -0.92 (-1.01, -0.83) 0.53 (0.42, 0.64) 
Middlesbrough PCT 0.60 (0.32, 0.88) -0.04 (-0.22, 0.14) 
Visit year, reference group: 1999 
2000 -0.41 (-0.74, -0.10) 0.04 (-0.25, 0.34) 
2001 -0.63 (-0.93, -0.33) 0.01 (-0.29, 0.30) 
2002 -0.86 (-1.16, -0.56) 0.03 (-0.26, 0.31) 
2003 -0.75 (-1.04, -0.46) -0.08 (-0.37, 0.21) 
2004 0.01 (-0.28, 0.28) 0.10 (-0.19, 0.39) 
2005 0.19 (-0.10, 0.47) 0.37 (0.07, 0.67) 
2006 0.57 (0.28, 0.84) -0.66 (-0.96, -0.36) 
2007 0.27 (-0.15, 0.68) 0.39 (0.10, 0.68) 
Interactions 
Lipid therapy, reference group: Low SES & Lipid therapy 
Mid SES*Lipid therapy -0.25 (-0.41, -0.09) 0.12 (-0.09, 0.33) 
High SES*Lipid therapy -0.11 (-0.26, 0.04) 0.08 (-0.13, 0.29) 
Cons -2.55 (-3.22, -1.98) -2.57 (-3.88, -1.19) 
Variance estimate at: 
Practice level 0.21 (0.13, 0.34) 0.05 (0.03, 0.10) 
Patient level 0.01 (0.00, 0.03) 0.00 (0.00, 0.02) 
Bayesian DIC 25462.27 14529.00 
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Shared care 
 
In chapter 6, shared care was consistently a statistically significant predictor of health outcomes 
in all the multilevel models. With the exception of cholesterol levels, shared care was associated 
with poorer health outcomes. As stated previously, these results were in general to be expected 
as referrals to specialist care should be for patients with poor control and complex needs. The 
graphical analyses of shared care by SES over time in chapter five revealed that it was high and 
low SES patients who had higher rates of receiving shared compared to mid SES patients, this 
pattern achieved statistical significance in a number of years (Figure 34). In contrast, when 
patients health statuses and other variables were taken into account the results from the 
multilevel analyses showed evidence that high SES patients were more likely to receive shared 
care over time compared to low SES patients (Table 17).  
The results from this section indicate that in most circumstances there were no differences in 
the association between shared care and health outcomes by SES. However, there were two 
exceptions: high SES patients receiving shared care were significantly more likely to have lower 
HbA1c levels and microalbuminuria rates compared to low SES patients receiving shared care. 
In contrast, mid SES patients receiving shared were significantly more likely to have higher 
rates of microalbuminuria compared to low SES patients receiving shared care.  
 
Table 33: Saturated linear regression multilevel models examining cholesterol levels with 
interaction effect between SES and lipid therapies by 1999 to 2007, conditional on relevant 
explanatory variables 
 HbA1c Cholesterol 
Social-economic status, reference group: low 
Mid -0.03 (-0.07, 0.01) 0.04 (0.01, 0.08) 
High -0.05 (-0.10, -0.01) 0.01 (-0.02, 0.04) 
Socio-demographic, anthropometric, lifestyle and health 
Age, reference group: <60 years 
Age: 60-74 years -0.33 (-0.36, -0.30) -0.20 (-0.23, -0.17) 
Age: 75+ years -0.41 (-0.46, -0.37) -0.26 (-0.30, -0.23) 
Duration of diabetes, reference group: 0-3 years  
Duration: 4-9 years 0.06 (0.02, 0.09) -0.09 (-0.11, -0.06) 
Duration 10+ years 0.06 (0.02, 0.10) -0.13 (-0.16, -0.10) 
Ethnicity, reference group: White 
South Asian  0.46 (0.39, 0.54) -0.08 (-0.14, -0.03) 
Other Ethnicity 0.47 (0.30, 0.63) 0.08 (-0.05, 0.20) 
Male -0.06 (-0.09, -0.03) -0.34 (-0.36, -0.32) 
Smoking status, reference: non-smoker 
Smoker 0.23 (0.19, 0.27) 0.08 (0.04, 0.11) 
E*-smoker 0.05 (0.02, 0.08) 0.00 (-0.03, 0.02) 
Obesity category, reference group: under and normal weight 
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Overweight 0.03 (-0.02, 0.07) 0.03 (0.00, 0.07) 
Obese 0.08 (0.04, 0.13) 0.03 (0.00, 0.07) 
Creatinine > 300 -0.81 (-1.06, -0.56)  
Hypertensive 0.10 (0.07, 0.13) 0.14 (0.12, 0.16) 
Ischaemic Cardiac 0.00 (-0.04, 0.03) -0.13 (-0.15, -0.10) 
Stroke or TIA -0.06 (-0.10, -0.01) -0.02 (-0.06, 0.01) 
PVD -0.07 (-0.12, -0.01) 0.01 (-0.03, 0.05) 
Interventions 
Quality of care, reference group: Low  
Mid  -0.13 (-0.16, -0.09) -0.10 (-0.13, -0.08) 
High -0.15 (-0.19, -0.11) -0.15 (-0.18, -0.11) 
Diabetes treatment, reference group diet alone  
Metformin/sulphonylureas only 0.81 (0.77, 0.85)  
Combination, with no insulin 1.25 (1.20, 1.29)  
Insulin only 1.67 (1.61, 1.73)  
Combination with insulin 1.75 (1.69, 1.82)  
Aspirin  -0.09 (-0.11, -0.06) 
Lipid therapy  -0.28 (-0.31, -0.26) 
Middlesbrough PCT  0.10 (0.01, 0.21) -0.03 (-0.09, 0.03) 
Shared care 0.22 (0.17, 0.26) -0.05 (-0.08, -0.01) 
Visit year, reference group: 1999 
2000 -0.32 (-0.40, -0.23) -0.20 (-0.29, -0.11) 
2001 -0.47 (-0.55, -0.39) -0.21 (-0.30, -0.12) 
2002 -0.55 (-0.63, -0.47) -0.22 (-0.30, -0.13) 
2003 -0.59 (-0.67, -0.52) -0.37 (-0.45, -0.29) 
2004 -0.63 (-0.71, -0.56) -0.58 (-0.66, -0.49) 
2005 -0.71 (-0.79, -0.64) -0.73 (-0.82, -0.65) 
2006 -1.18 (-1.25, -1.10) -0.83 (-0.92, -0.75) 
2007 -1.12 (-1.20, -1.04) -0.93 (-1.02, -0.85) 
Interactions 
Shared care, reference group: Low SES & Shared care  
Mid SES*Shared care -0.05 (-0.13, 0.03) -0.04 (-0.10, 0.03) 
High SES*Shared care -0.13 (-0.20, -0.05) -0.06 (-0.12, 0.00) 
Cons 7.58 (7.46, 7.70) 5.91 (5.8, 6.02) 
Variance estimate at: 
Practice level 0.02 (0.01, 0.04) 0.01 (0.00, 0.01) 
Patient level 0.00 (0.00, 0.02) 0.00 (0.00, 0.01) 
Visit year 1.91 (1.88, 1.94) 1.14 (1.13, 1.16) 
Bayesian DIC 133966.20 110335.80 
 
 
Table 34: Saturated logistic regression multilevel models incidences of ICD, stroke or TIA and 
PVD with interaction effect between SES and lipid therapies by 2000 to 2007, conditional on 
relevant explanatory variables 
 ICD Stroke or TIA PVD 
Social-economic status, reference group: low 
Mid -0.19 (-0.35, -0.01) 0.09 (-0.15, 0.33) -0.20 (-0.50, 0.09) 
High -0.12 (-0.27, 0.05) 0.09 (-0.13, 0.32) -0.07 (-0.35, 0.22) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years 0.33 (0.19, 0.48) 0.74 (0.51, 0.98) 0.62 (0.38, 0.87) 
Age: 75+ years 0.60 (0.41, 0.79) 1.10 (0.83, 1.38) 0.82 (0.52, 1.12) 
Duration of diabetes, reference group: 0-3 years   
Duration: 4-9 years -0.59 (-0.73, -0.45) -0.31 (-0.50, -0.12) 0.13 (-0.10, 0.35) 
Duration 10+ years -0.63 (-0.80, -0.46) -0.18 (-0.39, 0.03) 0.38 (0.15, 0.62) 
Ethnicity, reference group: White  
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South Asian  0.09 (-0.25, 0.41) 0.11 (-0.33, 0.53) -0.81 (-1.52, -0.18) 
Other Ethnicity -0.67 (-1.55, 0.09) -1.18 (-3.11, 0.16) -0.07 (-1.10, 0.82) 
Male 0.32 (0.20, 0.44) -0.11 (-0.27, 0.06) 0.39 (0.20, 0.58) 
Smoking status, reference: non-smoker  
Smoker 0.15 (-0.02, 0.33) 0.27 (0.05, 0.50) 0.93 (0.68, 1.18) 
Ex-smoker 0.31 (0.19, 0.44) 0.14 (-0.04, 0.31) 0.37 (0.15, 0.58) 
Obesity category, reference group: under and normal weight  
Overweight -0.02 (-0.19, 0.16) -0.08 (-0.30, 0.13) -0.20 (-0.45, 0.05) 
Obese 0.12 (-0.05, 0.29) -0.19 (-0.40, 0.02) -0.25 (-0.51, 0.00) 
eGFR -0.01 (-0.01, 0.00) -0.01 (-0.01, 0.00) -0.01 (-0.01, 0.00) 
Hypertensive -0.27 (-0.39, -0.16) 0.15 (-0.01, 0.30) 0.13 (-0.05, 0.31) 
Cholesterol -0.23 (-0.29, -0.17) -0.09 (-0.16, -0.02) -0.06 (-0.13, 0.03) 
HbA1c 0.07 (0.03, 0.11) 0.02 (-0.04, 0.08) 0.01 (-0.05, 0.07) 
Interventions 
Quality of care, reference group: Low   
Mid  -0.31 (-0.44, -0.17) -0.16 (-0.35, 0.03) -0.19 (-0.42, 0.05) 
High -0.40 (-0.56, -0.23) -0.03 (-0.24, 0.19) 0.17 (-0.07, 0.42) 
Diabetes treatment, reference group diet alone 
Metformin or sulphonylureas only -0.28 (-0.43, -0.13) -0.17 (-0.37, 0.03) -0.05 (-0.31, 0.20) 
Combination, with no insulin -0.40 (-0.60, -0.21) -0.29 (-0.56, -0.03) -0.11 (-0.42, 0.19) 
Insulin only 0.12 (-0.12, 0.36) -0.07 (-0.38, 0.23) 0.34 (0.01, 0.67) 
Combination with insulin -0.31 (-0.60, -0.02) -0.28 (-0.65, 0.10) 0.34 (-0.03, 0.72) 
BP treatment, reference group: no treatment 
ACE inhibitors only 0.27 (0.01, 0.53) 0.30 (0.00, 0.59) 0.48 (0.16, 0.81) 
Combination, with ACEI  1.50 (1.31, 1.70) 0.16 (-0.08, 0.40) 0.43 (0.15, 0.71) 
Combination, no ACEI 1.25 (1.05, 1.45) 0.18 (-0.05, 0.42) 0.38 (0.10, 0.66) 
Aspirin 1.37 (1.26, 1.49) 1.06 (0.89, 1.23) 0.58 (0.40, 0.76) 
Lipid therapy 0.61 (0.48, 0.74) 0.09 (-0.08, 0.27) 0.10 (-0.10, 0.30) 
Shared care 0.31 (0.11, 0.51) 0.60 (0.34, 0.86) 0.91 (0.63, 1.19) 
Middlesbrough PCT -0.2 (-0.38, -0.01) -0.12 (-0.38, 0.16) -0.19 (-0.59, 0.20) 
Visit year, reference group: 2000  
2001 -0.29 (-0.59, 0.01) 0.21 (-0.18, 0.60) -0.23 (-0.63, 0.19) 
2002 -0.31 (-0.58, -0.03) 0.04 (-0.32, 0.41) -0.24 (-0.62, 0.13) 
2003 -0.40 (-0.66, -0.13) 0.15 (-0.21, 0.50) 0.03 (-0.32, 0.40) 
2004 -0.67 (-0.93, -0.40) 0.03 (-0.32, 0.38) -0.01 (-0.37, 0.36) 
2005 -1.25 (-1.53, -0.96) -0.19 (-0.55, 0.17) -0.31 (-0.70, 0.09) 
2006 -1.68 (-1.96, -1.39) -0.80 (-1.20, -0.40) -0.79 (-1.19, -0.38) 
2007 -1.82 (-2.11, -1.52) -0.71 (-1.11, -0.31) -1.15 (-1.61, -0.69) 
Interactions 
Shared care, reference group: Low SES & Shared care 
Mid SES*Shared care 0.01 (-0.31, 0.33) -0.30 (-0.72, 0.11) 0.07 (-0.35, 0.51) 
High SES*Shared care -0.16 (-0.47, 0.14) -0.34 (-0.72, 0.04) -0.32 (-0.72, 0.09) 
Cons -3.88 (-5.04, -2.9) -5.14 (-6.50, -4.03) -5.95 (-7.37, -4.81) 
Variance estimate at: 
Practice level 0.05 (0.02, 0.11) 0.11 (0.04, 0.22) 0.28 (0.15, 0.50) 
Patient level 2.07 (0.55, 6.4) 1.35 (0.33, 4.51) 1.35 (0.33, 4.45) 
Bayesian DIC 9197.41 6132.89 5023.01 
Available cases (N)   30053 
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Table 35: Saturated logistic regression multilevel models examining incidences of ICD, stroke or 
TIA and PVD with interaction effect between SES and lipid therapies by 2000 to 2007, 
conditional on relevant explanatory variables 
 Microalbuminuria Retinopathy 
Social-economic status, reference group: low 
Mid -0.18 (-0.27, -0.09) -0.07 (-0.21, 0.08) 
High -0.05 (-0.14, 0.03) -0.04 (-0.18, 0.10) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years 0.01 (-0.07, 0.09) 0.01 (-0.10, 0.12) 
Age: 75+ years 0.38 (0.28, 0.47) -0.10 (-0.24, 0.04) 
Duration of diabetes, reference group: 0-3 years  
Duration: 4-9 years -0.02 (-0.09, 0.06) 0.47 (0.34, 0.60) 
Duration 10+ years 0.18 (0.09, 0.27) 1.60 (1.47, 1.73) 
Ethnicity, reference group: White 
South Asian  0.21 (0.04, 0.37) -0.15 (-0.39, 0.08) 
Other Ethnicity 0.31 (-0.08, 0.68) 0.52 (0.08, 0.95) 
Male 0.24 (0.18, 0.31) 0.25 (0.16, 0.34) 
Smoking status, reference: non-smoker 
Smoker 0.26 (0.17, 0.36) -0.13 (-0.27, 0.00) 
E*-smoker 0.07 (0.00, 0.14) -0.12 (-0.22, -0.02) 
Obesity category, reference group: under and normal weight 
Overweight -0.01 (-0.11, 0.08) -0.09 (-0.22, 0.04) 
Obese 0.06 (-0.04, 0.15) -0.10 (-0.24, 0.03) 
eGFR  -0.01 (-0.01, -0.01) 
Hypertensive 0.18 (0.12, 0.25) 0.33 (0.25, 0.42) 
Cholesterol 0.03 (0.00, 0.06) -0.01 (-0.05, 0.03) 
HbA1c 0.09 (0.06, 0.11) 0.05 (0.02, 0.08) 
Interventions 
Quality of care, reference group: Low  
Mid  -0.11 (-0.43, 0.26) 0.41 (-1.62, 2.64) 
High -0.22 (-0.55, 0.15) 0.34 (-1.68, 2.58) 
Diabetes treatment, reference group diet alone  
Metformin or sulphonylureas only 0.14 (0.04, 0.24) 0.40 (0.24, 0.57) 
Combination, with no insulin 0.02 (-0.09, 0.13) 0.70 (0.53, 0.88) 
Insulin only 0.18 (0.04, 0.32) 1.04 (0.86, 1.24) 
Combination with insulin 0.21 (0.11, 0.31) 1.16 (0.96, 1.36) 
BP treatments, reference group: No BP treatment 
ACE Inhibitors only 0.36 (0.26, 0.47) 0.32 (0.17, 0.46) 
Combination with ACI 0.53 (0.43, 0.62) 0.22 (0.09, 0.35) 
Combination no ACEI 0.32 (0.23, 0.41) 0.13 (-0.01, 0.26) 
Aspirin 0.08 (0.01, 0.14) 0.05 (-0.04, 0.14) 
Lipid therapy -0.05 (-0.12, 0.02) -0.06 (-0.16, 0.04) 
Shared care -0.97 (-1.08, -0.85) 0.56 (0.42, 0.70) 
Middlesbrough PCT 0.57 (0.27, 0.85) -0.05 (-0.22, 0.13) 
Visit year, reference group: 1999 
2000 -0.40 (-0.73, -0.07) 0.03 (-0.26, 0.33) 
2001 -0.61 (-0.92, -0.29) 0.00 (-0.29, 0.30) 
2002 -0.83 (-1.14, -0.52) 0.02 (-0.25, 0.32) 
2003 -0.73 (-1.02, -0.42) -0.09 (-0.37, 0.20) 
2004 0.03 (-0.26, 0.33) 0.09 (-0.20, 0.38) 
2005 0.21 (-0.08, 0.51) 0.36 (0.07, 0.65) 
2006 0.59 (0.30, 0.90) -0.67 (-0.97, -0.37) 
2007 0.29 (-0.13, 0.72) 0.38 (0.10, 0.69) 
Interactions 
Shared care, reference group: Low SES & Shared care 
Mid SES*Shared care 0.41 (0.23, 0.59) -0.02 (-0.23, 0.19) 
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High SES*Shared care -0.19 (-0.36, -0.01) -0.07 (-0.27, 0.13) 
Cons -2.47 (-3.04, -1.84) -3.45 (-5.75, -1.26) 
Variance estimate at: 
Practice level 0.21 (0.13, 0.34) 0.05 (0.03, 0.10) 
Patient level 0.01 (0.00, 0.03) 0.00 (0.00, 0.02) 
Bayesian DIC 25438.62 14530.78 
 
 
Primary care trust 
 
In chapter 6, being managed under Middlesbrough PCT, compared to Redcar & Cleveland PCT, 
was a significant predictor of ICD but not with any other health outcome. The result showed 
patients managed by Middlesbrough PCT were significant more likely to have lower incidences 
of ICD (Table 10). This variable was not analysed graphically or modelled as an outcome 
variable as being managed by one PCT compared to the other, was not a consequence of 
patients’ health or decisions in their care.   
However, the results outlined here show there were statistically significant interactions 
between PCT and health outcomes by SES. Mid and high SES patients managed by 
Middlesbrough PCT were significantly more likely to have lower cholesterol levels compared to 
low SES patients in Middlesbrough PCT. In contrast, mid SES were significantly more likely to 
have higher microalbuminuria rates compared to low SES patients in Middlesbrough PCT.  
 
Table 36: Saturated linear regression multilevel models examining HbA1c and cholesterol levels 
with interaction effect between SES and PCT by 1999 to 2007, conditional on relevant 
explanatory variables 
 HbA1c Cholesterol 
Social-economic status, reference group: low 
Mid -0.03 (-0.08, 0.01) 0.07 (0.04, 0.11) 
High -0.06 (-0.12, -0.01) 0.04 (0.00, 0.09) 
Socio-demographic, anthropometric, lifestyle and health 
Age, reference group: <60 years  
Age: 60-74 years -0.33 (-0.36, -0.29) -0.20 (-0.23, -0.17) 
Age: 75+ years -0.41 (-0.45, -0.37) -0.26 (-0.30, -0.23) 
Duration of diabetes, reference group: 0-3 years  
Duration: 4-9 years 0.06 (0.02, 0.09) -0.09 (-0.11, -0.06) 
Duration 10+ years 0.05 (0.01, 0.10) -0.13 (-0.16, -0.10) 
Ethnicity, reference group: White 
South Asian  0.46 (0.39, 0.54) -0.08 (-0.14, -0.03) 
Other Ethnicity 0.47 (0.31, 0.64) 0.08 (-0.05, 0.20) 
Male -0.06 (-0.09, -0.03) -0.34 (-0.36, -0.32) 
Smoking status, reference: non-smoker 
Smoker 0.23 (0.19, 0.27) 0.08 (0.04, 0.11) 
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Ex-smoker 0.05 (0.02, 0.08) 0.00 (-0.03, 0.02) 
Obesity category, reference group: under and normal weight 
Overweight 0.02 (-0.02, 0.07) 0.03 (0.00, 0.07) 
Obese 0.08 (0.04, 0.13) 0.03 (0.00, 0.07) 
Creatinine > 300 -0.81 (-1.05, -0.56)  
Hypertensive 0.10 (0.07, 0.13) 0.14 (0.12, 0.16) 
Ischaemic Cardiac 0.00 (-0.04, 0.03) -0.13 (-0.15, -0.10) 
Stroke or TIA -0.06 (-0.10, -0.01) -0.02 (-0.06, 0.01) 
PVD -0.06 (-0.12, -0.01) 0.01 (-0.03, 0.05) 
Interventions 
Quality of care, reference group: Low 
Mid  -0.13 (-0.16, -0.09) -0.10 (-0.13, -0.08) 
High -0.15 (-0.19, -0.11) -0.15 (-0.18, -0.11) 
Diabetes treatment, reference group diet alone  
Metformin or sulphonylureas only 0.81 (0.77, 0.85)  
Combination, with no insulin 1.25 (1.20, 1.29)  
Insulin only 1.67 (1.61, 1.73)  
Combination with insulin 1.75 (1.69, 1.82)  
Aspirin  -0.09 (-0.11, -0.06) 
Lipid therapy  -0.28 (-0.31, -0.26) 
Middlesbrough PCT  0.12 (0.02, 0.22) 0.02 (-0.05, 0.08) 
Shared care 0.17 (0.13, 0.21) -0.07 (-0.10, -0.04) 
Visit year, reference group: 1999 
2000 -0.32 (-0.40, -0.23) -0.20 (-0.29, -0.11) 
2001 -0.47 (-0.55, -0.38) -0.21 (-0.30, -0.12) 
2002 -0.55 (-0.63, -0.47) -0.22 (-0.30, -0.14) 
2003 -0.59 (-0.67, -0.52) -0.37 (-0.45, -0.29) 
2004 -0.63 (-0.71, -0.56) -0.58 (-0.66, -0.50) 
2005 -0.71 (-0.79, -0.64) -0.73 (-0.82, -0.65) 
2006 -1.18 (-1.26, -1.10) -0.83 (-0.92, -0.75) 
2007 -1.12 (-1.20, -1.04) -0.93 (-1.02, -0.85) 
Interactions 
Middlesbrough PCT, reference group: Low SES & Middlesbrough PCT 
Mid SES*Middlesbrough PCT -0.02 (-0.10, 0.06) -0.10 (-0.16, -0.03) 
High SES*Middlesbrough PCT -0.05 (-0.12, 0.03) -0.08 (-0.14, -0.03) 
Cons 7.58 (7.46, 7.71) 5.89 (5.78, 6.00) 
Variance estimate at: 
Practice level 0.02 (0.01, 0.04) 0.01 (0.00, 0.01) 
Patient level 0.00 (0.00, 0.02) 0.00 (0.00, 0.01) 
Visit year 1.91 (1.88, 1.94) 1.14 (1.13, 1.16) 
Bayesian DIC 133976.84 110328.06 
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Table 37: Saturated logistic regression multilevel models examining incidences of ICD, stroke or 
TIA and PVD with interaction effect between SES and PCT by 2000 to 2007, conditional on 
relevant explanatory variables 
 ICD Stroke or TIA PVD 
Social-economic status, reference group: low 
Mid -0.19 (-0.38, -0.01) 0.05 (-0.20, 0.30) -0.21 (-0.50, 0.08) 
High -0.11 (-0.31, 0.09) 0.08 (-0.19, 0.35) -0.08 (-0.41, 0.23) 
Covariates 
Age, reference group: <60 years   
Age: 60-74 years 0.33 (0.18, 0.48) 0.74 (0.51, 0.99) 0.62 (0.38, 0.88) 
Age: 75+ years 0.60 (0.41, 0.78) 1.10 (0.83, 1.37) 0.82 (0.53, 1.12) 
Duration of diabetes, reference group: 0-3 years   
Duration: 4-9 years -0.59 (-0.73, -0.45) -0.30 (-0.49, -0.11) 0.13 (-0.09, 0.35) 
Duration 10+ years -0.63 (-0.79, -0.46) -0.18 (-0.39, 0.02) 0.38 (0.15, 0.62) 
Ethnicity, reference group: White  
South Asian  0.08 (-0.24, 0.41) 0.10 (-0.35, 0.51) -0.81 (-1.55, -0.16) 
Other Ethnicity -0.67 (-1.55, 0.12) -1.16 (-3.02, 0.19) -0.05 (-1.12, 0.85) 
Male 0.32 (0.20, 0.44) -0.11 (-0.27, 0.05) 0.40 (0.21, 0.58) 
Smoking status, reference: non-smoker  
Smoker 0.15 (-0.02, 0.33) 0.27 (0.05, 0.50) 0.93 (0.68, 1.18) 
Ex-smoker 0.31 (0.18, 0.44) 0.13 (-0.04, 0.31) 0.37 (0.16, 0.57) 
Obesity category, reference group: under and normal weight  
Overweight -0.02 (-0.19, 0.16) -0.09 (-0.30, 0.13) -0.20 (-0.44, 0.05) 
Obese 0.12 (-0.05, 0.30) -0.19 (-0.41, 0.03) -0.25 (-0.49, 0.00) 
eGFR -0.01 (-0.01, 0.00) -0.01 (-0.01, 0.00) -0.01 (-0.01, 0.00) 
Hypertensive -0.27 (-0.39, -0.15) 0.15 (-0.01, 0.31) 0.13 (-0.04, 0.31) 
Cholesterol -0.23 (-0.29, -0.17) -0.09 (-0.17, -0.01) -0.05 (-0.14, 0.03) 
HbA1c 0.07 (0.03, 0.11) 0.02 (-0.03, 0.08) 0.01 (-0.05, 0.07) 
Interventions 
Quality of care, reference group: Low   
Mid  -0.31 (-0.45, -0.16) -0.16 (-0.35, 0.04) -0.18 (-0.41, 0.05) 
High -0.40 (-0.56, -0.24) -0.02 (-0.24, 0.19) 0.18 (-0.06, 0.43) 
Diabetes treatment, reference group diet alone 
Metformin or sulphonylureas only -0.28 (-0.43, -0.14) -0.18 (-0.38, 0.02) -0.05 (-0.31, 0.21) 
Combination, with no insulin -0.40 (-0.59, -0.21) -0.29 (-0.55, -0.04) -0.11 (-0.43, 0.20) 
Insulin only 0.12 (-0.13, 0.36) -0.08 (-0.39, 0.22) 0.33 (0.00, 0.67) 
Combination with insulin -0.31 (-0.60, -0.03) -0.28 (-0.66, 0.08) 0.33 (-0.04, 0.72) 
BP treatment, reference group: no treatment 
ACE inhibitors only 0.26 (0.01, 0.52) 0.30 (0.00, 0.59) 0.47 (0.15, 0.80) 
Combination, with ACEI  1.50 (1.31, 1.70) 0.16 (-0.08, 0.40) 0.42 (0.15, 0.70) 
Combination, no ACEI 1.24 (1.05, 1.44) 0.18 (-0.05, 0.42) 0.37 (0.09, 0.66) 
Aspirin 1.37 (1.26, 1.49) 1.06 (0.89, 1.23) 0.58 (0.40, 0.76) 
Lipid therapy 0.61 (0.47, 0.74) 0.09 (-0.09, 0.27) 0.10 (-0.10, 0.30) 
Shared care 0.28 (0.12, 0.43) 0.44 (0.24, 0.64) 0.84 (0.62, 1.06) 
Middlesbrough PCT -0.18 (-0.40, 0.04) -0.04 (-0.35, 0.26) -0.16 (-0.59, 0.27) 
Visit year, reference group: 2000  
2001 -0.29 (-0.59, 0.00) 0.21 (-0.17, 0.60) -0.23 (-0.65, 0.19) 
2002 -0.31 (-0.58, -0.03) 0.03 (-0.33, 0.40) -0.24 (-0.63, 0.13) 
2003 -0.4 (-0.66, -0.13) 0.13 (-0.22, 0.49) 0.03 (-0.33, 0.39) 
2004 -0.67 (-0.94, -0.40) 0.02 (-0.33, 0.38) -0.01 (-0.37, 0.35) 
2005 -1.25 (-1.52, -0.97) -0.21 (-0.57, 0.17) -0.31 (-0.69, 0.08) 
2006 -1.68 (-1.97, -1.38) -0.82 (-1.22, -0.42) -0.79 (-1.21, -0.38) 
2007 -1.82 (-2.12, -1.52) -0.72 (-1.13, -0.32) -1.14 (-1.60, -0.68) 
Interactions 
Middlesbrough PCT, reference group: Low SES & Middlesbrough PCT 
Mid SES*Middlesbrough PCT 0.06 (-0.27, 0.37) -0.13 (-0.57, 0.31) 0.20 (-0.28, 0.69) 
High SES*Middlesbrough PCT -0.09 (-0.37, 0.18) -0.19 (-0.56, 0.20) -0.24 (-0.68, 0.21) 
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Cons -4.01 (-5.55, -2.83) -5.04 (-6.14, -3.87) -5.99 (-7.20, -4.80) 
Variance estimate at: 
Practice level 0.05 (0.02, 0.11) 0.11 (0.04, 0.21) 0.28 (0.14, 0.49) 
Patient level 2.27 (0.55, 7.71) 1.33 (0.34, 4.54) 1.43 (0.34, 4.88) 
Bayesian DIC 9198.19 6135.54 5023.20 
 
 
Table 38: Saturated logistic regression multilevel models examining microalbuminuria and 
retinopathy rates with interaction effect between SES and PCT by 1999 to 2007, conditional on 
relevant explanatory variables 
 Microalbuminuria Retinopathy 
Social-economic status, reference group: low 
Mid -0.18 (-0.29, -0.07) -0.04 (-0.17, 0.10) 
High -0.18 (-0.30, -0.06) 0.00 (-0.16, 0.15) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years 0.01 (-0.06, 0.09) 0.01 (-0.10, 0.12) 
Age: 75+ years 0.38 (0.28, 0.47) -0.10 (-0.24, 0.04) 
Duration of diabetes, reference group: 0-3 years  
Duration: 4-9 years -0.01 (-0.09, 0.06) 0.47 (0.34, 0.59) 
Duration 10+ years 0.18 (0.09, 0.27) 1.60 (1.47, 1.73) 
Ethnicity, reference group: White 
South Asian  0.21 (0.05, 0.38) -0.15 (-0.39, 0.08) 
Other Ethnicity 0.30 (-0.07, 0.67) 0.52 (0.08, 0.94) 
Male 0.24 (0.18, 0.31) 0.25 (0.16, 0.34) 
Smoking status, reference: non-smoker 
Smoker 0.27 (0.18, 0.36) -0.13 (-0.27, 0.00) 
Ex-smoker 0.07 (0.00, 0.14) -0.12 (-0.22, -0.02) 
Obesity category, reference group: under and normal weight 
Overweight -0.01 (-0.10, 0.09) -0.09 (-0.22, 0.04) 
Obese 0.06 (-0.03, 0.16) -0.10 (-0.23, 0.03) 
eGFR  -0.01 (-0.01, -0.01) 
Hypertensive 0.18 (0.11, 0.24) 0.34 (0.25, 0.42) 
Cholesterol 0.03 (0.00, 0.06) -0.01 (-0.05, 0.03) 
HbA1c 0.09 (0.06, 0.11) 0.05 (0.02, 0.08) 
Interventions 
Quality of care, reference group: Low  
Mid  -0.08 (-0.46, 0.28) 0.85 (-0.79, 2.37) 
High -0.20 (-0.58, 0.17) 0.78 (-0.86, 2.32) 
Diabetes treatment, reference group diet alone  
Metformin or sulphonylureas only 0.14 (0.05, 0.24) 0.40 (0.24, 0.56) 
Combination, with no insulin 0.02 (-0.09, 0.14) 0.70 (0.52, 0.87) 
Insulin only 0.18 (0.04, 0.32) 1.04 (0.85, 1.23) 
Combination with insulin 0.21 (0.11, 0.30) 1.16 (0.96, 1.36) 
BP treatments, reference group: No BP treatment 
ACE Inhibitors only 0.37 (0.26, 0.48) 0.31 (0.16, 0.46) 
Combination with ACI 0.53 (0.44, 0.62) 0.22 (0.09, 0.35) 
Combination no ACEI 0.32 (0.23, 0.41) 0.13 (-0.01, 0.26) 
Aspirin 0.08 (0.01, 0.14) 0.05 (-0.03, 0.15) 
Lipid therapy -0.05 (-0.12, 0.02) -0.06 (-0.16, 0.03) 
Shared care -0.93 (-1.02, -0.84) 0.53 (0.43, 0.64) 
Middlesbrough PCT 0.51 (0.21, 0.81) 0.01 (-0.19, 0.21) 
Visit year, reference group: 1999 
2000 -0.40 (-0.73, -0.07) 0.03 (-0.27, 0.34) 
2001 -0.61 (-0.92, -0.29) 0.00 (-0.30, 0.30) 
2002 -0.84 (-1.15, -0.53) 0.02 (-0.27, 0.32) 
2003 -0.73 (-1.03, -0.44) -0.09 (-0.39, 0.21) 
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2004 0.02 (-0.27, 0.32) 0.09 (-0.20, 0.39) 
2005 0.21 (-0.08, 0.51) 0.36 (0.05, 0.67) 
2006 0.58 (0.29, 0.88) -0.67 (-0.98, -0.36) 
2007 0.27 (-0.15, 0.69) 0.39 (0.08, 0.69) 
Interactions 
Middlesbrough PCT, reference group: Low SES & Middlesbrough PCT 
Mid SES*Middlesbrough PCT 0.20 (0.03, 0.37) -0.08 (-0.33, 0.16) 
High SES*Middlesbrough PCT 0.14 (-0.01, 0.30) -0.13 (-0.35, 0.08) 
Cons -3.25 (-3.80, -2.71) -3.91 (-5.48, -2.26) 
Variance estimate at: 
Practice level 0.21 (0.13, 0.34) 0.05 (0.03, 0.10) 
Patient level 0.01 (0.00, 0.03) 0.00 (0.00, 0.02) 
Bayesian DIC 25465.93 14530.17 
 
 
Principle findings 
 
Overall, the findings from this chapter suggest that in most circumstances there were no 
differential association between type 2 diabetes interventions and health outcomes by SES. As 
such, little or no evidence of intervention generated inequalities. However, there were 
exceptions to this. Receiving high quality of care was found to be associated with higher levels of 
HbA1c but lower incidences of PVD for high SES patients compared to low SES patients. High 
quality of care was also found to be associated with higher incidences of ICD for mid SES 
patients compared to low SES patients. There was evidence suggesting being prescribed insulin 
only was associated with better health outcomes in terms of HbA1c and retinopathy but poorer 
rates of microalbuminuria for with higher SES patients than low SES patients. In addition, being 
prescribed insulin in combination with other diabetes treatments was associated with lower 
levels of HbA1c and ICD for high SES patients than low SES patients. There were a number of 
significant interactions between BP treatment regimens and SES, with association in lower rates 
of ICD and stroke or TIA but higher rates for PVD and retinopathy for mid and high SES patients 
than low SES patients. The results suggest that aspirin and lipid therapies are associated with 
lower cholesterol levels for higher SES patients than low SES patients. Interestingly, for high SES 
patients shared care was associated with lower HbA1c levels but lower incidences of stroke or 
TIA than low SES patients. PCT had significant differential impact on cholesterol and ICD rates; 
with contrasting relationships. From the limited conducted analyses in this chapter there 
appears to be no differential impact on long-term complications associated with timeliness of 
diagnosis by SES. 
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Chapter 9: What impact do general practices have on inequalities by 
socio-economic status in diabetes care and health outcomes? 
 
In the preceding results chapters, inequalities by SES have been examined in the intermediate 
and long-term health complications of type 2 diabetes, as well as the uptake and impact of type 
2 diabetes interventions. This chapter examines the impact of general practices on inequalities 
by SES in terms of level of deprivation of the practice population, practice list size, diabetes 
prevalence and QOF diabetes indicators. In addition, the level of variation at general practice 
level when analysing socio-economic inequalities in the health outcomes and interventions in 
the MLM in the preceding chapters. This was because the large variations between the general 
practices could imply that the general practice at which patients are registered have an 
important influence on their health and care aside from the individual care they receive.  
 
Multilevel analyses 
 
Table 39 shows the results from the saturated linear regression multilevel models for HbA1c 
and cholesterol with general practice data and interaction effects between SES and visit year. 
There were 22,056 and 22,135 available cases for HbA1c and cholesterol, respectively. 
 
Table 39: Saturated linear regression multilevel models examining HbA1c and cholesterol by 
SES from 1999 to 2007, with general practice data and interaction effects between SES and visit 
year, conditional on explanatory variables 
 HbA1c Cholesterol 
Social-economic status, reference group: Low SES 
Medium SES -0.04 (-0.13, 0.06) 0.01 (-0.06, 0.09) 
High SES -0.07 (-0.16, 0.02) -0.02 (-0.09, 0.05) 
Visit year, reference group: 2004 
2005 -0.03 (-0.12, 0.05) -0.10 (-0.16, -0.03) 
2006 -0.40 (-0.50, -0.31) -0.10 (-0.18, -0.03) 
2007 -0.33 (-0.44, -0.22) -0.17 (-0.25, -0.08) 
SES x Visit year, reference group: Low SES x 2004 
Medium SES x 2005 -0.02 (-0.15, 0.11) -0.03 (-0.14, 0.08) 
Medium SES x 2006 0.00 (-0.13, 0.12) 0.07 (-0.03, 0.17) 
Medium SES x 2007 0.04 (-0.10, 0.16) 0.02 (-0.09, 0.13) 
High SES x 2005 -0.07 (-0.19, 0.05) -0.01 (-0.11, 0.09) 
High SES x 2006 -0.02 (-0.13, 0.10) 0.07 (-0.02, 0.16) 
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High SES x 2007 -0.03 (-0.15, 0.08) 0.00 (-0.10, 0.09) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years -0.36 (-0.40, -0.31) -0.21 (-0.24, -0.17) 
Age: 75+ years -0.40 (-0.46, -0.35) -0.26 (-0.30, -0.22) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years 0.03 (-0.02, 0.07) -0.14 (-0.17, -0.11) 
Duration 10+ years 0.03 (-0.02, 0.08) -0.22 (-0.26, -0.18) 
Ethnicity, reference group: White 
South Asian 0.46 (0.37, 0.55) -0.05 (-0.12, 0.03) 
Other Ethnicity 0.33 (0.13, 0.52) 0.13 (-0.03, 0.28) 
Male -0.02 (-0.06, 0.02) -0.31 (-0.34, -0.28) 
Smoking status, reference group: Non smoker 
Smoker 0.23 (0.17, 0.28) 0.11 (0.06, 0.15) 
Ex-smoker 0.03 (-0.01, 0.07) 0.01 (-0.02, 0.04) 
BMI status, reference group: Low & normal weight 
Overweight -0.01 (-0.06, 0.05) 0.02 (-0.02, 0.07) 
Obese 0.06 (0.01, 0.12) 0.01 (-0.03, 0.05) 
Creatinine > 300 -0.78 (-1.08, -0.49)  
Hypertensive 0.12 (0.08, 0.16) 0.15 (0.12, 0.18) 
Ischaemic Cardiac 0.01 (-0.03, 0.05) -0.12 (-0.15, -0.08) 
Stroke or TIA -0.08 (-0.13, -0.02) -0.03 (-0.07, 0.02) 
PVD -0.05 (-0.12, 0.01) 0.00 (-0.05, 0.05) 
Interventions, Patient level 
Quality of Care level, reference group: Low quality 
Medium quality -0.17 (-0.21, -0.12) -0.14 (-0.18, -0.10) 
High quality -0.21 (-0.27, -0.16) -0.24 (-0.28, -0.19) 
Diabetes treatment, reference group diet alone 
Metformin or sulphonylureas only 0.74 (0.69, 0.79)  
Combination, no insulin 1.14 (1.09, 1.20)  
Insulin only 1.64 (1.56, 1.72)  
Combination with insulin 1.74 (1.67, 1.82)  
Aspirin  -0.08 (-0.11, -0.05) 
Lipid therapy(s)  -0.37 (-0.40, -0.33) 
Shared care 0.07 (0.02, 0.12) -0.07 (-0.10, -0.03) 
Middlesbrough PCT 0.08 (-0.04, 0.21) -0.04 (-0.11, 0.03) 
Interventions, Practice level  
Practice deprivation, reference group: High 
Mid 0.12 (0.00, 0.24) 0.02 (-0.05, 0.09) 
Low 0.15 (-0.05, 0.36) 0.13 (0.02, 0.24) 
Practice list size, reference: <7,000 
7,000 – 9,999 0.07 (-0.03, 0.18) 0.00 (-0.07, 0.06) 
≥10,000 0.06 (-0.08, 0.21) 0.00 (-0.08, 0.09) 
Diabetes prevalence -0.09 (-0.18, 0.00) 0.01 (-0.04, 0.07) 
BMI recording level 0.00 (-0.01, 0.01) 0.00 (-0.01, 0.01) 
HbA1c ≤ 10% -0.02 (-0.03, -0.01) -0.01 (-0.02, 0.00) 
Peripheral pulses recording level 0.00 (-0.01, 0.01) 0.00 (-0.01, 0.01) 
Neuropathy test recording test 0.00 (-0.01, 0.01) 0.00 (-0.01, 0.00) 
BP recording level 0.00 (-0.02, 0.02) -0.01 (-0.02, 0.01) 
BP ≤ 145/85 (mmHg) level (%) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 
Microalbuminuria recording level 0.00 (0.00, 0.01) 0.00 (0.00, 0.00) 
Proteinuria/microalbuminuria treated with ACEI level 0.00 (0.00, 0.01) 0.00 (0.00, 0.00) 
Cholesterol recording level 0.03 (0.01, 0.04) 0.03 (0.02, 0.04) 
Cholesterol ≤ 5mmol/l (%) -0.01 (-0.02, 0.00) -0.02 (-0.02, -0.01) 
Influenza immunisation level 0.00 (-0.01, 0.00) 0.00 (-0.01, 0.00) 
Cons 6.79 (5.91, 7.66) 5.45 (4.80, 6.10) 
Variance estimate at: 
Practice level 0.02 (0.01, 0.04) 0.01 (0.00, 0.01) 
Patient level 0.01 (0.00, 0.05) 0.01 (0.00, 0.04) 
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Visit year 1.67 (1.64, 1.70) 1.11 (1.09, 1.13) 
Bayesian DIC 73120.25 65260.66 
Available cases (N) 22,056 22,135 
 
The results in Table 39 show that there no significant differences in HbA1c and cholesterol, both 
overall and over time. These results were consistent across each step of the analyses for the 
cholesterol model. When HbA1c was modelled with the SES and visit year interaction only there 
were significant differences with higher SES associated with lower levels, however, this finding 
was not significant once socio-demographic, anthropometric, lifestyle and health status data 
were introduced into the model. As such, the results here suggest that general practices were 
not associated with differences by SES in terms of intermediate outcomes. However, there were 
statistically significant results suggesting that differences in general practice patients’ health 
outcomes. As expected, the results indicated that general practices with patient level 
characteristics were associated with higher numbers of patients meeting care targets for HbA1c 
and cholesterol which were significantly associated with lower levels at the individual level. In 
contrast, however, higher cholesterol recording levels was significantly associated with higher 
levels in both outcomes. No other general practice indicator was statistically significant. 
However, this data did explain more of the variation in both models as measured by the 
Bayesian DIC statistics. 
 
Table 40: Saturated linear regression multilevel models examining HbA1c and cholesterol by 
SES from 1999 to 2007, with general practice data and interaction effects between SES and visit 
year, conditional on explanatory variables  
 HbA1c Cholesterol 
Social-economic status, reference group: Low SES 
Medium SES -0.04 (-0.13, 0.06) 0.01 (-0.06, 0.09) 
High SES -0.07 (-0.16, 0.02) -0.02 (-0.09, 0.05) 
Visit year, reference group: 2004 
2005 -0.03 (-0.12, 0.05) -0.10 (-0.16, -0.03) 
2006 -0.40 (-0.50, -0.31) -0.10 (-0.18, -0.03) 
2007 -0.33 (-0.44, -0.22) -0.17 (-0.25, -0.08) 
SES x Visit year, reference group: Low SES x 2004 
Medium SES x 2005 -0.02 (-0.15, 0.11) -0.03 (-0.14, 0.08) 
Medium SES x 2006 0.00 (-0.13, 0.12) 0.07 (-0.03, 0.17) 
Medium SES x 2007 0.04 (-0.10, 0.16) 0.02 (-0.09, 0.13) 
High SES x 2005 -0.07 (-0.19, 0.05) -0.01 (-0.11, 0.09) 
High SES x 2006 -0.02 (-0.13, 0.10) 0.07 (-0.02, 0.16) 
High SES x 2007 -0.03 (-0.15, 0.08) 0.00 (-0.10, 0.09) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years -0.36 (-0.40, -0.31) -0.21 (-0.24, -0.17) 
Age: 75+ years -0.40 (-0.46, -0.35) -0.26 (-0.30, -0.22) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years 0.03 (-0.02, 0.07) -0.14 (-0.17, -0.11) 
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Duration 10+ years 0.03 (-0.02, 0.08) -0.22 (-0.26, -0.18) 
Ethnicity, reference group: White 
South Asian 0.46 (0.37, 0.55) -0.05 (-0.12, 0.03) 
Other Ethnicity 0.33 (0.13, 0.52) 0.13 (-0.03, 0.28) 
Male -0.02 (-0.06, 0.02) -0.31 (-0.34, -0.28) 
Smoking status, reference group: Non smoker 
Smoker 0.23 (0.17, 0.28) 0.11 (0.06, 0.15) 
Ex-smoker 0.03 (-0.01, 0.07) 0.01 (-0.02, 0.04) 
BMI status, reference group: Low & normal weight 
Overweight -0.01 (-0.06, 0.05) 0.02 (-0.02, 0.07) 
Obese 0.06 (0.01, 0.12) 0.01 (-0.03, 0.05) 
Creatinine > 300 -0.78 (-1.08, -0.49)  
Hypertensive 0.12 (0.08, 0.16) 0.15 (0.12, 0.18) 
Ischaemic Cardiac 0.01 (-0.03, 0.05) -0.12 (-0.15, -0.08) 
Stroke or TIA -0.08 (-0.13, -0.02) -0.03 (-0.07, 0.02) 
PVD -0.05 (-0.12, 0.01) 0.00 (-0.05, 0.05) 
Interventions, Patient level 
Quality of Care level, reference group: Low quality 
Medium quality -0.17 (-0.21, -0.12) -0.14 (-0.18, -0.10) 
High quality -0.21 (-0.27, -0.16) -0.24 (-0.28, -0.19) 
Diabetes treatment, reference group diet alone 
Metformin or sulphonylureas only 0.74 (0.69, 0.79)  
Combination, no insulin 1.14 (1.09, 1.20)  
Insulin only 1.64 (1.56, 1.72)  
Combination with insulin 1.74 (1.67, 1.82)  
Aspirin  -0.08 (-0.11, -0.05) 
Lipid therapy(s)  -0.37 (-0.40, -0.33) 
Shared care 0.07 (0.02, 0.12) -0.07 (-0.10, -0.03) 
Middlesbrough PCT 0.08 (-0.04, 0.21) -0.04 (-0.11, 0.03) 
Interventions, Practice level  
Practice deprivation, reference group: High 
Mid 0.12 (0.00, 0.24) 0.02 (-0.05, 0.09) 
Low 0.15 (-0.05, 0.36) 0.13 (0.02, 0.24) 
Practice list size, reference: <7,000 
7,000 – 9,999 0.07 (-0.03, 0.18) 0.00 (-0.07, 0.06) 
≥10,000 0.06 (-0.08, 0.21) 0.00 (-0.08, 0.09) 
Diabetes prevalence -0.09 (-0.18, 0.00) 0.01 (-0.04, 0.07) 
BMI recording level 0.00 (-0.01, 0.01) 0.00 (-0.01, 0.01) 
HbA1c ≤ 10% -0.02 (-0.03, -0.01) -0.01 (-0.02, 0.00) 
Peripheral pulses recording level 0.00 (-0.01, 0.01) 0.00 (-0.01, 0.01) 
Neuropathy test recording test 0.00 (-0.01, 0.01) 0.00 (-0.01, 0.00) 
BP recording level 0.00 (-0.02, 0.02) -0.01 (-0.02, 0.01) 
BP ≤ 145/85 (mmHg) level (%) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 
Microalbuminuria recording level 0.00 (0.00, 0.01) 0.00 (0.00, 0.00) 
Proteinuria/microalbuminuria treated with ACEI level 0.00 (0.00, 0.01) 0.00 (0.00, 0.00) 
Cholesterol recording level 0.03 (0.01, 0.04) 0.03 (0.02, 0.04) 
Cholesterol ≤ 5mmol/l (%) -0.01 (-0.02, 0.00) -0.02 (-0.02, -0.01) 
Influenza immunisation level 0.00 (-0.01, 0.00) 0.00 (-0.01, 0.00) 
Cons 6.79 (5.91, 7.66) 5.45 (4.80, 6.10) 
Variance estimate at: 
Practice level 0.02 (0.01, 0.04) 0.01 (0.00, 0.01) 
Patient level 0.01 (0.00, 0.05) 0.01 (0.00, 0.04) 
Visit year 1.67 (1.64, 1.70) 1.11 (1.09, 1.13) 
Bayesian DIC 73120.25 65260.66 
Available cases (N) 22,056 22,135 
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Practice level variation 
 
This section reviews the intra class correlation coefficient (ICC) at practice level of the null 
multilevel models fitted for the research questions in the current and preceding results 
chapters. to establish the importance of patients’ general practice on their health outcomes and 
care. These were summarised in Table 41.  
Overall, the variance estimates and ICC results revealed that only a limited amount of the 
variance occurred at the general practice level. The vast majority of the multilevel models 
exhibited approximately 3% of variance or less of between practices. This potentially negates 
the need for multilevel analyses for many of these models. However, there were some notable 
exceptions. The modelling of intervention data as the outcome variable resulted in some cases 
where about 5% occurred between general practices. This was namely with diabetes being 
treated by diet alone (4.62%) and the most marked, receiving shared care (19.31%). This 
suggests that the practice a patient was registered with has some influence on the receipt of 
these interventions, particularly with shared care. 
When modelling health outcomes, there was about 2%  or less of the variance in intermediate 
outcomes and long term complications was accounted for at the general practice level. This 
suggests that differences in patients’ health were explained by other factors and not the practice 
they were registered with. 
 
Table 41: Intra class correlation coefficient results from the multilevel analyses ordered by 
research question and outcome variable 
  Practice level Patient level Visit year 
Are there socio-economic inequalities in intermediate outcomes and complications associated with type 
2 diabetes over time? (Chapter 6) 
Intermediate health 
outcomes 
Hba1c 0.04 0.01 99.95 
Cholesterol 0.01 0.00 99.99 
Long-term 
complications 
ICD 0.02 64.40 35.59 
Stroke or TIA 0.21 31.43 68.36 
PVD 1.58 21.54 76.88 
Micro-albuminuria 1.58 0.07 98.34 
Retinopathy 0.15 0.97 98.88 
Are there socio-economic inequalities in interventions associated with type 2 diabetes over time? 
(Chapter 7) 
 Timeliness of diagnosis 0.14 76.06 23.84 
 Quality of care 0.51 0.00 99.97 
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Diabetes treatments Diet alone 4.62 0.35 95.03 
Metformin or sulphonylureas 0.15 0.25 99.61 
Combination, no insulin 0.19 0.00 99.81 
Insulin only 0.68 0.19 99.13 
Combination with insulin 0.19 0.08 99.73 
BP treatments No BP treatments 0.25 0.00 99.75 
ACEI only 0.37 0.00 99.63 
ACEI combination 0.05 0.00 99.95 
Other combination 0.08 0.00 99.92 
Antithrombotic & lipid 
profile treatments 
Lipid therapies 0.37 0.00 99.63 
Aspirin 0.19 0.00 99.80 
 Shared care 19.31 0.48 80.21 
Are there intervention-generated inequalities in type 2 diabetes care? (Chapter 8) 
 HbA1c 0.04 0.01 99.95 
Cholesterol 0.01 0.00 99.99 
ICD 0.02 64.40 35.59 
Stroke or TIA 0.21 31.43 68.36 
PVD 2.03 18.67 79.31 
Microalbuminuria 1.58 0.07 98.34 
Retinopathy 0.15 0.97 98.98 
Timeliness of diagnosis Retinopathy  0.43 0.59 98.98 
Microalbuminuria 6.04 0.05 93.91 
What impact do general practices have on inequalities by socio-economic status in diabetes care and 
health outcomes? (Chapter 9) 
 HbA1c 0.01 0.00 99.98 
 Cholesterol 0.01 0.01 99.98 
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Principle findings 
 
The analyses conducted here and in previous chapters, suggest that where a patient was 
registered for their primary care has little association with their health outcomes and 
interventions they receive. However, shared care was a notable exception with varied between 
practices.  
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Chapter 10: Discussion 
 
This chapter discusses the results from the secondary data analyses outlined in the preceding 
five chapters, drawing upon the findings from the systematic review. Firstly, the principle 
findings are summarised by research question. This was followed by a discussion the strengths 
and limitations of the study. Next, the meaning of the study and implications for practitioners 
and policy makers were discussed, including what contribution this study has made to the 
understanding of intervention generated inequalities. Finally, unanswered questions and future 
research were identified. 
 
Summary of results 
 
Are there socio-economic inequalities in intermediate outcomes and complications 
associated with type 2 diabetes over time? 
 
The multilevel analyses in chapter six found some, but inconsistent evidence of SES inequalities 
in intermediate outcomes. High SES patients were more likely to have lower HbA1c over time, 
but higher levels of cholesterol compared to low SES patients. In contrast, there were few 
differences in long-term complications by SES and no evidence of differences SES over time. 
However, in 2003 mid SES patients were more likely to have higher rates of ICD than low SES 
patients in 1999.  
 
Are there socio-economic inequalities in interventions associated with type 2 diabetes 
over time? 
 
In comparison to low SES patients in 1999, there was some evidence to suggest that mid SES 
patients received a more timely diagnosis, have their diabetes managed through diet alone and 
were less likely to be prescribed a monotherapy of metformin or sulphonlureas over time. Also, 
high SES patients were more likely to receive higher quality of care and shared care than low 
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SES patients in 1999. In addition, high SES patients were also more likely to be prescribed a 
monotherapy of metformin or sulphonylureas, insulin only and in combination with another 
diabetes treatment, any BP treatment and a combination of BP treatments with no ACEI than 
low SES patients in 1999.  
 
Are there intervention-generated inequalities in type 2 diabetes care? 
 
The majority of the interaction results presented in chapter eight indicated that in most 
circumstances there were no differential association between type 2 diabetes interventions and 
health outcomes by SES. There were some exceptions indicating that there were intervention-
generated inequalities in type 2 diabetes care as the association between interventions and 
health outcomes differed by SES.  
High quality of care was associated with higher HbA1c level but lower incidences of PVD for 
high SES patients and higher incidences of ICD for mid SES patients compared to low SES 
patients receiving the same care. Prescriptions for the same treatments were associated with 
differences in health outcomes by SES. Prescriptions for insulin only were associated with lower 
HbA1c and retinopathy but with higher rates of microalbuminuria for high SES patients 
compared to low SES patients. Prescriptions for insulin in combination with other diabetes 
treatments were associated with lower HbA1c and lower incidences of ICD for high SES patients 
compared to low SES patients. BP treatments were associated with lower incidences of ICD and 
stroke or TIA and higher rates of PVD and retinopathy for mid and high SES patients compared 
to low SES patients. Aspirin and lipid therapies were associated with lower cholesterol levels for 
high SES patients than low SES patients. Finally, receiving shared care was associated with 
lower HbA1c levels but higher incidences of stroke or TIA for high SES patients than low SES 
patients. PCT had significant differential association with cholesterol and ICD incidences; with 
contrasting relationships.  
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What impact do general practices have on inequalities by socio-economic status in 
diabetes care and health outcomes? 
 
The results in chapter nine and the review of the analyses conducted in the preceding chapters 
indicated that characteristics of general practices in the South Tees area, which were included in 
the analyses, have no association with socio-economic inequalities in intermediate outcomes. In 
addition, the ICC results indicated that for patients in South Tees the choice of general practice 
at which they registered with had limited association in the variation in patients with health 
outcomes and diabetes care. However, notable proportion of the variation in receiving shared 
care was explained at the practice level.  
 
Principle findings 
 
In most of the models featured in analyses in this thesis visit year was a statistically significant 
explanatory variable. The multilevel models, also supported by the graphical analyses, showed 
that quality of care, levels of HbA1c, cholesterol and ICD had improved over the study period. 
This could be partly attributed to policy level interventions such as the NSF Diabetes Strategy 
introduced in 2001 [200] and NICE clinical guidelines [46] introduced in 2002. However, the 
trend appears to have started prior to the publication of these policies therefore other factors 
are likely to be more important. For example, not surprisingly treatments were also associated 
with these health outcomes with statistical significance. The results in chapter seven showed 
statistically significant changes in all treatments over time. These may explain the 
improvements in health over time. However, it is unclear from these analyses whether 
treatments have driven the improvements or that there is an increase need for these 
treatments, that is patients health is deteriorating more over the study period.  
One of the key findings from these analyses was the statistically significance differences in 
receiving no diabetes treatments over time by SES. The graphical analyses suggests that 
proportion of high SES patients receiving no diabetes treatments remain similar over time, 
there was a steady reduction to the proportion of low SES managing their diabetes through 
lifestyle changes alone. The stepwise models in appendix G shows the by including many of the 
explanatory variables mediates this relationship. However, there were still some statistically 
significant differences between medium and low SES patients. This potentially suggests that 
continued inequalities in type 2 diabetes patients health by SES may be generated by factors 
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that cannot be directly addressed by healthcare interventions alone. For example, health related 
behaviours, such as smoking, alcohol consumption, diet, and exercise, which have been shown 
to vary by area deprivation [201].  
However, there was some evidence where diabetes care could be improved to reduce the 
differences in the receipt of care and the health outcomes they are associated with. Namely, 
quality of care and shared care. Both the graphical analyses and multilevel models indicated 
that whilst quality has in general improved overtime, patients from more advantaged 
backgrounds receive greater quality of care.  The graphical analyses showed that the proportion 
of patients receiving shared care have decreased over time. This is likely to be explained partly 
by the governments drive to have more chronic conditions managed in primary care [58]. In 
addition, the capacity to managed patients in the hospital based diabetes clinic has remained 
steady over the study period [202], as such the reduction to the proportion of patients receiving 
such care is likely to be the increase in the number of diagnosed patients. In contrast to 
graphical analyses, the multilevel model showed when conditional on other factors high SES 
were more likely to receive shared care. This suggests access to a limited, specialist resource 
was not solely determined by patient need.  
In addition, there statistical significant findings which indicated that when patients were 
receiving the same level of quality of care and shared care there were instances of differential 
health outcomes. However, the direction of these relationships need to be explored further.  
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Strengths and limitations of the study 
 
The major strength of this study was being able to investigate a wide range of aspects of the 
type 2 diabetes care pathway, from diagnosis to secondary and tertiary preventions, in the same 
population over a long period. Comparisons with QOF prevalence showed that patients with 
type 2 diabetes captured through the diabetes register were approximately at the expected level 
for practices in the South Tees area (see Appendix J). This was important as it has been 
hypothesised that intervention generated inequalities could be introduced at any stage of the 
intervention pathway [1, 27]. In doing so, this study was able to contribute to the existing 
evidence base which lacked analyses of data with repeat measurements and investigation into 
inequalities associated with particular interventions, namely: timeliness of diagnosis, quality of 
care and place of care.  
The statistical techniques used for the secondary data analyses were also a particular strength 
of this study. By using multilevel regression techniques these analyses were able to control for 
and investigate the effect general practices have on the variation of patients’ health outcomes 
and diabetes care. Whilst in the most part this analyses was found to unnecessary, this is in 
itself an important finding as it suggests that general practices, or interventions such QOF, 
operating at this level have limited impact and it appear to be the individual level factors which 
have the greatest impact on patients’ health and the interventions they receive. However, these 
findings need to be supported by further investigation both outside South Tees and within as 
the impact of general practice on patients’ health and care may only be the case with type 2 
diabetes. Using interaction effects between SES and time, these analyses were also able to 
investigate trends over time in health outcomes and diabetes care, which were also lacking from 
the evidence base. There are many other more sophisticated techniques, such as time-lag and 
autoregressive using random coefficient multilevel models, which could have been employed. 
However, the choice of which technique is generally always taken on practical grounds rather 
than what is the most ideal, with the former approach taken for this thesis. It was not possible to 
use the more complex techniques due to the quality of the data available and the analyses failing 
to provide robust results. However, as with all such longitudinal analyses examining change 
there are problems with interpretation and, therefore, it is recommended that multiple sets of 
analyses using different techniques should be conducted in order to validate about the findings 
[194]. 
Like all secondary data analysis the quality and availability of the data limits the possibility of 
the study. As mentioned previously the completeness of the data and recording errors meant 
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that the quality of the data for multilevel modeling was poor. Whilst the robustness of the 
results was improved by using MCMC, a compromise was made regarding how much the 
analyses could have been strengthened against how much time was available. The results could 
have benefitted from using a greater number of iterations, however, because running each 
model took several hours this process was limited to ensure that as many relevant stepwise 
models as possible could be included in the final set of analyses. In addition, preliminary 
analyses indicated that missing data was significantly related to SES. As such, by using available 
cases only may bias the results as records with missing data may be patients who are 
consistently in worse health. For example, patients who do not engage on an annual basis with 
services, or at all, may also have worse health as such these results and may not to be a robust 
reflection of all type 2 diabetes patients.  
As highlighted by the Bayesian DIC diagnostic statistics, another problematic feature of this 
study was the amount of unexplained variance in the multilevel models. This indicates there 
was a lot of information that was not accounted for in the models that could have potentially 
explained the variation in the outcomes. In particular, there were no individual level measures 
of SES. Using IMD data can only operate as a proxy indicator and therefore does not necessarily 
reflect a patients’ individual circumstances. In addition, from the analyses conducted here it was 
not possible to determine whether there was reverse causation of IMD i.e. poor health results in 
increased deprivation rather than the other way around. Individual level measurement of SES 
could potentially overcome this. For example, using education level as this is likely to have been 
established prior to a diagnosis of type 2 diabetes. However, gaining this additional information 
would have been both very costly and time consuming. Such a process could also introduce 
potential bias into the analyses as patient consent would be required. If this is not equitable 
across the study population, and any subsequent analyses may have been biased.  
Another issue regarding the availability data was surrounding comorbidities, which was 
discussed in Chapter 4. Comorbidities is an important area as it can greatly impact on the type 
and quality of care a patient receives and also their ability to cope and manage the level of, and 
potentially competing, health demands [148]. The research proposal submitted to the ethics 
committee had planned to measure comorbidity using HES data. Unfortunately, it was not until 
the latter stages of this study that it was discovered that whilst patient identifiable data, namely 
patient NHS numbers, could not be released to individuals who did not have prior access to 
them and a section 251 exemption having to be applied for. This was required for permission to 
be granted to enable one organisation to pass this data to another organisation. The section 251 
was subsequently applied for and permission was granted. However, steps had to be taken to 
ensure that patients, whose data was to be used, were informed and allowed to dissent from the 
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study. Due to the time constraints that this imposed, as well as the length of time needed for the 
HES data to be extracted, cleaned and formatted, along with the potential bias that dissenting 
patient could introduce, this step had to be abandoned.  
As well as the constraints that gaining access to this data imposed, there was always the risk 
that HES was not an appropriate data source to construct a comorbidity index. This is because it 
predominantly records inpatient data therefore only other health conditions which are 
sufficiently serious enough to result in a hospital admission or referral would be accounted for 
and therefore would miss other important information [153]. Conditions such as depression 
have been shown to have a particular detrimental impact on patients care and ability to cope 
with their condition [203].  Ideally, data from patients general practices would have been used 
to measure comorbidity, however, due to the large amounts of data to be extracted from all 
general practices in the South Tees area, which do not all use the same information systems, this 
would have made this a particularly laborious task. 
As mentioned elsewhere in this thesis, this study was not able include details about patients’ 
treatments such as the dose and delivery system and also whether patients adhered to their 
prescription instructions as these were not captured through the diabetes register proforma. 
The interpretation of the results related to patients’ treatments was therefore limited to their 
access to treatment. In addition, it was not clear from this data who was offered but refused that 
treatment. 
Additional general practice information was the other area of data collection that had been 
planned for in the research proposal. This included practice list size, number of patients with 
type 2 diabetes, staffing levels and skills per year from 1999 to 2007 that was not publically 
available elsewhere. Using a freedom of information request was advised as a method of data 
collection, however, this met with particular animosity from practice managers. This made 
voluntary contributions preferable so as not to alienate practices from taking part in future 
research in relation to this study. As such, practice managers were initially telephoned so that 
the background to the study and the importance of this information could be explained. 
Following that discussion, an agreement was made to send the data extraction form via email to 
either the practice manager or a nominated member of staff. However, whilst follow up calls 
were made, the majority of practices did not respond with the data. Some explained that too 
much staff time would be needed to fulfil this request. Furthermore, of those that did respond, 
there was considerable variation in how much data was returned, for example, with some 
completing the only few a years. Therefore, no data was used to the potential bias of the results. 
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There were also a number of social determinants of health, as outlined by Dahlgren, 1991 [141], 
which have been demonstrated elsewhere to impact upon patients’ health outcomes associated 
with diabetes. For example, other constitutional factors such as birth weight [204], lifestyle such 
as physical activity and dietary behaviours [205-207], social and community networks such as 
(e.g. [208, 209]; living and working conditions including issues such as unemployment and work 
related stress (e.g. [210, 211]), and other general socio-economic, cultural and environmental 
conditions (e.g. [212]). At the other end of the scale, population level policies such as cigarette 
pricing, and Change 4 Life campaign, were not accounted for which could have a differential 
impact on patients health by SES [30].  
In terms of contribution to the understanding of intervention generated inequalities an 
important weakness of the study was the observational nature of the study. Whilst significant 
associations have been found, causation cannot be determined as it was not clear whether the 
associations between health and an intervention by SES were evidence of the inverse care law, 
where care was not provided based on need. Alternatively, the findings indicate that the 
interventions in question have a differential efficacy for patients by SES. In either context, 
inequalities have occurred at some stage of the intervention process and further research is 
required to unpick the particular set of circumstances, to enable this to happen.  The next 
sections draws upon research elsewhere to discuss to the possible circumstances which have 
enabled inequalities to occur at some stage of the intervention process.  
 
Strengths and limitations in relation to other studies 
 
The results from the systematic review in chapter three showed that there were inconsistent 
findings in socio-economic inequalities, as measured by education, employment, income and 
composite measures, in intermediate and long-term complications [92, 95, 113, 114, 116, 118, 
121]. The results presented here have added to this evidence base using repeat measurements 
with interaction effects between SES and time, methods that were not utilised by any of the 
studies in the review.  
In comparison to the existing evidence, the results in chapter six add support to the cross-
sectional analyses conducted in Germany, which found inequalities in HbA1c but not in long-
term complications by SES, occupation and education. The German study did, however, find 
evidence socio-economic inequalities in retinopathy but in only one of the two sources of data 
used in the analyses [108]. The statistical significant inequalities in HbA1c levels by SES in the 
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German study was also not accounted for by differences in age, sex, duration, obesity, diabetes 
medication and physical activity. The results in chapter six showed, with the exception of one 
incidence of socio-economic inequalities in ICD rates, there were no inequalities in long-term 
complications. This was in contrast to the one study, included in the review, which utilised 
longitudinal data to measure time to first CV event for patients in New Zealand. This study used 
a cox proportional hazards model and found significant inequalities by SES [116]. This 
highlights one of the drawbacks of the analyses outlined whereby vascular disease was 
recorded as in the diabetes register as history of vascular disease but it was not clear when this 
event occurred. Another limitation was the relatively low prevalence of long-term 
complications, coupled with the poor recording rates of microalbuminuria and retinopathy, 
which made determining inequalities by SES difficult.  
Only one other study in the systematic review examined patients’ health status at diagnosis and 
found no inequalities by SES [168]. The study from the review and the analyses outlined in this 
thesis both used data collected by a NHS Trust. The contrasting results may be due to the 
outcome variables used being different. Retinopathy develops after prolonged uncontrolled 
HbA1c. The data extraction process for this analysis meant that it included all data during 
patients first year of diagnosis which could arguably be interpreted as an analysis of inequalities 
of HbA1c as a consequence of patients first year of care.  
Three studies in the systematic review examined inequalities in prescriptions of treatments by 
indicator(s) of SES. Two of these studies which focused on diabetes treatments using univariate 
analyses, found no inequalities in being managed by diet alone [92] and prescriptions of 
diabetes medication by SES [108]. In contrast, cross-sectional multiple regression analyses 
conducted in New Zealand found the most deprived patients were significantly less likely to be 
prescribed a combination therapy use, that is, a statin or other lipid lowering medication and an 
ACEI or other anti-hypertensive treatment [101]. The analyses here, therefore, have contributed 
to an under researched area and were able to examine trends over time and importantly 
controlled for patients health status.  
One study in the systematic review examined inequalities by SES across interventions broadly 
categorised as services. The study conducted in Spain found that the average number of 
consultations per year were higher amongst lower status patients [113], something which could 
not being examined here due to the method of data extraction from the register. No other 
studies in the review examined inequalities in quality of care or place of care by SES. 
There were limited comparisons to be made with studies included in the systematic review with 
analyses examining the impact of general practices on inequalities by SES. No other study that 
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met the systematic review criteria used QOF data. This is likely because the QOF diabetes 
domain targets and measures type 1 and type 2 patients together, therefore, it makes sense to 
investigate the impact of this policy intervention on both groups of patients together.  
Two Australian studies used multilevel analyses to adjust for clustering of management 
processes [110] and cardiovascular risk factors [120] at patient, practice and division levels. 
Both studies found that the results were greatly affected by clustering at the practice level. 
These findings contrasts with the results in this chapter but this may be due to the differences in 
the number of practices included in the samples. The Australian study used the same population 
covering 250 practices in 16 Divisions. This study featured patients from 43 different practices. 
Conducting multilevel analyses of a greater number of general practices in England would help 
to establish, with more certainty, the impact of general practices on diabetes care and patients 
outcomes.  
A systematic review examining whether the introduction of QOF has improved the management 
of diabetes in the UK found evidence to suggest that the policy has accelerated improvements 
but it is difficult to distinguish this from other national initiatives [213]. While the analyses 
conducted in chapter nine suggests that there has been an improvement in HbA1c and 
cholesterol since 2004 the limited significant QOF variables suggest that these had not 
contributed to this trend. In addition, the graphical analyses of HbA1c, cholesterol and quality of 
care in chapters five all indicated that trends towards better outcomes started several years 
before QOF was introduced.  
 
Meaning of the study and implications for practitioners and policy makers 
 
Overall, the results from the secondary data analyses in this thesis indicate that patients’ health 
has improved over time. These were likely to reflect the changes in diabetes care, which were 
also evidenced over the same period. However, there were a number of examples where 
inequalities associated with the management of type 2 diabetes where further work may be 
required to improve care for all patient groups.  
Whilst there were socio-economic inequalities in intermediate outcomes, these results are 
potentially reassuring to diabetes practitioners and policy makers are there were no significant 
inequalities in long-term complications over time. However, further analyses should be 
conducted to support and confirm these results as the systematic review, and the wider 
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evidence base, indicates that these findings remain variable. For example, a review of studies 
across Europe over a similar time period found that higher mortality rates in more 
disadvantaged patients as a consequence of type 2 diabetes [44]. The findings from this review 
suggests that patients would have poorer control and long-term complications thereby resulting 
in differences in mortality rates. 
One explanation for the discrepancy between intermediate and long-term complications could 
be survivor bias, with higher mortality rates from long-term complications amongst low SES 
patients. Another study conducted using the South Tees diabetes register found that excess 
mortality was significantly worsen with increase deprivation [159]. This data examined the 5 
year period before the data used here and examined both type 1 and type 2, however, the 
results would support the theory that excess mortality may bias the examination of inequalities 
in long-term complications. Other studies examining both type 1 and type 2, that did not meet 
the systematic review criteria and are not directly comparable, have found evidence of socio-
economic status being associated with increased prevalence of long-term complications [214-
217]. As type 2 diabetes account for the majority of these samples the discrepancy between the 
results is unlikely to be due to the inclusion of type 1 diabetes patients in these analyses.  
One explanation for inequalities in HbA1c level by SES in Germany put forward by the authors 
was that more disadvantaged patients were receiving a level of care inappropriate to their 
needs. The current analyses were able to control for this and the stepwise analyses indicated 
that they diabetes care only partially attenuated inequalities in HbA1c levels. As such, these 
findings could potentially suggest that diabetes care was not delivered equitably in order to 
overcome the inequalities that occur in intermediate outcomes.  
The theory that more disadvantage patients were receiving a level of care inappropriate to their 
needs was evidenced throughout the secondary analyses. The descriptive analyses showed that 
high SES patients had a higher mean number of care process recorded compared to low 
patients, though they were less likely to receive shared care. Interestingly, high SES patients 
were significantly more likely to receive shared care than mid SES patients. These trends were 
also seen over time in the graphical analyses and multilevel analyses where quality of care and 
shared care were included as explanatory variables and where they were modelled as 
dependent variables.  
In terms of explanatory variables, few were statistically significant in the model that had quality 
of care as the dependent variable (Table 13). Though age was significant, it supported the NDA 
findings that younger patients receive poor quality of care. However, patients aged 75 years and 
over were more likely to receive poorer care compared to those aged less than 60 years [218]. 
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The significance of shared care in this model has suggested that patients were likely to receive 
greater quality of care in the secondary care compared to primary care. This may be because 
diabetes specialist practitioners are more responsive of the clinical guidelines and experienced 
at administering the nine recommended care processes compared to general practitioners. It 
could also be due to the use of the diabetes register proforma, and interest in maintaining the 
dataset being higher in the diabetes care centre where the register is hosted. Using a proforma 
may be a successful intervention in itself for improving care [219, 220].  
Contrary to this argument and the inverse care law, which suggests care inversely related to 
patient need [221], shared care may be acting as a proxy indicator of patients who have poorer 
health and therefore needing more specialist care and greater quality of care. That is, the receipt 
of care was based on the complexity of patients’ disease management. The receipt of shared 
care and higher quality of care were significantly associated with prescriptions of diabetes 
treatments regimes. There was also evidence which suggested that interventions during 
patients’ first year of diagnosis were found to mediate inequalities in HbA1c by SES at diagnosis. 
This could indicate that care administered during patients’ first year of diagnosis was, at least, 
administered appropriately. Whilst the relationship with shared care was expected, patients 
with more complex needs are more likely to be referred for specialist care. The relationship 
with quality of care was not expected to occur which could be regarded as appropriate with 
more care being based on greater need. However, without undertaking all care processes, early 
detection of complications could be missed and appropriate action not taken in order to prevent 
or treat the problem.  
In addition, there was also evidence relating to the uptake and health association by SES with 
shared care in chapter eight. These findings showed that shared care was associated with more 
favourable HbA1c and rates of microalbuminuria for high SES patients compared to low SES 
patients. In contrast, mid SES patients were more likely to have microalbuminuria compared to 
low SES patients when both using shared care. Furthermore, there were significant interactions 
between quality of care and SES. The results suggest that high SES had poorer HbA1c and mid 
SES had poorer rates of PVD compared to low SES receiving shared care. This may be because 
higher SES patients only receive increased quality of care when their health deteriorates. It 
could also indicate a potential source of reducing inequalities, that is, by increasing the quality 
of care in low SES patients it could improve their HbA1c and reduce the significant differences, 
compared to high SES who were found to receive higher quality of care and healthier HbA1c 
levels overall and over time.  
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There has been a wide range of research investigating socio-economic inequalities associated 
with specialist services (e.g. [222-224]). The differences in shared care use may be due to lower 
SES patients having more barriers to accessing specialist services, such as transport costs, 
inflexible service delivery and cultural barriers such as language [223]. In addition, high SES 
may be more assertive in requesting specialist care compared to low SES [222]. One study also 
suggested that general practitioners in deprived areas may be generally less likely to refer 
overall rather than more socially disadvantaged patients being less likely to be referred than 
more advantaged patients within the same practice [224]. Yet, the results from chapter seven 
showed that patients in Middlesbrough PCT were more likely to receive shared care and the 
descriptive analyses indicated that practices in this PCT served more deprived populations 
overall compared to Redcar & Cleveland PCT. For this study population the differences in 
referral rates may be related to the diabetes care centre being located in Middlesbrough and 
factors such as travel times becoming a major contributor as more practices in Middlesbrough 
are located in urban places compared to Redcar & Cleveland, which is a much larger, mainly 
rural area. The cultural barriers and high SES patients’ assertiveness may also explain the 
differences in the association with HbA1c levels and shared care by SES as there may be more 
effective communication between these patients and specialists. The contrasting results in the 
interaction effects between PCT with cholesterol level and microalbuminuria by SES are hard to 
explain and require further investigation. However, it suggests that patients interact with 
factors measured at the PCT level differently.  
Patients’ age may also be an important explanatory factor of where there were inequalities in 
the receipt of long-term complications and level of care. In the analysis of the NDA, being 
younger at the onset of diabetes was found to be associated social deprivation and the social 
gradient in type 2 diabetes prevalence was more common in patients aged less than 55 years 
compared to older patients. In addition, younger patients were also more likely to receive 
poorer quality of care [218]. The secondary analyses here supported the NDA findings, with 
older patients significantly more likely to receive share care. The relationship between younger 
patients and care may also be explained by younger patients experiencing greater barriers in 
engaging with health services, such as work demands, compared to older patients who are more 
likely to be of retirement age and may already be more engaged with health services.  
Another important factor was ethnicity. Having a South Asian ethnicity is also a known risk 
factor of type 2 diabetes [176]. The results from these analyses show that being South Asian was 
significantly associated with a poorer HbA1c level at diagnosis. The finding suggesting this 
group, who along with younger patients, were overrepresented in the lower SES groups in this 
study population and were being provide with lower quality of care. The significant relationship 
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between poorer HbA1c at diagnosis and South Asian ethnicity may be a result of ineffective 
communication between patients and providers and differences in cultural values, health 
behaviours and healthcare preferences compared to the white population [225].  These 
explanations were given in the possible mechanisms in the inequalities in diagnostic delays 
found by age, ethnicity and social class in six common cancers. In addition, different levels of 
knowledge of symptoms and access to services were also discussed as possible mechanisms 
[226]. However, in contrast, South Asian patients were significantly more likely to receive 
greater quality of care compared to white patients. In addition, South Asian patients were also 
significantly likely to have both poor and more favourable health outcomes, therefore, these 
explanations are not consistent across all diabetes care.  
By being able to control for patients health status and other relevant factors these analyses 
were able to determine whether treatments were being administered systematically. The 
results in chapter seven showed that there were significant inequalities over time in the 
prescription of all treatments except for combination of diabetes treatments with no insulin, 
ACEI only and in combination with other BP treatments, lipid therapies and aspirin following 
adjustment for patients’ health status and other factors. The statistically significant trends in 
prescription rates in the descriptive analyses were not simply a reflection of inequalities in 
health status. In addition to the inequalities in prescription of appropriate treatments, the 
results from chapter eight indicated that were significant differences by SES in the association 
with health outcomes with particular treatments. Namely, being prescribed insulin, solely and in 
combination, ACEI only, BP treatments with no ACEI, aspirin and lipid therapies. 
The results in chapter seven indicated that there were no differences in the prescriptions in 
lipid therapies and aspirin by SES but the findings in chapter eight showed that more favourable 
levels of cholesterol levels for higher SES patients being prescribed these treatments compared 
to low SES patients. These results may be a consequence of delays in the initiation of these 
treatments and/or non-adherence for low SES patients. Mid SES patients prescribed lipid 
therapies were also more likely to have better microalbuminuria rates compared to low SES 
patients. These findings were in contrast to a UK wide study which analysed socioeconomic 
trends in CHD mortality. The authors found that medical treatments accounted for a 50% 
decline in rates over 2007 to 2007 and the effect was equitable across SES patient groups [199].  
Delays in the initiation and non-adherence may also explain the significant inequalities in four 
out of five diabetes treatments over time. Discrepancies between guidelines and treatment 
practices have been found worldwide [227, 228]. Though these studies have not examined 
whether these discrepancies in the adherence to treatment guidelines were socially stratified. 
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Factors such as patients’ attitudes to their condition and healthcare, lack of resources and co-
morbidities were suggested as contributing to these differences and it possible that these are 
related to SES.  
Discrepancies between guidelines and treatment practice may also contribute to the differences 
in the associated between insulin, both on its own and in combination with other therapies, and 
HbA1c and incidences of ICD, microalbuminuria and retinopathy by SES. Higher SES patients 
were more likely to have more favourable outcomes on these treatments than low SES. 
Interestingly, mid SES patients were more likely to have poorer microalbuminuria rates when 
prescribed insulin only compared to low SES patients. Using insulin requires timely 
recommendation and effective implementation of the treatment, which then must be adhered to 
by the patient and should then be continually reviewed and if necessary intensified. This 
requires the patient to adopt a new treatment regimen. A recent international survey examined 
groups of patients and practitioners and their attitudes to insulin use and found that 
explanations given for insulin non-adherence were similar from both groups. These included 
skipping meals, logistical problems such as being busy and travelling, psychosocial problems 
such as stress, emotions and embarrassment. Patients also suggested forgetting was another 
issue. Using insulin was also perceived negatively with groups seeing the treatment regimen as 
restrictive and wanted it to be more flexible in accordance with daily activities [228]. Whilst the 
authors of this study did not analyse its findings by SES and these problems are likely to be 
experienced across the social spectrum. However, high SES patients may have more resources 
to draw upon to overcome these barriers compared to low SES patients. A finding, which is of 
particular relevance to practitioners and policy makers, was the amount of variation at the 
general practice level of patients being managed by diet alone. It was not clear from these 
analyses whether this indicates that some practices are better at delaying patients’ progression 
to treatments or whether these delays were appropriate or not and should be investigated 
further.  
As general practice spending is such a political issue at present [13], the results relating to QOF 
data were disappointing as the data yielded little statistical significance. The evidence presented 
in this thesis, in terms of using QOF data and the adjustment for clustering at the practice level, 
suggested that interventions targeted at the practice level have limited impact on the 
improvement of diabetes patients’ care and outcomes. However, there are a number of 
criticisms of QOF in its current inception, including the lack of targets set to improve patients 
communication, engagement and empowerment [213] and the notable differences between 
NICE and QOF treatment targets. Initiatives, such as QOF, for diabetes care in their current form, 
are likely to have a limited role in improving care and reducing inequalities by SES.   
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The NICE Type 2 diabetes care guideline [46], NSF for Diabetes [49, 52], QOF [47], NDA [50] and 
the NHS Diabetic Eye Screening Programme [48] are all designed to improve and systematically 
deliver equitable care for all diabetes patients. However, whilst these policies and programmes 
may have played a role in improving care and health outcomes for patients overall during the 
study period, the results presented here have shown that there were socio-economic 
inequalities associated with outcomes and interventions. This is particularly evident in the 
intermediate health outcomes and the receipt of quality of care, combinations of BP treatments 
and shared care over time and the different association with health outcomes by SES in patients 
using insulin and lipid treatments, shared care and being managed by PCT.  
The evidence presented in this thesis arguably supports many of the previous theories 
regarding intervention generated inequalities. Gaining effective diabetes control requires long-
term engagement with health services as well as making substantial lifestyle changes and 
adapting to changes in treatments. Whilst practitioners are there to support and ensure patients 
receive the appropriate care in a timely manner, interventions such as attending retinal 
screening services, attending annual reviews and adhering to treatment regimens can be 
described as ‘agentic’ interventions as they rely upon individuals sustaining behaviour change 
[229]. However, evidence published elsewhere suggests that these types of interventions 
actually increase inequalities as they do not address the exposure to the risk factors [28]. In the 
case of type 2 diabetes, interventions investigated here do not tackle social environment and 
circumstances, which lead them to develop the condition and are more reactionary as patients’ 
health deteriorate. That is, they are not ‘structural strategies’ which have been found to have a 
more equitable impact on population health [28, 229] [1].  
There was also evidence to support Ali’s [33] argument that the way health systems operate and 
the personalisation of the NHS could exacerbate inequalities [33]. In particular, the receipt of 
shared care and its association with health outcomes varies by SES. This highlights that the 
current arrangements of this care may not be meeting all patients’ needs equally. Addressing 
this disparity may require examining the referral practices of GPs, who act as gate-keepers to 
this care, or if the service could be redesigned to ensure that patients from low SES groups are 
able to overcome the personal and structural barriers which prevent them benefitting from this 
care.  
A recent review examining interventions which improve care in socially disadvantaged diabetes 
patients found that culturally tailoring, community educators, one-to-one interventions, 
treatment algorithms, focusing on behaviour-related tasks, patient feedback and high intensity 
interventions were found to have consistent impact on reducing inequalities [230]. Many of 
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these interventions would address some of the explanations given as to why there were 
inequalities found in these analyses. There are many potential opportunities for diabetes 
practitioners and policy makers to improve patients’ health and address where there were 
socio-economic inequalities in patients health outcomes and receipt of care. Many of these 
interventions would require long-term planning and investment. In the short term, 
practitioners should ensure that all patients receive the recommended care processes and that 
treatments algorithms implemented appropriately, as outlined in NICE guidelines. Not following 
these recommendations for all patients have been shown to be possible sources of intervention 
generated inequalities.  
 
Unanswered questions and future research 
 
The findings from this thesis indicates that in most circumstances there were no evidence of 
inequalities associated with type 2 diabetes health and care in the South Tees area. However, 
there were notable exceptions and further research is required to fully understand how this 
arises. Due to the observational nature of the analyses there are many areas which could be 
expanded upon to determine causation. However, what is particularly important, where there 
was evidence of intervention generated inequalities, is to unpick whether these were a result of 
interventions not being appropriately accessed and/or administered based on need or if the 
efficacy of these interventions differed by SES.  
If inequalities arise due to efficacy of the interventions by SES, future research should be 
conducted to determine which strategies could be implement to avoid this. The work by Glazier 
et al [230] has found that there are interventions which could implemented to improve the care 
of the most disadvantaged populations. Particularly, the incorporation of treatment algorithms, 
providing intense care over long periods and interventions based on health behaviours. These 
could be implemented locally and evaluated to establish if they work for the type 2 diabetes 
population in South Tees. 
Equitable access by patients need is particularly important in context of the new health 
landscape as general practitioners in the form of Clinical Commissioning Groups (CCGs) are now 
in control of the majority of the health care budget. This means that they decide what healthcare 
is commissioned and who can access these services. General Practitioners and CCGs therefore 
are dominant gatekeepers to health care services [13, 15, 16]. The new reforms may ensure 
access to specialist diabetes care may even become more equitable across South Tees as the 49 
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general practices in South Tees now make up the South Tees Clinical Commissioning Group 
[231]. This Group aims to work closely with South Tees Hospitals NHS Foundation Trust as well 
the constituent general practices working closely to reduce health inequalities and improve 
health and wellbeing of their patients [231]. These findings could potentially inform the 
priorities of this clinical commissioning group as well as encouraging other CCGs and specialist 
services to reflect upon whether they are providing equitable care and health outcomes for their 
patients.   
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Appendix A. The terms and strategies used to search each database in 
the systematic review 
 
Pubmed (U.S. National Library of Medicine National Institutes of Health):  
 
#1  (diabetes[Title/Abstract] or diabetic[Title/Abstract])  
#2  ("type 2" OR "type II" OR "type two" OR "non*insulin*dependent" OR NIDDM)  
#3  ((sex[Title/Abstract] or gender[Title/Abstract] or ethnicity[Title/Abstract] or 
ethnic[Title/Abstract]) and (inequalit*[Title/Abstract] or inequit*[Title/Abstract] or 
disparit*[Title/Abstract] or equit*[Title/Abstract] or bias[Title/Abstract]))  
#4 (deprived[Title/Abstract] or deprivation[Title/Abstract] or income[Title/Abstract] or 
poverty[Title/Abstract] or education*[Title/Abstract] or "social class*"[Title/Abstract] 
or "socio*economic class*"[Title/Abstract] or "socio*economic status"[Title/Abstract] 
or "socio*economic position"[Title/Abstract] or "socio*economic 
factor*"[Title/Abstract] or (urban[Title/Abstract] AND rural[Title/Abstract])) 
#5  #3 OR #4 
#6  ("Spain" or "Portugal" or "Greece" or "Italy" or "Great Britain" or "United Kingdom" or 
"Scotland" or "Wales" or "Northern Ireland" or England or "Ireland" or "France" or 
"Germany" or "Austria" or "Belgium" or "Netherlands" or "Holland" or "Denmark" or 
"Finland" or "Norway" or "Sweden" OR Swedish or "Canada" or "Japan" or "Australia" or 
"New Zealand" or "South Korea" or "Luxembourg" or "Iceland") 
#7   #1 AND #2 AND #5 AND #6 
#8  "Animals"[Mesh]  
#9 "Humans"[Mesh] 
#10 #8 NOT #9 
#11 #7 NOT #10 
#12 #11 Limits English language, 1998 onwards 
 
Embase (OvidSP, Wolters Kluwer Health): 
 
1  (diabetes or diabetic).ti,ab.  
 2  limit 1 to (english language and yr="1998 -Current")  
 3  ("type 2" or "type II" or "type two" or "non*insulin*dependent" or NIDDM).af.  
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 4  limit 3 to (english language and yr="1998 -Current")  
 5  ((sex or gender or ethnicity or ethnic) and (inequalit* or inequit* or disparit* or equit* 
or bias)).ti,ab.  
 6  limit 5 to (english language and yr="1998 -Current")  
 7  (deprived or deprivation or income or poverty or education* or social class* or 
socio*economic class* or socio*economic status or socio*economic position or 
socio*economic factor* or (urban and rural)).ti,ab.  
 8  limit 7 to (english language and yr="1998 -Current")  
 9  6 or 8  
 10  ("Spain" or "Portugal" or "Greece" or "Italy" or "Great Britain" or "United Kingdom" or 
"Scotland" or "Wales" or "Northern Ireland" or England or "Ireland" or "France" or 
"Germany" or "Austria" or "Belgium" or "Netherlands" or "Holland" or "Denmark" or 
"Finland" or "Norway" or "Sweden" or Swedish or "Canada" or "Japan" or "Australia" or 
"New Zealand" or "South Korea" or "Luxembourg" or "Iceland").af.  
 11  limit 10 to (english language and yr="1998 -Current")  
 12  2 and 4 and 9 and 11  
 13  exp humans/  
 14  exp animals/  
 15  14 not 13  
 16  12 not 15 
 
CINALH (Ebscohost): 
 
S1    TI ( (diabetes or diabetic) ) or AB ( (diabetes or diabetic) )   Search modes - 
Boolean/Phrase  
S2    ("type 2" or "type II" or "type two" or "non*insulin*dependent" or NIDDM)   Search 
modes - Boolean/Phrase  
S3    TI ( ((sex or gender or ethnicity or ethnic) and (inequalit* or inequit* or disparit* or 
equit* or bias)) ) or AB ( ((sex or gender or ethnicity or ethnic) and (inequalit* or 
inequit* or disparit* or equit* or bias)) )   Search modes - Boolean/Phrase  
S4    TI ( (deprived or deprivation or income or poverty or education* or social class* or 
socio*economic class* or socio*economic status or socio*economic position or 
socio*economic factor* or (urban and rural)) ) or AB ( (deprived or deprivation or 
income or poverty or education* or social class* or socio*economic class* or 
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socio*economic status or socio*economic position or socio*economic factor* or (urban 
and rural)) )   Search modes - Boolean/Phrase  
S5 S2 or S4   Search modes - Boolean/Phrase  
S6    ("Spain" or "Portugal" or "Greece" or "Italy" or "Great Britain" or "United Kingdom" or 
"Scotland" or "Wales" or "Northern Ireland" or England or "Ireland" or "France" or 
"Germany" or "Austria" or "Belgium" or "Netherlands" or "Holland" or "Denmark" or 
"Finland" or "Norway" or "Sweden" or Swedish or "Canada" or "Japan" or "Australia" or 
"New Zealand" or "South Korea" or "Luxembourg" or "Iceland")   Search modes - 
Boolean/Phrase  
S7    S1 and S2 and S5 and S6   Search modes - Boolean/Phrase  
S8    S7   Limiters - Published Date from: 19980101-20121231; English Language  
 
ASSIA search: 
 
#1 TI=(diabetes or diabetic) or AB=(diabetes or diabetic)  
#2 "type 2" or "type II" or "type two" or "non*insulin*dependent" or NIDDM  
#3  TI=((sex or gender or ethnicity or ethnic) and (inequalit* or inequit* or disparit* or 
equit* or bias)) or AB=((sex or gender or ethnicity or ethnic) and (inequalit* or inequit* 
or disparit* or equit* or bias))  
#4  AB=(deprived or deprivation or income or poverty or education* or social class* or 
socio*economic class* or socio*economic status or socio*economic position or 
socio*economic factor* or (urban and rural)) or TI=(deprived or deprivation or income 
or poverty or education* or social class* or socio*economic class* or socio*economic 
status or socio*economic position or socio*economic factor* or (urban and rural))  
#5  #3 OR #4  
#6  "Spain" or "Portugal" or "Greece" or "Italy" or "Great Britain" or "United Kingdom" or 
"Scotland" or "Wales" or "Northern Ireland" or England or "Ireland" or "France" or 
"Germany" or "Austria" or "Belgium" or "Netherlands" or "Holland" or "Denmark" or 
"Finland" or "Norway" or "Sweden" or Swedish or "Canada" or "Japan" or "Australia" or 
"New Zealand" or "South Korea" or "Luxembourg" or "Iceland"  
#7   #1 AND #2 AND #5 AND #6  
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Appendix B: Copies of access and ethical approval letters 
 
 School of Medicine and Health Ethics Committee, Durham University 
Ref: ESC2/2010/12 
 County Durham & Tees Valley Research Ethics Committee, National Research Ethics 
Service 
Ref: 10/H0908/63 
 Research & Development / Academic Division, South Tees Hospitals NHS Foundation 
Trust 
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Appendix C: Data source and variable construction 
 
This appendix outlines the name of each variable, where it was sourced, what is measures and 
any additional formatting. 
 
Table 42: Socio-demographic, socio-economic, anthropometric and lifestyle data 
Variable name Source Measurement/derivation/formatting 
Visit year Diabetes 
register 
 
Refers to the year in which the patients visit was recorded. 
Derived from ‘Date of Visit’ which was the last visit the patient 
had during a calendar year. Each variable included was the latest 
recording of that variable in the calendar year recorded.  
Age Subjects’ age in years at the end of 2007 was part of the original 
data extraction, derived from patients’ date of birth by the 
register data manager. ‘Age’ was constructed to establish patients’ 
age at the end of the year in which the visit was recorded and 
calculated as follows: [Age end 2007])-(2007-[Visit year]) 
SES ONS,  
Diabetes 
register 
 
Patients’ socio-economic status was measured using Index of 
Multiple Deprivation 2004.  A table of postcodes in the South Tees 
area and the lower super output area (LSOA) the majority each 
postcode falls into was linked by Database Manager using to 
register extract via patients address. The addresses were then 
removed. 
The national rank of all England LSOA according its Index of 
Multiple Deprivation 2004 score was extracted from ONS data. 
These ranks were divided into quintiles with 1 indicating the 
lowest socio-economic status group. These were then assigned to 
the register extract via patients LSOA for that year. 
Quintiles were used for the descriptive analyses, however, the 
quintiles three, four and five (the three highest SES groups) were 
then recoded into one group for the subsequent analyses.   
Age at 
diagnosis 
Diabetes 
register 
The year which patients were diagnosed was extracted from the 
diabetes register. The age in years at the end of the year the 
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 patient was diagnosed and calculated as follows:  
[Age end 2007]-(2007-[Year of Diagnosis]) 
Duration of 
diabetes 
This variable measures the years since diagnosis to current year 
of visit. Calculated as follows: [Age]-[Age at diagnosis]. Recording 
of ‘0’ indicates that the visit was recorded the same year the 
patient was diagnosed. 
The year the patient was diagnosed as recorded in the register. 
112 records (85 patients) had the year of diagnosis as a year 
following the recorded visit. These values were removed. 
Sex This is recorded in the register as 1 = Male, 2 = Female. One 
patient did not have their sex recorded so all their data was 
removed. 
Ethnicity In the register patients have their ethnic origin recorded as one of 
four categories: Europid, South Asian, Afro-Caribbean and Other. 
46 patients were recorded as Afro-Caribbean and 74 patients as 
‘Other’ therefore to give more power to the analysis these two 
categories were grouped into one category. As such Ethnicity has 
three categories coded as follows: 1 = White, 2 = South Asian and 
3 = ‘Other’ 
Weight Subjects weight in kilograms (kg).  
Further formatting: On the recommendations by the register staff 
values outside the range 0 to 220 were considered to be a result 
of inaccurate recording and were removed. 
BMI Body mass index is calculated from height and weight: (kg/m2) by 
the data input team. BMI and Height was not extracted from the 
register directly, however, it calculated from weight and BMI 
fields as follows: √(Weight/BMI). This was done to check the 
validity of the weight and BMI fields which were extracted from 
the register. Following recommendations height was limited to 
values greater than or equal to 0.8 and less than or equal to 2.1 
metres, with values outside this range were removed. By 
producing a cross tabulated table of subjects’ height per year it 
was clear from eye-balling the data that approximately 33% of the 
study population’s height ranged by over 10cms. In order to 
reduce the bias resulting from measurement error subjects’ 
median height was calculated for subjects with three or more 
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height recordings over the study period. By using median instead 
of mean reduces the influence that extreme values have on the 
final statistic. 
Due to the nature of diabetes, many patients can experience 
sudden weight gain and loss over a short period of time. It would 
be impossible to judge whether any large variation in subjects’ 
BMI was a result of recording and/or measurement errors or an 
accurate reflection of their body mass due to changes in health 
and/or result of treatments. To ensure that it is not a recording or 
measurement error of subjects’ height or weight BMI was 
recalculated once the extreme values of these indicators were 
removed and using the median height of each subject. The new 
values which were greater than 100 were removed. 
Smoking status Patients’ smoking status was recorded in the diabetes register 
using the following categories: 0 = No, 1 = Yes, 2 = Ex. All three 
categories should be offered to subjects as options for the self 
report of their smoking status. However, from eye balling the data 
it was clear that some patients have been categorised as non-
smokers even though they have been recorded as a smoker in 
previous years. As such any recording of ‘0’ following a recording 
of ‘1’ in an earlier year was changed to a recording of ‘2’ to reflect 
the previous and current smoking status per patient. This was 
based on the assumption that an ex-smoker was more likely to be 
recorded as a non smoker than an inaccurate recording of being a 
smoker previously. 
 
 
Table 43: Intermediate outcomes and long-term complications 
Variable name Source Measurement/derivation/formatting 
sBP Diabetes 
register 
 
Systolic blood pressure measured in mmHg. 
Further formatting: as recommended by the register staff all 
values which were equal to or less than the patient’s diastolic 
blood pressure values were removed. No specific limits were 
given. 
dBP Diastolic blood pressure measured in mmHg. 
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Further formatting: As recommended by the register staff all 
values which were equal to or less than its corresponding systolic 
blood pressure values were removed. No specific limits were 
given. 
Hypertensive Patients were classified as being hypertensive if their blood 
pressure was above the NICE recommended target of 130/80 
mmHg: 1 = if both patient dBP≤80 And their sBP≤130; 0 = if not. 
HbA1c Glycosylated haemoglobin is measured as a percentage.  
Further formatting: As recommended by the register staff values 
were limited to those greater than or equal to 2.5 and less than or 
equal to 23. Values outside this range were removed. 
Cholesterol Total cholesterol measured in mmol/l. 
Further formatting: As recommended by the register staff values 
were limited to those greater than or equal to 1.5 and less than to 
or equal to 40. Values outside this range were removed. 
Creatinine Creatinine measured in μmol/l.  
Further formatting: As recommended by register staff values 
were limited to those greater than or equal to 20 and less than or 
equal to 1400. Values outside this range were removed. 
CreatinineGrea
ter300 
This variable derived from Creatinine to indicate records with 
creatinine measurements greater than 300 μmol/l as ‘1’; and ‘0’ if 
not. This was necessary covariate to be controlled for when 
analysing HbA1c outcomes, as recommended by register staff. 
ICD  Recorded as ‘1’ if a patient has ever had a history of ischaemic 
cardiac disease; and ‘0’ if not. 
Further formatting: Due to how these indicators are recorded, 
values of ‘0’ if a subject had a recording of ‘1’ in a previous year. 
Stroke or TIA Recorded as ‘1’ if a patient has ever had a history of stroke or 
transient ischaemic attack; and ‘0’ if not. 
Further formatting: Due to how these indicators are recorded, 
values of ‘0’ if a subject had a recording of ‘1’ in a previous year. 
PVD Recorded as ‘1’ if a patient has ever had a history of peripheral 
vascular disease; and ‘0’ if not. 
Further formatting: Due to how these indicators are recorded, 
values of ‘0’ if a subject had a recording of ‘1’ in a previous year. 
Micro- This is based on a patients’ albumin/creatinine ratio (ACR, 
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albuminuria mg/mmol). Patients were classified as having microalbuminuria 
and recorded as ‘1’ if ACR≥3 for men, ACR≥3.5 for women; and ‘0’ 
if not. 
eGFR This was calculated using abbreviated Modification of Diet in 
Renal Disease equation as recommended by NICE, SIGN, and 
Renal Association: 
eGFRml/min/1.73m2 = 186 x (Creatinine/88.4)-1.154 x (Age)-
0.203 x (0.742 if female) x (1.210 if black). 
This was kept as a continuous variable, however, the lower the 
number indicates worse kidney function [66]. 
Retinopathy Diabetes 
register, 
screening 
program-
me 
Retinopathy is currently (2010) recorded in the diabetes register 
as follows: 0 = None, 1 = Background, 2 = Pre-Proliferative, 3 = 
Proliferative. However, during the study period the way 
retinopathy has been recorded has changed several times as such 
the database manager recoded the data as follows: 0 = None, 1 = 
Background, 2 = Advanced; where advanced retinopathy is 
anything more serious than background retinopathy. 
Further formatting: The data from the diabetic retinal screening 
programme for 2006 and 2007 was recorded as follows: R0M0 = 
No diabetic retinopathy, no maculopathy; R1M0 = Background 
diabetic retinopathy, no maculopathy; R1M1 = Background 
diabetic retinopathy, maculopathy; R2M0 = Pre-proliferative 
diabetic retinopathy, no maculopathy; R2M1 = Pre-proliferative 
diabetic retinopathy, maculopathy; R3M0 = Proliferative diabetic 
retinopathy, maculopathy; R3M1 = Proliferative diabetic 
retinopathy, maculopathy. However, the prevalence of each these 
grades were very low, particular at the severe end of the scale. As 
such this data was recorded into three above categories. 
A new indicator was created combining these two sources of 
retinopathy data. In a 180 cases the values between the sources 
conflicted. In these cases the values from the retinal screening 
programme were favoured as this a more direct source. 
 
 
Table 44: Diabetes interventions data 
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Variable name Source Measurement/derivation/formatting 
Diagnosis at 
HbA1c 
Diabetes 
register 
 
This is the HbA1c value measured during the year patient was 
diagnosed. This variable acts a proxy measurement to the severity 
of patients’ condition at diabetes. 
Diabetes 
treatments  
This variable recoded the following diabetes treatments, which 
are recorded as ‘1’ receiving that treatment and ‘0’ not receiving 
the treatment, into one categorical variable: diet alone, 
metformin, sulphonylureas, metformin, acarbose, glitazone and 
insulin. 
The new variable were coded based on the NICE type 2 diabetes 
guidelines as the following: 
1 = Diet alone, 2 = Metformin or sulphonylureas only, 3 = Diabetes 
treatment combination excluding insulin, 4 = Insulin only and 5 = 
Diabetes treatment combination including insulin. 
BP treatments This variable recoded the following BP treatments, which are 
recorded as ‘1’ receiving that treatment and ‘0’ not receiving the 
treatment, into one categorical variable: diuretics, beta blockers, 
alpha blockers, ACE inhibitors and calcium antagonists The new 
variable were coded based on the NICE type 2 diabetes guidelines 
as the following: 
1 = No BP treatment, 2 = ACEIs only, 3 = ACEIs plus any 
combination of other BP treatments and 4 = other treatment(s). 
Aspirin Recorded as ‘1’ if patient was being treated with aspirin, ‘0’ if not. 
Lipid therapies The diabetes register records what lipid therapies a patient is 
receiving within one indicator as follows: 
0 = None, 1 = Statin only, 2 = Fibrate only, 3 = Other only, 4 = 
Multiple lipid therapies. However, the prevalence of the use of 
fibrates, other and multiple lipid therapies was very low therefore 
this was recoded into one binary variable:  
‘1’ if the patient was in receipt of one or more lipid therapies, ‘0’ if 
not. 
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Quality of care This variable was constructed in stages. Firstly, new variables 
were coded on the basis of a recording of any value for each of the 
following indicators which should be recorded on an annual basis 
according to the NICE type 2 diabetes: BMI, HbA1c, BP, albumin, 
creatinine, cholesterol, smoking status and retinopathy. This was 
done prior to the omission of extreme values on the assumption 
that the practitioner who noted the recording would act on the 
primary data at the time of measurement rather the secondary 
data from the register. 0 = Not recorded, 1 = Recorded. Next, this 
was added into one overall score, which potentially ranged from 0 
to 8. However, as only available cases were used, this ranged from 
4 to 8 depending on which set of variables were included in the 
model. The overall score, therefore, was recoded into a categorical 
variable: 1 = less than 7, 2 = 7 and 3 = 8 care processes received. 
These are described in the results section as poor, medium or high 
quality of care. 
 
 
Table 45: Provider data 
Variable name Source Measurement/derivation/formatting 
Practice 
deprivation 
PHO The PHOs of England calculated the overall deprivation of general 
practice populations using the Index of Multiple Deprivation 
(IMD) 2007 applied proportionally to the Attribution Dataset 
practice populations, 2010 (see below for more information 
regarding IMD). Based on this score all practices in England were 
ranked with 1 representing the most deprived practice 
population. In order to identify non-linear trends these ranks 
were divided into quartiles with ‘1’ indicating the most deprived 
25% of practices. None of the practices in the South Tees area 
were in the 25% least deprived practice populations as such the 
three included categories were coded as: ‘1’ high, ‘2’ mid, and ‘3’ 
low deprivation. These variables were assigned to each patient 
record based on the general practice they were registered with for 
that year. 
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Practice list 
size 
QOF This continuous variable was extracted from the QOF dataset and 
is the number of patients on the clinical register for each general 
practice. To establish non-linear trends it was recoded ‘1’ if than 
7,000, ‘2’ if there between 7,000 and 9,999 inclusively, and ‘3’ if 
there were 10,000 or more patients registered with the practice. 
These variables were assigned to each patient record based on the 
general practice they were registered with for that year. 
Diabetes 
prevalence 
This was extracted from the QOF dataset and is the prevalence of 
diabetes patients aged 17 years old and over, calculated as 
follows:  
(Diabetes register/Practice List Size)*100. 
These variables were assigned to each patient record based on the 
general practice they were registered with for that year. 
BMI recording 
Level 
The percentage of patients with diabetes whose notes record BMI 
in the previous 15 months. 
HbA1c ≤ 10% The percentage of patients with diabetes in whom the last HbA1c 
is 10 or less (or equivalent test/reference range depending on 
local laboratory) in last 15 months. 
Peripheral 
pulses 
Recording 
level 
The percentage of patients with diabetes with a record of the 
presence or absence of peripheral pulses in the previous 15 
months. 
Neuropathy 
test recording 
level 
The percentage of patients with diabetes with a record of 
neuropathy testing in the previous 15 months. 
BP recording 
level 
The percentage of patients with diabetes who have a record of the 
blood pressure in the previous 15 months. 
BP ≤ 145/85 
level 
The percentage of patients with diabetes in whom the last blood 
pressure is 145/85 or less. 
Microalbuminu
ria recording 
level 
The percentage of patients with diabetes who have a record of 
micro-albuminuria testing in the previous 15 months (exception 
reporting for patients with proteinuria). 
Proteinuria/ 
microalbuminu
ria treated 
The percentage of patients with diabetes with a diagnosis of 
proteinuria or micro-albuminuria who are treated with ACE 
inhibitors (or A2 antagonists). 
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with ACEI level 
Total 
cholesterol 
Recording 
level 
The percentage of patients with diabetes who have a record of 
total cholesterol in the previous 15 months. 
Total 
cholesterol ≤ 5 
mmol/l level 
The percentage of patients with diabetes whose last measured 
total cholesterol within the previous 15 months is 5mmol/l or 
less. 
Influenza 
immunisation 
level 
The percentage of patients with diabetes who have had influenza 
immunisation in the preceding 1 September to 31 March. 
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Appendix D: Missing data per variable over time 
 
The following tables indicate what percentage of each indicator is complete by year following 
the data cleaning, which is outlined in chapter 4. The colour is graded from red to yellow with 
the latter indicating the most complete fields.  
Table 46 shows that, overall, the completeness of population data for the study period is high. 
Completeness of the anthropometric and lifestyle data has steadily improved over the study but 
there was a decline in 2007. Similarly Table 47 shows a steady increase in the recording of 
intermediate outcomes from 1999, however, this seems to peak around 2004 and then begin to 
drop off again. This may because from this year onwards primary practitioners also have to 
input data onto the QOF system, which is separate from the practice systems and the paper 
proforma of the diabetes register. As the QOF system determines a significant part of GPs pay 
this work is likely to be prioritised above populating the diabetes register. The redness in this 
table also highlights the poor recording of patients lipid profiles with LDL cholesterol which was 
only introduced as a separate field in 2007. Due to this poor level of recording only total 
cholesterol out the lipid profile was used in the analyses. In addition, estimated cardiovascular 
risk was not examined either. 
The recording of patients’ history of vascular disease is relatively high with recording levels of 
over 80% for each indicator per year. The calculation for patients’ eGFR level are based upon 
their creatinine levels. Both these indicators reflect the trend described above: a steady increase 
until 2004 with levels beginning to fall after this year. There are poor recording levels for 
proteinuria, microalbuminuria and retinopathy. These results are particularly worrying as the 
recording of patients’ microalbuminuria and retinopathy are two of the nine key care processes 
recommended by NICE [46]. The retinopathy levels are falling far short of the target set as part 
of the NHS Diabetes Retinal Screening programme [48]. Estimated GFR, proteinuria and 
microalbuminuria are all indicators of kidney function, as eGFR was the most complete over the 
study variable was used as a covariate in the analyses.  
The recording of diabetes treatments are very high with 90% complete for each indicator per 
year. Similarly with blood pressure and lipid treatments which have achieved the same high 
levels since 2002. The conspicuous lack of data is the recording of patients’ lipid therapies in 
1999 which achieved only about 30% completeness. Table 15 highlights the introduction of QOF 
over the study period and also when particular indicators were introduced and/or suspended.
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Table 46: The percentage of population, anthropometric and lifestyle data complete by study year 
 
1999 2000 2001 2002 2003 2004 2005 2006 2007 Total 
LSOA 100 100 100 100 100 100 100 100 100 100 
Sex 100 100 100 100 100 100 100 100 100 100 
Ethnicity 100 100 100 100 100 100 100 100 100 100 
Age (years) 100 100 100 100 100 100 100 100 100 100 
Age at diagnosis (years) 99.3 99.8 99.2 99.6 99.5 99.7 99.5 99.3 98.9 99.4 
Duration of diabetes (years) 99.3 99.8 99.2 99.6 99.5 99.7 99.5 99.3 98.9 99.4 
BMI (kg/m2) 64.1 66.3 68.7 72.9 77.7 83.2 84.4 83.9 76.4 76.6 
Weight (kg) 75.3 75.1 76.9 79.1 80.4 84.7 87.2 86.3 76.5 80.8 
Smoking Status 67.9 72.3 78.6 86.4 86.7 91.2 91.4 90.7 84.6 84.7 
 
Table 47: The percentage of intermediate health outcomes data complete by study year 
 
1999 2000 2001 2002 2003 2004 2005 2006 2007 Total 
sBP  80.9 83.1 85.2 86.2 90.0 93.1 93.8 93.9 90.0 89.3 
dBP 76.6 78.1 77.0 78.4 89.9 93.0 93.9 93.9 89.9 87.0 
Hypertension 76.6 78.0 77.0 78.4 89.9 93.0 93.8 93.9 89.9 86.9 
HbA1c 73.3 78.4 82.9 92.9 93.6 94.6 90.9 90.5 87.0 88.1 
Cholesterol 70.0 70.3 74.7 92.4 95.1 96.2 90.6 91.9 86.2 86.8 
HDL 3.2 9.1 17.2 52.5 62.8 77.0 69.5 71.9 69.7 53.2 
LDL 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 60.1 8.3 
Triglycerides 7.0 12.1 25.7 53.8 62.6 75.8 67.3 71.0 70.0 54.2 
Creatinine 69.5 73.4 77.5 92.6 94.3 96.2 90.9 91.2 88.2 87.4 
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Table 48: Percentage of long term complications complete by study year 
 
1999 2000 2001 2002 2003 2004 2005 2006 2007 Total 
eGFR 68.6 71.5 74.8 88.9 89.8 90.9 85.6 85.4 82.5 83.1 
Ischiaemic cardiac  82.9 83.8 87.0 85.6 89.9 89.9 88.7 90.3 85.5 87.4 
Stroke or TIA) 82.9 84.1 86.6 85.0 88.8 88.9 87.9 89.4 84.7 86.8 
PVD 82.3 82.2 85.9 84.5 87.4 87.5 87.2 88.9 84.2 85.9 
Microalbuminuria 23.9 27.4 39.0 47.1 51.2 68.6 66.8 65.0 3.6 45.1 
Proteinuria 54.2 57.8 60.2 64.3 61.9 68.7 72.1 67.8 44.7 61.7 
Retinopathy 41.8 47.1 45.1 45.4 43.6 38.2 27.1 52.2 58.3 44.5 
 
Table 49: Percentage of study population with HbA1c at diagnosis recorded in dataset 
 
1999 2000 2001 2002 2003 2004 2005 2006 2007 Total 
HbA1c at Diagnosis 6.5 12.7 18.7 26.2 32.8 39.2 43.9 47.0 49.1 33.6 
 
Table 50: Percentage of diabetes treatments complete by study year 
 
1999 2000 2001 2002 2003 2004 2005 2006 2007 Total 
Diet alone 97.1 97.7 96.4 97.2 97.7 98.0 99.0 99.1 95.5 97.6 
Insulin 97.1 97.7 96.4 97.2 97.1 98.0 99.0 99.1 94.6 97.4 
Sulphonylurea 97.1 97.7 96.4 97.2 97.4 98.0 98.9 99.1 95.0 97.5 
Metformin 97.1 97.7 96.4 97.2 97.5 98.0 98.9 99.1 95.2 97.5 
Acarbose 97.1 97.7 96.4 97.2 97.1 98.0 98.9 99.1 94.6 97.4 
Glitazone 97.1 97.7 96.4 97.2 97.1 98.0 98.9 99.1 94.7 97.4 
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Table 51: Percentage of blood pressure and lipid treatments complete by study year 
 
1999 2000 2001 2002 2003 2004 2005 2006 2007 Total 
Diuretics 80.7 82.3 87.7 92.7 93.8 95.1 95.8 96.3 93.0 91.8 
Beta Blockers 79.1 81.2 87.2 92.5 93.1 94.5 94.2 94.9 92.5 90.9 
Alpha Blockers 76.5 78.4 85.2 92.1 92.0 93.8 93.5 94.0 91.6 89.7 
ACE Inhibitor 80.2 82.6 88.1 92.9 94.4 95.9 95.3 95.8 93.4 91.9 
AT2 Blockers 66.7 78.3 85.3 92.2 92.1 93.7 93.9 94.4 92.1 89.1 
Calcium Antagonist 79.3 81.1 87.3 92.6 93.4 94.7 94.4 95.1 92.5 91.0 
Aspirin 79.7 83.0 88.0 92.8 93.9 95.6 95.4 95.9 93.9 91.9 
Lipid Therapy 28.8 76.6 85.6 92.0 94.3 95.9 95.8 96.8 94.7 87.5 
 
Table 52: Percentage of practice level data complete by study year 
 
1999 2000 2001 2002 2003 2004 2005 2006 2007 Total 
Practice deprivation score 100 100 100 100 100 100 100 100 100 100 
Practice list size 0.0 0.0 0.0 0.0 0.0 88.5 88.7 100 100 50.2 
Diabetes register 0.0 0.0 0.0 0.0 0.0 88.5 88.7 100 100 50.2 
DM QOF Prevalence 0.0 0.0 0.0 0.0 0.0 88.5 88.7 100 100 50.2 
Exception reporting level of DM indicators  0.0 0.0 0.0 0.0 0.0 88.5 88.7 100 100 50.2 
BMI recording level 0.0 0.0 0.0 0.0 0.0 88.5 88.7 100 100 50.2 
Smoking recording level 0.0 0.0 0.0 0.0 0.0 88.5 88.7 0.0 0.0 22.5 
HbA1c recording level 0.0 0.0 0.0 0.0 0.0 88.5 88.7 100 100 50.2 
Patients achieving HbA1c ≤ 7.4% 0.0 0.0 0.0 0.0 0.0 88.5 88.7 0.0 0.0 22.5 
Patients achieving HbA1c ≤ 10% 0.0 0.0 0.0 0.0 0.0 88.5 88.7 100 100 50.2 
Retinal screening level (1) 0.0 0.0 0.0 0.0 0.0 88.5 88.7 0.0 0.0 22.5 
Peripheral pulses recording level 0.0 0.0 0.0 0.0 0.0 88.5 88.7 100 100 50.2 
Neuropathy test recording level 0.0 0.0 0.0 0.0 0.0 88.5 88.7 100 100 50.2 
BP recording level 0.0 0.0 0.0 0.0 0.0 88.5 88.7 100 100 50.2 
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Patients achieving BP ≤ 145/85 (mmHg) 0.0 0.0 0.0 0.0 0.0 88.5 88.7 100 100 50.2 
Microalbuminuria recording level 0.0 0.0 0.0 0.0 0.0 88.5 88.7 100 100 50.2 
Serum creatinine recording level 0.0 0.0 0.0 0.0 0.0 88.5 88.7 0.0 0.0 22.5 
Proteinuria/microalbuminuria treated with 
ACE inhibitors level 0.0 0.0 0.0 0.0 0.0 88.5 88.7 100 100 50.2 
Total cholesterol recording level 0.0 0.0 0.0 0.0 0.0 88.5 88.7 100 100 50.2 
Patients achieving total cholesterol ≤ 
5mmol/l (%) 0.0 0.0 0.0 0.0 0.0 88.5 88.7 100 100 50.2 
Influenza immunisation level 0.0 0.0 0.0 0.0 0.0 88.5 88.7 100 100 50.2 
Patients achieving HbA1c ≤ 7.5% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100 100 27.7 
Retinal screening level (2) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100 100 27.7 
eGFR or serum creatinine recording 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100 100 27.7 
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Appendix E: Analyses of missing data mechanisms 
 
 
Table 53 shows that there were statistically significant association between deprivation 
level and the odds of missing data on the outcome variables. The least deprived were 
likely less to have missing data on the intermediate outcomes, eGFR and retinopathy. 
However, this association was more complex with the vascular disease variables. There 
were statistically significant association between missing data on the intermediate 
outcomes, eGFR and retinopathy with patients from white and south Asian backgrounds 
less likely to have missing data. The statistically significant odds ratio for age and gender 
shows that these have a small effect on likelihood of missing data. 
 
Table 54 shows that the least deprived groups were less likely to have missing data on 
all the diabetes treatments, with statistical significance. Table 55 shows a statistically 
significant relationship with the least deprived quintile being about half as likely to have 
missing data on blood pressure treatment than patients from the most deprived quintile. 
The ethnicity, gender and age of patients do not predict missing data on diabetes and 
blood pressure treatments. Table four shows that male patients have statistically 
significant reduced odds of having missing data on aspirin treatment than women but no 
other demographic predict odds of having missing data on lipid treatments.  
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Table 53: Logistic regression analyses of missing data on outcome variables allowing for demographic variables 
 Hba1c 
missing 
Cholesterol 
missing 
sBP missing eGFR missing Ischiac 
Cardiac 
missing 
Stroke or TIA 
missing 
PVD missing Retinopathy 
missing 
Ref. group: Most deprived 
Q2 0.83 (0.78, 
0.88) 0.000 
0.80 (0.76, 
0.85) 0.000 
0.82 (0.77, 
0.87) 0.000 
0.86 (0.81, 
0.9) 0.000 
1.28 (1.21, 
1.35) 0.000 
1.26 (1.19, 
1.33) 0.000 
1.25 (1.19, 
1.32) 0.000 
0.82 (0.79, 
0.85) 0.000 
Q3 0.83 (0.78, 
0.89) 0.000 
0.83 (0.78, 
0.89) 0.000 
0.81 (0.75, 
0.87) 0.000 
0.88 (0.83, 
0.94) 0.000 
0.93 (0.87, 
1.00) 0.044 
0.93 (0.87, 
0.99) 0.032 
0.93 (0.87, 
0.99) 0.028 
0.89 (0.85, 
0.93) 0.000 
Q4 0.84 (0.77, 
0.91) 0.000 
0.86 (0.80, 
0.93) 0.000 
0.85 (0.78, 
0.92) 0.000 
0.90 (0.84, 
0.96) 0.001 
1.3 (1.21, 
1.40) 0.000 
1.28 (1.20, 
1.37) 0.000 
1.25 (1.17, 
1.34) 0.000 
0.86 (0.82, 
0.90) 0.000 
Q5: Least 
deprived 
0.54 (0.46, 
0.65) 0.000 
0.71 (0.62, 
0.83) 0.000 
0.53 (0.44, 
0.64) 0.000 
0.82 (0.72, 
0.93) 0.002 
0.46 (0.38, 
0.56) 0.000 
0.44 (0.37, 
0.53) 0.000 
0.46 (0.38, 
0.55) 0.000 
0.84 (0.77, 
0.92) 0.000 
White 0.54 (0.41, 
0.71) 0.000 
0.65 (0.49, 
0.86) 0.002 
0.56 (0.42, 
0.74) 0.000 
0.57 (0.45, 
0.73) 0.000 
1.07 (0.76, 
1.52) 0.687 
1.17 (0.82, 
1.66) 0.386 
1.11 (0.79, 
1.55) 0.56 
0.94 (0.75, 
1.17) 0.586 
South Asian 0.78 (0.58, 
1.04) 0.086 
0.95 (0.71, 
1.26) 0.702 
0.73 (0.54, 
0.99) 0.042 
0.75 (0.58, 
0.97) 0.029 
1.04 (0.72, 
1.5) 0.825 
1.09 (0.76, 
1.58) 0.636 
1.06 (0.74, 
1.50) 0.759 
1.31 (1.04, 
1.65) 0.022 
Afro 
Caribbean 
0.8 (0.52, 
1.24) 0.318 
0.89 (0.58, 
1.37) 0.603 
1.01 (0.66, 
1.56) 0.957 
0.70 (0.47, 
1.04) 0.076 
1.11 (0.66, 
1.86) 0.696 
1.17 (0.7, 
1.97) 0.541 
1.19 (0.73, 
1.94) 0.492 
1.11 (0.79, 
1.55) 0.561 
Age 1.00 (1.00, 
1.00) 0.251 
1.00 (0.99, 
1.00) 0.000 
1.00 (1.00, 
1.00) 0.312 
0.99 (0.99, 
0.99) 0.000 
1.00 (1.00, 
1.00) 0.002 
1.00 (1.00, 
1.01) 0.000 
1.01 (1.00, 
1.01) 0.000 
1.00 (1.00, 
1.00) 0.000 
Male 0.94 (0.90, 
0.99) 0.013 
0.93 (0.89, 
0.98) 0.002 
0.91 (0.87, 
0.96) 0.000 
0.95 (0.91, 
0.99) 0.014 
0.96 (0.91, 
1.00) 0.047 
0.99 (0.94, 
1.03) 0.538 
1.00 (0.96, 
1.04) 0.910 
0.96 (0.93, 
0.99) 0.006 
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Table 54: Logistic regression analyses of missing data on diabetes treatments allowing for demographic variables 
 Diet alone 
missing 
Insulin 
missing 
Sulphonylurea 
missing 
Metformin 
missing 
Acarbose 
missing 
Glitazone 
missing 
Ref. group: Most deprived 
Q2 0.82 (0.73, 
0.93) 0.002 
0.87 (0.78, 
0.98) 0.022 
0.86 (0.76, 
0.97) 0.013 
0.83 (0.74, 
0.94) 0.003 
0.87 (0.77, 
0.97) 0.015 
0.86 (0.76, 
0.97) 0.012 
Q3 0.78 (0.67, 
0.90) 0.001 
0.78 (0.68, 
0.90) 0.001 
0.78 (0.67, 
0.90) 0.001 
0.79 (0.68, 
0.92) 0.002 
0.78 (0.67, 
0.90) 0.001 
0.78 (0.67, 
0.90) 0.001 
Q4 0.74 (0.62, 
0.87) 0.000 
0.84 (0.72, 
0.98) 0.029 
0.76 (0.64, 
0.89) 0.001 
0.77 (0.65, 
0.91) 0.002 
0.82 (0.70, 
0.96) 0.014 
0.81 (0.69, 
0.95) 0.011 
Q5: Least 
deprived 
0.37 (0.24, 
0.58) 0.000 
0.39 (0.25, 
0.59) 0.000 
0.36 (0.23, 
0.56) 0.000 
0.38 (0.25, 
0.59) 0.000 
0.38 (0.25, 
0.59) 0.000 
0.39 (0.25, 
0.59) 0.000 
White 0.90 (0.45, 
1.83) 0.78 
0.96 (0.47, 
1.94) 0.906 
0.94 (0.46, 
1.90) 0.865 
0.92 (0.46, 
1.87) 0.828 
0.96 (0.48, 
1.95) 0.920 
0.96 (0.47, 
1.93) 0.900 
South Asian 0.92 (0.44, 
1.92) 0.814 
0.95 (0.45, 
1.99) 0.893 
0.94 (0.45, 
1.97) 0.873 
0.94 (0.45, 
1.97) 0.870 
0.96 (0.46, 
2.02) 0.924 
0.96 (0.46, 
2.02) 0.923 
Afro 
Caribbean 
1.27 (0.47, 
3.44) 0.637 
1.60 (0.62, 
4.11) 0.333 
1.45 (0.55, 
3.81) 0.455 
1.27 (0.47, 
3.43) 0.639 
1.44 (0.55, 
3.79) 0.463 
1.43 (0.54, 
3.77) 0.468 
Age 1.02 (1.01, 
1.02) 0.000 
1.02 (1.01, 
1.02) 0.000 
1.02 (1.01, 
1.02) 0.000 
1.02 (1.01, 
1.02) 0.000 
1.02 (1.01, 
1.02) 0.000 
1.02 (1.01, 
1.02) 0.000 
Male 0.97 (0.88, 
1.07) 0.520 
0.97 (0.88, 
1.07) 0.525 
0.95 (0.86, 
1.04) 0.278 
0.97 (0.88, 
1.06) 0.473 
0.96 (0.87, 
1.05) 0.380 
0.97 (0.88, 
1.06) 0.504 
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Table 55: Logistic regression analyses of missing data on blood pressure and lipid treatments allowing for demographic variables 
 Diuretics 
missing 
Beta blockers 
missing 
Alpha 
blockers 
missing 
ACE 
inhibitors 
missing 
AT2 blockers 
missing 
Calcium 
anatagonists 
missing 
Aspirin 
missing 
Lipid therapy 
missing 
Ref. group: Most deprived 
Q2 0.96 (0.90, 
1.03) 0.291 
0.90 (0.84, 
0.96) 0.002 
0.92 (0.87, 
0.98) 0.012 
0.94 (0.88, 
1.01) 0.086 
0.91 (0.85, 
0.96) 0.002 
0.93 (0.87, 
0.99) 0.030 
0.97 (0.90, 
1.03) 0.32 
0.93 (0.88, 
0.98) 0.011 
Q3 0.98 (0.90, 
1.06) 0.616 
0.93 (0.86, 
1.00) 0.062 
0.96 (0.89, 
1.03) 0.255 
0.97 (0.90, 
1.06) 0.53 
0.95 (0.88, 
1.02) 0.141 
0.95 (0.88, 
1.03) 0.219 
0.98 (0.91, 
1.07) 0.695 
0.92 (0.86, 
0.99) 0.017 
Q4 1.08 (0.99, 
1.18) 0.077 
1.00 (0.92, 
1.09) 0.938 
1.05 (0.97, 
1.13) 0.261 
0.99 (0.90, 
1.08) 0.825 
1.01 (0.94, 
1.10) 0.725 
1.04 (0.96, 
1.14) 0.344 
1.03 (0.94, 
1.12) 0.579 
0.98 (0.91, 
1.06) 0.667 
Q5: Least 
deprived 
0.52 (0.42, 
0.64) 0.000 
0.52 (0.43, 
0.64) 0.000 
0.49 (0.40, 
0.60) 0.000 
0.52 (0.42, 
0.65) 0.000 
0.55 (0.45, 
0.66) 0.000 
0.49 (0.39, 
0.60) 0.000 
0.55 (0.45, 
0.68) 0.000 
0.55 (0.46, 
0.65) 0.000 
White 0.82 (0.57, 
1.17) 0.272 
0.70 (0.50, 
0.97) 0.032 
0.84 (0.60, 
1.17) 0.301 
0.73 (0.51, 
1.04) 0.083 
0.95 (0.68, 
1.35) 0.787 
0.88 (0.61, 
1.26) 0.488 
0.74 (0.52, 
1.05) 0.095 
1.01 (0.72, 
1.41) 0.963 
South Asian 1.03 (0.71, 
1.50) 0.872 
0.82 (0.58, 
1.16) 0.272 
1.000 (0.70, 
1.42) 0.993 
0.92 (0.64, 
1.33) 0.66 
1.09 (0.76, 
1.56) 0.638 
1.06 (0.73, 
1.55) 0.744 
0.82 (0.57, 
1.19) 0.293 
1.14 (0.81, 
1.61) 0.456 
Afro 
Caribbean 
1.24 (0.73, 
2.10) 0.424 
1.20 (0.74, 
1.95) 0.454 
1.22 (0.75, 
1.99) 0.425 
1.13 (0.67, 
1.91) 0.636 
1.55 (0.96, 
2.51) 0.071 
1.15 (0.68, 
1.97) 0.598 
1.17 (0.70, 
1.96) 0.548 
1.46 (0.91, 
2.34) 0.112 
Age 0.99 (0.99, 
1.00) 0.000 
1.00 (1.00, 
1.00) 0.939 
1.00 (1.00, 
1.00) 0.339 
1.00 (1.00, 
1.00) 0.304 
1.00 (1.00, 
1.00) 0.835 
1.00 (1.00, 
1.00) 0.12 
0.99 (0.99, 
1.00) 0.000 
1.00 (1.00, 
1.00) 0.042 
Male 1.07 (1.01, 
1.13) 0.023 
0.94 (0.89, 
0.99) 0.015 
0.95 (0.90, 
1.00) 0.044 
0.90 (0.86, 
0.95) 0.000 
0.99 (0.95, 
1.04) 0.803 
0.94 (0.9, 
1.00) 0.034 
0.88 (0.84, 
0.93) 0.000 
0.98 (0.94, 
1.03) 0.408 
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Appendix F. Stepwise models for intermediate outcomes and 
long-term complications with interaction between visit year and 
socio-economic status 
 
Intermediate health outcomes 
 
Table 56: Stepwise linear regression multilevel models examining HbA1c by SES from 
1999 to 2007, with interaction effect between SES and visit year and conditional on 
relevant explanatory variables 
 Null Model 1 Model 2 Model 3 
Social-economic status & visit year 
Social-economic status, reference group: Low SES 
Medium SES  -0.04 (-0.21, 
0.14) 
-0.05 (-0.22, 
0.12) 
-0.09 (-0.26, 
0.06) 
High SES  0.02 (-0.14, 0.18) 0.08 (-0.08, 0.23) 0.04 (-0.10,  
0.19) 
Visit year, reference group: 1999 
2000  -0.17 (-0.31, -
0.04) 
-0.18 (-0.31, -
0.05) 
-0.24 (-0.37, -
0.12) 
2001  -0.45 (-0.59, -
0.32) 
-0.43 (-0.56, -
0.30) 
-0.47 (-0.59, -
0.35) 
2002  -0.52 (-0.64, -
0.39) 
-0.51 (-0.62, -
0.39) 
-0.49 (-0.60, -
0.38) 
2003  -0.55 (-0.67, -
0.43) 
-0.54 (-0.65, -
0.42) 
-0.53 (-0.64, -
0.43) 
2004  -0.62 (-0.74, -
0.50) 
-0.62 (-0.74, -
0.51) 
-0.61 (-0.71, -
0.50) 
2005  -0.69 (-0.81, -
0.58) 
-0.70 (-0.81, -
0.59) 
-0.68 (-0.79, -
0.58) 
2006  -1.22 (-1.34, -
1.10) 
-1.21 (-1.33, -
1.10) 
-1.16 (-1.27, -
1.06) 
2007  -1.08 (-1.19, -
0.96) 
-1.09 (-1.21, -
0.98) 
-1.11 (-1.22, -
1.00) 
SES x Visit year, reference group: Low SES x 1999 
Medium SES x 2000  -0.13 (-0.37, 
0.11) 
-0.08 (-0.31, 
0.16) 
0.01 (-0.20, 0.23) 
Medium SES x 2001  -0.01 (-0.24, 
0.22) 
0.05 (-0.18, 0.27) 0.14 (-0.07, 0.35) 
Medium SES x 2002  -0.17 (-0.38, 
0.05) 
-0.11 (-0.31, 
0.10) 
-0.04 (-0.23, 
0.15) 
Medium SES x 2003  -0.15 (-0.35, 
0.07) 
-0.08 (-0.28, 
0.12) 
0.01 (-0.18, 0.20) 
Medium SES x 2004  -0.10 (-0.31, 
0.10) 
-0.02 (-0.22, 
0.18) 
0.03 (-0.15, 0.22) 
Medium SES x 2005  -0.09 (-0.29, 
0.11) 
-0.01 (-0.21, 
0.19) 
0.05 (-0.13, 0.24) 
Medium SES x 2006  -0.03 (-0.23, 
0.17) 
0.04 (-0.16, 0.23) 0.08 (-0.11, 0.26) 
Medium SES x 2007  -0.02 (-0.22, 
0.19) 
0.06 (-0.15, 0.26) 0.11 (-0.07, 0.30) 
High SES x 2000  -0.32 (-0.54, -
0.10) 
-0.31 (-0.52, -
0.10) 
-0.26 (-0.46, -
0.06) 
High SES x 2001  -0.15 (-0.36, 
0.07) 
-0.17 (-0.37, 
0.04) 
-0.09 (-0.28, 
0.10) 
High SES x 2002  -0.21 (-0.40, -
0.01) 
-0.18 (-0.37, 
0.02) 
-0.16 (-0.34, 
0.02) 
High SES x 2003  -0.25 (-0.44, - -0.24 (-0.43, - -0.20 (-0.37, -
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N = 38,413 
 
0.06) 0.06) 0.02) 
High SES x 2004  -0.16 (-0.34, 
0.02) 
-0.12 (-0.30, 
0.06) 
-0.11 (-0.28, 
0.06) 
High SES x 2005  -0.23 (-0.41, -
0.04) 
-0.18 (-0.36, 
0.00) 
-0.14 (-0.31, 
0.03) 
High SES x 2006  -0.19 (-0.37, 
0.00) 
-0.16 (-0.34, 
0.01) 
-0.11 (-0.28, 
0.05) 
High SES x 2007  -0.24 (-0.42, -
0.06) 
-0.19 (-0.37, -
0.01) 
-0.13 (-0.30, 
0.04) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age, reference group: <60 years 
Age: 60-74 years   -0.46 (-0.50, -
0.42) 
-0.33 (-0.36, -
0.29) 
Age: 75+ years   -0.69 (-0.73, -
0.64) 
-0.41 (-0.46, -
0.37) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   0.38 (0.35, 0.41) 0.06 (0.02, 0.09) 
Duration 10+ years   0.70 (0.66, 0.74) 0.05 (0.01, 0.10) 
Ethnicity, reference group: White 
South Asian   0.47 (0.39, 0.55) 0.46 (0.39, 0.54) 
Other Ethnicity   0.66 (0.48, 0.83) 0.47 (0.31, 0.63) 
Male   -0.12 (-0.15, -
0.09) 
-0.06 (-0.09, -
0.03) 
Smoking status, reference group: Non smoker 
Smoker   0.25 (0.21, 0.30) 0.23 (0.19, 0.27) 
Ex-smoker   0.07 (0.04, 0.11) 0.05 (0.02, 0.08) 
BMI status, reference group: Low & normal weight 
Overweight   0.06 (0.01, 0.10) 0.02 (-0.02, 0.07) 
Obese   0.19 (0.15, 0.24) 0.08 (0.04, 0.13) 
Creatinine > 300   -0.85 (-1.10, -
0.59) 
-0.81 (-1.06, -
0.56) 
Hypertensive   0.14 (0.11, 0.17) 0.10 (0.07, 0.13) 
Ischaemic Cardiac   0.05 (0.01, 0.08) 0.00 (-0.04, 0.03) 
Stroke or TIA   -0.01 (-0.06, 
0.04) 
-0.06 (-0.10, -
0.01) 
PVD   0.09 (0.04, 0.15) -0.06 (-0.12, -
0.01) 
Interventions 
Quality of Care level, reference group: Low quality 
Medium quality    -0.13 (-0.16, -
0.09) 
High quality    -0.15 (-0.19, -
0.11) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas only    0.81 (0.77, 0.85) 
Combination with no insulin    1.25 (1.20, 1.29) 
Insulin only    1.67 (1.61, 1.73) 
Combination with insulin    1.75 (1.69, 1.82) 
Shared care    0.17 (0.13, 0.21) 
Middlesbrough PCT    0.10 (0.00, 0.20) 
Cons 7.62  
(7.49, 7.74) 
8.50 (8.37, 8.62) 8.25 (8.13, 8.38) 7.56 (7.42, 7.70) 
Variance estimate at: 
Practice level 0.05 (0.03, 
0.08) 
0.04 (0.03, 0.07) 0.03 (0.02, 0.05) 0.02 (0.01, 0.04)  
Patient level 0.02 (0.01, 
0.06) 
0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 0.00 (0.00, 0.02)  
Visit year 2.47 (2.43, 
2.50) 
2.36 (2.32, 2.39) 2.20 (2.17, 2.23) 1.91 (1.88, 1.94)  
Bayesian DIC 145158.08 143556.00 140856.59 133988.98 
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Table 57: Stepwise linear regression multilevel models examining cholesterol by SES 
from 1999 to 2007, with interaction effect between SES and visit year and conditional on 
relevant explanatory variables 
 Null Model 1 Model 2 Model 3 
Social-economic status & visit year 
Social-economic status, reference group: Lowest SES 
Medium SES  0.05 (-0.15, 0.25) 0.07 (-0.13, 0.27) 0.06 (-0.13, 0.26) 
High SES  -0.24 (-0.42, -
0.06) 
-0.21 (-0.38, -
0.03) 
-0.22 (-0.40, -
0.05) 
Visit year, reference group: 1999 
2000  -0.27 (-0.41, -
0.14) 
-0.25 (-0.38, -
0.12) 
-0.25 (-0.38, -
0.12) 
2001  -0.32 (-0.45, -
0.18) 
-0.29 (-0.42, -
0.16) 
-0.28 (-0.41, -
0.16) 
2002  -0.35 (-0.48, -
0.22) 
-0.31 (-0.43, -
0.19) 
-0.29 (-0.41, -
0.16) 
2003  -0.55 (-0.68, -
0.43) 
-0.50 (-0.62, -
0.38) 
-0.43 (-0.55, -
0.31) 
2004  -0.80 (-0.93, -
0.68) 
-0.75 (-0.87, -
0.63) 
-0.64 (-0.76, -
0.52) 
2005  -0.98 (-1.10, -
0.85) 
-0.91 (-1.03, -
0.79) 
-0.79 (-0.91, -
0.67) 
2006  -1.14 (-1.27, -
1.02) 
-1.06 (-1.18, -
0.95) 
-0.92 (-1.04, -
0.80) 
2007  -1.18 (-1.31, -
1.06) 
-1.1 (-1.22, -0.98) -0.99 (-1.11, -
0.87) 
SES x Visit year, reference group: Low SES x 1999 
Medium SES x 2000  0.01 (-0.23, 0.25) -0.01 (-0.25, 
0.22) 
-0.01 (-0.24, 
0.22) 
Medium SES x 2001  -0.01 (-0.24, 
0.23) 
-0.02 (-0.25, 
0.20) 
-0.02 (-0.24, 
0.20) 
Medium SES x 2002  -0.03 (-0.26, 
0.19) 
-0.03 (-0.25, 
0.19) 
-0.02 (-0.23, 
0.20) 
Medium SES x 2003  -0.04 (-0.26, 
0.18) 
-0.04 (-0.26, 
0.18) 
-0.04 (-0.25, 
0.17) 
Medium SES x 2004  -0.07 (-0.29, 
0.14) 
-0.07 (-0.29, 
0.14) 
-0.06 (-0.27, 
0.15) 
Medium SES x 2005  -0.09 (-0.3, 0.13) -0.09 (-0.30, 
0.12) 
-0.08 (-0.29, 
0.13) 
Medium SES x 2006  0.02 (-0.20, 0.23) 0.01 (-0.20, 0.22) 0.02 (-0.18, 0.23) 
Medium SES x 2007  -0.05 (-0.26, 
0.17) 
-0.04 (-0.26, 
0.17) 
-0.03 (-0.24, 
0.18) 
High SES x 2000  0.17 (-0.04, 0.39) 0.16 (-0.05, 0.36) 0.16 (-0.05, 0.37) 
High SES x 2001  0.27 (0.07, 0.49) 0.26 (0.05, 0.46) 0.26 (0.06, 0.46) 
High SES x 2002  0.20 (0.00, 0.40) 0.20 (0.00, 0.39) 0.22 (0.02, 0.41) 
High SES x 2003  0.19 (0.00, 0.39) 0.19 (0.00, 0.38) 0.20 (0.01, 0.39) 
High SES x 2004  0.20 (0.00, 0.39) 0.20 (0.01, 0.38) 0.22 (0.04, 0.41) 
High SES x 2005  0.20 (0.02, 0.40) 0.20 (0.02, 0.39) 0.22 (0.04, 0.41) 
High SES x 2006  0.24 (0.05, 0.43) 0.24 (0.05, 0.43) 0.27 (0.08, 0.45) 
High SES x 2007  0.19 (0.00, 0.39) 0.19 (0.01, 0.38) 0.21 (0.02, 0.39) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age, reference group: <60 years 
Age: 60-74 years   -0.21 (-0.23, -
0.18) 
-0.20 (-0.23, -
0.17) 
Age: 75+ years   -0.23 (-0.26, -
0.20) 
-0.26 (-0.30, -
0.23) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   -0.11 (-0.13, -
0.08) 
-0.09 (-0.11, -
0.06) 
Duration 10+ years   -0.16 (-0.19, -
0.13) 
-0.13 (-0.16, -
0.10) 
Ethnicity, reference group: White 
South Asian   -0.06 (-0.12, - -0.08 (-0.14, -
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0.01) 0.02) 
Other Ethnicity   0.11 (-0.02, 0.24) 0.08 (-0.05, 0.20) 
Male   -0.33 (-0.35, -
0.31) 
-0.34 (-0.36, -
0.32) 
Smoking status, reference group: Non smoker 
Smoker   0.08 (0.05, 0.11) 0.08 (0.05, 0.11) 
Ex-smoker   -0.02 (-0.04, 
0.01) 
0.00 (-0.03, 0.02) 
BMI, reference group: Under or normal weight 
Overweight   0.00 (-0.03, 0.04) 0.03 (0.00, 0.07) 
Obese   0.00 (-0.04, 0.03) 0.03 (0.00, 0.07) 
Hypertensive   0.14 (0.12, 0.16) 0.14 (0.12, 0.16) 
Ischaemic Cardiac   -0.21 (-0.24, -
0.19) 
-0.13 (-0.15, -
0.10) 
Stroke or TIA   -0.05 (-0.09, -
0.02) 
-0.02 (-0.06, 
0.01) 
PVD   -0.02 (-0.06, 
0.03) 
0.01 (-0.03, 0.05) 
Interventions 
Quality of Care level, reference group: Low quality 
Medium quality    -0.10 (-0.13, -
0.07) 
High quality    -0.15 (-0.18, -
0.11) 
Aspirin    -0.09 (-0.11, -
0.06) 
Lipid therapy    -0.28 (-0.31, -
0.26) 
M. PCT    -0.03 (-0.09, 
0.03) 
Shared care    -0.07 (-0.10, -
0.04) 
Cons 4.65 (4.60, 
4.70) 
5.40 (5.26, 5.54) 5.79 (5.66, 5.92) 5.98 (5.85, 6.12) 
Variance estimates (Standard Error): 
Practice level 0.01 (0.01, 
0.02) 
0.01 (0.01, 0.02) 0.01 (0.01, 0.02) 0.01 (0.01, 0.01) 
Patient level 0.00 (0.00, 
0.01) 
0.01 (0.00, 0.03) 0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 
Visit year 1.35 (1.33, 
1.37) 
1.24 (1.22, 1.25) 1.17 (1.15, 1.18) 1.14 (1.13, 1.16) 
Bayesian DIC 116373.88 113194.24 111042.23 110350.13 
N = 37,085 
 
Long-term complications 
 
Table 58: Stepwise logistic regression multilevel models examining incidences of ICD by 
SES 2000 to 2007, with interaction effect between SES and visit year and conditional on 
relevant explanatory variables 
 Null Model 1 Model 2 Model 3 
Social-economic status & visit year 
Social-economic status, reference group: Low 
Medium  -0.55 (-1.05, -
0.07) 
-0.66 (-1.17, -
0.17) 
-0.73 (-1.31, -
0.15) 
High  -0.40 (-0.85, 
0.03) 
-0.36 (-0.85, 
0.11) 
-0.30 (-0.83, 
0.23) 
Visit year, reference group: 2000 
2001  -0.28 (-0.65, 
0.08) 
-0.42 (-0.80, -
0.04) 
-0.55 (-0.97, -
0.10) 
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2002  -0.13 (-0.45, 
0.18) 
-0.23 (-0.55, 
0.11) 
-0.36 (-0.73, 
0.03) 
2003  -0.18 (-0.49, 
0.11) 
-0.32 (-0.63, 
0.00) 
-0.68 (-1.04, -
0.30) 
2004  -0.22 (-0.52, 
0.07) 
-0.43 (-0.75, -
0.11) 
-0.84 (-1.20, -
0.45) 
2005  -0.60 (-0.92, -
0.30) 
-0.89 (-1.22, -
0.55) 
-1.34 (-1.72, -
0.94) 
2006  -1.15 (-1.48, -
0.82) 
-1.47 (-1.82, -
1.12) 
-1.89 (-2.27, -
1.46) 
2007  -1.01 (-1.35, -
0.67) 
-1.34 (-1.70, -
0.98) 
-1.95 (-2.35, -
1.52) 
SES x Visit year, reference group: Low SES x 2000 
Medium SES x 2001  0.45 (-0.20, 1.10) 0.53 (-0.15, 1.20) 0.54 (-0.26, 1.31) 
Medium SES x 2002  0.37 (-0.21, 0.95) 0.43 (-0.17, 1.05) 0.41 (-0.28, 1.09) 
Medium SES x 2003  0.72 (0.16, 1.30) 0.80 (0.21, 1.38) 0.91 (0.25, 1.58) 
Medium SES x 2004  0.56 (0.00, 1.14) 0.59 (0.01, 1.17) 0.60 (-0.09, 1.24) 
Medium SES x 2005  0.36 (-0.22, 0.96) 0.40 (-0.23, 1.00) 0.41 (-0.28, 1.08) 
Medium SES x 2006  0.53 (-0.09, 1.15) 0.63 (0.00, 1.26) 0.69 (-0.02, 1.37) 
Medium SES x 2007  0.37 (-0.25, 0.99) 0.40 (-0.24, 1.05) 0.37 (-0.37, 1.08) 
High SES x 2001  0.37 (-0.24, 0.99) 0.34 (-0.30, 0.98) 0.49 (-0.23, 1.21) 
High SES x 2002  0.18 (-0.37, 0.73) 0.04 (-0.54, 0.63) -0.11 (-0.76, 
0.53) 
High SES x 2003  0.26 (-0.25, 0.79) 0.20 (-0.34, 0.75) 0.30 (-0.32, 0.92) 
High SES x 2004  0.33 (-0.19, 0.85) 0.21 (-0.33, 0.78) 0.13 (-0.48, 0.73) 
High SES x 2005  0.17 (-0.37, 0.72) 0.08 (-0.50, 0.69) 0.02 (-0.60, 0.63) 
High SES x 2006  0.40 (-0.15, 0.97) 0.33 (-0.25, 0.94) 0.20 (-0.45, 0.84) 
High SES x 2007  0.30 (-0.26, 0.87) 0.22 (-0.37, 0.82) 0.18 (-0.47, 0.83) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age, reference group: <60 years 
Age: 60-74 years   0.65 (0.51, 0.79) 0.33 (0.18, 0.48) 
Age: 75+ years   0.83 (0.66, 1.01) 0.60 (0.41, 0.78) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   -0.63 (-0.75, -
0.50) 
-0.59 (-0.74, -
0.45) 
Duration 10+ years   -0.56 (-0.70, -
0.42) 
-0.63 (-0.80, -
0.47) 
Ethnicity, reference group: White 
South Asian    -0.11 (-0.42, 
0.18) 
0.08 (-0.25, 0.40) 
Other Ethnicity   -0.63 (-1.44, 
0.08) 
-0.68 (-1.55, 
0.09) 
Male   0.36 (0.24, 0.47) 0.33 (0.21, 0.45) 
Smoking status, reference group: non smoker 
Smoker   0.16 (0.00, 0.32) 0.15 (-0.02, 0.32) 
Ex-smoker   0.34 (0.22, 0.46) 0.31 (0.18, 0.44) 
Obesity category, reference group: under & normal weight 
Overweight   0.10 (-0.06, 0.27) -0.02 (-0.20, 
0.15) 
Obese   0.35 (0.19, 0.51) 0.12 (-0.06, 0.29) 
HbA1c   0.06 (0.02, 0.09) 0.07 (0.03, 0.11) 
Hypertensive   -0.19 (-0.30, -
0.08) 
-0.28 (-0.40, -
0.16) 
Cholesterol   -0.33 (-0.38, -
0.27) 
-0.23 (-0.29, -
0.17) 
eGFR   -0.02 (-0.02, -
0.01) 
-0.01 (-0.01, 
0.00) 
Interventions 
Quality of care level, reference group: Low quality 
Medium quality    -0.31 (-0.44, -
0.17) 
High quality    -0.40 (-0.57, -
0.24) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas only    -0.28 (-0.42, -
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0.13) 
Combination, no insulin    -0.40 (-0.60, -
0.20) 
Insulin only    0.12 (-0.12, 0.37) 
Combination with insulin    -0.29 (-0.58, -
0.01) 
Blood pressure treatment, reference group: No treatments 
ACE inhibitors only    0.26 (0.00, 0.52) 
ACEI + other(s)    1.50 (1.31, 1.70) 
Combination/other    1.25 (1.05, 1.44) 
Aspirin    1.38 (1.26, 1.50) 
Lipid therapy    0.61 (0.48, 0.74) 
M. PCT    -0.20 (-0.39, -
0.01) 
Shared care    0.27 (0.11, 0.43) 
Cons -3.98 (-5.22, -
2.58) 
-3.60 (-4.76, -
2.58) 
-1.89 (-3.91, -
0.24) 
-3.50 (-4.69, -
2.18) 
Variance estimate at: 
Practice level 0.04 (0.02, 
0.09) 
0.04 (0.01, 0.08) 0.03 (0.01, 0.07) 0.05 (0.02, 0.11) 
Patient level 2.44 (0.59, 
8.18) 
2.48 (0.65, 7.79) 2.70 (0.61, 9.53) 2.15 (0.53, 7.50) 
Bayesian DIC 11620.93 11425.04 10735.28 9208.63 
N = 24,004
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Table 59: Stepwise logistic regression multilevel models examining incidences of stroke 
or TIA by SES 2000 to 2007 with interaction effect between SES and visit year, 
conditional on relevant explanatory variables 
 Null Model 1 Model 2 Model 3 
Social-economic status & visit year 
Social-economic status, reference group: Low SES 
Medium  0.05 (-0.67, 0.72) 0.06 (-0.68, 0.78) 0.20 (-0.50, 0.93) 
High  -0.10 (-0.82, 
0.61) 
-0.12 (-0.87, 
0.58) 
0.05 (-0.69, 0.80) 
Visit year, reference group: 2000 
2001  0.21 (-0.34, 0.76) 0.16 (-0.40, 0.71) 0.32 (-0.25, 0.92) 
2002  0.11 (-0.38, 0.61) 0.06 (-0.45, 0.58) 0.21 (-0.32, 0.78) 
2003  0.25 (-0.22, 0.75) 0.22 (-0.27, 0.71) 0.31 (-0.19, 0.85) 
2004  0.00 (-0.46, 0.49) -0.05 (-0.53, 
0.44) 
0.09 (-0.41, 0.64) 
2005  -0.31 (-0.80, 
0.19) 
-0.35 (-0.86, 
0.15) 
-0.20 (-0.71, 
0.39) 
2006  -0.98 (-1.52, -
0.42) 
-1.04 (-1.59, -
0.49) 
-0.87 (-1.45, -
0.24) 
2007  -0.62 (-1.13, -
0.09) 
-0.67 (-1.21, -
0.14) 
-0.53 (-1.11, 
0.09) 
SES x Visit year, reference group: Low SES x 2000 
Medium SES x 2001  -0.17 (-1.07, 
0.75) 
-0.18 (-1.12, 
0.77) 
-0.25 (-1.20, 
0.67) 
Medium SES x 2002  -0.04 (-0.85, 
0.82) 
-0.09 (-0.96, 
0.79) 
-0.24 (-1.12, 
0.62) 
Medium SES x 2003  0.02 (-0.76, 0.86) 0.00 (-0.84, 0.85) -0.05 (-0.89, 
0.77) 
Medium SES x 2004  -0.21 (-1.03, 
0.64) 
-0.27 (-1.12, 
0.59) 
-0.41 (-1.25, 
0.41) 
Medium SES x 2005  0.07 (-0.74, 0.92) -0.03 (-0.88, 
0.86) 
-0.20 (-1.07, 
0.65) 
Medium SES x 2006  0.39 (-0.47, 1.29) 0.35 (-0.53, 1.27) 0.16 (-0.75, 1.04) 
Medium SES x 2007  -0.37 (-1.28, 
0.56) 
-0.46 (-1.42, 
0.49) 
-0.70 (-1.67, 
0.26) 
High SES x 2001  -0.11 (-1.05, 
0.83) 
-0.08 (-1.03, 
0.89) 
-0.13 (-1.09, 
0.82) 
High SES x 2002  -0.25 (-1.15, 
0.64) 
-0.27 (-1.16, 
0.67) 
-0.40 (-1.32, 
0.50) 
High SES x 2003  -0.47 (-1.36, 
0.37) 
-0.49 (-1.33, 
0.39) 
-0.56 (-1.44, 
0.29) 
High SES x 2004  0.32 (-0.48, 1.12) 0.29 (-0.50, 1.13) 0.16 (-0.67, 0.98) 
High SES x 2005  0.39 (-0.42, 1.23) 0.32 (-0.50, 1.19) 0.17 (-0.71, 1.02) 
High SES x 2006  0.30 (-0.59, 1.22) 0.28 (-0.62, 1.21) 0.06 (-0.88, 0.99) 
High SES x 2007  0.12 (-0.75, 0.99) 0.09 (-0.77, 1.00) -0.07 (-1.00, 
0.83) 
Age, reference group: <60 years 
Age: 60-74 years   0.86 (0.63, 1.09) 0.74 (0.50, 0.99) 
Age: 75+ years   1.21 (0.95, 1.48) 1.10 (0.82, 1.38) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   -0.31 (-0.50, -
0.13) 
-0.31 (-0.49, -
0.12) 
Duration 10+ years   -0.04 (-0.22, 
0.15) 
-0.18 (-0.39, 
0.03) 
Ethnicity, reference group: White 
South Asian    0.04 (-0.39, 0.43) 0.11 (-0.34, 0.53) 
Other Ethnicity   -1.20 (-3.04, 
0.13) 
-1.17 (-3.07, 
0.17) 
Male   0.01 (-0.15, 0.17) -0.11 (-0.28, 
0.06) 
Smoking status, reference group: non smoker 
Smoker   0.31 (0.08, 0.53) 0.28 (0.05, 0.51) 
Ex-smoker   0.21 (0.04, 0.38) 0.14 (-0.04, 0.31) 
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Obesity category, reference group: under & normal weight 
Overweight   -0.06 (-0.27, 
0.15) 
-0.08 (-0.29, 
0.13) 
Obese   -0.09 (-0.30, 
0.11) 
-0.19 (-0.41, 
0.03) 
HbA1c   0.02 (-0.03, 0.07) 0.02 (-0.03, 0.07) 
Hypertensive   0.15 (0.00, 0.31) 0.14 (-0.01, 0.30) 
Cholesterol   -0.11 (-0.19, -
0.04) 
-0.09 (-0.17, -
0.02) 
eGFR   -0.01 (-0.02, -
0.01) 
-0.01 (-0.01, 
0.00) 
Interventions 
Quality of care level, reference group: Low quality 
Medium quality    -0.17 (-0.36, 
0.03) 
High quality    -0.03 (-0.24, 
0.19) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas only    -0.18 (-0.38, 
0.02) 
Combo., no insulin    -0.30 (-0.56, -
0.04) 
Insulin only    -0.08 (-0.39, 
0.23) 
Combo., with insulin    -0.29 (-0.68, 
0.08) 
Blood pressure treatment, reference group: No treatments 
ACE inhibitors only    0.31 (0.03, 0.61) 
ACE + other(s)    0.16 (-0.08, 0.40) 
Combination/other    0.18 (-0.05, 0.43) 
Aspirin    1.06 (0.89, 1.23) 
Lipid therapy    0.08 (-0.09, 0.26) 
M. PCT    -0.12 (-0.39, 
0.14) 
Shared care    0.45 (0.24, 0.65) 
Cons -4.63 (-5.38, -
3.86) 
-4.56 (-5.92, -
3.61) 
-4.2 (-5.32, -
3.17) 
-5.14 (-6.50, -
4.01) 
Variance estimate at: 
Practice level 0.10 (0.04, 
0.21) 
0.08 (0.03, 0.18) 0.07 (0.01, 0.16) 0.11 (0.04, 0.22) 
Patient level 1.23 (0.31, 
4.03) 
1.45 (0.34, 5.10) 1.33 (0.33, 4.41) 1.36 (0.33, 4.57) 
Bayesian DIC 6705.64 6651.42 6444.78 6143.66 
N = 29,800 
  
Table 60: Stepwise logistic regression multilevel models examining incidences of PVD by 
SES 2000 to 2007 with interaction effect between SES and visit year, conditional on 
relevant explanatory variables 
 Null Model 1 Model 2 Model 3 
Social-economic status & visit year 
Social-economic status, reference group: Low 
Medium  -0.35 (-1.06, 
0.33) 
-0.33 (-1.08, 
0.39) 
-0.19 (-0.98, 
0.53) 
High  -0.26 (-0.95, 
0.39) 
-0.18 (-0.85, 
0.50) 
-0.03 (-0.77, 
0.65) 
Visit year, reference group: 2000 
2001  -0.56 (-1.15, 
0.02) 
-0.54 (-1.16, 
0.09) 
-0.38 (-1.00, 
0.23) 
2002  -0.34 (-0.84, 
0.15) 
-0.34 (-0.85, 
0.18) 
-0.17 (-0.71, 
0.37) 
2003  -0.15 (-0.61, -0.09 (-0.55, 0.11 (-0.39, 0.63) 
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0.31) 0.39) 
2004  -0.20 (-0.64, 
0.27) 
-0.12 (-0.57, 
0.37) 
0.16 (-0.34, 0.67) 
2005  -0.80 (-1.29, -
0.31) 
-0.74 (-1.24, -
0.22) 
-0.40 (-0.94, 
0.14) 
2006  -1.01 (-1.51, -
0.52) 
-0.88 (-1.39, -
0.38) 
-0.62 (-1.18, -
0.06) 
2007  -1.55 (-2.15, -
0.97) 
-1.47 (-2.08, -
0.87) 
-1.09 (-1.76, -
0.45) 
SES x Visit year, reference group: Low SES x 2000 
Medium SES x 2001  0.65 (-0.31, 1.64) 0.63 (-0.38, 1.63) 0.47 (-0.52, 1.49) 
Medium SES x 2002  0.47 (-0.37, 1.35) 0.49 (-0.40, 1.40) 0.39 (-0.49, 1.32) 
Medium SES x 2003  -0.07 (-0.91, 
0.77) 
-0.06 (-0.97, 
0.86) 
-0.12 (-1.04, 
0.80) 
Medium SES x 2004  0.03 (-0.78, 0.86) 0.00 (-0.86, 0.89) -0.18 (-1.04, 
0.73) 
Medium SES x 2005  0.28 (-0.60, 1.15) 0.24 (-0.68, 1.16) -0.05 (-0.99, 
0.93) 
Medium SES x 2006  0.00 (-0.94, 0.91) -0.06 (-1.03, 
0.90) 
-0.23 (-1.21, 
0.75) 
Medium SES x 2007  0.24 (-0.83, 1.27) 0.15 (-0.93, 1.26) -0.02 (-1.10, 
1.10) 
High SES x 2001  0.30 (-0.68, 1.26) 0.20 (-0.80, 1.17) 0.13 (-0.87, 1.13) 
High SES x 2002  -0.62 (-1.57, 
0.35) 
-0.63 (-1.62, 
0.30) 
-0.81 (-1.81, 
0.19) 
High SES x 2003  0.06 (-0.72, 0.87) -0.05 (-0.86, 
0.75) 
-0.17 (-0.98, 
0.68) 
High SES x 2004  -0.08 (-0.86, 
0.73) 
-0.20 (-1.01, 
0.61) 
-0.42 (-1.25, 
0.44) 
High SES x 2005  0.61 (-0.18, 1.45) 0.57 (-0.25, 1.38) 0.35 (-0.48, 1.22) 
High SES x 2006  -0.22 (-1.13, 
0.70) 
-0.33 (-1.26, 
0.58) 
-0.46 (-1.40, 
0.49) 
High SES x 2007  0.04 (-0.98, 1.05) -0.02 (-1.06, 
0.98) 
-0.14 (-1.21, 
0.91) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age, reference group: <60 years 
Age: 60-74 years   0.67 (0.42, 0.91) 0.63 (0.38, 0.89) 
Age: 75+ years   0.72 (0.42, 1.01) 0.83 (0.52, 1.14) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   0.25 (0.04, 0.45) 0.13 (-0.10, 0.35) 
Duration 10+ years   0.74 (0.53, 0.94) 0.38 (0.14, 0.62) 
Ethnicity, reference group: White 
South Asian    -0.88 (-1.60, -
0.25) 
-0.79 (-1.52, -
0.16) 
Other Ethnicity   0.02 (-1.02, 0.89) -0.04 (-1.10, 
0.84) 
Male   0.40 (0.22, 0.58) 0.39 (0.20, 0.58) 
Smoking status, reference group: non smoker 
Smoker   0.90 (0.66, 1.14) 0.94 (0.68, 1.19) 
Ex-smoker   0.42 (0.22, 0.63) 0.38 (0.17, 0.59) 
Obesity category, reference group: under & normal weight 
Overweight   -0.13 (-0.36, 
0.11) 
-0.20 (-0.46, 
0.05) 
Obese   -0.06 (-0.29, 
0.17) 
-0.25 (-0.50, 
0.00) 
HbA1c   0.07 (0.01, 0.12) 0.01 (-0.05, 0.07) 
Hypertensive   0.17 (0.00, 0.35) 0.13 (-0.05, 0.31) 
Cholesterol   -0.13 (-0.21, -
0.05) 
-0.05 (-0.13, 
0.03) 
eGFR   -0.01 (-0.02, -
0.01) 
-0.01 (-0.01, 
0.00) 
Interventions 
Quality of care level, reference group: Low quality 
Medium quality    -0.18 (-0.42, 
0.06) 
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High quality    0.19 (-0.06, 0.43) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas only    -0.05 (-0.31, 
0.21) 
Combo., no insulin    -0.12 (-0.43, 
0.20) 
Insulin only    0.33 (0.00, 0.67) 
Combo., with insulin    0.33 (-0.05, 0.71) 
Blood pressure treatment, reference group: No treatments 
ACE inhibitors only    0.50 (0.17, 0.83) 
Combination, with ACEI     0.43 (0.15, 0.72) 
Combination, no ACEI    0.38 (0.10, 0.67) 
Aspirin    0.57 (0.40, 0.76) 
Lipid therapy    0.10 (-0.09, 0.30) 
M. PCT    -0.17 (-0.54, 
0.21) 
Shared care    0.85 (0.63, 1.07) 
Cons -4.80 (-5.55, -
4.12) 
-4.17 (-4.99, -
3.32) 
-4.68 (-5.89, -
3.36) 
-6.09 (-7.60, -
4.69) 
Variance estimate at: 
Practice level 0.26 (0.13, 
0.45) 
0.26 (0.14, 0.47) 0.26 (0.14, 0.47) 0.28 (0.14, 0.48) 
Patient level 0.96 (0.26, 
2.98) 
0.99 (0.27, 3.08) 1.14 (0.31, 3.52) 1.43 (0.34, 4.92) 
Bayesian DIC 5910.02 5576.48 5325.55 5033.64 
N = 30,053 
 
Table 61: Stepwise logistic regression multilevel models examining incidences of 
microalbuminuria by SES 2000 to 2007 with interaction effect between SES and visit 
year, conditional on relevant explanatory variables 
 Null Model 1 Model 2 Model 3 
Social-economic status & visit year 
Social-economic status, reference group: Lowest SES 
Medium SES  0.38 (-0.31, 1.04) 0.33 (-0.32, 1.11) 0.52 (-0.20, 1.29) 
High SES  0.35 (-0.25, 0.86) 0.22 (-0.42, 0.78) 0.36 (-0.27, 1.07) 
Visit year, reference group: 1999 
2000  -0.02 (-0.43, 
0.41) 
-0.08 (-0.57, 
0.39) 
-0.11 (-0.60, 
0.41) 
2001  -0.16 (-0.56, 
0.26) 
-0.21 (-0.68, 
0.24) 
-0.35 (-0.83, 
0.16) 
2002  -0.37 (-0.75, 
0.04) 
-0.43 (-0.89, 
0.01) 
-0.75 (-1.20, -
0.25) 
2003  0.05 (-0.30, 0.44) 0.00 (-0.44, 0.42) -0.44 (-0.89, 
0.05) 
2004  0.78 (0.43, 1.15) 0.75 (0.31, 1.17) 0.30 (-0.14, 0.78) 
2005  1.05 (0.71, 1.42) 1.03 (0.59, 1.44) 0.51 (0.07, 1.00) 
2006  1.36 (1.02, 1.75) 1.38 (0.94, 1.80) 0.90 (0.46, 1.38) 
2007  0.91 (0.26, 1.55) 0.90 (0.22, 1.57) 0.56 (-0.15, 1.27) 
SES x Visit year, reference group: Low SES x 1999 
Medium SES x 2000  -0.35 (-1.14, 
0.47) 
-0.32 (-1.20, 
0.46) 
-0.49 (-1.38, 
0.36) 
Medium SES x 2001  -0.20 (-0.94, 
0.56) 
-0.14 (-0.99, 
0.61) 
-0.45 (-1.28, 
0.38) 
Medium SES x 2002  -0.05 (-0.77, 
0.69) 
0.03 (-0.79, 0.74) -0.20 (-1.01, 
0.57) 
Medium SES x 2003  -0.41 (-1.11, 
0.31) 
-0.34 (-1.14, 
0.35) 
-0.53 (-1.32, 
0.23) 
Medium SES x 2004  -0.54 (-1.21, 
0.18) 
-0.47 (-1.26, 
0.19) 
-0.66 (-1.43, 
0.08) 
Medium SES x 2005  -0.62 (-1.30, 
0.08) 
-0.56 (-1.35, 
0.11) 
-0.69 (-1.47, 
0.04) 
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Medium SES x 2006  -0.58 (-1.25, 
0.12) 
-0.53 (-1.32, 
0.13) 
-0.69 (-1.46, 
0.03) 
Medium SES x 2007  -0.38 (-1.31, 
0.55) 
-0.32 (-1.29, 
0.62) 
-0.63 (-1.60, 
0.35) 
High SES x 2000  -0.85 (-1.56, -
0.11) 
-0.67 (-1.43, 
0.10) 
-0.67 (-1.50, 
0.11) 
High SES x 2001  -0.48 (-1.11, 
0.21) 
-0.33 (-1.00, 
0.37) 
-0.52 (-1.29, 
0.21) 
High SES x 2002  -0.24 (-0.82, 
0.43) 
-0.08 (-0.70, 
0.60) 
-0.18 (-0.93, 
0.50) 
High SES x 2003  -0.62 (-1.18, 
0.02) 
-0.47 (-1.07, 
0.19) 
-0.57 (-1.31, 
0.10) 
High SES x 2004  -0.42 (-0.95, 
0.21) 
-0.27 (-0.85, 
0.38) 
-0.39 (-1.10, 
0.25) 
High SES x 2005  -0.52 (-1.05, 
0.10) 
-0.36 (-0.94, 
0.30) 
-0.46 (-1.18, 
0.18) 
High SES x 2006  -0.55 (-1.09, 
0.06) 
-0.41 (-0.99, 
0.25) 
-0.51 (-1.23, 
0.13) 
High SES x 2007  -0.55 (-1.82, 
0.67) 
-0.38 (-1.66, 
0.87) 
-0.45 (-1.78, 
0.82) 
Socio-demographic, anthropometric, lifestyle and health covariates 
Age, reference group: <60 years 
Age: 60-74 years   0.13 (0.05, 0.20) 0.01 (-0.06, 0.09) 
Age: 75+ years   0.53 (0.44, 0.62) 0.38 (0.28, 0.47) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   -0.01 (-0.08, 
0.06) 
-0.01 (-0.09, 
0.06) 
Duration 10+ years   0.08 (0.00, 0.16) 0.18 (0.09, 0.27) 
Ethnicity, reference group: White 
South Asian   0.16 (0.00, 0.32) 0.22 (0.05, 0.38) 
Other Ethnicity   0.19 (-0.18, 0.55) 0.30 (-0.07, 0.67) 
Male   0.23 (0.17, 0.30) 0.24 (0.18, 0.31) 
Smoking status, reference group: Non smoker 
Smoker   0.28 (0.19, 0.37) 0.26 (0.17, 0.36) 
Ex-smoker   0.08 (0.01, 0.15) 0.07 (0.00, 0.14) 
BMI, reference group: Under or normal weight 
Overweight   0.03 (-0.06, 0.13) -0.01 (-0.11, 
0.08) 
Obese   0.12 (0.03, 0.21) 0.06 (-0.04, 0.16) 
Hypertensive   0.14 (0.07, 0.20) 0.18 (0.11, 0.24) 
Cholesterol   0.03 (0.00, 0.05) 0.03 (0.00, 0.06) 
HbA1c   0.06 (0.04, 0.08) 0.09 (0.06, 0.11) 
Interventions 
Quality of Care level, reference group: Low quality 
Medium quality    -0.13 (-0.54, 
0.25) 
High quality    -0.25 (-0.66, 
0.14) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas 
only 
   0.14 (0.04, 0.24) 
Combination, no insulin    0.02 (-0.10, 0.13) 
Insulin only    0.18 (0.04, 0.32) 
Combination with insulin    0.20 (0.10, 0.30) 
Blood pressure treatment, reference group: No treatments 
ACE inhibitors only    0.36 (0.25, 0.47) 
Combination with ACEI    0.52 (0.43, 0.61) 
Combination, no ACEI    0.32 (0.22, 0.41) 
Aspirin    0.08 (0.01, 0.14) 
Lipid therapy    -0.05 (-0.12, 
0.02) 
Middlesbrough PCT    0.58 (0.29, 0.86) 
Shared care    -0.92 (-1.01, -
0.83) 
Cons -1.06 (-1.33, - -1.61 (-2.01, - -2.69 (-3.21, - -2.73 (-3.43, -
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0.84) 1.25) 2.11) 2.11) 
Variance estimates (Standard Error): 
Practice level 0.23 (0.15, 
0.37) 
0.24 (0.15, 0.39) 0.24 (0.15, 0.38) 0.21 (0.13, 0.34) 
Patient level 0.05 (0.01, 
0.21) 
0.01 (0.00 0.04) 0.01 (0.00, 0.04) 0.01 (0.00, 0.03) 
Bayesian DIC 27573.79 26339.88 26095.32 25480.02 
N = 23,304 
 
Table 62: Stepwise logistic regression multilevel models examining incidences of 
retinopathy by SES 2000 to 2007 with interaction effect between SES and visit year, 
conditional on relevant explanatory variables 
 Null Model 1 Model 2 Model 3 
Social-economic status & visit year 
Social-economic status, reference group: Low 
Medium 
 
-0.11 (-0.69, 
0.41) 
-0.26 (-0.94, 
0.37) 
-0.37 (-1.07, 
0.29) 
High 
 
-0.14 (-0.68, 
0.37) 
-0.42 (-1.00, 
0.17) 
-0.45 (-1.09, 
0.11) 
Visit year, reference group: 1999 
2000 
 
-0.23 (-0.59, 
0.14) 
-0.22 (-0.63, 
0.19) 
-0.17 (-0.60, 
0.26) 
2001 
 
-0.46 (-0.82, -
0.10) 
-0.34 (-0.73, 
0.06) 
-0.25 (-0.67, 
0.17) 
2002 
 
-0.43 (-0.77, -
0.09) 
-0.25 (-0.63, 
0.15) 
-0.10 (-0.51, 
0.30) 
2003 
 
-0.53 (-0.88, -
0.19) 
-0.30 (-0.69, 
0.08) 
-0.17 (-0.56, 
0.23) 
2004 
 
-0.57 (-0.91, -
0.23) 
-0.27 (-0.65, 
0.12) 
-0.06 (-0.46, 
0.34) 
2005 
 
-0.42 (-0.77, -
0.08) 
-0.10 (-0.50, 
0.31) 
0.11 (-0.31, 0.53) 
2006 
 
-1.72 (-2.08, -
1.36) 
-1.14 (-1.53, -
0.73) 
-0.94 (-1.36, -
0.50) 
2007 
 
-0.63 (-0.95, -
0.30) 
-0.02 (-0.39, 
0.37) 
0.23 (-0.18, 0.64) 
SES x Visit year, reference group: Low SES x 1999 
Medium SES x 2000  0.35 (-0.28, 1.03) 0.39 (-0.37, 1.17) 0.46 (-0.29, 1.25) 
Medium SES x 2001  0.33 (-0.29, 0.98) 0.34 (-0.39, 1.09) 0.48 (-0.26, 1.25) 
Medium SES x 2002 
 
-0.07 (-0.66, 
0.57) 
0.01 (-0.70, 0.76) 0.10 (-0.62, 0.85) 
Medium SES x 2003 
 
-0.38 (-0.98, 
0.25) 
-0.21 (-0.91, 
0.52) 
-0.05 (-0.77, 
0.71) 
Medium SES x 2004 
 
-0.05 (-0.62, 
0.58) 
0.13 (-0.56, 0.87) 0.24 (-0.47, 0.98) 
Medium SES x 2005 
 
-0.08 (-0.66, 
0.54) 
0.17 (-0.54, 0.90) 0.31 (-0.41, 1.05) 
Medium SES x 2006  0.26 (-0.34, 0.89) 0.39 (-0.31, 1.13) 0.54 (-0.16, 1.29) 
Medium SES x 2007  0.05 (-0.50, 0.65) 0.27 (-0.41, 0.98) 0.37 (-0.31, 1.10) 
High SES x 2000  0.15 (-0.47, 0.78) 0.40 (-0.29, 1.09) 0.36 (-0.32, 1.11) 
High SES x 2001  0.16 (-0.44, 0.78) 0.40 (-0.27, 1.06) 0.48 (-0.18, 1.20) 
High SES x 2002  0.16 (-0.41, 0.76) 0.42 (-0.23, 1.05) 0.39 (-0.23, 1.10) 
High SES x 2003  0.08 (-0.49, 0.68) 0.34 (-0.29, 0.98) 0.35 (-0.26, 1.04) 
High SES x 2004  0.03 (-0.52, 0.63) 0.32 (-0.33, 0.94) 0.35 (-0.27, 1.05) 
High SES x 2005  0.16 (-0.42, 0.75) 0.55 (-0.10, 1.19) 0.62 (-0.01, 1.32) 
High SES x 2006  0.08 (-0.51, 0.68) 0.37 (-0.28, 1.02) 0.45 (-0.18, 1.15) 
High SES x 2007 
 
-0.13 (-0.67, 
0.44) 
0.20 (-0.44, 0.81) 0.22 (-0.38, 0.89) 
Socio-demographic, anthropometric, lifestyle and health covariates 
 
Age: 60-74 years 
 
 -0.05 (-0.16, 
0.05) 
0.00 (-0.11, 0.11) 
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Age: 75+ years 
 
 -0.29 (-0.42, -
0.15) 
-0.11 (-0.25, 
0.03) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   0.64 (0.51, 0.77) 0.47 (0.34, 0.60) 
Duration 10+ years   2.00 (1.88, 2.13) 1.60 (1.47, 1.73) 
Ethnicity, reference group: White 
South Asian   -0.23 (-0.47, 
0.00) 
-0.16 (-0.39, 
0.08) 
Other Ethnicity   0.64 (0.21, 1.07) 0.53 (0.08, 0.95) 
Male   0.25 (0.16, 0.34) 0.25 (0.16, 0.34) 
Smoking status, reference group: non smoker 
Smoker   -0.14 (-0.27, -
0.01) 
-0.13 (-0.27, 
0.00) 
Ex-smoker   -0.10 (-0.19, -
0.01) 
-0.12 (-0.22, -
0.03) 
Obesity status, reference group: under and normal weight 
Overweight   -0.05 (-0.19, 
0.08) 
-0.09 (-0.22, 
0.04) 
Obese   0.02 (-0.11, 0.15) -0.10 (-0.23, 
0.03) 
HbA1c   0.16 (0.13, 0.19) 0.05 (0.02, 0.08) 
Hypertensive   0.38 (0.29, 0.47) 0.33 (0.25, 0.42) 
Cholesterol   -0.05 (-0.09, -
0.01) 
-0.02 (-0.06, 
0.03) 
eGFR   -0.01 (-0.02, -
0.01) 
-0.01 (-0.01, -
0.01) 
Interventions 
Quality of care level, reference group: Mid quality 
High quality    -0.07 (-0.17, 
0.04) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas only    0.40 (0.24, 0.56) 
Combination, no insulin    0.70 (0.52, 0.87) 
Insulin only    1.05 (0.86, 1.23) 
Combination with insulin    1.16 (0.96, 1.36) 
Blood pressure treatment, reference group: No treatments 
ACE inhibitors only    0.32 (0.17, 0.46) 
Combination with ACEI     0.22 (0.10, 0.35) 
Combination, no ACEI    0.13 (0.00, 0.26) 
Aspirin    0.05 (-0.04, 0.15) 
Lipid therapy    -0.06 (-0.16, 
0.04) 
Middlesbrough PCT    -0.05 (-0.22, 
0.13) 
Shared care    0.52 (0.42, 0.63) 
Cons -1.19 (-1.50, -
0.88) 
-0.39 (-0.87, 
0.11) 
-2.44 (-3.00, -
1.89) 
-2.83 (-3.48, -
2.19) 
Variance estimate at: 
Practice level 0.07 (0.04, 
0.12) 
0.08 (0.04, 0.13) 0.06 (0.03, 0.10) 0.05 (0.03, 0.10) 
Patient level 0.18 (0.05, 
0.55) 
0.34 (0.10, 1.03) 0.02 (0.00, 0.07) 0.00 (0.00, 0.02) 
Bayesian DIC 17531.30 17098.58 15146.30 14536.53 
N= 18,665  
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Appendix G: Stepwise models of interventions with interaction 
between visit year and socio-economic status 
 
Timeliness of diagnosis 
 
Table 63: Stepwise linear regression multilevel models examining timeliness of 
diagnosis with interaction effect between SES and visit from 1999 to 2007, conditional 
on relevant explanatory variables 
 Null Model 1 Model 2 Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  0.83 (-0.16, 1.78) 0.71 (-0.23, 1.64) 0.69 (-0.20, 1.55) 
High  0.38 (-0.46, 1.21) 0.35 (-0.46, 1.16) 0.27 (-0.49, 1.03) 
Visit year, reference group: 1999 
2000  -0.03 (-0.73, 0.68) -0.02 (-0.72, 0.68) -0.24 (-0.90, 0.39) 
2001  -0.82 (-1.47, -0.18) -0.80 (-1.43, -0.16) -0.76 (-1.37, -0.18) 
2002  -0.25 (-0.84, 0.34) -0.23 (-0.82, 0.35) -0.12 (-0.68, 0.42) 
2003  -0.67 (-1.26, -0.09) -0.64 (-1.22, -0.07) -0.42 (-0.95, 0.12) 
2004  -0.58 (-1.16, -0.02) -0.52 (-1.09, 0.03) -0.42 (-0.97, 0.11) 
2005  -0.81 (-1.39, -0.24) -0.77 (-1.35, -0.21) -0.59 (-1.14, -0.05) 
2006  -1.19 (-1.76, -0.62) -1.15 (-1.73, -0.57) -0.99 (-1.54, -0.44) 
2007  -1.30 (-1.89, -0.71) -1.24 (-1.84, -0.65) -1.14 (-1.73, -0.57) 
SES*Visit year, reference group: Low SES*1999 
Mid. SES*2000  -0.79 (-1.99, 0.43) -0.56 (-1.74, 0.64) -0.40 (-1.50, 0.71) 
Mid. SES*2001  0.02 (-1.13, 1.16) 0.17 (-0.93, 1.29) 0.25 (-0.80, 1.31) 
Mid. SES*2002  -1.35 (-2.42, -0.28) -1.23 (-2.28, -0.19) -1.11 (-2.08, -0.12) 
Mid. SES*2003  -0.76 (-1.80, 0.31) -0.68 (-1.70, 0.34) -0.64 (-1.60, 0.32) 
Mid. SES*2004  -1.21 (-2.23, -0.18) -1.05 (-2.03, -0.04) -0.91 (-1.84, 0.04) 
Mid. SES*2005  -0.76 (-1.79, 0.31) -0.58 (-1.58, 0.46) -0.41 (-1.35, 0.54) 
Mid. SES*2006  -0.54 (-1.58, 0.52) -0.37 (-1.40, 0.66) -0.37 (-1.33, 0.60) 
Mid. SES*2007  -0.44 (-1.48, 0.65) -0.33 (-1.37, 0.72) -0.45 (-1.41, 0.55) 
High SES*2000  -1.14 (-2.22, -0.06) -1.13 (-2.18, -0.07) -0.76 (-1.75, 0.23) 
High SES*2001  -0.22 (-1.24, 0.79) -0.13 (-1.13, 0.88) -0.03 (-0.96, 0.90) 
High SES*2002  -1.01 (-1.91, -0.08) -0.88 (-1.77, 0.05) -0.70 (-1.53, 0.16) 
High SES*2003  -0.77 (-1.69, 0.15) -0.64 (-1.54, 0.27) -0.50 (-1.33, 0.34) 
High SES*2004  -0.59 (-1.49, 0.31) -0.51 (-1.38, 0.36) -0.33 (-1.14, 0.49) 
High SES*2005  -0.72 (-1.62, 0.19) -0.61 (-1.50, 0.31) -0.44 (-1.28, 0.39) 
High SES*2006  -0.84 (-1.76, 0.08) -0.69 (-1.59, 0.19) -0.43 (-1.26, 0.42) 
High SES*2007  -0.57 (-1.50, 0.37) -0.43 (-1.32, 0.49) -0.24 (-1.08, 0.61) 
Covariates 
Age at diagnosis, reference group: <60 
60-74   -0.27 (-0.42, -0.11) -0.08 (-0.22, 0.07) 
75+   -0.36 (-0.58, -0.14) -0.12 (-0.33, 0.08) 
Ethnicity, reference group: white 
South Asian   0.63 (0.31, 0.94) 0.47 (0.17, 0.77) 
Other Ethnicity   0.55 (-0.14, 1.25) 0.32 (-0.32, 0.98) 
Male   0.01 (-0.12, 0.14) 0.05 (-0.08, 0.17) 
Smoking status, reference group: non-smoker 
Smoker   0.31 (0.14, 0.48) 0.21 (0.05, 0.36) 
Ex-smoker   0.04 (-0.11, 0.18) 0.03 (-0.11, 0.16) 
Obesity status, reference group: Under and normal weight 
Overweight   0.05 (-0.16, 0.25) 0.16 (-0.03, 0.35) 
Obese   -0.07 (-0.27, 0.13) 0.05 (-0.14, 0.24) 
Hypertensive   0.02 (-0.11, 0.15) 0.04 (-0.08, 0.17) 
Cholesterol   0.15 (0.10, 0.19) 0.16 (0.12, 0.20) 
Creatinine > 300   0.21 (-2.24, 2.64) 0.53 (-1.78, 2.75) 
eGFR   0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 
Ischaemic Cardiac   -0.01 (-0.17, 0.16) 0.09 (-0.09, 0.26) 
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Stroke or TIA   -0.16 (-0.45, 0.13) -0.10 (-0.37, 0.18) 
PVD   -0.01 (-0.44, 0.42) -0.01 (-0.41, 0.39) 
Interventions 
Care level, reference group: <7 
Care level: 7    -0.20 (-0.34, -0.05) 
Care level: 8    -0.11 (-0.29, 0.08) 
Diabetes treatment, reference group diet alone 
Metformin only    1.01 (0.87, 1.15) 
Sulphonylurea only    1.03 (0.82, 1.25) 
Insulin only    2.00 (1.65, 2.35) 
Combination/other    1.64 (1.44, 1.84) 
BP treatment, reference group no treatments 
ACE inhibitors only    -0.32 (-0.54, -0.10) 
ACE & other(s)    -0.25 (-0.42, -0.07) 
Other BP     -0.13 (-0.29, 0.03) 
Aspirin    0.04 (-0.11, 0.19) 
Lipid therapy    -0.11 (-0.24, 0.03) 
Shared care    0.20 (0.01, 0.38) 
M. PCT    0.14 (-0.09, 0.38) 
Cons 7.71 (7.59, 
7.85) 
8.54 (8.00, 9.07) 7.51 (6.79, 8.26) 6.79 (6.06, 7.50) 
Variance estimate at: 
Practice level 0.12 (0.06, 
0.22) 
0.10 (0.05, 0.19) 0.09 (0.04, 0.17) 0.10 (0.05, 0.18) 
Patient level 3.24 (3.08, 
3.41) 
3.10 (2.95, 3.26) 2.98 (2.83, 3.14) 2.57 (2.45, 2.71) 
Bayesian DIC 12356.02 12244.78 12139.62 11700.65 
N = 3,071 
 
Quality of care 
 
Table 64: Stepwise linear regression multilevel models examining quality of care with 
interaction effect between SES and visit from 1999 to 2007, conditional on relevant 
explanatory variables  
 Null Model 1 Model 2 Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  -0.02 (-0.15, 0.11) -0.03 (-0.15, 0.10) -0.04 (-0.16, 0.09) 
High  -0.18 (-0.30, -0.07) -0.20 (-0.31, -0.08) -0.16 (-0.28, -0.05) 
Visit year, reference group: 1999 
2000  0.04 (-0.05, 0.13) 0.03 (-0.05, 0.12) 0.05 (-0.03, 0.14) 
2001  0.06 (-0.02, 0.14) 0.05 (-0.03, 0.14) 0.11 (0.02, 0.19) 
2002  -0.01 (-0.09, 0.07) -0.02 (-0.10, 0.06) 0.06 (-0.02, 0.14) 
2003  -0.01 (-0.09, 0.07) -0.03 (-0.10, 0.05) 0.06 (-0.01, 0.14) 
2004  0.08 (0.00, 0.15) 0.05 (-0.03, 0.13) 0.15 (0.07, 0.23) 
2005  -0.06 (-0.14, 0.01) -0.10 (-0.18, -0.02) 0.02 (-0.06, 0.10) 
2006  0.19 (0.11, 0.27) 0.15 (0.07, 0.22) 0.27 (0.19, 0.34) 
2007  -0.47 (-0.55, -0.39) -0.51 (-0.59, -0.43) -0.40 (-0.47, -0.32) 
SES*Visit year, reference group: Low SES*1999 
Mid. SES*2000  -0.07 (-0.22, 0.08) -0.06 (-0.21, 0.09) -0.03 (-0.18, 0.12) 
Mid. SES*2001  -0.05 (-0.20, 0.10) -0.05 (-0.19, 0.10) -0.01 (-0.16, 0.13) 
Mid. SES*2002  0.09 (-0.05, 0.23) 0.09 (-0.05, 0.23) 0.11 (-0.03, 0.24) 
Mid. SES*2003  0.05 (-0.09, 0.19) 0.06 (-0.08, 0.19) 0.07 (-0.07, 0.21) 
Mid. SES*2004  -0.02 (-0.15, 0.12) -0.01 (-0.15, 0.12) -0.01 (-0.14, 0.13) 
Mid. SES*2005  0.03 (-0.11, 0.17) 0.03 (-0.10, 0.17) 0.03 (-0.10, 0.17) 
Mid. SES*2006  0.06 (-0.07, 0.20) 0.07 (-0.07, 0.20) 0.06 (-0.07, 0.20) 
Mid. SES*2007  0.09 (-0.05, 0.23) 0.09 (-0.05, 0.22) 0.08 (-0.05, 0.22) 
High SES*2000  0.10 (-0.04, 0.24) 0.11 (-0.03, 0.24) 0.09 (-0.05, 0.22) 
High SES*2001  0.12 (-0.01, 0.25) 0.13 (0.00, 0.26) 0.11 (-0.02, 0.24) 
High SES*2002  0.24 (0.11, 0.36) 0.25 (0.12, 0.37) 0.21 (0.09, 0.33) 
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High SES*2003  0.20 (0.08, 0.32) 0.21 (0.09, 0.33) 0.17 (0.05, 0.29) 
High SES*2004  0.22 (0.09, 0.34) 0.22 (0.10, 0.34) 0.18 (0.06, 0.30) 
High SES*2005  0.23 (0.11, 0.35) 0.24 (0.12, 0.36) 0.19 (0.07, 0.31) 
High SES*2006  0.24 (0.12, 0.36) 0.25 (0.13, 0.37) 0.21 (0.09, 0.32) 
High SES*2007  0.19 (0.07, 0.31) 0.19 (0.07, 0.31) 0.16 (0.03, 0.28) 
Covariates 
Age, reference group: <60 
60-74   0.02 (0.00, 0.04) 0.04 (0.02, 0.06) 
75+   -0.05 (-0.07, -0.02) -0.01 (-0.03, 0.02) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   0.08 (0.06, 0.09) 0.06 (0.04, 0.07) 
Duration 10+ years   0.07 (0.05, 0.09) 0.01 (-0.01, 0.03) 
Ethnicity, reference group: white 
South Asian   -0.08 (-0.12, -0.05) -0.08 (-0.12, -0.04) 
Other Ethnicity   -0.06 (-0.14, 0.03) -0.08 (-0.16, 0.00) 
Male   -0.02 (-0.03, 0.00) -0.01 (-0.03, 0.00) 
Smoking status, reference group: non-smoker 
Smoker   -0.08 (-0.10, -0.06) -0.06 (-0.09, -0.04) 
Ex-smoker   0.02 (0.00, 0.04) 0.02 (0.00, 0.04) 
Obesity status, reference group: Under and normal weight 
Overweight   0.04 (0.02, 0.06) 0.03 (0.01, 0.05) 
Obese   0.02 (0.00, 0.05) 0.00 (-0.02, 0.02) 
Hypertensive   -0.01 (-0.02, 0.01) -0.03 (-0.04, -0.01) 
HbA1c   0.00 (0.00, 0.01) -0.01 (-0.02, -0.01) 
Cholesterol   -0.03 (-0.04, -0.02) -0.02 (-0.03, -0.02) 
Creatinine > 300   -0.07 (-0.20, 0.06) -0.07 (-0.19, 0.06) 
eGFR   0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 
Ischaemic Cardiac   -0.02 (-0.03, 0.00) -0.03 (-0.05, -0.01) 
Stroke or TIA   0.00 (-0.02, 0.03) -0.01 (-0.03, 0.02) 
PVD   0.06 (0.03, 0.09) 0.02 (-0.01, 0.04) 
Interventions 
Diabetes treatment, reference group diet alone 
Sulphonylures / metformin only   0.05 (0.03, 0.08) 
OHA comb.    0.02 (-0.01, 0.04) 
Insulin only    0.02 (-0.01, 0.05) 
Insulin & OHAs    0.04 (0.02, 0.07) 
BP treatment, reference group no treatments 
ACE inhibitors only    0.04 (0.01, 0.06) 
ACE & other(s)    0.02 (0.00, 0.05) 
Other BP     0.02 (0.00, 0.04) 
Aspirin    0.00 (-0.02, 0.01) 
Lipid therapy    0.02 (0.00, 0.03) 
Shared care    0.27 (0.25, 0.29) 
M. PCT    -0.07 (-0.18, 0.03) 
Cons 7.12 (7.05, 7.19) 7.13 (7.03, 7.23) 7.18 (7.06, 7.29) 7.06 (6.93, 7.19) 
Variance estimate at: 
Practice level 0.03 (0.02, 0.05) 0.03 (0.02, 0.04) 0.03 (0.02, 0.04) 0.03 (0.02, 0.05) 
Patient level 0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 
Visit year level 0.47 (0.47, 0.48) 0.43 (0.43, 0.44) 0.43 (0.42, 0.44) 0.42 (0.41, 0.43) 
Bayesian DIC 69260.18 66475.44 66137.73 65285.29 
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Table 65: Stepwise logistic regression multilevel model examining no blood glucose 
treatments with interaction effect between SES and visit from 1999 to 2007, conditional 
on relevant explanatory variables 
 Null Model 1 Model 2  Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  -0.34 (-0.64, -0.03) -0.36 (-0.70, -0.03) -0.31 (-0.65, 0.03) 
High  -0.04 (-0.31, 0.23) -0.03 (-0.32, 0.29) -0.05 (-0.34, 0.25) 
Visit year, reference group: 1999 
2000  -0.25 (-0.49, 0.00) -0.46 (-0.73, -0.17) -0.45 (-0.71, -0.17) 
2001  -0.15 (-0.38, 0.09) -0.57 (-0.85, -0.30) -0.69 (-0.96, -0.43) 
2002  -0.09 (-0.31, 0.13) -0.43 (-0.67, -0.17) -0.62 (-0.87, -0.37) 
2003  -0.20 (-0.40, 0.02) -0.51 (-0.75, -0.27) -0.74 (-0.97, -0.51) 
2004  -0.32 (-0.51, -0.10) -0.53 (-0.77, -0.29) -0.81 (-1.04, -0.58) 
2005  -0.39 (-0.60, -0.18) -0.60 (-0.84, -0.35) -0.95 (-1.18, -0.72) 
2006  -0.26 (-0.47, -0.06) -0.79 (-1.03, -0.55) -1.15 (-1.37, -0.92) 
2007  -0.46 (-0.67, -0.25) -0.83 (-1.07, -0.58) -1.21 (-1.45, -0.98) 
SES*Visit year, reference group: Low SES*1999 
Mid. SES*2000  0.30 (-0.12, 0.73) 0.27 (-0.19, 0.72) 0.10 (-0.38, 0.57) 
Mid. SES*2001  0.39 (-0.01, 0.80) 0.44 (0.00, 0.89) 0.27 (-0.17, 0.72) 
Mid. SES*2002  0.34 (-0.03, 0.70) 0.28 (-0.13, 0.68) 0.17 (-0.26, 0.57) 
Mid. SES*2003  0.47 (0.11, 0.84) 0.45 (0.06, 0.85) 0.37 (-0.04, 0.77) 
Mid. SES*2004  0.47 (0.11, 0.82) 0.35 (-0.04, 0.74) 0.29 (-0.11, 0.67) 
Mid. SES*2005  0.61 (0.25, 0.96) 0.56 (0.17, 0.94) 0.54 (0.15, 0.94) 
Mid. SES*2006  0.43 (0.08, 0.78) 0.40 (0.02, 0.78) 0.39 (0.00, 0.76) 
Mid. SES*2007  0.50 (0.14, 0.85) 0.47 (0.08, 0.85) 0.47 (0.08, 0.87) 
High SES*2000  0.32 (-0.05, 0.69) 0.15 (-0.28, 0.57) 0.10 (-0.33, 0.53) 
High SES*2001  0.14 (-0.21, 0.50) 0.15 (-0.27, 0.55) 0.09 (-0.32, 0.49) 
High SES*2002  0.10 (-0.24, 0.43) -0.05 (-0.43, 0.32) 0.01 (-0.37, 0.38) 
High SES*2003  0.16 (-0.17, 0.48) 0.01 (-0.36, 0.36) 0.05 (-0.31, 0.40) 
High SES*2004  0.21 (-0.11, 0.52) 0.00 (-0.36, 0.35) 0.05 (-0.30, 0.39) 
High SES*2005  0.26 (-0.05, 0.57) 0.09 (-0.27, 0.43) 0.15 (-0.20, 0.48) 
High SES*2006  0.21 (-0.10, 0.51) 0.07 (-0.29, 0.40) 0.14 (-0.20, 0.47) 
High SES*2007  0.38 (0.06, 0.69) 0.21 (-0.16, 0.56) 0.25 (-0.10, 0.59) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years   0.29 (0.21, 0.37) 0.19 (0.11, 0.27) 
Age: 75+ years   0.60 (0.50, 0.70) 0.44 (0.34, 0.54) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 yrs   -1.09 (-1.16, -1.02) -1.07 (-1.14, -1.00) 
Duration 10+ yrs   -1.78 (-1.87, -1.69) -1.64 (-1.74, -1.55) 
Ethnicity, reference group: white 
South Asian   0.12 (-0.06, 0.30) 0.13 (-0.06, 0.32) 
Other Ethnicity   -0.06 (-0.47, 0.33) 0.10 (-0.33, 0.51) 
Male   0.27 (0.20, 0.33) 0.28 (0.22, 0.35) 
Smoking status, reference group: non-smoker 
Smoker   -0.02 (-0.11, 0.07) -0.07 (-0.16, 0.03) 
Ex-smoker   -0.09 (-0.16, -0.02) -0.09 (-0.16, -0.02) 
Obesity categories, reference group: under and normal weight 
Overweight   -0.23 (-0.32, -0.14) -0.23 (-0.32, -0.14) 
Obese   -0.44 (-0.53, -0.35) -0.43 (-0.52, -0.34) 
HbA1c   -0.85 (-0.88, -0.81) -0.82 (-0.85, -0.79) 
Hypertensive   -0.03 (-0.09, 0.04) 0.03 (-0.04, 0.09) 
Cholesterol   0.25 (0.22, 0.28) 0.24 (0.21, 0.27) 
Creatinine > 300   -0.24 (-0.77, 0.27) -0.18 (-0.75, 0.34) 
eGFR   0.00 (-0.01, 0.00) 0.00 (-0.01, 0.00) 
Ischaemic Cardiac   0.02 (-0.05, 0.08) 0.06 (-0.01, 0.13) 
Stroke or TIA   -0.13 (-0.23, -0.02) -0.08 (-0.19, 0.03) 
PVD   -0.45 (-0.59, -0.32) -0.33 (-0.46, -0.19) 
Interventions 
Care level, reference group: <7 
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Care level: 7    -0.15 (-0.22, -0.07) 
Care level: 8    -0.14 (-0.23, -0.05) 
Shared care    -1.33 (-1.43, -1.23) 
M’brough PCT    0.01 (-0.34, 0.36) 
Cons -1.72 (-2.03, -
1.44) 
-1.53 (-1.86, -1.17) 4.7 (2.29, 5.37) 5.43 (5.02, 5.88) 
Variance estimate at:  
Practice level 0.40 (0.25, 0.64) 0.39 (0.24, 0.62) 0.4 (0.24, 0.64) 0.32 (0.2, 0.51) 
Patient level 0.11 (0.03, 0.32) 0.12 (0.04, 0.35) 0.42 (0, 6.4) 0.01 (0, 0.03) 
Bayesian DIC 35856.53 35826.93 27984.07 27148.92 
 
Table 66: Stepwise logistic regression multilevel model examining metformin or 
sulphonylureas only with interaction effect between SES and visit from 1999 to 2007, 
conditional on relevant explanatory variables  
 Null Model 1 Model 2  Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  0.20 (-0.12, 0.55) 0.24 (-0.09, 0.57) 0.27 (-0.04, 0.59) 
High  -0.53 (-0.89, -0.14) -0.48 (-0.85, -0.16) -0.49 (-0.87, -0.14) 
Visit year, reference group: 1999 
2000  0.09 (-0.17, 0.37) 0.11 (-0.16, 0.37) 0.11 (-0.14, 0.37) 
2001  0.14 (-0.12, 0.41) 0.15 (-0.13, 0.40) 0.10 (-0.15, 0.34) 
2002  0.25 (0.02, 0.49) 0.25 (0.00, 0.49) 0.17 (-0.05, 0.39) 
2003  0.29 (0.06, 0.52) 0.28 (0.04, 0.50) 0.17 (-0.04, 0.39) 
2004  0.44 (0.23, 0.67) 0.46 (0.22, 0.67) 0.30 (0.09, 0.51) 
2005  0.48 (0.26, 0.70) 0.49 (0.25, 0.71) 0.31 (0.10, 0.52) 
2006  0.59 (0.38, 0.81) 0.54 (0.31, 0.76) 0.34 (0.14, 0.55) 
2007  0.66 (0.44, 0.89) 0.68 (0.45, 0.90) 0.53 (0.32, 0.75) 
SES*Visit year, reference group: Low SES*1999 
Mid. SES*2000  -0.18 (-0.64, 0.26) -0.23 (-0.68, 0.23) -0.28 (-0.73, 0.16) 
Mid. SES*2001  -0.38 (-0.82, 0.05) -0.44 (-0.88, 0.01) -0.52 (-0.95, -0.08) 
Mid. SES*2002  -0.25 (-0.67, 0.14) -0.29 (-0.69, 0.12) -0.34 (-0.73, 0.05) 
Mid. SES*2003  -0.20 (-0.59, 0.18) -0.27 (-0.66, 0.12) -0.31 (-0.68, 0.06) 
Mid. SES*2004  -0.18 (-0.56, 0.18) -0.24 (-0.61, 0.14) -0.25 (-0.60, 0.10) 
Mid. SES*2005  -0.29 (-0.68, 0.07) -0.33 (-0.70, 0.04) -0.34 (-0.70, 0.01) 
Mid. SES*2006  -0.38 (-0.75, -0.02) -0.39 (-0.75, -0.02) -0.40 (-0.76, -0.05) 
Mid. SES*2007  -0.39 (-0.77, -0.02) -0.44 (-0.81, -0.06) -0.44 (-0.80, -0.09) 
High SES*2000  0.01 (-0.49, 0.50) -0.07 (-0.53, 0.42) -0.09 (-0.59, 0.40) 
High SES*2001  0.30 (-0.17, 0.75) 0.25 (-0.17, 0.71) 0.22 (-0.23, 0.68) 
High SES*2002  0.27 (-0.15, 0.70) 0.22 (-0.17, 0.65) 0.23 (-0.19, 0.66) 
High SES*2003  0.36 (-0.07, 0.77) 0.32 (-0.06, 0.73) 0.33 (-0.06, 0.76) 
High SES*2004  0.34 (-0.08, 0.74) 0.29 (-0.07, 0.69) 0.31 (-0.08, 0.72) 
High SES*2005  0.46 (0.05, 0.86) 0.43 (0.07, 0.83) 0.45 (0.07, 0.87) 
High SES*2006  0.41 (0.01, 0.80) 0.41 (0.06, 0.80) 0.43 (0.05, 0.84) 
High SES*2007  0.43 (0.03, 0.82) 0.39 (0.04, 0.78) 0.41 (0.03, 0.82) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years   0.02 (-0.05, 0.09) -0.03 (-0.09, 0.04) 
Age: 75+ years   0.06 (-0.03, 0.16) -0.01 (-0.10, 0.08) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   -0.44 (-0.50, -0.38) -0.42 (-0.48, -0.36) 
Duration 10+ years   -1.29 (-1.37, -1.20) -1.20 (-1.28, -1.11) 
Ethnicity, reference: White 
South Asian   0.07 (-0.07, 0.21) 0.07 (-0.08, 0.21) 
Other Ethnicity   -0.44 (-0.79, -0.10) -0.37 (-0.73, -0.04) 
Male   -0.19 (-0.24, -0.13) -0.18 (-0.24, -0.12) 
Smoking status, reference group: non-smoker 
Smoker   0.07 (-0.01, 0.16) 0.06 (-0.02, 0.14) 
Ex-smoker   0.03 (-0.03, 0.10) 0.03 (-0.03, 0.09) 
Obesity category, reference: Under and normal weight 
Overweight   0.47 (0.37, 0.56) 0.46 (0.36, 0.56) 
Obese   0.62 (0.53, 0.72) 0.63 (0.54, 0.73) 
HbA1c   -0.09 (-0.11, -0.07) -0.07 (-0.09, -0.06) 
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Hypertensive   -0.05 (-0.11, 0.00) -0.02 (-0.08, 0.04) 
Cholesterol   0.00 (-0.03, 0.02) -0.01 (-0.04, 0.02) 
Creatinine > 300   -3.13 (-6.33, -1.20) -3.11 (-6.17, -1.20) 
eGFR   0.01 (0.01, 0.01) 0.01 (0.01, 0.01) 
Ischaemic Cardiac   -0.06 (-0.13, 0.00) -0.04 (-0.11, 0.02) 
Stroke or TIA   -0.09 (-0.19, 0.01) -0.07 (-0.17, 0.03) 
PVD   -0.12 (-0.24, -0.01) -0.06 (-0.18, 0.05) 
Interventions 
Care level, reference group: <7 
Care level: 7    0.08 (0.00, 0.15) 
Care level: 8    0.15 (0.06, 0.23) 
Shared care    -0.54 (-0.61, -0.46) 
Middlesbrough PCT    0.14 (-0.05, 0.32) 
Cons -1.59 (-1.87, -1.36) -1.92 (-2.22, -1.67) -1.77 (-2.10, -1.40) -1.73 (-2.08, -1.40) 
Variance estimate at:  
Practice level 0.07 (0.04, 0.12) 0.07 (0.04, 0.11) 0.07 (0.04, 0.12) 0.09 (0.05, 0.14) 
Patient level 0.09 (0.02, 0.28) 0.06 (0.02, 0.19) 0.01 (0.00, 0.02) 0.00 (0.00, 0.02) 
Bayesian DIC 35249.83 35041.67 33153.45 32952.79 
 
Table 67: Stepwise logistic regression multilevel model examining blood glucose 
treatments, with no insulin, with interaction effect between SES and visit from 1999 to 
2007, conditional on relevant explanatory variables 
 Null Model 1 Model 2  Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  0.21 (-0.06, 0.48) 0.20 (-0.08, 0.49) 0.24 (-0.06, 0.53) 
High  0.12 (-0.14, 0.37) 0.02 (-0.27, 0.28) 0.00 (-0.28, 0.27) 
Visit year, reference group: 1999 
2000  -0.27 (-0.50, -0.04) -0.28 (-0.52, -0.03) -0.25 (-0.51, 0.00) 
2001  -0.30 (-0.52, -0.07) -0.36 (-0.59, -0.13) -0.39 (-0.64, -0.14) 
2002  -0.32 (-0.52, -0.11) -0.37 (-0.58, -0.15) -0.45 (-0.68, -0.23) 
2003  -0.58 (-0.78, -0.38) -0.61 (-0.82, -0.39) -0.72 (-0.94, -0.49) 
2004  -0.91 (-1.12, -0.70) -0.94 (-1.16, -0.72) -1.10 (-1.32, -0.88) 
2005  -0.93 (-1.13, -0.72) -0.96 (-1.18, -0.75) -1.17 (-1.40, -0.94) 
2006  -1.02 (-1.22, -0.82) -1.06 (-1.28, -0.84) -1.25 (-1.48, -1.02) 
2007  -1.23 (-1.45, -0.99) -1.28 (-1.51, -1.04) -1.48 (-1.73, -1.24) 
SES*Visit year, reference group: Low SES*1999 
Mid. SES*2000  0.15 (-0.23, 0.53) 0.11 (-0.29, 0.50) 0.03 (-0.37, 0.44) 
Mid. SES*2001  0.02 (-0.36, 0.39) -0.01 (-0.40, 0.36) -0.11 (-0.51, 0.29) 
Mid. SES*2002  -0.18 (-0.52, 0.17) -0.21 (-0.58, 0.16) -0.27 (-0.64, 0.12) 
Mid. SES*2003  -0.11 (-0.46, 0.24) -0.13 (-0.50, 0.22) -0.19 (-0.55, 0.19) 
Mid. SES*2004  0.03 (-0.32, 0.37) -0.02 (-0.38, 0.34) -0.06 (-0.42, 0.31) 
Mid. SES*2005  -0.26 (-0.61, 0.09) -0.31 (-0.68, 0.04) -0.33 (-0.71, 0.05) 
Mid. SES*2006  -0.17 (-0.52, 0.18) -0.24 (-0.60, 0.12) -0.25 (-0.62, 0.12) 
Mid. SES*2007  -0.21 (-0.60, 0.17) -0.25 (-0.65, 0.14) -0.28 (-0.68, 0.13) 
High SES*2000  0.06 (-0.30, 0.42) 0.10 (-0.28, 0.49) 0.08 (-0.30, 0.47) 
High SES*2001  0.15 (-0.20, 0.49) 0.20 (-0.16, 0.58) 0.19 (-0.18, 0.57) 
High SES*2002  0.10 (-0.22, 0.43) 0.13 (-0.21, 0.48) 0.17 (-0.17, 0.53) 
High SES*2003  0.13 (-0.18, 0.45) 0.18 (-0.15, 0.52) 0.22 (-0.12, 0.56) 
High SES*2004  0.11 (-0.20, 0.44) 0.12 (-0.22, 0.46) 0.16 (-0.18, 0.50) 
High SES*2005  -0.01 (-0.33, 0.32) 0.00 (-0.34, 0.34) 0.05 (-0.29, 0.40) 
High SES*2006  -0.03 (-0.34, 0.30) -0.02 (-0.35, 0.33) 0.02 (-0.31, 0.37) 
High SES*2007  0.02 (-0.33, 0.36) 0.02 (-0.34, 0.39) 0.04 (-0.32, 0.42) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years   0.27 (0.18, 0.36) 0.21 (0.12, 0.30) 
Age: 75+ years   0.63 (0.52, 0.73) 0.52 (0.41, 0.63) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 yrs   0.11 (0.03, 0.19) 0.14 (0.07, 0.22) 
Duration 10+ yrs   -0.39 (-0.48, -0.30) -0.27 (-0.36, -0.18) 
Ethnicity, reference group: white 
South Asian   0.12 (-0.06, 0.28) 0.12 (-0.06, 0.29) 
Other Ethnicity   -0.17 (-0.63, 0.24) -0.11 (-0.56, 0.31) 
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Male   0.34 (0.27, 0.41) 0.34 (0.26, 0.41) 
Smoking status, reference group: non-smoker 
Smoker   0.09 (-0.01, 0.19) 0.07 (-0.03, 0.17) 
Ex-smoker   0.00 (-0.07, 0.08) 0.02 (-0.06, 0.09) 
Obesity category, reference group: under and normal weight 
Overweight   -0.26 (-0.35, -0.17) -0.25 (-0.34, -0.17) 
Obese   -0.72 (-0.82, -0.63) -0.70 (-0.79, -0.61) 
HbA1c   -0.01 (-0.04, 0.01) 0.01 (-0.01, 0.04) 
Hypertensive   -0.01 (-0.08, 0.06) 0.02 (-0.05, 0.09) 
Cholesterol   0.01 (-0.02, 0.04) 0.00 (-0.03, 0.03) 
Creatinine > 300   0.23 (-0.22, 0.67) 0.25 (-0.21, 0.69) 
eGFR   -0.01 (-0.02, -0.01) -0.01 (-0.02, -0.01) 
Ischaemic Cardiac   -0.03 (-0.11, 0.04) -0.01 (-0.08, 0.06) 
Stroke or TIA   0.03 (-0.08, 0.13) 0.06 (-0.04, 0.17) 
PVD   -0.18 (-0.31, -0.06) -0.09 (-0.22, 0.03) 
Interventions 
Care level, reference group: <7 
Care level: 7    0.06 (-0.03, 0.14) 
Care level: 8    -0.05 (-0.15, 0.05) 
Shared care    -0.62 (-0.71, -0.53) 
M’brough PCT    -0.01 (-0.19, 0.18) 
Cons -1.97 (-2.08, -1.87) -1.37 (-1.56, -1.19) -0.39 (-0.72, -0.03) -0.22 (-0.65, 0.19) 
Variance estimate at: 
Practice level 0.08 (0.05, 0.15) 0.07 (0.04, 0.13) 0.07 (0.04, 0.11) 0.07 (0.04, 0.13) 
Patient level 0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 
Bayesian DIC 27417.14 26846.58 25873.66 25654.38 
 
Table 68: Stepwise logistic regression multilevel model examining insulin only with 
interaction effect between SES and visit from 1999 to 2007, conditional on relevant 
explanatory variables 
 Null Model 1 Model 2  Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  0.00 (-0.31, 0.31) -0.08 (-0.42, 0.28) -0.26 (-0.61, 0.09) 
High  -0.04 (-0.32, 0.25) -0.13 (-0.44, 0.17) -0.11 (-0.45, 0.24) 
Visit year, reference group: 1999 
2000  0.12 (-0.11, 0.35) 0.08 (-0.18, 0.34) 0.06 (-0.22, 0.33) 
2001  -0.03 (-0.26, 0.20) -0.06 (-0.31, 0.21) 0.11 (-0.17, 0.39) 
2002  -0.41 (-0.63, -0.19) -0.48 (-0.73, -0.23) -0.23 (-0.49, 0.03) 
2003  -0.46 (-0.66, -0.24) -0.53 (-0.77, -0.28) -0.21 (-0.46, 0.04) 
2004  -0.58 (-0.78, -0.37) -0.66 (-0.90, -0.42) -0.14 (-0.39, 0.11) 
2005  -0.69 (-0.90, -0.48) -0.79 (-1.03, -0.54) -0.12 (-0.38, 0.13) 
2006  -0.83 (-1.04, -0.62) -0.73 (-0.97, -0.48) -0.05 (-0.31, 0.21) 
2007  -0.71 (-0.93, -0.49) -0.71 (-0.96, -0.46) -0.03 (-0.29, 0.24) 
SES*Visit year, reference group: Low SES*1999 
Mid. SES*2000  -0.30 (-0.73, 0.12) -0.15 (-0.63, 0.32) -0.01 (-0.50, 0.46) 
Mid. SES*2001  -0.45 (-0.88, -0.03) -0.37 (-0.84, 0.10) -0.11 (-0.59, 0.37) 
Mid. SES*2002  0.05 (-0.34, 0.44) 0.22 (-0.22, 0.66) 0.46 (0.00, 0.90) 
Mid. SES*2003  -0.10 (-0.48, 0.28) 0.17 (-0.25, 0.58) 0.40 (-0.04, 0.84) 
Mid. SES*2004  -0.11 (-0.48, 0.27) 0.07 (-0.37, 0.48) 0.19 (-0.25, 0.62) 
Mid. SES*2005  0.08 (-0.30, 0.46) 0.28 (-0.14, 0.68) 0.36 (-0.06, 0.80) 
Mid. SES*2006  0.14 (-0.24, 0.52) 0.28 (-0.16, 0.70) 0.37 (-0.06, 0.80) 
Mid. SES*2007  0.07 (-0.32, 0.46) 0.27 (-0.16, 0.68) 0.40 (-0.04, 0.84) 
High SES*2000  0.08 (-0.30, 0.47) 0.34 (-0.07, 0.76) 0.34 (-0.12, 0.80) 
High SES*2001  -0.07 (-0.44, 0.32) 0.07 (-0.34, 0.48) 0.07 (-0.38, 0.52) 
High SES*2002  0.17 (-0.18, 0.54) 0.44 (0.05, 0.84) 0.38 (-0.04, 0.80) 
High SES*2003  0.18 (-0.16, 0.53) 0.45 (0.08, 0.82) 0.38 (-0.03, 0.79) 
High SES*2004  0.19 (-0.14, 0.54) 0.40 (0.05, 0.77) 0.31 (-0.10, 0.72) 
High SES*2005  0.16 (-0.20, 0.51) 0.38 (0.01, 0.76) 0.23 (-0.19, 0.65) 
High SES*2006  0.31 (-0.03, 0.66) 0.51 (0.14, 0.89) 0.46 (0.05, 0.86) 
High SES*2007  0.10 (-0.25, 0.46) 0.34 (-0.03, 0.73) 0.32 (-0.11, 0.73) 
Covariates 
Age, reference group: <60 years 
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Age: 60-74 years   -0.62 (-0.71, -0.53) -0.46 (-0.55, -0.36) 
Age: 75+ years   -0.99 (-1.11, -0.88) -0.63 (-0.76, -0.50) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 yrs   0.69 (0.58, 0.79) 0.57 (0.46, 0.68) 
Duration 10+ yrs   1.77 (1.67, 1.87) 1.42 (1.31, 1.53) 
Ethnicity, reference group: white 
South Asian   -0.51 (-0.70, -0.33) -0.58 (-0.77, -0.39) 
Other Ethnicity   0.72 (0.37, 1.04) 0.55 (0.19, 0.89) 
Male   -0.07 (-0.15, 0.00) -0.07 (-0.15, 0.01) 
Smoking status, reference group: non-smoker 
Smoker   0.01 (-0.09, 0.12) 0.16 (0.05, 0.27) 
Ex-smoker   0.00 (-0.08, 0.08) 0.00 (-0.08, 0.08) 
Obesity status, reference group: under and normal weight 
Overweight   -0.31 (-0.41, -0.21) -0.40 (-0.51, -0.30) 
Obese   -0.61 (-0.71, -0.51) -0.87 (-0.97, -0.76) 
HbA1c   0.31 (0.28, 0.33) 0.24 (0.22, 0.26) 
Hypertensive   0.03 (-0.04, 0.10) -0.13 (-0.21, -0.05) 
Cholesterol   -0.03 (-0.06, 0.01) 0.02 (-0.01, 0.05) 
Creatinine > 300   0.34 (-0.09, 0.76) 0.46 (-0.01, 0.93) 
eGFR   -0.03 (-0.03, -0.02) -0.02 (-0.03, -0.02) 
Ischaemic Cardiac   0.25 (0.18, 0.33) 0.18 (0.10, 0.27) 
Stroke or TIA   0.23 (0.12, 0.33) 0.15 (0.04, 0.26) 
PVD   0.65 (0.55, 0.76) 0.38 (0.27, 0.50) 
Interventions 
Care level, reference group: <7 
Care level: 7    -0.07 (-0.17, 0.03) 
Care level: 8    -0.04 (-0.15, 0.07) 
Shared care    2.12 (2.04, 2.21) 
M’brough PCT    -0.13 (-0.35, 0.08) 
Cons -1.81 (-2.04, -1.57) -1.40 (-1.65, -1.15) -2.44 (-2.83, -2.06) -3.42 (-3.88, -2.97) 
Variance estimate at:  
Practice level 0.15 (0.09, 0.25) 0.15 (0.09, 0.25) 0.12 (0.07, 0.20) 0.11 (0.06, 0.18) 
Patient level 0.08 (0.02, 0.23) 0.05 (0.01, 0.16) 0.01 (0.00, 0.02) 0.00 (0.00, 0.01) 
Bayesian DIC 26513.48 26310.16 22115.83 19561.96 
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Table 69: Stepwise logistic regression multilevel model examining no other blood 
glucose treatments with interaction effect between SES and visit from 1999 to 2007, 
conditional on relevant explanatory variables 
 Null Model 1 Model 2  Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  -0.05 (-0.34, 0.25) -0.07 (-0.37, 0.22) -0.10 (-0.42, 0.20) 
High  0.21 (-0.05, 0.47) 0.25 (-0.02, 0.50) 0.22 (-0.06, 0.50) 
Visit year, reference group: 1999 
2000  0.29 (0.07, 0.50) 0.32 (0.09, 0.54) 0.29 (0.06, 0.52) 
2001  0.32 (0.11, 0.53) 0.49 (0.26, 0.71) 0.47 (0.24, 0.70) 
2002  0.46 (0.27, 0.66) 0.65 (0.44, 0.86) 0.64 (0.44, 0.84) 
2003  0.69 (0.51, 0.88) 0.81 (0.61, 1.01) 0.80 (0.61, 1.00) 
2004  0.86 (0.68, 1.04) 0.97 (0.77, 1.16) 0.96 (0.76, 1.15) 
2005  0.93 (0.76, 1.11) 1.03 (0.83, 1.23) 1.04 (0.84, 1.24) 
2006  0.86 (0.68, 1.03) 1.04 (0.84, 1.23) 1.03 (0.84, 1.23) 
2007  0.94 (0.75, 1.12) 1.05 (0.85, 1.24) 1.08 (0.88, 1.27) 
SES*Visit year, reference group: Low SES*1999 
Mid. SES*2000  -0.01 (-0.40, 0.37) 0.12 (-0.27, 0.51) 0.16 (-0.24, 0.56) 
Mid. SES*2001  0.2 (-0.16, 0.56) 0.32 (-0.06, 0.70) 0.36 (-0.02, 0.76) 
Mid. SES*2002  0.01 (-0.34, 0.35) 0.09 (-0.27, 0.45) 0.12 (-0.23, 0.50) 
Mid. SES*2003  -0.07 (-0.40, 0.25) 0.01 (-0.32, 0.35) 0.04 (-0.29, 0.39) 
Mid. SES*2004  -0.11 (-0.44, 0.22) -0.04 (-0.36, 0.30) 0.00 (-0.33, 0.35) 
Mid. SES*2005  -0.09 (-0.42, 0.23) -0.02 (-0.34, 0.32) 0.01 (-0.33, 0.36) 
Mid. SES*2006  0.05 (-0.27, 0.36) 0.11 (-0.22, 0.44) 0.14 (-0.20, 0.48) 
Mid. SES*2007  0.07 (-0.26, 0.39) 0.11 (-0.21, 0.45) 0.13 (-0.20, 0.48) 
High SES*2000  -0.36 (-0.71, -0.01) -0.27 (-0.62, 0.08) -0.24 (-0.61, 0.13) 
High SES*2001  -0.32 (-0.65, 0.02) -0.28 (-0.63, 0.06) -0.25 (-0.61, 0.11) 
High SES*2002  -0.36 (-0.67, -0.05) -0.33 (-0.65, 0.00) -0.30 (-0.64, 0.03) 
High SES*2003  -0.44 (-0.73, -0.13) -0.41 (-0.70, -0.10) -0.38 (-0.71, -0.06) 
High SES*2004  -0.38 (-0.67, -0.09) -0.32 (-0.60, -0.02) -0.30 (-0.60, 0.02) 
High SES*2005  -0.41 (-0.70, -0.12) -0.35 (-0.63, -0.04) -0.33 (-0.64, -0.01) 
High SES*2006  -0.40 (-0.68, -0.11) -0.38 (-0.66, -0.09) -0.35 (-0.66, -0.04) 
High SES*2007  -0.45 (-0.74, -0.15) -0.38 (-0.67, -0.08) -0.36 (-0.67, -0.04) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years   -0.01 (-0.07, 0.05) 0.00 (-0.06, 0.06) 
Age: 75+ years   -0.32 (-0.41, -0.24) -0.31 (-0.39, -0.22) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 yrs   1.15 (1.09, 1.21) 1.14 (1.08, 1.20) 
Duration 10+ yrs   1.45 (1.39, 1.52) 1.43 (1.36, 1.50) 
Ethnicity, reference group: white 
South Asian   0.08 (-0.05, 0.20) 0.08 (-0.05, 0.21) 
Other Ethnicity   -0.17 (-0.44, 0.11) -0.18 (-0.45, 0.09) 
Male   -0.18 (-0.23, -0.12) -0.17 (-0.23, -0.12) 
Smoking status, reference group: non-smoker 
Smoker   -0.06 (-0.14, 0.01) -0.05 (-0.13, 0.02) 
Ex-smoker   0.05 (-0.01, 0.11) 0.05 (-0.01, 0.10) 
Obesity category, reference group: under and normal weight 
Overweight   0.33 (0.24, 0.41) 0.32 (0.24, 0.40) 
Obese   0.73 (0.65, 0.81) 0.72 (0.65, 0.81) 
HbA1c   0.27 (0.26, 0.29) 0.27 (0.25, 0.28) 
Hypertensive   0.05 (0.00, 0.10) 0.04 (-0.01, 0.09) 
Cholesterol   -0.18 (-0.20, -0.16) -0.18 (-0.20, -0.15) 
Creatinine > 300   -1.14 (-1.78, -0.56) -1.15 (-1.79, -0.56) 
eGFR   0.01 (0.01, 0.01) 0.01 (0.01, 0.01) 
Ischaemic Cardiac   -0.11 (-0.17, -0.05) -0.11 (-0.17, -0.06) 
Stroke or TIA   -0.03 (-0.11, 0.05) -0.04 (-0.12, 0.04) 
PVD   -0.08 (-0.17, 0.01) -0.09 (-0.18, 0.00) 
Interventions 
Care level, reference group: <7 
Care level: 7    0.10 (0.03, 0.16) 
Care level: 8    0.12 (0.05, 0.20) 
Shared care    0.09 (0.03, 0.15) 
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M’brough PCT    -0.08 (-0.28, 0.10) 
Cons -0.49 (-0.65, -0.32) -1.12 (-1.38, -0.84) -4.71 (-5.01, -4.38) -4.76 (-5.12, -4.41) 
Variance estimate at: 
Practice level 0.08 (0.05, 0.13) 0.07 (0.04, 0.12) 0.08 (0.05, 0.13) 0.09 (0.05, 0.14) 
Patient level 0.05 (0.01, 0.14) 0.08 (0.02, 0.24) 0.01 (0, 0.02) 0.01 (0, 0.02) 
Bayesian DIC 45701.39 45279.41 40377.85 40361.07 
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Blood pressure treatments 
 
Table 70: Stepwise logistic regression multilevel model examining no blood pressure 
treatments with interaction effect between SES and visit from 1999 to 2007, conditional 
on relevant explanatory variables 
 Null Model 1 Model 2  Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  0.15 (-0.12, 0.42) 0.12 (-0.21, 0.43) 0.11 (-0.18, 0.42) 
High  0.37 (0.13, 0.62) 0.37 (0.09, 0.65) 0.35 (0.06, 0.63) 
Visit year, reference group: 1999 
2000  -0.23 (-0.45, -0.01) -0.22 (-0.47, 0.03) -0.21 (-0.45, 0.03) 
2001  -0.33 (-0.54, -0.12) -0.29 (-0.53, -0.05) -0.27 (-0.50, -0.04) 
2002  -0.45 (-0.64, -0.25) -0.47 (-0.70, -0.24) -0.45 (-0.66, -0.24) 
2003  -0.64 (-0.83, -0.45) -0.75 (-0.97, -0.53) -0.73 (-0.94, -0.52) 
2004  -0.73 (-0.92, -0.54) -0.83 (-1.06, -0.62) -0.81 (-1.01, -0.60) 
2005  -0.93 (-1.12, -0.74) -1.01 (-1.23, -0.79) -0.99 (-1.20, -0.79) 
2006  -0.89 (-1.07, -0.70) -0.95 (-1.18, -0.74) -0.92 (-1.12, -0.71) 
2007  -1.05 (-1.24, -0.85) -1.10 (-1.32, -0.88) -1.11 (-1.33, -0.89) 
SES*Visit year, reference group: Low SES*1999 
Mid. SES*2000  -0.11 (-0.49, 0.26) -0.18 (-0.61, 0.26) -0.17 (-0.59, 0.24) 
Mid. SES*2001  -0.22 (-0.58, 0.13) -0.19 (-0.61, 0.22) -0.18 (-0.58, 0.21) 
Mid. SES*2002  -0.27 (-0.60, 0.06) -0.20 (-0.57, 0.19) -0.18 (-0.55, 0.18) 
Mid. SES*2003  -0.17 (-0.49, 0.15) -0.07 (-0.44, 0.32) -0.06 (-0.42, 0.30) 
Mid. SES*2004  -0.12 (-0.43, 0.19) 0.02 (-0.34, 0.40) 0.02 (-0.33, 0.37) 
Mid. SES*2005  -0.20 (-0.52, 0.12) -0.10 (-0.47, 0.28) -0.09 (-0.44, 0.26) 
Mid. SES*2006  -0.25 (-0.57, 0.07) -0.15 (-0.51, 0.23) -0.14 (-0.48, 0.21) 
Mid. SES*2007  -0.29 (-0.62, 0.04) -0.19 (-0.55, 0.19) -0.18 (-0.56, 0.18) 
High SES*2000  0.04 (-0.30, 0.37) -0.02 (-0.40, 0.36) 0.00 (-0.38, 0.38) 
High SES*2001  -0.17 (-0.50, 0.14) -0.21 (-0.57, 0.16) -0.20 (-0.56, 0.17) 
High SES*2002  -0.46 (-0.77, -0.16) -0.44 (-0.78, -0.09) -0.42 (-0.76, -0.07) 
High SES*2003  -0.43 (-0.73, -0.14) -0.41 (-0.74, -0.07) -0.39 (-0.72, -0.06) 
High SES*2004  -0.37 (-0.67, -0.09) -0.30 (-0.63, 0.02) -0.29 (-0.61, 0.05) 
High SES*2005  -0.37 (-0.66, -0.07) -0.29 (-0.62, 0.04) -0.27 (-0.59, 0.06) 
High SES*2006  -0.38 (-0.67, -0.10) -0.32 (-0.64, 0.00) -0.30 (-0.61, 0.03) 
High SES*2007  -0.34 (-0.63, -0.04) -0.27 (-0.60, 0.06) -0.26 (-0.59, 0.08) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years   -0.43 (-0.50, -0.36) -0.43 (-0.50, -0.36) 
Age: 75+ years   -0.42 (-0.52, -0.32) -0.41 (-0.51, -0.31) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 yrs   -0.24 (-0.31, -0.18) -0.24 (-0.31, -0.18) 
Duration 10+ yrs   -0.21 (-0.29, -0.13) -0.21 (-0.29, -0.13) 
Ethnicity, reference group: white 
South Asian   0.45 (0.32, 0.59) 0.44 (0.31, 0.58) 
Other Ethnicity   0.21 (-0.07, 0.51) 0.20 (-0.09, 0.49) 
Male   0.01 (-0.05, 0.07) 0.01 (-0.05, 0.07) 
Smoking status, reference group: non-smoker 
Smoker   0.25 (0.17, 0.33) 0.25 (0.17, 0.33) 
Ex-smoker   -0.07 (-0.14, -0.01) -0.07 (-0.14, 0.00) 
Obesity category, reference group: under and normal weight 
Overweight   -0.37 (-0.46, -0.29) -0.37 (-0.45, -0.29) 
Obese   -0.87 (-0.95, -0.78) -0.87 (-0.95, -0.78) 
sBP   -0.02 (-0.02, -0.02) -0.02 (-0.02, -0.02) 
dBP   0.01 (0.00, 0.01) 0.01 (0.00, 0.01) 
HbA1c   0.07 (0.05, 0.08) 0.07 (0.05, 0.08) 
Cholesterol   0.14 (0.12, 0.17) 0.14 (0.12, 0.17) 
eGFR   0.02 (0.02, 0.02) 0.02 (0.02, 0.02) 
Ischaemic Cardiac   -1.66 (-1.75, -1.57) -1.66 (-1.75, -1.58) 
Stroke or TIA   -0.49 (-0.61, -0.37) -0.49 (-0.61, -0.37) 
PVD   -0.32 (-0.46, -0.19) -0.32 (-0.46, -0.19) 
Interventions 
Care level, reference group: <7 
Anna Christie Page 271 
Care level: 7    -0.03 (-0.10, 0.05) 
Care level: 8    -0.14 (-0.22, -0.05) 
M. PCT    0.08 (-0.12, 0.28) 
Shared care    0.05 (-0.03, 0.12) 
Cons -1.12 (-1.24, -1.01) -0.48 (-0.69, -0.28) 1.06 (0.59, 1.51) 1.05 (0.55, 1.49) 
Variance estimate at: 
Practice level 0.09 (0.05, 0.16) 0.09 (0.05, 0.16) 0.09 (0.06, 0.16) 0.10 (0.06, 0.16) 
Patient level 0.01 (0.00, 0.02) 0.02 (0.01, 0.06) 0.00 (0.00, 0.02) 0.00 (0.00, 0.02) 
Bayesian DIC 37784.65 37165.96 31026.01 31019.58 
N = 34,231 
 
Table 71: Stepwise logistic regression multilevel model examining ACE inhibitors only 
with interaction effect between SES and visit from 1999 to 2007, conditional on relevant 
explanatory variables 
 Null Model 1 Model 2  Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  0.37 (-0.04, 0.81) 0.30 (-0.15, 0.75) 0.30 (-0.14, 0.74) 
High  0.39 (0.01, 0.77) 0.33 (-0.10, 0.73) 0.33 (-0.07, 0.73) 
Visit year, reference group: 1999 
2000  0.35 (0.02, 0.68) 0.41 (0.06, 0.76) 0.40 (0.05, 0.75) 
2001  0.37 (0.05, 0.69) 0.47 (0.13, 0.81) 0.46 (0.12, 0.80) 
2002  0.36 (0.06, 0.66) 0.48 (0.16, 0.80) 0.48 (0.16, 0.79) 
2003  0.37 (0.09, 0.67) 0.44 (0.14, 0.75) 0.44 (0.14, 0.75) 
2004  0.31 (0.03, 0.60) 0.38 (0.07, 0.68) 0.37 (0.07, 0.67) 
2005  0.40 (0.13, 0.70) 0.51 (0.20, 0.80) 0.50 (0.21, 0.81) 
2006  0.46 (0.19, 0.75) 0.58 (0.27, 0.88) 0.56 (0.27, 0.87) 
2007  0.47 (0.19, 0.76) 0.58 (0.27, 0.89) 0.60 (0.31, 0.91) 
SES*Visit year, reference group: Low SES*1999 
Mid. SES*2000  0.00 (-0.56, 0.54) 0.03 (-0.54, 0.62) 0.04 (-0.53, 0.62) 
Mid. SES*2001  -0.07 (-0.61, 0.44) -0.03 (-0.58, 0.52) -0.02 (-0.56, 0.51) 
Mid. SES*2002  -0.21 (-0.73, 0.27) -0.17 (-0.69, 0.36) -0.17 (-0.68, 0.33) 
Mid. SES*2003  -0.39 (-0.89, 0.09) -0.31 (-0.83, 0.20) -0.31 (-0.81, 0.19) 
Mid. SES*2004  -0.38 (-0.87, 0.09) -0.29 (-0.79, 0.22) -0.28 (-0.77, 0.21) 
Mid. SES*2005  -0.33 (-0.82, 0.14) -0.25 (-0.74, 0.26) -0.25 (-0.74, 0.24) 
Mid. SES*2006  -0.31 (-0.80, 0.15) -0.23 (-0.72, 0.27) -0.23 (-0.71, 0.25) 
Mid. SES*2007  -0.20 (-0.69, 0.27) -0.13 (-0.62, 0.38) -0.13 (-0.61, 0.35) 
High SES*2000  -0.24 (-0.75, 0.27) -0.26 (-0.78, 0.27) -0.26 (-0.79, 0.28) 
High SES*2001  -0.36 (-0.86, 0.12) -0.36 (-0.88, 0.15) -0.36 (-0.87, 0.15) 
High SES*2002  -0.20 (-0.67, 0.25) -0.2 (-0.67, 0.30) -0.2 (-0.66, 0.28) 
High SES*2003  -0.25 (-0.68, 0.19) -0.21 (-0.66, 0.27) -0.21 (-0.67, 0.26) 
High SES*2004  -0.34 (-0.76, 0.09) -0.27 (-0.71, 0.19) -0.27 (-0.72, 0.19) 
High SES*2005  -0.39 (-0.83, 0.03) -0.34 (-0.78, 0.14) -0.34 (-0.79, 0.12) 
High SES*2006  -0.35 (-0.77, 0.07) -0.31 (-0.75, 0.15) -0.32 (-0.76, 0.13) 
High SES*2007  -0.28 (-0.71, 0.15) -0.23 (-0.67, 0.24) -0.23 (-0.67, 0.23) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years   -0.13 (-0.21, -0.04) -0.13 (-0.21, -0.05) 
Age: 75+ years   -0.37 (-0.49, -0.25) -0.37 (-0.49, -0.25) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 yrs   0.32 (0.24, 0.40) 0.32 (0.24, 0.40) 
Duration 10+ yrs   0.43 (0.34, 0.52) 0.42 (0.33, 0.52) 
Ethnicity, reference group: white 
South Asian   -0.05 (-0.22, 0.12) -0.05 (-0.22, 0.12) 
Other Ethnicity   -1.01 (-1.55, -0.53) -1.01 (-1.55, -0.53) 
Male   0.25 (0.18, 0.32) 0.25 (0.18, 0.33) 
Smoking status, reference group: non-smoker 
Smoker   0.00 (-0.10, 0.10) 0.01 (-0.10, 0.11) 
Ex-smoker   0.05 (-0.03, 0.12) 0.04 (-0.03, 0.12) 
Obesity category, reference group: under and normal weight 
Overweight   0.01 (-0.09, 0.12) 0.01 (-0.09, 0.11) 
Obese   -0.10 (-0.20, 0.01) -0.10 (-0.20, 0.00) 
sBP   0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 
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dBP   0.01 (0.01, 0.02) 0.01 (0.01, 0.02) 
HbA1c   0.02 (-0.01, 0.04) 0.01 (-0.01, 0.04) 
Cholesterol   -0.02 (-0.05, 0.01) -0.02 (-0.05, 0.01) 
eGFR   0.01 (0.00, 0.01) 0.01 (0.00, 0.01) 
Ischaemic Cardiac   -0.93 (-1.02, -0.84) -0.93 (-1.03, -0.84) 
Stroke or TIA   0.2 (0.09, 0.32) 0.2 (0.09, 0.32) 
PVD   0.29 (0.17, 0.41) 0.29 (0.16, 0.41) 
Interventions 
Care level, reference group: <7 
Care level: 7    0.04 (-0.05, 0.13) 
Care level: 8    0.10 (0.00, 0.20) 
M’brough PCT    0.01 (-0.21, 0.25) 
Shared care    0.01 (-0.07, 0.09) 
Cons -1.92 (-2.05, -1.78) -2.35 (-2.64, -2.07) -3.8 (-4.27, -3.3) -3.81 (-4.33, -3.28) 
Variance estimate at: 
Practice level 0.11 (0.06, 0.18) 0.11 (0.07, 0.18) 0.12 (0.07, 0.19) 0.12 (0.07, 0.20) 
Patient level 0.01 (0.00, 0.04) 0.01 (0.00, 0.04) 0.01 (0.00, 0.02) 0.01 (0.00, 0.03) 
Bayesian DIC 25520.15 25527.71 24579.91 24581.11 
 
Table 72: Stepwise logistic regression multilevel model examining ACE inhibitors and 
other blood pressure treatments with interaction effect between SES and visit from 
1999 to 2007, conditional on relevant explanatory variables 
 Null Model 1 Model 2  Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  0.00 (-0.34, 0.32) -0.01 (-0.34, 0.34) 0.00 (-0.37, 0.35) 
High  -0.32 (-0.68, 0.03) -0.35 (-0.73, -0.02) -0.36 (-0.72, 0.00) 
Visit year, reference group: 1999 
2000  0.37 (0.10, 0.63) 0.30 (0.04, 0.57) 0.30 (0.03, 0.58) 
2001  0.63 (0.38, 0.88) 0.57 (0.32, 0.82) 0.57 (0.30, 0.83) 
2002  0.82 (0.58, 1.06) 0.77 (0.54, 1.00) 0.78 (0.52, 1.03) 
2003  0.90 (0.67, 1.13) 0.88 (0.66, 1.10) 0.89 (0.65, 1.13) 
2004  0.99 (0.76, 1.21) 0.95 (0.73, 1.16) 0.96 (0.71, 1.20) 
2005  1.06 (0.83, 1.29) 0.98 (0.76, 1.20) 0.99 (0.75, 1.22) 
2006  1.05 (0.83, 1.28) 0.97 (0.75, 1.20) 0.98 (0.73, 1.22) 
2007  1.15 (0.92, 1.38) 1.04 (0.82, 1.26) 1.06 (0.82, 1.30) 
SES*Visit year, reference group: Low SES*1999 
Mid. SES*2000  -0.05 (-0.48, 0.39) 0.04 (-0.42, 0.49) 0.02 (-0.44, 0.50) 
Mid. SES*2001  0.01 (-0.39, 0.41) 0.01 (-0.41, 0.42) 0.00 (-0.42, 0.44) 
Mid. SES*2002  0.01 (-0.36, 0.39) -0.01 (-0.40, 0.37) -0.03 (-0.42, 0.38) 
Mid. SES*2003  0.10 (-0.25, 0.47) 0.11 (-0.28, 0.48) 0.09 (-0.29, 0.49) 
Mid. SES*2004  -0.01 (-0.36, 0.36) -0.05 (-0.42, 0.32) -0.06 (-0.45, 0.34) 
Mid. SES*2005  0.00 (-0.34, 0.37) 0.00 (-0.38, 0.36) -0.01 (-0.40, 0.38) 
Mid. SES*2006  0.02 (-0.31, 0.38) 0.00 (-0.37, 0.36) -0.01 (-0.40, 0.38) 
Mid. SES*2007  0.04 (-0.30, 0.41) 0.03 (-0.35, 0.39) 0.01 (-0.38, 0.41) 
High SES*2000  0.11 (-0.34, 0.55) 0.21 (-0.23, 0.68) 0.22 (-0.23, 0.68) 
High SES*2001  0.03 (-0.40, 0.45) 0.07 (-0.36, 0.50) 0.07 (-0.35, 0.50) 
High SES*2002  0.18 (-0.22, 0.58) 0.17 (-0.22, 0.60) 0.18 (-0.21, 0.58) 
High SES*2003  0.31 (-0.08, 0.69) 0.33 (-0.03, 0.74) 0.34 (-0.05, 0.72) 
High SES*2004  0.36 (-0.02, 0.74) 0.37 (0.00, 0.77) 0.37 (-0.01, 0.76) 
High SES*2005  0.25 (-0.13, 0.63) 0.26 (-0.11, 0.66) 0.26 (-0.12, 0.65) 
High SES*2006  0.21 (-0.17, 0.58) 0.21 (-0.15, 0.61) 0.21 (-0.17, 0.59) 
High SES*2007  0.19 (-0.19, 0.57) 0.21 (-0.15, 0.62) 0.22 (-0.16, 0.60) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years   0.19 (0.13, 0.26) 0.19 (0.13, 0.26) 
Age: 75+ years   0.01 (-0.08, 0.09) 0.01 (-0.07, 0.09) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 yrs   0.23 (0.18, 0.29) 0.23 (0.17, 0.29) 
Duration 10+ yrs   0.40 (0.33, 0.46) 0.39 (0.33, 0.46) 
Ethnicity, reference: white 
South Asian   -0.54 (-0.69, -0.39) -0.53 (-0.68, -0.39) 
Other Ethnicity   -0.10 (-0.42, 0.20) -0.10 (-0.41, 0.19) 
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Male   0.27 (0.22, 0.32) 0.27 (0.22, 0.32) 
Smoking status, reference: non-smoker 
Smoker   -0.12 (-0.19, -0.04) -0.11 (-0.19, -0.04) 
Ex-smoker   0.03 (-0.03, 0.08) 0.02 (-0.03, 0.08) 
Obesity category, reference: under and normal weight 
Overweight   0.29 (0.21, 0.37) 0.29 (0.21, 0.37) 
Obese   0.58 (0.51, 0.66) 0.58 (0.50, 0.66) 
sBP   0.01 (0.01, 0.01) 0.01 (0.01, 0.01) 
dBP   -0.01 (-0.01, -0.01) -0.01 (-0.01, -0.01) 
HbA1c   -0.03 (-0.04, -0.01) -0.03 (-0.05, -0.01) 
Cholesterol   -0.11 (-0.14, -0.09) -0.11 (-0.14, -0.09) 
eGFR   -0.01 (-0.02, -0.01) -0.01 (-0.02, -0.01) 
Ischaemic Cardiac   0.81 (0.76, 0.86) 0.81 (0.76, 0.86) 
Stroke or TIA   0.16 (0.08, 0.24) 0.16 (0.08, 0.23) 
PVD   0.03 (-0.06, 0.12) 0.02 (-0.07, 0.11) 
Interventions 
Care level, reference group: <7 
Care level: 7    0.01 (-0.05, 0.08) 
Care level: 8    0.04 (-0.03, 0.12) 
M’brough PCT    -0.08 (-0.22, 0.07) 
Shared care    0.03 (-0.03, 0.10) 
Cons -0.68 (-0.77, -0.58) -1.55 (-1.78, -1.31) -2.00 (-2.4, -1.58) -1.96 (-2.39, -1.60) 
Variance estimate at: 
Practice level 0.04 (0.02, 0.07) 0.04 (0.02, 0.07) 0.04 (0.02, 0.07) 0.04 (0.02, 0.08) 
Patient level 0.01 (0.00, 0.02) 0.02 (0, 0.05) 0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 
Bayesian DIC 43407.29 42922.75 39650.30 39653.78 
 
Table 73: Stepwise logistic regression multilevel model examining of blood pressure 
with no ACE inhibitors treatments with interaction effect between SES and visit from 
1999 to 2007, conditional on relevant explanatory variables 
 Null Model 1 Model 2  Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  -0.27 (-0.57, 0.02) -0.20 (-0.49, 0.09) -0.23 (-0.52, 0.08) 
High  -0.34 (-0.61, -0.05) -0.26 (-0.54, 0.00) -0.31 (-0.62, -0.01) 
Visit year, reference group: 1999 
2000  -0.17 (-0.39, 0.05) -0.20 (-0.42, 0.02) -0.23 (-0.46, 0.00) 
2001  -0.30 (-0.51, -0.08) -0.38 (-0.60, -0.17) -0.44 (-0.66, -0.21) 
2002  -0.36 (-0.56, -0.16) -0.44 (-0.64, -0.25) -0.51 (-0.72, -0.30) 
2003  -0.27 (-0.46, -0.07) -0.33 (-0.51, -0.14) -0.40 (-0.60, -0.19) 
2004  -0.25 (-0.43, -0.05) -0.30 (-0.49, -0.12) -0.38 (-0.58, -0.18) 
2005  -0.20 (-0.39, -0.02) -0.27 (-0.45, -0.09) -0.36 (-0.56, -0.15) 
2006  -0.26 (-0.44, -0.07) -0.33 (-0.52, -0.15) -0.43 (-0.63, -0.23) 
2007  -0.26 (-0.45, -0.07) -0.33 (-0.52, -0.14) -0.42 (-0.63, -0.21) 
SES*Visit year, reference group: Low SES*1999 
Mid. SES*2000  0.13 (-0.25, 0.53) 0.10 (-0.30, 0.49) 0.11 (-0.29, 0.50) 
Mid. SES*2001  0.21 (-0.16, 0.59) 0.15 (-0.22, 0.53) 0.16 (-0.23, 0.55) 
Mid. SES*2002  0.31 (-0.04, 0.66) 0.24 (-0.12, 0.59) 0.25 (-0.10, 0.60) 
Mid. SES*2003  0.18 (-0.15, 0.53) 0.09 (-0.25, 0.43) 0.11 (-0.24, 0.46) 
Mid. SES*2004  0.26 (-0.07, 0.59) 0.15 (-0.18, 0.48) 0.18 (-0.16, 0.51) 
Mid. SES*2005  0.27 (-0.05, 0.60) 0.18 (-0.16, 0.50) 0.20 (-0.14, 0.54) 
Mid. SES*2006  0.28 (-0.03, 0.62) 0.19 (-0.14, 0.51) 0.22 (-0.12, 0.54) 
Mid. SES*2007  0.20 (-0.13, 0.54) 0.10 (-0.23, 0.45) 0.14 (-0.20, 0.47) 
High SES*2000  0.00 (-0.37, 0.37) -0.02 (-0.39, 0.36) 0.02 (-0.37, 0.42) 
High SES*2001  0.40 (0.05, 0.75) 0.39 (0.04, 0.75) 0.43 (0.05, 0.81) 
High SES*2002  0.48 (0.15, 0.81) 0.43 (0.09, 0.76) 0.47 (0.12, 0.82) 
High SES*2003  0.33 (0.02, 0.65) 0.27 (-0.04, 0.59) 0.32 (-0.02, 0.67) 
High SES*2004  0.27 (-0.04, 0.59) 0.18 (-0.12, 0.49) 0.23 (-0.11, 0.57) 
High SES*2005  0.41 (0.10, 0.71) 0.31 (0.01, 0.62) 0.37 (0.03, 0.71) 
High SES*2006  0.45 (0.14, 0.76) 0.38 (0.08, 0.69) 0.43 (0.11, 0.76) 
High SES*2007  0.38 (0.07, 0.69) 0.29 (-0.01, 0.60) 0.35 (0.01, 0.68) 
Covariates 
Age, reference group: <60 years 
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Age: 60-74 years   0.40 (0.33, 0.46) 0.39 (0.32, 0.45) 
Age: 75+ years   0.61 (0.53, 0.69) 0.59 (0.50, 0.67) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   -0.19 (-0.25, -0.13) -0.18 (-0.24, -0.13) 
Duration 10+ years   -0.47 (-0.54, -0.40) -0.44 (-0.51, -0.37) 
Ethnicity, reference: White 
South Asian   -0.04 (-0.17, 0.10) -0.03 (-0.17, 0.10) 
Other Ethnicity   0.21 (-0.08, 0.50) 0.24 (-0.06, 0.53) 
Male   -0.40 (-0.46, -0.35) -0.40 (-0.46, -0.35) 
Smoking status, reference: non-smoker 
Smoker   -0.10 (-0.17, -0.02) -0.10 (-0.18, -0.03) 
Ex-smoker   0.01 (-0.04, 0.07) 0.01 (-0.04, 0.07) 
Obesity category, reference: under and normal weight 
Overweight   0.03 (-0.05, 0.11) 0.03 (-0.05, 0.11) 
Obese   0.17 (0.09, 0.24) 0.17 (0.10, 0.25) 
sBP   0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 
dBP   0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 
HbA1c   -0.04 (-0.06, -0.03) -0.04 (-0.06, -0.02) 
Cholesterol   0.00 (-0.02, 0.02) 0.00 (-0.03, 0.02) 
eGFR   0.00 (-0.01, 0.00) 0.00 (-0.01, 0.00) 
Ischaemic Cardiac   0.48 (0.42, 0.53) 0.48 (0.43, 0.54) 
Stroke or TIA   -0.05 (-0.13, 0.03) -0.04 (-0.12, 0.04) 
PVD   -0.08 (-0.17, 0.01) -0.06 (-0.15, 0.03) 
Interventions 
Care level, reference group: <7 
Care level: 7    0.00 (-0.06, 0.07) 
Care level: 8    0.02 (-0.05, 0.10) 
M. PCT    0.00 (-0.14, 0.15) 
Shared care    -0.16 (-0.23, -0.10) 
Cons -0.94 (-1.03, -0.85) -0.69 (-0.87, -0.51) -0.70 (-1.06, -0.38) -0.68 (-1.11, -0.28) 
Variance estimate at: 
Practice level 0.05 (0.03, 0.09) 0.05 (0.03, 0.09) 0.05 (0.03, 0.09) 0.05 (0.03, 0.09) 
Patient level 0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 
Bayesian DIC 41236.49 41249.01 39766.32 39748.14 
 
 
Antithrombotic and Lipid profile treatments 
 
Table 74: Saturated logistic regression multilevel model examining lipid therapies with 
interaction effect between SES and visit from 1999 to 2007, conditional on relevant 
explanatory variables 
 Null Model 1 Model 2  Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  -0.14 (-0.65, 0.38) -0.10 (-0.66, 0.39) -0.05 (-0.52, 0.41) 
High  0.07 (-0.42, 0.46) 0.12 (-0.31, 0.49) 0.11 (-0.34, 0.52) 
Visit year, reference group: 1999 
2000  0.20 (-0.14, 0.52) 0.15 (-0.19, 0.47) 0.16 (-0.17, 0.47) 
2001  0.41 (0.09, 0.72) 0.39 (0.07, 0.69) 0.39 (0.07, 0.69) 
2002  0.90 (0.59, 1.20) 0.90 (0.59, 1.18) 0.89 (0.59, 1.17) 
2003  1.54 (1.24, 1.84) 1.58 (1.27, 1.86) 1.56 (1.27, 1.84) 
2004  2.12 (1.82, 2.42) 2.13 (1.82, 2.41) 2.11 (1.81, 2.38) 
2005  2.45 (2.14, 2.75) 2.42 (2.11, 2.70) 2.38 (2.08, 2.66) 
2006  2.61 (2.30, 2.91) 2.60 (2.29, 2.88) 2.56 (2.27, 2.84) 
2007  2.73 (2.42, 3.03) 2.71 (2.39, 3.00) 2.70 (2.39, 2.98) 
SES*Visit year, reference group: Low SES*1999 
Mid. SES*2000  0.14 (-0.44, 0.73) 0.20 (-0.38, 0.81) 0.15 (-0.40, 0.70) 
Mid. SES*2001  0.19 (-0.36, 0.77) 0.21 (-0.33, 0.81) 0.15 (-0.38, 0.67) 
Mid. SES*2002  0.17 (-0.38, 0.70) 0.18 (-0.33, 0.76) 0.13 (-0.37, 0.63) 
Mid. SES*2003  0.10 (-0.43, 0.65) 0.08 (-0.43, 0.66) 0.03 (-0.46, 0.52) 
Mid. SES*2004  0.20 (-0.34, 0.74) 0.17 (-0.34, 0.74) 0.12 (-0.38, 0.61) 
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Mid. SES*2005  0.16 (-0.38, 0.70) 0.16 (-0.35, 0.74) 0.12 (-0.38, 0.61) 
Mid. SES*2006  0.04 (-0.50, 0.57) 0.04 (-0.47, 0.62) -0.01 (-0.50, 0.49) 
Mid. SES*2007  0.17 (-0.37, 0.72) 0.16 (-0.36, 0.74) 0.11 (-0.40, 0.62) 
High SES*2000  -0.13 (-0.60, 0.41) -0.09 (-0.57, 0.42) -0.08 (-0.58, 0.43) 
High SES*2001  -0.19 (-0.64, 0.33) -0.17 (-0.61, 0.32) -0.16 (-0.62, 0.32) 
High SES*2002  -0.15 (-0.57, 0.36) -0.13 (-0.54, 0.34) -0.12 (-0.56, 0.35) 
High SES*2003  -0.28 (-0.69, 0.23) -0.29 (-0.70, 0.17) -0.28 (-0.71, 0.20) 
High SES*2004  -0.08 (-0.49, 0.43) -0.08 (-0.49, 0.37) -0.08 (-0.51, 0.39) 
High SES*2005  -0.16 (-0.58, 0.34) -0.14 (-0.55, 0.30) -0.13 (-0.57, 0.33) 
High SES*2006  -0.12 (-0.53, 0.38) -0.09 (-0.50, 0.37) -0.08 (-0.51, 0.39) 
High SES*2007  -0.21 (-0.63, 0.29) -0.19 (-0.60, 0.26) -0.19 (-0.63, 0.29) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years   0.02 (-0.05, 0.08) 0.01 (-0.06, 0.08) 
Age: 75+ years   -0.65 (-0.74, -0.57) -0.67 (-0.75, -0.58) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 yrs   0.04 (-0.02, 0.10) 0.04 (-0.02, 0.10) 
Duration 10+ yrs   -0.12 (-0.19, -0.05) -0.10 (-0.17, -0.03) 
Ethnicity, reference: White 
South Asian   -0.35 (-0.48, -0.22) -0.35 (-0.49, -0.22) 
Other Ethnicity   -0.71 (-0.99, -0.42) -0.71 (-0.98, -0.42) 
Male   -0.33 (-0.39, -0.28) -0.33 (-0.39, -0.28) 
Smoking status, reference: non-smoker 
Smoker   0.09 (0.01, 0.17) 0.09 (0.01, 0.17) 
Ex-smoker   0.10 (0.04, 0.15) 0.10 (0.04, 0.15) 
Obesity category, reference: under and normal weight 
Overweight   0.43 (0.35, 0.51) 0.43 (0.35, 0.51) 
Obese   0.45 (0.37, 0.52) 0.45 (0.37, 0.53) 
Hypertensive   -0.02 (-0.07, 0.03) -0.01 (-0.07, 0.04) 
HbA1c   0.05 (0.04, 0.07) 0.06 (0.04, 0.08) 
Cholesterol   -0.28 (-0.30, -0.25) -0.28 (-0.30, -0.25) 
eGFR   0.00 (-0.01, 0.00) -0.01 (-0.01, 0.00) 
Ischaemic Cardiac   0.95 (0.89, 1.01) 0.95 (0.89, 1.01) 
Stroke or TIA   0.23 (0.14, 0.32) 0.23 (0.15, 0.32) 
PVD   0.16 (0.06, 0.26) 0.17 (0.07, 0.27) 
Interventions 
Care level, reference group: <7 
Care level: 7    0.14 (0.07, 0.21) 
Care level: 8    0.10 (0.03, 0.18) 
M. PCT    0.17 (-0.03, 0.37) 
Shared care    -0.10 (-0.16, -0.03) 
Cons 0.51 (0.40, 0.62) -1.17 (-1.49, -0.85) -0.41 (-0.81, 0.01) -0.41 (-0.98, 1.64) 
Variance estimate at: 
Practice level 0.11 (0.07, 0.18) 0.09 (0.06, 0.16) 0.09 (0.06, 0.16) 0.09 (0.05, 0.15) 
Patient level 0.00 (0.00, 0.01) 0.05 (0.01, 0.15) 0.03 (0.00, 0.1) 0.41 (0.00, 5.15) 
Bayesian DIC 43995.34 39063.65 36576.41 36560.43 
 
 
Table 75: Stepwise logistic regression multilevel model examining aspirin with 
interaction effect between SES and visit from 1999 to 2007, conditional on relevant 
explanatory variables 
 Null Model 1 Model 2  Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  -0.12 (-0.53, 0.31) -0.07 (-0.51, 0.41) -0.02 (-0.56, 0.45) 
High  -0.28 (-0.65, 0.09) -0.29 (-0.70, 0.08) -0.19 (-0.67, 0.23) 
Visit year, reference group: 1999 
2000  0.10 (-0.17, 0.39) -0.02 (-0.32, 0.27) 0.06 (-0.29, 0.38) 
2001  0.16 (-0.11, 0.44) 0.04 (-0.25, 0.34) 0.16 (-0.17, 0.48) 
2002  0.16 (-0.09, 0.43) 0.00 (-0.28, 0.27) 0.14 (-0.18, 0.44) 
2003  0.43 (0.18, 0.70) 0.27 (0.00, 0.53) 0.42 (0.11, 0.72) 
2004  0.54 (0.30, 0.81) 0.37 (0.10, 0.64) 0.55 (0.23, 0.84) 
2005  0.64 (0.39, 0.91) 0.45 (0.18, 0.71) 0.64 (0.32, 0.94) 
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2006  0.69 (0.44, 0.95) 0.52 (0.25, 0.79) 0.72 (0.40, 1.02) 
2007  0.83 (0.59, 1.10) 0.67 (0.40, 0.94) 0.86 (0.53, 1.16) 
SES*Visit year, reference group: Low SES*1999 
Mid. SES*2000  0.03 (-0.47, 0.51) 0.13 (-0.42, 0.65) 0.10 (-0.45, 0.70) 
Mid. SES*2001  -0.07 (-0.56, 0.41) -0.06 (-0.59, 0.45) -0.08 (-0.62, 0.50) 
Mid. SES*2002  0.17 (-0.30, 0.63) 0.18 (-0.34, 0.67) 0.14 (-0.38, 0.69) 
Mid. SES*2003  0.07 (-0.40, 0.50) 0.03 (-0.47, 0.50) -0.01 (-0.51, 0.54) 
Mid. SES*2004  0.14 (-0.32, 0.57) 0.09 (-0.42, 0.55) 0.04 (-0.45, 0.59) 
Mid. SES*2005  0.15 (-0.30, 0.59) 0.14 (-0.36, 0.60) 0.08 (-0.41, 0.63) 
Mid. SES*2006  0.14 (-0.31, 0.58) 0.12 (-0.37, 0.58) 0.06 (-0.44, 0.61) 
Mid. SES*2007  0.18 (-0.27, 0.62) 0.18 (-0.32, 0.64) 0.11 (-0.39, 0.66) 
High SES*2000  -0.07 (-0.51, 0.36) 0.04 (-0.43, 0.54) -0.06 (-0.56, 0.48) 
High SES*2001  -0.21 (-0.63, 0.21) -0.19 (-0.64, 0.28) -0.28 (-0.75, 0.26) 
High SES*2002  0.08 (-0.32, 0.48) 0.15 (-0.27, 0.59) 0.04 (-0.42, 0.55) 
High SES*2003  0.07 (-0.33, 0.46) 0.13 (-0.28, 0.56) 0.02 (-0.43, 0.53) 
High SES*2004  0.23 (-0.16, 0.61) 0.27 (-0.13, 0.71) 0.16 (-0.27, 0.66) 
High SES*2005  0.19 (-0.20, 0.57) 0.24 (-0.16, 0.68) 0.12 (-0.31, 0.62) 
High SES*2006  0.24 (-0.15, 0.62) 0.32 (-0.08, 0.75) 0.21 (-0.23, 0.71) 
High SES*2007  0.12 (-0.27, 0.50) 0.19 (-0.21, 0.62) 0.08 (-0.36, 0.58) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years   0.44 (0.38, 0.51) 0.47 (0.40, 0.53) 
Age: 75+ years   0.41 (0.33, 0.50) 0.46 (0.37, 0.54) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   0.08 (0.02, 0.14) 0.07 (0.01, 0.13) 
Duration 10+ years   0.26 (0.19, 0.32) 0.20 (0.14, 0.27) 
Ethnicity, reference: White 
South Asian   0.03 (-0.10, 0.16) 0.03 (-0.11, 0.16) 
Other Ethnicity   0.04 (-0.26, 0.32) -0.01 (-0.31, 0.29) 
Male   0.27 (0.21, 0.32) 0.27 (0.21, 0.32) 
Smoking status, reference: non-smoker 
Smoker   0.21 (0.13, 0.28) 0.22 (0.14, 0.30) 
Ex-smoker   0.10 (0.04, 0.15) 0.10 (0.04, 0.15) 
Obesity category, reference: under and normal weight 
Overweight   0.22 (0.14, 0.30) 0.22 (0.14, 0.30) 
Obese   0.33 (0.25, 0.41) 0.32 (0.24, 0.40) 
Hypertensive   0.08 (0.03, 0.13) 0.06 (0.01, 0.11) 
HbA1c   0.01 (-0.01, 0.02) 0.00 (-0.02, 0.01) 
Cholesterol   -0.12 (-0.14, -0.09) -0.11 (-0.13, -0.08) 
eGFR   0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 
Ischaemic Cardiac   1.74 (1.68, 1.79) 1.73 (1.67, 1.79) 
Stroke or TIA   0.87 (0.79, 0.96) 0.86 (0.78, 0.95) 
PVD   0.37 (0.27, 0.46) 0.33 (0.23, 0.43) 
Interventions 
Care level, reference group: <7 
Care level: 7    0.04 (-0.03, 0.10) 
Care level: 8    -0.01 (-0.09, 0.07) 
M. PCT    0.12 (-0.14, 0.38) 
Shared care    0.29 (0.22, 0.36) 
Cons -0.21 (-0.32, -
0.10) 
-0.62 (-0.93, -0.33) -1.49 (-1.88, -1.04) -1.78 (-2.22, -1.24) 
Variance estimate at: 
Practice level 0.08 (0.05, 0.14) 0.09 (0.06, 0.15) 0.16 (0.10, 0.26) 0.16 (0.10, 0.26) 
Patient level 0.01 (0.00, 0.02) 0.03 (0.01, 0.09) 0.00 (0.00, 0.02) 0.00 (0.00, 0.01) 
Bayesian DIC 45543.27 44955.91 37700.8 37629.34 
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Shared care 
 
Table 76: Stepwise logistic regression multilevel model examining shared care with 
interaction effect between SES and visit from 1999 to 2007, conditional on relevant 
explanatory variables 
 Null Model 1 Model 2 Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  0.30 (-0.18, 0.78) 0.25 (-0.28, 0.73) 0.25 (-0.27, 0.80) 
High  -0.52 (-0.90, -0.13) -0.66 (-1.05, -0.25) -0.61 (-1.08, -0.17) 
Visit year, reference group: 1999 
2000  -0.54 (-0.85, -0.22) -0.57 (-0.89, -0.25) -0.82 (-1.19, -0.46) 
2001  -1.18 (-1.49, -0.88) -1.19 (-1.49, -0.87) -1.51 (-1.88, -1.17) 
2002  -1.61 (-1.90, -1.31) -1.68 (-1.97, -1.38) -1.91 (-2.26, -1.59) 
2003  -1.96 (-2.25, -1.66) -2.07 (-2.36, -1.77) -2.35 (-2.70, -2.03) 
2004  -2.27 (-2.55, -1.98) -2.47 (-2.76, -2.17) -2.84 (-3.20, -2.52) 
2005  -2.59 (-2.88, -2.30) -2.84 (-3.14, -2.54) -3.16 (-3.51, -2.84) 
2006  -2.91 (-3.20, -2.62) -3.00 (-3.29, -2.71) -3.52 (-3.88, -3.19) 
2007  -2.81 (-3.10, -2.51) -3.01 (-3.32, -2.70) -3.08 (-3.44, -2.75) 
SES*Visit year, reference group: Low SES*1999 
Mid. SES*2000  -0.52 (-1.05, 0.03) -0.44 (-1.00, 0.16) -0.30 (-0.93, 0.33) 
Mid. SES*2001  -0.60 (-1.13, -0.07) -0.58 (-1.14, 0.00) -0.51 (-1.13, 0.09) 
Mid. SES*2002  -0.43 (-0.94, 0.09) -0.32 (-0.85, 0.24) -0.42 (-1.01, 0.15) 
Mid. SES*2003  -0.43 (-0.94, 0.09) -0.30 (-0.82, 0.27) -0.33 (-0.93, 0.24) 
Mid. SES*2004  -0.23 (-0.72, 0.27) -0.09 (-0.62, 0.46) -0.04 (-0.63, 0.53) 
Mid. SES*2005  -0.05 (-0.56, 0.47) 0.12 (-0.41, 0.68) 0.14 (-0.45, 0.71) 
Mid. SES*2006  0.02 (-0.49, 0.53) 0.15 (-0.38, 0.71) 0.15 (-0.43, 0.72) 
Mid. SES*2007  -0.01 (-0.52, 0.51) 0.15 (-0.39, 0.71) 0.13 (-0.46, 0.72) 
High SES*2000  0.31 (-0.16, 0.76) 0.51 (0.02, 0.98) 0.47 (-0.06, 1.01) 
High SES*2001  0.33 (-0.12, 0.76) 0.45 (-0.02, 0.91) 0.44 (-0.06, 0.97) 
High SES*2002  0.59 (0.16, 1.01) 0.83 (0.38, 1.26) 0.72 (0.24, 1.23) 
High SES*2003  0.61 (0.18, 1.03) 0.84 (0.39, 1.28) 0.76 (0.29, 1.26) 
High SES*2004  0.62 (0.20, 1.02) 0.86 (0.41, 1.29) 0.76 (0.28, 1.25) 
High SES*2005  0.66 (0.22, 1.07) 0.93 (0.47, 1.36) 0.85 (0.37, 1.34) 
High SES*2006  0.63 (0.20, 1.04) 0.85 (0.40, 1.28) 0.72 (0.24, 1.22) 
High SES*2007  0.49 (0.05, 0.91) 0.76 (0.30, 1.21) 0.69 (0.20, 1.19) 
Covariates 
Age, reference group: <60 
60-74   -0.55 (-0.62, -0.48) -0.46 (-0.53, -0.38) 
75+   -1.06 (-1.16, -0.96) -0.85 (-0.96, -0.75) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   0.41 (0.34, 0.49) 0.01 (-0.07, 0.09) 
Duration 10+ years   1.27 (1.19, 1.35) 0.54 (0.45, 0.63) 
Ethnicity, reference group: white 
South Asian   -0.04 (-0.18, 0.10) 0.13 (-0.02, 0.28) 
Other Ethnicity   0.76 (0.44, 1.07) 0.72 (0.39, 1.05) 
Male   0.02 (-0.05, 0.08) 0.06 (0.00, 0.13) 
Smoking status, reference group: non-smoker 
Smoker   -0.32 (-0.42, -0.24) -0.32 (-0.42, -0.22) 
Ex-smoker   -0.01 (-0.08, 0.06) -0.04 (-0.12, 0.03) 
Obesity status, reference group: Under and normal weight 
Overweight   0.03 (-0.07, 0.12) 0.08 (-0.02, 0.18) 
Obese   0.28 (0.19, 0.38) 0.39 (0.28, 0.49) 
HbA1c   0.26 (0.24, 0.28) 0.11 (0.09, 0.13) 
Hypertensive    0.42 (0.36, 0.48) 0.47 (0.41, 0.54) 
Cholesterol   -0.13 (-0.16, -0.1) -0.08 (-0.11, -0.05) 
Creatinine > 300   0.21 (-0.26, 0.66) 0.06 (-0.47, 0.58) 
eGFR   -0.01 (-0.01, -0.01) -0.01 (-0.01, 0.00) 
Ischaemic Cardiac   0.25 (0.19, 0.32) 0.21 (0.13, 0.29) 
Stroke or TIA   0.24 (0.15, 0.34) 0.17 (0.06, 0.27) 
PVD   0.87 (0.77, 0.97) 0.7 (0.59, 0.81) 
Interventions 
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Care level, reference group: <7 
Care level: 7    0.60 (0.52, 0.69) 
Care level: 8    1.25 (1.15, 1.35) 
Diabetes treatment, reference group diet alone 
Sulphonylures / metformin only   0.75 (0.62, 0.88) 
OHA comb.    0.78 (0.65, 0.92) 
Insulin only    3.28 (3.14, 3.43) 
Insulin & OHAs    1.59 (1.47, 1.71) 
BP treatment, reference group no treatments 
ACE inhibitors only    -0.04 (-0.15, 0.07) 
ACE & other(s)    -0.01 (-0.10, 0.08) 
Other BP     -0.10 (-0.19, -0.01) 
Aspirin    0.22 (0.15, 0.30) 
Lipid therapy    -0.20 (-0.28, -0.13) 
M. PCT    0.65 (0.17, 1.21) 
Cons -0.73 (-1.06, -
0.37) 
1.33 (0.92, 1.75) -0.06 (-0.55, 0.41) 
-1.19 (-1.77, -0.50) 
Variance estimate at: 
Practice level 0.89 (0.54, 1.41) 0.94 (0.58, 1.52) 0.96 (0.59, 1.56) 1.00 (0.62, 1.62) 
Patient level 0.14 (0.04, 0.39) 0.06 (0.02, 0.17) 0.02 (0.00, 0.06) 0.01 (0.00, 0.03) 
Bayesian DIC 35835.41 33341.44 29475.68 25638.09 
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Appendix H. Stepwise models for intermediate outcomes and 
long-term complications with interaction between interventions 
and socio-economic status 
 
Intermediate outcomes 
 
Table 77: Stepwise linear regression multilevel models examining HbA1c by SES from 
1999 to 2007, conditional on relevant explanatory variables 
 Null Model 1 Model 2 Model 3 
Social-economic status 
Social-economic status, reference group: Low SES 
Mid. SES  -0.11 (-0.15, -
0.07) 
-0.06 (-0.10, -
0.02) 
-0.05 (-0.08, -
0.01) 
High SES  -0.19 (-0.23, -
0.15) 
-0.10 (-0.14, -
0.06) 
-0.09 (-0.13, -
0.06) 
Visit year, reference group: 1999 
2000   -0.29 (-0.38, -
0.20) 
-0.32 (-0.40, -
0.23) 
2001   -0.47 (-0.56, -
0.38) 
-0.47 (-0.55, -
0.38) 
2002   -0.59 (-0.67, -
0.50) 
-0.55 (-0.62, -
0.47) 
2003   -0.63 (-0.71, -
0.55) 
-0.59 (-0.66, -
0.52) 
2004   -0.67 (-0.74, -
0.59) 
-0.63 (-0.71, -
0.56) 
2005   -0.75 (-0.83, -
0.68) 
-0.71 (-0.79, -
0.64) 
2006   -1.26 (-1.33, -
1.18) 
-1.18 (-1.25, -
1.10) 
2007   -1.14 (-1.22, -
1.06) 
-1.12 (-1.20, -
1.04) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years   -0.46 (-0.50, -
0.42) 
-0.33 (-0.36, -
0.29) 
Age: 75+ years   -0.69 (-0.73, -
0.64) 
-0.41 (-0.46, -
0.37) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   0.38 (0.35, 0.42) -0.09 (-0.13, -
0.06) 
Duration 10+ years   0.70 (0.66, 0.74) 0.06 (0.02, 0.09) 
Ethnicity, reference group: White 
South Asian   0.47 (0.39, 0.55) 0.46 (0.39, 0.54) 
Other Ethnicity   0.66 (0.48, 0.83) 0.47 (0.31, 0.64) 
Male   -0.12 (-0.15, -
0.09) 
-0.06 (-0.09, -
0.03) 
Smoking status, reference group: Non smoker 
Smoker   0.25 (0.21, 0.30) 0.23 (0.19, 0.27) 
Ex-smoker   0.07 (0.04, 0.11) 0.05 (0.02, 0.08) 
BMI status, reference group: Low & normal weight 
Overweight   0.06 (0.01, 0.10) 0.02 (-0.02, 0.07) 
Obese   0.19 (0.14, 0.24) 0.08 (0.04, 0.13) 
Creatinine > 300   -0.84 (-1.09, -
0.58) 
-0.81 (-1.05, -
0.56) 
Hypertensive   0.14 (0.11, 0.17) 0.10 (0.07, 0.13) 
Ischaemic Cardiac   0.05 (0.01, 0.08) 0.00 (-0.04, 0.03) 
Stroke or TIA   -0.01 (-0.06, 
0.04) 
-0.06 (-0.1, -
0.01) 
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N = 38,413 
 
Table 78: Stepwise linear regression multilevel models examining cholesterol by SES 
from 1999 to 2007, conditional on relevant explanatory variables 
 Null Model 1 Model 2 Model 3 
Social-economic status 
Social-economic status, reference group: Lowest SES 
Mid. SES  0.01 (-0.02, 0.04) 0.03 (0.00, 0.06) 0.03 (0.00, 0.06) 
High SES  -0.03 (-0.06, 
0.00) 
0.00 (-0.03, 0.02) -0.01 (-0.03, 
0.02) 
Visit year, reference group: 1999 
2000   -0.20 (-0.29, -
0.11) 
-0.20 (-0.29, -
0.11) 
2001   -0.21 (-0.30, -
0.12) 
-0.21 (-0.30, -
0.12) 
2002   -0.25 (-0.34, -
0.17) 
-0.22 (-0.30, -
0.14) 
2003   -0.44 (-0.53, -
0.36) 
-0.37 (-0.46, -
0.29) 
2004   -0.70 (-0.78, -
0.62) 
-0.58 (-0.66, -
0.50) 
2005   -0.86 (-0.94, -
0.78) 
-0.73 (-0.82, -
0.65) 
2006   -0.98 (-1.07, -
0.90) 
-0.83 (-0.92, -
0.75) 
2007   -1.05 (-1.13, -
0.96) 
-0.93 (-1.01, -
0.85) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years   -0.21 (-0.24, -
0.18) 
-0.20 (-0.23, -
0.17) 
Age: 75+ years   -0.23 (-0.26, -
0.20) 
-0.26 (-0.30, -
0.23) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   -0.11 (-0.13, -
0.08) 
-0.09 (-0.11, -
0.06) 
PVD   0.09 (0.04, 0.15) -0.06 (-0.12, -
0.01) 
Interventions 
Quality of Care level, reference group: Low quality 
Mid. quality    -0.13 (-0.16, -
0.09) 
High quality    -0.15 (-0.19, -
0.11) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas only    0.81 (0.77, 0.85) 
Combination with no insulin    1.25 (1.20, 1.29) 
Insulin only    1.67 (1.61, 1.73) 
Combination with insulin    1.75 (1.69, 1.82) 
Shared care    0.17 (0.13, 0.21) 
Middlesbrough PCT    0.10 (0.01, 0.20) 
Cons 7.62 (7.49, 
7.74) 
7.84 (7.73, 7.95) 8.31 (8.20, 8.42) 7.60 (7.47, 7.72) 
Variance estimate at: 
Practice level 0.05 (0.03, 
0.08) 
0.05 (0.03, 0.07) 0.03 (0.02, 0.05) 0.02 (0.01, 0.04) 
Patient level 0.02 (0.01, 
0.06) 
0.01 (0.00, 0.04) 0.00 (0.00, 0.01) 0.00 (0.00, 0.02) 
Visit year 2.47 (2.43, 
2.50) 
2.47 (2.43, 2.5) 2.2 (2.17, 2.23) 1.91 (1.88, 1.94) 
Bayesian DIC 145158.08 145299.58 140844.98 133975.02 
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Duration 10+ years   -0.16 (-0.19, -
0.13) 
-0.13 (-0.16, -
0.10) 
Ethnicity, reference group: White 
South Asian   -0.07 (-0.12, -
0.01) 
-0.08 (-0.14, -
0.02) 
Other Ethnicity   0.11 (-0.02, 0.23) 0.08 (-0.05, 0.20) 
Male   -0.33 (-0.35, -
0.31) 
-0.34 (-0.36, -
0.32) 
Smoking status, reference group: Non smoker 
Smoker   0.08 (0.05, 0.11) 0.08 (0.05, 0.11) 
Ex-smoker   -0.02 (-0.04, 
0.01) 
0.00 (-0.03, 0.02) 
BMI, reference group: Under or normal weight 
Overweight   0.00 (-0.03, 0.04) 0.03 (0.00, 0.07) 
Obese   0.00 (-0.04, 0.03) 0.03 (0.00, 0.07) 
Hypertensive   0.14 (0.12, 0.16) 0.14 (0.12, 0.16) 
Ischaemic Cardiac   -0.21 (-0.24, -
0.19) 
-0.13 (-0.15, -
0.10) 
Stroke or TIA   -0.05 (-0.09, -
0.01) 
-0.02 (-0.06, 
0.01) 
PVD   -0.02 (-0.06, 
0.03) 
0.01 (-0.03, 0.05) 
Interventions 
Quality of Care level, reference group: Low quality 
Mid. quality    -0.10 (-0.13, -
0.07) 
High quality    -0.15 (-0.18, -
0.11) 
Aspirin    -0.09 (-0.11, -
0.06) 
Lipid therapy    -0.28 (-0.31, -
0.26) 
Middlesbrough PCT    -0.03 (-0.09, 
0.03) 
Shared care    -0.07 (-0.10, -
0.04) 
Cons 4.65 (4.60, 
4.70) 
4.66 (4.6, 4.71) 5.73 (5.63, 5.84) 5.92 (5.81, 6.02) 
Variance estimates (Standard Error): 
Practice level 0.01 (0.01, 
0.02) 
0.01 (0.01, 0.02) 0.01 (0.01, 0.02) 0.01 (0.00, 0.01) 
Patient level 0.00 (0.00, 
0.01) 
0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 
Visit year 1.35 (1.33, 
1.37) 
1.35 (1.33, 1.37) 1.17 (1.15, 1.18) 1.15 (1.13, 1.16) 
Bayesian DIC 116373.88 116369.85 111026.13 110335.6 
N = 37,085 
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Long-term complications 
 
Table 79: Stepwise linear regression multilevel models examining ischaemic cardiac 
disease socio-economic status from 2000 to 2007, conditional on relevant explanatory 
variables 
 Null Model 1 Model 2 Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  -0.09 (-0.22, 
0.04) 
-0.14 (-0.28, 
0.00) 
-0.18 (-0.33, -
0.04) 
High  -0.15 (-0.28, -
0.03) 
-0.18 (-0.30, -
0.05) 
-0.16 (-0.29, -
0.02) 
Visit year, reference group: 2000 
2001   -0.21 (-0.47, 
0.06) 
-0.29 (-0.59, 
0.01) 
2002   -0.13 (-0.37, 
0.11) 
-0.31 (-0.57, -
0.04) 
2003   -0.09 (-0.32, 
0.14) 
-0.40 (-0.66, -
0.14) 
2004   -0.25 (-0.48, -
0.01) 
-0.67 (-0.94, -
0.40) 
2005   -0.78 (-1.03, -
0.54) 
-1.25 (-1.53, -
0.97) 
2006   -1.25 (-1.50, -
0.98) 
-1.67 (-1.96, -
1.38) 
2007   -1.20 (-1.45, -
0.93) 
-1.81 (-2.11, -
1.51) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years   0.65 (0.51, 0.79) 0.34 (0.19, 0.49) 
Age: 75+ years   0.83 (0.66, 1.00) 0.60 (0.42, 0.79) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   -0.62 (-0.75, -
0.50) 
-0.59 (-0.73, -
0.45) 
Duration 10+ years   -0.56 (-0.70, -
0.42) 
-0.63 (-0.79, -
0.46) 
Ethnicity, reference group: White 
South Asian    -0.11 (-0.41, 
0.18) 
0.09 (-0.25, 0.41) 
Other Ethnicity   -0.63 (-1.45, 
0.08) 
-0.67 (-1.56, 
0.09) 
Male   0.35 (0.24, 0.46) 0.32 (0.20, 0.44) 
Smoking status, reference group: non smoker 
Smoker   0.16 (0.00, 0.32) 0.15 (-0.02, 0.33) 
Ex-smoker   0.35 (0.23, 0.46) 0.31 (0.19, 0.44) 
Obesity category, reference group: under & normal weight 
Overweight   0.1 (-0.06, 0.26) -0.01 (-0.19, 
0.16) 
Obese   0.35 (0.19, 0.51) 0.12 (-0.05, 0.30) 
HbA1c   0.06 (0.02, 0.09) 0.07 (0.03, 0.11) 
Hypertensive   -0.19 (-0.30, -
0.08) 
-0.27 (-0.39, -
0.15) 
Cholesterol   -0.33 (-0.38, -
0.28) 
-0.23 (-0.29, -
0.17) 
eGFR   -0.02 (-0.02, -
0.01) 
-0.01 (-0.01, 
0.00) 
Interventions 
Quality of care level, reference group: Low quality 
Mid. quality    -0.30 (-0.44, -
0.16) 
High quality    -0.40 (-0.56, -
0.24) 
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Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas only    -0.28 (-0.43, -
0.14) 
Combination, no insulin    -0.40 (-0.59, -
0.21) 
Insulin only    0.12 (-0.12, 0.36) 
Combination with insulin    -0.31 (-0.60, -
0.02) 
Blood pressure treatment, reference group: No treatments 
ACE inhibitors only    0.27 (0.01, 0.53) 
ACEI + other(s)    1.51 (1.31, 1.70) 
Combination/other    1.25 (1.05, 1.45) 
Aspirin    1.37 (1.26, 1.49) 
Lipid therapy    0.61 (0.47, 0.74) 
Middlesbrough PCT    -0.20 (-0.39, 
0.00) 
Shared care    0.27 (0.11, 0.43) 
Cons -3.98 (-5.22, -
2.58) 
-4.02 (-5.28, -
2.72) 
-1.87 (-2.86, -
0.85) 
-3.96 (-4.98, -
3.00) 
Variance estimate at: 
Practice level 0.04 (0.02, 
0.09) 
0.05 (0.02, 0.09) 0.03 (0.01, 0.07) 0.05 (0.02, 0.11) 
Patient level 2.44 (0.59, 
8.18) 
2.48 (0.61, 8.09) 2.18 (0.59, 6.78) 2.05 (0.55, 6.71) 
Bayesian DIC 11620.93 11617.33 10718.16 9194.77 
N = 24,004  
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Table 80: Stepwise linear regression multilevel models examining stroke or TIA socio-
economic status from 2000 to 2007, conditional on relevant explanatory variables 
 Null Model 1 Model 2 Model 3 
Social-economic status, reference group: Low 
Mid.  0.01 (-0.18, 0.20) -0.01 (-0.21, 
0.18) 
-0.01 (-0.21, 
0.18) 
High  -0.03 (-0.21, 
0.15) 
-0.07 (-0.25, 
0.12) 
-0.02 (-0.20, 
0.17) 
Covariates 
Visit year, reference group: 2000 
2001   0.10 (-0.29, 0.50) 0.21 (-0.17, 0.61) 
2002   -0.02 (-0.38, 
0.34) 
0.04 (-0.31, 0.41) 
2003   0.10 (-0.25, 0.45) 0.14 (-0.21, 0.51) 
2004   -0.02 (-0.35, 
0.34) 
0.04 (-0.32, 0.39) 
2005   -0.26 (-0.61, 
0.11) 
-0.19 (-0.56, 
0.18) 
2006   -0.86 (-1.24, -
0.47) 
-0.80 (-1.20, -
0.41) 
2007   -0.74 (-1.12, -
0.34) 
-0.71 (-1.11, -
0.31) 
Age, reference group: <60 years 
Age: 60-74 years   0.87 (0.64, 1.10) 0.75 (0.51, 0.99) 
Age: 75+ years   1.22 (0.96, 1.49) 1.10 (0.83, 1.39) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   -0.31 (-0.49, -
0.13) 
-0.30 (-0.50, -
0.11) 
Duration 10+ years   -0.04 (-0.22, 
0.15) 
-0.18 (-0.40, 
0.02) 
Ethnicity, reference group: White 
South Asian    0.04 (-0.39, 0.43) 0.11 (-0.34, 0.53) 
Other Ethnicity   -1.18 (-3.09, 
0.12) 
-1.16 (-3.06, 
0.17) 
Male   0.01 (-0.15, 0.17) -0.10 (-0.27, 
0.06) 
Smoking status, reference group: non smoker 
Smoker   0.31 (0.09, 0.53) 0.27 (0.04, 0.50) 
Ex-smoker   0.21 (0.03, 0.38) 0.13 (-0.04, 0.31) 
Obesity category, reference group: under & normal weight 
Overweight   -0.06 (-0.27, 
0.16) 
-0.09 (-0.30, 
0.13) 
Obese   -0.09 (-0.31, 
0.13) 
-0.20 (-0.42, 
0.02) 
HbA1c   0.03 (-0.02, 0.07) 0.02 (-0.03, 0.08) 
Hypertensive   0.16 (0.00, 0.31) 0.15 (-0.01, 0.30) 
Cholesterol   -0.11 (-0.18, -
0.04) 
-0.09 (-0.16, -
0.01) 
eGFR   -0.01 (-0.02, -
0.01) 
-0.01 (-0.01, 
0.00) 
Interventions 
Quality of care level, reference group: Low quality 
Mid. quality    -0.16 (-0.35, 
0.03) 
High quality    -0.03 (-0.24, 
0.19) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas only    -0.18 (-0.38, 
0.03) 
Combo., no insulin    -0.30 (-0.56, -
0.03) 
Insulin only    -0.08 (-0.40, 
0.23) 
Combo., with insulin    -0.29 (-0.67, 
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0.08) 
Blood pressure treatment, reference group: No treatments 
ACE inhibitors only    0.30 (0.01, 0.59) 
ACE + other(s)    0.15 (-0.09, 0.39) 
Combination/other    0.18 (-0.06, 0.42) 
Aspirin    1.06 (0.89, 1.23) 
Lipid therapy    0.09 (-0.08, 0.26) 
M. PCT    -0.12 (-0.39, 
0.14) 
Shared care    0.44 (0.24, 0.65) 
Cons -4.63 (-5.38, -
3.86) 
-4.63 (-5.42, -
3.84) 
-4.24 (-5.33, -
3.11) 
-5.09 (-6.24, -
3.99) 
Variance estimate at: 
Practice level 0.10 (0.04, 
0.21) 
0.10 (0.04, 0.21) 0.07 (0.02, 0.16) 0.11 (0.04, 0.22) 
Patient level 1.23 (0.31, 
4.03) 
1.23 (0.32, 3.96) 1.31 (0.33, 4.27) 1.32 (0.33, 4.37) 
Bayesian DIC 6705.64 6709.29 6434.63 6133.11 
N = 29,800 
  
Table 81: Stepwise linear regression multilevel models examining peripheral vascular 
disease socio-economic status from 2000 to 2007, conditional on relevant explanatory 
variables 
 Null Model 1 Model 2 Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  -0.16 (-0.37, 
0.05) 
-0.16 (-0.38, 
0.06) 
-0.17 (-0.40, 
0.05) 
High  -0.21 (-0.42, 
0.00) 
-0.20 (-0.42, 
0.01) 
-0.21 (-0.43, 
0.01) 
Visit year, reference group: 2000 
2001   -0.31 (-0.71, 
0.10) 
-0.22 (-0.63, 
0.19) 
2002   -0.34 (-0.70, 
0.03) 
-0.24 (-0.62, 
0.14) 
2003   -0.12 (-0.46, 
0.23) 
0.03 (-0.32, 0.40) 
2004   -0.18 (-0.52, 
0.16) 
0.00 (-0.36, 0.36) 
2005   -0.51 (-0.87, -
0.16) 
-0.30 (-0.68, 
0.08) 
2006   -0.98 (-1.35, -
0.59) 
-0.79 (-1.19, -
0.38) 
2007   -1.44 (-1.87, -
1.01) 
-1.13 (-1.59, -
0.66) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years   0.66 (0.43, 0.90) 0.62 (0.38, 0.88) 
Age: 75+ years   0.72 (0.44, 1.00) 0.81 (0.51, 1.12) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   0.25 (0.04, 0.46) 0.13 (-0.09, 0.35) 
Duration 10+ years   0.74 (0.53, 0.95) 0.38 (0.15, 0.62) 
Ethnicity, reference group: White 
South Asian    -0.89 (-1.61, -
0.25) 
-0.81 (-1.53, -
0.15) 
Other Ethnicity   0.01 (-1.03, 0.88) -0.06 (-1.14, 
0.84) 
Male   0.40 (0.22, 0.58) 0.40 (0.21, 0.59) 
Smoking status, reference group: non smoker 
Smoker   0.90 (0.65, 1.14) 0.93 (0.68, 1.18) 
Ex-smoker   0.42 (0.21, 0.63) 0.37 (0.16, 0.58) 
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Obesity category, reference group: under & normal weight 
Overweight   -0.12 (-0.36, 
0.12) 
-0.2 (-0.45, 0.05) 
Obese   -0.06 (-0.29, 
0.18) 
-0.25 (-0.51, 
0.00) 
HbA1c   0.07 (0.01, 0.12) 0.01 (-0.05, 0.07) 
Hypertensive   0.17 (0.00, 0.34) 0.13 (-0.05, 0.31) 
Cholesterol   -0.13 (-0.21, -
0.05) 
-0.05 (-0.13, 
0.03) 
eGFR   -0.01 (-0.02, -
0.01) 
-0.01 (-0.01, 
0.00) 
Interventions 
Quality of care level, reference group: Low quality 
Mid. quality    -0.18 (-0.41, 
0.06) 
High quality    0.18 (-0.06, 0.42) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas 
only 
   -0.06 (-0.31, 
0.20) 
Combo., no insulin    -0.12 (-0.42, 
0.19) 
Insulin only    0.33 (0.01, 0.66) 
Combo., with insulin    0.34 (-0.03, 0.72) 
Blood pressure treatment, reference group: No treatments 
ACE inhibitors only    0.48 (0.15, 0.80) 
Combination, with ACEI     0.42 (0.15, 0.70) 
Combination, no ACEI    0.37 (0.09, 0.65) 
Aspirin    0.58 (0.39, 0.76) 
Lipid therapy    0.10 (-0.10, 0.29) 
M. PCT    -0.18 (-0.55, 
0.19) 
Shared care    0.84 (0.63, 1.06) 
Cons -4.77 (-5.45, -
4.14) 
-4.66 (-5.51, -
3.84) 
-4.75 (-6.16, -
3.57) 
-5.92 (-7.33, -
4.75) 
Variance estimate at: 
Practice level 0.29 (0.15, 0.49) 0.29 (0.15, 0.51) 0.26 (0.13, 0.48) 0.27 (0.14, 0.48) 
Patient level 0.88 (0.23, 2.63) 0.94 (0.24, 3.01) 1.17 (0.3, 3.84) 1.38 (0.33, 4.62) 
Bayesian DIC 5658.78 5657.99 5315.63 5022.90 
N = 30,053 
 
Table 82: Stepwise linear regression multilevel models examining microalbuminuria 
socio-economic status from 1999 to 2007, conditional on relevant explanatory variables 
 Null Model 1 Model 2 Model 3 
Social-economic status 
Social-economic status, reference group: Lowest SES 
Mid. SES  -0.11 (-0.18, -
0.03) 
-0.11 (-0.19, -
0.03) 
-0.09 (-0.17, -
0.01) 
High SES  -0.13 (-0.20, -
0.06) 
-0.12 (-0.20, -
0.05) 
-0.09 (-0.17, -
0.01) 
Visit year, reference group: 1999 
2000   -0.33 (-0.66, -
0.00) 
-0.42 (-0.75, -
0.09) 
2001   -0.34 (-0.65, -
0.03) 
-0.63 (-0.94, -
0.31) 
2002   -0.44 (-0.74, -
0.16) 
-0.86 (-1.16, -
0.55) 
2003   -0.22 (-0.52, 
0.07) 
-0.75 (-1.05, -
0.45) 
2004   0.55 (0.26, 0.84) -0.00 (-0.29, 
0.31) 
2005   0.79 (0.50, 1.07) 0.19 (-0.10, 
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0.49) 
2006   1.13 (0.84, 1.41) 0.56 (0.27, 0.87) 
2007   0.76 (0.35, 1.17) 0.26 (0.27, 0.87) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years   0.13 (0.05, 0.20) -0.01 (-0.06, 
0.09) 
Age: 75+ years   0.53 (0.44, 0.62) 0.37 (0.28, 0.47) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   -0.01 (-0.08, 
0.07) 
-0.01 (-0.09, 
0.06) 
Duration 10+ years   0.08 (0.00, 0.16) 0.18 (0.09, 0.27) 
Ethnicity, reference group: White 
South Asian   0.16 (-0.00, 0.32) 0.21 (0.05, 0.38) 
Other Ethnicity   0.19 (-0.18, 0.54) 0.30 (-0.09, 
0.67) 
Male   0.23 (0.17, 0.30) 0.24 (0.18, 0.31) 
Smoking status, reference group: Non smoker 
Smoker   0.28 (0.19, 0.37) 0.26 (0.17, 0.36) 
Ex-smoker   0.08 (0.01, 0.15) 0.07 (-0.00, 
0.14) 
BMI, reference group: Under or normal weight 
Overweight   0.04 (-0.06, 0.13) -0.01 (-0.11, 
0.09) 
Obese   0.12 (0.03, 0.21) 0.06 (-0.03, 
0.15) 
Hypertensive   0.14 (0.07, 0.20) 0.18 (0.11, 0.24) 
Cholesterol   0.03 (-0.00, 0.05) 0.03 (0.00, 0.06) 
HbA1c   0.06 (0.03, 0.07) 0.09 (0.06, 0.11) 
Interventions 
Quality of Care level, reference group: Low quality 
Mid. quality    -0.11 (-0.54, 
0.35) 
High quality    -0.22 (-0.65, 
0.23) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas 
only 
   0.14 (0.04, 0.24) 
Combination, no insulin    0.02 (-0.09, 
0.14) 
Insulin only    0.18 (0.04, 0.32) 
Combination with insulin    0.21 (0.11, 0.31) 
Blood pressure treatment, reference group: No treatments 
ACE inhibitors only    0.37 (0.26, 0.47) 
Combination with ACEI    0.53 (0.44, 0.62) 
Combination, no ACEI    0.32 (0.23, 0.41) 
Aspirin    0.07 (0.01, 0.14) 
Lipid therapy    -0.05 (-0.12, 
0.02) 
Middlesbrough PCT    0.58 (0.28, 0.87) 
Shared care    -0.93 (-1.02, -
0.84) 
Cons -1.06 (-1.33, -
0.84) 
-0.99 (-1.24, -
0.77) 
-2.47 (-2.86, -
2.05) 
-2.45 (-3.04, -
1.89) 
Variance estimates (Standard Error): 
Practice level 0.23 (0.15, 
0.37) 
0.23 (0.14, 0.37) 0.24 (0.15, 0.38) 0.21 (0.13, 0.34) 
Patient level 0.05 (0.01, 
0.21) 
0.05 (0.01, 0.19) 0.01 (0.00, 0.04) 0.01 (0.00, 0.03) 
Bayesian DIC 27573.79 27,564.87 26,091.68 25467.71 
N = 23,304 
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Table 83: Stepwise linear regression multilevel models examining any retinopathy 
socio-economic status from 1999 to 2007, conditional on relevant explanatory variables 
 Null Model 1 Model 2 Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid.  -0.09 (-0.19, 0.01) -0.08 (-0.19, 0.02) -0.08 (-0.19, 0.04) 
High  -0.08 (-0.18, 0.01) -0.07 (-0.18, 0.03) -0.07 (-0.18, 0.03) 
Visit year, reference group: 1999 
2000   -0.03 (-0.32, 0.26) 0.03 (-0.26, 0.33) 
2001   -0.16 (-0.44, 0.13) 0.00 (-0.29, 0.30) 
2002   -0.14 (-0.42, 0.14) 0.02 (-0.26, 0.31) 
2003   -0.27 (-0.55, 0.01) -0.09 (-0.38, 0.20) 
2004   -0.17 (-0.45, 0.11) 0.09 (-0.20, 0.39) 
2005   0.08 (-0.21, 0.38) 0.36 (0.06, 0.66) 
2006   -0.94 (-1.24, -0.65) -0.67 (-0.97, -0.37) 
2007   0.08 (-0.20, 0.37) 0.39 (0.08, 0.69) 
Covariates 
 
Age: 60-74 years   -0.06 (-0.16, 0.05) 0.01 (-0.11, 0.11) 
Age: 75+ years   -0.29 (-0.42, -0.15) -0.10 (-0.24, 0.04) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   0.64 (0.51, 0.76) 0.47 (0.34, 0.59) 
Duration 10+ years   2.00 (1.87, 2.12) 1.60 (1.47, 1.72) 
Ethnicity, reference group: White 
South Asian   -0.23 (-0.46, 0.00) -0.15 (-0.38, 0.08) 
Other Ethnicity   0.64 (0.21, 1.06) 0.52 (0.07, 0.94) 
Male   0.25 (0.16, 0.34) 0.25 (0.16, 0.34) 
Smoking status, reference group: non smoker 
Smoker   -0.14 (-0.27, 0.00) -0.13 (-0.27, 0.00) 
Ex-smoker   -0.10 (-0.19, 0.00) -0.12 (-0.22, -0.02) 
Obesity status, reference group: under and normal weight 
Overweight   -0.06 (-0.19, 0.07) -0.09 (-0.22, 0.05) 
Obese   0.02 (-0.11, 0.15) -0.10 (-0.24, 0.04) 
HbA1c   0.16 (0.13, 0.19) 0.05 (0.02, 0.08) 
Hypertensive   0.38 (0.29, 0.47) 0.33 (0.24, 0.42) 
Cholesterol   -0.05 (-0.09, -0.01) -0.01 (-0.05, 0.03) 
eGFR   -0.01 (-0.02, -0.01) -0.01 (-0.01, -0.01) 
Interventions 
Quality of care level, reference group: Low and Medium quality 
High quality    -0.06 (-0.17, 0.04) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas only    0.40 (0.24, 0.56) 
Combination, no insulin    0.70 (0.53, 0.87) 
Insulin only    1.04 (0.85, 1.23) 
Combination with insulin    1.16 (0.96, 1.36) 
Blood pressure treatment, reference group: No treatments 
ACE inhibitors only    0.32 (0.17, 0.46) 
Combination with ACEI     0.22 (0.09, 0.34) 
Combination, no ACEI    0.13 (0.00, 0.26) 
Aspirin    0.05 (-0.04, 0.14) 
Lipid therapy    -0.06 (-0.16, 0.04) 
Middlesbrough PCT    -0.04 (-0.21, 0.13) 
Shared care    0.53 (0.43, 0.64) 
Cons -1.19 (-1.50, -0.88) -1.15 (-1.47, -0.81) -2.55 (-3.05, -2.04) -3.03 (-3.56, -2.49) 
Variance estimate at: 
Practice level 0.07 (0.04, 0.12) 0.07 (0.03, 0.11) 0.06 (0.03, 0.10) 0.05 (0.03, 0.10) 
Patient level 0.18 (0.05, 0.55) 0.18 (0.05, 0.58) 0.02 (0.00, 0.07) 0.00 (0.00, 0.02) 
Bayesian DIC 17531.30 17532.21 15136.72 14525.43 
N= 18,665 
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Table 84: Stepwise linear regression multilevel models examining microalbuminuria 
socio-economic status from 1999 to 2007, conditional on relevant explanatory variables 
(timeliness of diagnosis model) 
 Null Model 1 Model 2 Model 3 
Social-economic status 
Social-economic status, reference group: Lowest SES 
Mid. SES  -0.13 (-0.26, 
0.01) 
-0.14 (-0.28, 
0.00) 
-0.12 (-0.26, 
0.02) 
High SES  -0.11 (-0.23, 
0.02) 
-0.10 (-0.23, 
0.03) 
-0.07 (-0.21, 
0.05) 
Visit year, reference group: 1999 
2000   -1.33 (-2.43, -
0.24) 
-1.53 (-2.59, -
0.49) 
2001   -0.84 (-1.73, 
0.11) 
-1.53 (-2.37, -
0.64) 
2002   -0.84 (-1.68, 
0.06) 
-1.77 (-2.57, -
0.92) 
2003   -0.48 (-1.29, 
0.41) 
-1.58 (-2.36, -
0.76) 
2004   0.49 (-0.31, 
1.37) 
-0.65 (-1.41, 
0.15) 
2005   0.75 (-0.05, 
1.63) 
-0.46 (-1.22, 
0.35) 
2006   1.13 (0.33, 2.01) -0.02 (-0.78, 
0.79) 
2007   0.58 (-0.33, 
1.56) 
-0.52 (-1.41, 
0.41) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years   0.01 (-0.12, 
0.13) 
-0.11 (-0.24, 
0.02) 
Age: 75+ years   0.26 (0.09, 0.43) 0.17 (-0.01, 0.34) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   0.00 (-0.12, 
0.11) 
-0.01 (-0.14, 
0.11) 
Ethnicity, reference group: White 
South Asian   0.25 (-0.06, 
0.56) 
0.22 (-0.11, 0.55) 
Other Ethnicity   -0.06 (-0.80, 
0.66) 
0.19 (-0.58, 0.94) 
Male   0.13 (0.03, 0.25) 0.18 (0.07, 0.30) 
Smoking status, reference group: Non smoker 
Smoker   0.39 (0.24, 0.55) 0.37 (0.21, 0.53) 
Ex-smoker   0.23 (0.11, 0.35) 0.22 (0.10, 0.34) 
BMI, reference group: Under or normal weight 
Overweight   0.20 (0.03, 0.38) 0.13 (-0.04, 0.31) 
Obese   0.30 (0.13, 0.47) 0.20 (0.02, 0.37) 
eGFR   -0.01 (-0.01, 
0.00) 
-0.01 (-0.01, 
0.00) 
Hypertensive   0.11 (-0.01, 
0.22) 
0.17 (0.06, 0.29) 
Cholesterol   0.02 (-0.03, 
0.07) 
0.03 (-0.02, 0.08) 
Interventions 
HbA1c at diagnosis    0.04 (0.01, 0.07) 
Quality of Care level, reference group: Low quality 
Mid. quality    0.32 (-0.53, 1.26) 
High quality    0.09 (-0.76, 1.02) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas 
only 
   0.20 (0.06, 0.34) 
Combination, no insulin    0.05 (-0.13, 0.24) 
Insulin only    0.09 (-0.24, 0.42) 
Combination with insulin    0.32 (0.15, 0.48) 
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Blood pressure treatment, reference group: No treatments 
ACE inhibitors only    0.26 (0.08, 0.45) 
Combination with ACEI    0.34 (0.19, 0.50) 
Combination, no ACEI    0.14 (-0.01, 0.29) 
Aspirin    -0.04 (-0.15, 
0.08) 
Lipid therapy    0.12 (0.00, 0.25) 
Middlesbrough PCT    0.76 (0.37, 1.15) 
Shared care    -1.26 (-1.45, -
1.08) 
Cons -0.93 (-1.20, -
0.66) 
-0.88 (-1.16, -
0.60) 
-1.63 (-2.69, -
0.72) 
-1.57 (-2.74, -
0.40) 
Variance estimates at: 
Practice level 0.46 (0.28, 
0.75) 
0.45 (0.27, 0.73) 0.46 (0.28, 0.76) 0.38 (0.23, 0.63) 
Patient level 0.04 (0.00, 
0.18) 
0.04 (0.00, 0.17) 0.01 (0.00, 0.04) 0.01 (0.00, 0.04) 
Bayesian DIC 9767.56 9767.53 9178.9 8917.21 
N = 8,260 
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Table 85: Stepwise linear regression multilevel models examining any retinopathy 
socio-economic status from 1999 to 2007, conditional on relevant explanatory variables 
(timeliness of diagnosis model) 
 Null Model 1 Model 2 Model 3 
Social-economic status 
Social-economic status, reference group: Low 
Mid  -0.10 (-0.32, 0.13) -0.09 (-0.33, 0.14) -0.11 (-0.35, 0.14) 
High  0.08 (-0.13, 0.30) 0.04 (-0.19, 0.28) 0.08 (-0.16, 0.31) 
Visit year, reference group: 1999 
2000   -0.64 (-1.89, 0.71) -0.68 (-1.90, 0.68) 
2001   -0.28 (-1.34, 0.93) -0.27 (-1.28, 0.93) 
2002   -0.20 (-1.12, 0.95) -0.23 (-1.19, 0.94) 
2003   -0.26 (-1.22, 0.91) -0.25 (-1.18, 0.94) 
2004   -0.10 (-1.04, 1.07) -0.01 (-0.95, 1.17) 
2005   0.30 (-0.66, 1.44) 0.38 (-0.56, 1.57) 
2006   -1.18 (-2.14, -0.00) -1.04 (-1.99, 0.12) 
2007   0.45 (-0.48) 0.59 (-0.33, 1.77) 
Covariates 
Age: 60-74 years   -0.01 (-0.24, 0.23) 0.07 (-0.18, 0.32) 
Age: 75+ years   0.81 (-0.06, 1.60) 0.13 (-0.19, 0.45) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   0.31 (-0.52, 0.73) 0.15 (-0.07, 0.38) 
Ethnicity, reference group: White 
South Asian   0.13 (-0.52, 0.73) 0.10 (-0.56, 0.70) 
Other Ethnicity   0.81 (-0.06, 1.59) 0.73 (-0.18, 1.54) 
Male   0.17 (-0.03, 0.37) 0.15 (-0.05, 0.35) 
Smoking status, reference group: non smoker 
Smoker   -0.07 (-0.38, 0.21) -0.13 (-0.44, 0.17) 
Ex-smoker   0.00 (-0.21, 0.21) 0.00 (-0.21, 0.21) 
Obesity status, reference group: under and normal weight 
Overweight   -0.22 (-0.52, 0.07) -0.25 (-0.54, 0.04) 
Obese   -0.30 (-0.58, -0.02) -0.40 (-0.68, -0.12) 
Hypertensive   0.55 (0.36, 0.75) 0.48 (0.28, 0.68) 
Cholesterol   -0.08 (-0.17, 0.01) -0.05 (-0.15, 0.04) 
eGFR   -0.01 (-0.02, -0.01) -0.01 (-0.02, -0.00) 
Interventions 
HbA1c at diagnosis    0.10 (0.05, 0.15) 
Quality of care level, reference group: Low and Mid. quality 
High quality    -0.05 (-0.31, 0.21) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas only    0.34 (0.08, 0.61) 
Combination, no insulin    0.57 (0.24, 0.89) 
Insulin only    0.33 (-0.17, 0.79) 
Combination with insulin    0.68 (0.19, 1.15) 
Blood pressure treatment, reference group: No treatments 
ACE inhibitors only    0.48 (0.14, 0.81) 
Combination with ACEI     0.46 (0.17, 0.75) 
Combination, no ACEI    0.22 (-0.07, 0.51) 
Aspirin    -0.00 (-0.20, 0.21) 
Lipid therapy    -0.10 (-0.33, 0.12) 
Middlesbrough PCT    -0.17 (-0.50, 0.16) 
Shared care    0.28 (0.02, 0.55) 
Cons -2.32 (-2.65, -1.91) -2.32 (-2.64, -1.89) -1.35 (-2.75, -0.22) -2.91 (-4.46, -1.60) 
Variance estimate at: 
Practice level 0.12 (0.04, 0.25) 0.12 (0.04, 0.25) 0.13 (0.05, 0.27) 0.15 (0.05, 0.30) 
Patient level 0.14 (0.02, 0.58) 0.15 (0.02, 0.63) 0.02 (0.00, 0.10) 0.01 (0.00, 0.07) 
Bayesian DIC 3757.30 3,758.73  3512.47 
N= 7,012 
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Appendix I. Stepwise models for intermediate outcomes with 
interaction between visit year and socio-economic status prior 
to general practice level data being added to the model 
 
 
Table 86: Stepwise linear regression multilevel models examining HbA1c by SES from 
1999 to 2007, with interaction effect between SES and visit year conditional on relevant 
explanatory variables, prior to general practice level data being added to the model 
 Null Model 1 Model 2 Model 3 
Social-economic status 
Social-economic status, reference group: Low SES 
Mid. SES  -0.14 (-0.24, -
0.03) 
-0.07 (-0.17, 
0.03) 
-0.07 (-0.16, 
0.02) 
High SES  -0.16 (-0.25, -
0.07) 
-0.06 (-0.15, 
0.03) 
-0.08 (-0.17, 
0.01) 
Visit year, reference group: 2004 
2005  -0.05 (-0.14, 
0.02) 
-0.05 (-0.13, 
0.03) 
-0.06 (-0.14, 
0.01) 
2006  -0.59 (-0.67, -
0.51) 
-0.57 (-0.65, -
0.50) 
-0.55 (-0.62, -
0.49) 
2007  -0.46 (-0.54, -
0.38) 
-0.46 (-0.54, -
0.38) 
-0.52 (-0.60, -
0.45) 
SES x Visit year, reference group: Low SES x 2004 
Mid SES x 2005  -0.01 (-0.16, 
0.13) 
-0.01 (-0.15, 
0.13) 
0.01 (-0.12, 
0.14) 
Mid SES x 2006  0.06 (-0.08, 
0.20) 
0.05 (-0.09, 
0.18) 
0.03 (-0.09, 
0.16) 
Mid SES x 2007  0.09 (-0.06, 
0.23) 
0.08 (-0.06, 
0.21) 
0.08 (-0.04, 
0.21) 
High SES x 2005  -0.08 (-0.21, 
0.04) 
-0.08 (-0.20, 
0.04) 
-0.06 (-0.18, 
0.07) 
High SES x 2006  -0.04 (-0.16, 
0.09) 
-0.05 (-0.17, 
0.07) 
-0.01 (-0.12, 
0.10) 
High SES x 2007  -0.08 (-0.21, 
0.04)  
-0.07 (-0.20, 
0.05) 
-0.02 (-0.14, 
0.10) 
Covariates 
Age, reference group: <60 years 
Age: 60-74 years   -0.48 (-0.52, -
0.43) 
-0.36 (-0.40, -
0.31) 
Age: 75+ years   -0.67 (-0.72, -
0.61) 
-0.4 (-0.46, -
0.35) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   0.31 (0.27, 0.36) 0.03 (-0.01, 
0.07) 
Duration 10+ years   0.67 (0.62, 0.72) 0.04 (-0.01, 
0.09) 
Ethnicity, reference group: White 
South Asian   0.46 (0.36, 0.55) 0.46 (0.37, 0.55) 
Other Ethnicity   0.47 (0.26, 0.68) 0.33 (0.14, 0.52) 
Male   -0.05 (-0.09, -
0.02) 
-0.02 (-0.06, 
0.02) 
Smoking status, reference group: Non smoker 
Smoker   0.24 (0.18, 0.29) 0.22 (0.17, 0.28) 
Ex-smoker   0.01 (-0.03, 
0.06) 
0.03 (-0.01, 
0.07) 
BMI status, reference group: Low & normal weight 
Overweight   0.02 (-0.04, 
0.08) 
-0.01 (-0.06, 
0.05) 
Obese   0.17 (0.11, 0.22) 0.07 (0.01, 0.12) 
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Table 87: Stepwise linear regression multilevel models examining cholesterol by SES 
from 1999 to 2007, with interaction effect between SES and visit year conditional on 
relevant explanatory variables, prior to general practice level data being added to the 
model 
Creatinine > 300   -0.85 (-1.16, -
0.54) 
-0.78 (-1.08, -
0.49) 
Hypertensive   0.18 (0.14, 0.22) 0.12 (0.08, 0.16) 
Ischaemic Cardiac   0.05 (0.01, 0.09) 0.01 (-0.03, 
0.04) 
Stroke or TIA   -0.03 (-0.09, 
0.03) 
-0.08 (-0.13, -
0.02) 
PVD   0.10 (0.03, 0.17) -0.05 (-0.12, 
0.01) 
Interventions, Patient level 
Quality of Care level, reference group: Low quality 
Mid. quality    -0.16 (-0.21, -
0.12) 
High quality    -0.20 (-0.26, -
0.15) 
Diabetes treatment, reference group diet alone 
Metformin/sulphonylureas 
only 
   
0.74 (0.69, 0.78) 
Combination with no insulin    1.14 (1.08, 1.20) 
Insulin only    1.64 (1.56, 1.72) 
Combination with insulin    1.74 (1.66, 1.82) 
Shared care    0.07 (0.02, 0.13) 
Middlesbrough PCT    0.09 (-0.03, 
0.20) 
Cons 7.46 (7.37, 
7.55) 
7.84 (7.73, 7.95) 7.67 (7.55, 7.79) 7.13 (6.98, 7.29) 
Variance estimate at: 
Practice level 0.05 (0.03, 
0.08) 
0.04 (0.02, 0.06) 0.03 (0.01, 0.04) 0.03 (0.02, 0.05) 
Patient level 0.00 (0.00, 
0.02) 
0.01 (0.00, 0.02) 0.01 (0.00, 0.03) 0.01 (0.00, 0.04) 
Visit year 2.14 (2.10, 
2.18) 
2.08 (2.04, 2.12) 1.92 (1.89, 1.96) 1.67 (1.64, 1.70) 
Bayesian DIC 79447.87 78770.17 77070.99 73133.00 
 Null Model 1 Model 2 Model 3 
Social-economic status 
Social-economic status, reference group: Low SES 
Mid. SES  -0.02 (-0.10, 0.06) 0.00 (-0.08, 0.07) 0.00 (-0.08, 0.07) 
High SES  -0.06 (-0.14, 0.01) -0.03 (-0.10, 0.04) -0.03 (-0.10, 0.04) 
Visit year, reference group: 2004 
2005  -0.18 (-0.24, -
0.12) 
-0.17 (-0.23, -
0.11) 
-0.16 (-0.22, -
0.11) 
2006  -0.34 (-0.40, -
0.28) 
-0.32 (-0.38, -
0.27) 
-0.29 (-0.34, -
0.23) 
2007  -0.38 (-0.44, -
0.32) 
-0.35 (-0.42, -
0.29) 
-0.38 (-0.44, -
0.32) 
SES x Visit year, reference group: Low SES x 2004 
Mid SES x 2005  -0.01 (-0.12, 0.10) -0.01 (-0.12, 0.09) -0.01 (-0.11, 0.10) 
Mid SES x 2006  0.09 (-0.02, 0.19) 0.09 (-0.01, 0.19) 0.09 (0.00, 0.19) 
Mid SES x 2007  0.03 (-0.08, 0.14) 0.04 (-0.06, 0.15) 0.05 (-0.05, 0.16) 
High SES x 2005  0.03 (-0.08, 0.13) 0.02 (-0.08, 0.12) 0.02 (-0.08, 0.11) 
High SES x 2006  0.07 (-0.03, 0.17) 0.07 (-0.02, 0.16) 0.08 (-0.01, 0.17) 
High SES x 2007  0.03 (-0.07, 0.12) 0.02 (-0.08, 0.12) 0.02 (-0.08, 0.11) 
Covariates 
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Age, reference group: <60 years 
Age: 60-74 years   -0.23 (-0.27, -
0.20) 
-0.21 (-0.24, -
0.17) 
Age: 75+ years   -0.24 (-0.28, -
0.19) 
-0.26 (-0.30, -
0.22) 
Duration of diabetes, reference group: 0-3 years 
Duration: 4-9 years   -0.17 (-0.20, -
0.14) 
-0.14 (-0.17, -
0.10) 
Duration 10+ years   -0.25 (-0.29, -
0.21) 
-0.22 (-0.25, -
0.18) 
Ethnicity, reference group: White 
South Asian   -0.02 (-0.10, 0.05) -0.05 (-0.12, 0.03) 
Other Ethnicity   0.19 (0.04, 0.35) 0.14 (-0.01, 0.29) 
Male   -0.30 (-0.33, -
0.27) 
-0.31 (-0.34, -
0.28) 
Smoking status, reference group: Non smoker 
Smoker   0.11 (0.07, 0.16) 0.11 (0.06, 0.15) 
Ex-smoker   0.00 (-0.03, 0.03) 0.01 (-0.03, 0.04) 
BMI status, reference group: Low & normal weight 
Overweight   -0.02 (-0.07, 0.03) 0.02 (-0.02, 0.07) 
Obese   -0.04 (-0.08, 0.01) 0.01 (-0.03, 0.06) 
Hypertensive   0.15 (0.12, 0.18) 0.15 (0.12, 0.18) 
Ischaemic Cardiac   -0.20 (-0.23, -
0.16) 
-0.12 (-0.15, -
0.09) 
Stroke or TIA   -0.05 (-0.09, 0.00) -0.03 (-0.07, 0.02) 
PVD   -0.02 (-0.07, 0.03) 0.00 (-0.05, 0.05) 
Interventions, Patient level 
Quality of Care level, reference group: Low quality 
Mid. quality    -0.14 (-0.18, -
0.10) 
High quality    -0.23 (-0.27, -
0.18) 
Aspirin    -0.08 (-0.11, -
0.05) 
Lipid therapies    -0.37 (-0.40, -
0.34) 
Shared care    -0.06 (-0.10, -
0.03) 
Middlesbrough PCT    -0.03 (-0.12, 0.05) 
Cons 4.38 (4.24, 
4.51) 
4.62 (4.42, 4.77) 5.1 (4.98, 5.22) 5.49 (5.37, 5.61) 
Variance estimate at: 
Practice level 0.02 (0.01, 
0.03) 
0.02 (0.01, 0.03) 0.02 (0.01, 0.03) 0.02 (0.01, 0.03) 
Patient level 0.02 (0, 0.1) 0.03 (0.24, 0.16) 0.01 (0, 0.05) 0.01 (0.00, 0.03) 
Visit year 1.24 (1.22, 
1.27) 
1.22 (0.20, 1.25) 1.15 (1.13, 1.17) 1.11 (1.09, 1.14) 
Bayesian DIC 67652.43 67343.07 65945.30 65294.04 
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Appendix J: Representativeness of South Tees Hospitals NHS 
Trust Diabetes Register of type 2 diabetes patients in the South 
Tees area  
 
 
Table 88 compares the prevalence of type 2 diabetes patients per practice as identified 
through the South Tees Hospitals NHS Trust Diabetes Register with Quality and 
Outcome Framework (QOF) diabetes prevalence per year. Both prevalence indicators 
use the practice list sizes per practice from the QOF as the denominator to allow 
comparison between indicators. Comparing these indicators with other figures should 
be cautious as the denominator counts patients of all ages whereas the Diabetes Register 
and QOF prevalence numerator [47] have patients 17 and above only. 
The third column calculates the proportion of diabetes prevalence of QOF prevalence. 
England and worldwide estimates indicate that type 2 diabetes make up between 90-
95% of all diabetes patients [41]. Those proportions which fall into this range are 
highlighted in bold indicating, arguably, the data are representative of type 2 diabetes 
for these practices for that year. There are a number of practices which capture more 
than 95% of the expected number of type 2 diabetes patients. This maybe because there 
a number of diabetes patients in the South Tees area known to secondary care but in 
primary care [50]. There are also a number of practices which notably fewer type 2 
diabetes patients than what is expected. This maybe because be due to a drop off in data 
being collected from primary care. This could also explain the sharp drop off in the 
number of type 2 diabetes from some practices which can be seen in Figure one.  
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Table 88: Prevalence of type 2 diabetes in South Tees Hospitals NHS Trust Diabetes Register, Prevalence of type 1 and type 2 diabetes in Quality and 
Outcomes Framework and Proportion of South Tees Hospitals NHS Trust Diabetes Register of Quality and Outcomes Framework prevalence 
 
2004 
  
2005 
  
2006 
  
2007 
  
Practice 
S. Tees 
Register 
Prevalence 
QOF 
Prevalence 
Proportion 
of S. Tees 
of QOF 
prevalence  
S. Tees 
Register 
Prevalence 
QOF 
Prevalence 
Proportion 
of S. Tees 
of QOF 
prevalence  
S. Tees 
Register 
Prevalence 
QOF 
Prevalence 
Proportion 
of S. Tees 
of QOF 
prevalence  
S. Tees 
Register 
Prevalence 
QOF 
Prevalence 
Proportion 
of S. Tees 
of QOF 
prevalence  
1 3.62 4.13 87.80 4.08 4.36 93.40 4.08 4.38 93.23 4.39 4.48 97.95 
2     
 
    
 
3.48 3.63 95.96 3.78 3.87 97.78 
3 3.00 3.47 86.63 3.43 3.82 89.72 3.77 3.69 102.05 1.36 4.08 33.33 
4 2.29 2.67 85.94 2.38 2.78 85.45 2.64 2.80 94.05 1.26 2.95 42.71 
5 3.52 3.72 94.76 3.82 4.01 95.08 3.89 4.20 92.56 3.82 4.13 92.34 
6 2.68 3.09 86.75     
 
3.64 4.02 90.50 3.86 4.17 92.64 
7 3.33 3.63 91.74 3.63 3.76 96.75 3.56 3.84 92.74 3.82 3.79 100.83 
8 3.12 3.22 96.80 3.12 3.43 90.85 3.13 3.31 94.63 3.29 3.53 93.23 
9 3.41 3.74 91.12 3.92 4.24 92.47 4.32 4.61 93.70 4.50 4.89 92.13 
10 3.09 3.21 96.44 3.25 3.50 93.07 3.45 3.43 100.57 3.35 3.43 97.73 
11 3.58 3.61 99.31 3.48 3.58 97.19 3.75 3.52 106.45 3.71 3.72 99.66 
12 3.74 3.39 110.37 3.88 3.56 109.21 4.21 3.64 115.59 4.38 3.83 114.19 
13 2.71 2.93 92.24 3.02 3.33 90.76 3.36 3.56 94.19 3.32 3.74 88.92 
14 0.82 2.75 29.69     
 
0.97 3.12 31.22 0.79 3.25 24.24 
15 2.83 2.97 95.44 2.98 3.22 92.47 3.18 3.09 103.14 3.30 3.44 95.91 
16 3.13 3.46 90.43 3.31 3.56 92.89 3.42 3.68 92.97 3.77 4.01 93.97 
17 2.52 2.72 92.63 2.76 2.95 93.49 2.95 2.93 100.90 3.09 3.41 90.74 
18 2.55 2.95 86.44     
 
2.79 3.15 88.69 3.09 3.46 89.34 
19     
 
3.27 3.32 98.47 3.43 3.48 98.59 3.66 3.76 97.39 
20 2.77 2.96 93.77 2.93 3.11 93.97 3.15 3.14 100.57 3.18 3.55 89.39 
21 3.12 3.47 89.97 3.39 3.63 93.25 3.68 3.84 96.02 3.88 4.04 96.19 
 
2004 
  
2005 
  
2006 
  
2007 
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Practice 
S. Tees 
Register 
Prevalence 
QOF 
Prevalence 
Proportion 
of S. Tees 
of QOF 
prevalence  
S. Tees 
Register 
Prevalence 
QOF 
Prevalence 
Proportion 
of S. Tees 
of QOF 
prevalence  
S. Tees 
Register 
Prevalence 
QOF 
Prevalence 
Proportion 
of S. Tees 
of QOF 
prevalence  
S. Tees 
Register 
Prevalence 
QOF 
Prevalence 
Proportion 
of S. Tees 
of QOF 
prevalence  
22     
 
3.93 4.46 88.10 4.35 4.57 95.32 4.53 4.86 93.26 
23 2.87 3.32 86.57 3.20 3.51 91.20 3.23 3.62 89.33 3.84 4.16 92.31 
24 2.59 2.88 89.91 3.05 3.36 90.64 3.29 3.59 91.67 1.65 3.63 45.55 
25     
 
3.78 4.07 92.83 3.64 4.17 87.30 4.07 4.37 92.97 
26 3.61 3.94 91.54 3.62 4.06 89.31 4.03 4.31 93.48 4.20 4.63 90.82 
27 4.22 4.53 93.19 4.41 4.66 94.65 4.34 4.67 93.03 4.93 5.15 95.59 
28 3.67 3.74 98.01 3.88 3.90 99.52 4.23 4.36 97.00 2.15 4.49 47.90 
29 2.81 3.25 86.29 3.05 3.44 88.80 3.32 3.58 92.94 3.45 3.80 90.85 
30 3.42 3.63 94.24 3.56 3.88 91.69 4.01 4.30 93.41 4.15 4.34 95.61 
31 4.21 4.39 95.95 4.61 4.69 98.26 4.89 4.97 98.35 5.07 4.82 105.14 
32 3.03 3.28 92.28 3.11 3.42 90.78 3.30 3.53 93.58 3.44 3.71 92.58 
33 1.86 2.23 83.54 2.18 2.47 88.14 2.35 2.60 90.58 2.58 2.84 90.57 
34 2.41 2.79 86.23 2.40 2.71 88.69 2.59 2.80 92.61 2.62 2.86 91.40 
35 2.66 3.03 87.76 2.92 3.34 87.50 2.96 3.79 77.97 3.84 4.00 96.03 
36     
 
    
 
4.13 4.08 101.23 1.44 4.18 34.57 
37 3.21 3.11 103.13     
 
3.16 3.49 90.54 3.43 3.53 97.37 
38     
 
3.98 4.23 94.19 2.78 2.85 97.58 3.00 3.24 92.47 
39 3.35 3.66 91.52 3.73 3.90 95.47 3.75 3.98 94.12 3.53 3.92 89.96 
40 
   
1.86 1.95 95.56 1.78 2.09 85.42 2.12 2.39 89.09 
41 
   
    
 
0.09 0.52 16.67 0.09 0.51 16.67 
42 
   
1.43 1.00 142.86 1.10 1.24 88.89 0.81 1.30 62.50 
43 3.03 3.27 92.93 
   
3.67 3.92 93.44 3.76 3.89 96.67 
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